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A PEGuilação de proteínas é a ligação covalente de polímeros de 
polietilenoglicol (PEG) a resíduos de aminoácidos da proteína e é uma 
das técnicas mais promissoras para melhorar o efeito terapêutico dos 
biofármacos e a estabilidade a longo prazo de biossensores proteícos. 
Esta modificação química traz vantagens aos produtos 
biofarmacêuticos, como um aumento da meia-vida, maior estabilidade 
e imunogenicidade reduzida. Além disso, no campo analítico, a 
PEGuilação melhora as múltiplas propriedades dos biossensores 
baseados em proteínas, incluindo biocompatibilidade, estabilidade 
térmica e a longo prazo, e solubilidade em solventes orgânicos. No 
entanto, o uso de conjugados PEGuilados em campos analíticos e 
terapêuticos não tem sido amplamente explorado. A aplicação 
industrial limitada dos bioconjugados PEGuilados pode ser atribuída ao 
facto de as etapas de reacção e separação serem atualmente um 
desafio. A seleção correcta do design da reacção de PEGuilação e do 
processo de purificação são importantes desafios no campo da 
bioconjugação.  Neste sentido, a concepção e otimização de reações 
de PEGuilação sítio-específicas e aplicação de  sistemas aquosos 
bifásicos (ABS) como plataformas de purificação de conjugados 
PEGuilados são os dois principais objetivos desta tese. No que 
concerne à etapa de purificação foi estudado o eficiente fracionamento 
(i) dos conjugados PEGuilados, da proteína nativa e (ii) dos conjugados 
PEGuilados baseados no seu grau de PEGuilação.  A cromatografia 
por partição centrífuga (CPC) foi aplicada como uma plataforma de 
regime contínuo baseada na tecnologia de ABS para purificar 
eficientemente as proteínas PEGuiladas. 
As duas proteínas em estudo são a L-asparaginase, importante 
biofármaco aplicado no tratamento da leucemia linfoblástica aguda e o 
citocromo c, um potencial biossensor. 
A partir dos trabalhos desenvolvidos, é possível confirmar o grande 
potencial dos ABS no fracionamento de proteínas PEGuiladas, em 
regime contínuo e descontínuo. Além disso, a recuperação in situ dos 
produtos PEGuilados através da integração em uma única etapa de 
bioconjugação e purificação por ABS foi comprovada com sucesso 
para ambas as enzimas estudadas. Embora ainda sejam necessários 
estudos adicionais sobre a viabilidade destes sistemas em larga 
escala, os resultados aqui apresentados demonstram a relevância dos 
ABS para o desenvolvimento de processos de separação de proteínas 
PEGuiladas. 
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Protein PEGylation is the covalent bonding of polyethylene glycol 
(PEG) polymers to amino acid residues of the protein and it is one of 
the most promising techniques for improving the therapeutic effect of 
biopharmaceuticals and long-term stability of protein-based biosensors. 
This chemical modification brings advantages to biopharmaceuticals, 
such as an increased half-life, enhanced stability, and reduced 
immunogenicity. Moreover, in the analytical field, PEGylation improves 
the multiple properties of protein-based biosensors including 
biocompatibility, thermal and long-term stability, and solubility in 
organic solvents. However, the use of PEGylated conjugates in the 
analytical and therapeutic fields has not been widely explored. The 
limited industrial application of PEGylated bioconjugates can be 
attributed to the fact that the reaction and separation steps are currently 
a challenge. The correct selection of the PEGylation reaction design 
and the purification process are important challenges in the field of 
bioconjugation.  In this sense, the design and optimization of site-
specific PEGylation reactions and application of aqueous biphasic 
systems (ABS) as purification platforms for PEGylated conjugates are 
the two main objectives of this thesis.   Regarding the purification step, 
the efficient fractionation (i) of the PEGylated conjugates from the native 
protein and (ii) of the PEGylated conjugates based on their degree of 
PEGylation was studied.  Centrifugal partition chromatography (CPC) 
was applied as a continuous regime platform based on ABS technology 
to efficiently purify the PEGylated proteins. 
The two proteins under study are L-asparaginase, an important 
biopharmaceutical applied in the treatment of acute lymphoblastic 
leukemia and cytochrome c, a promising biosensor.  
The current work developed in this thesis demonstrates the great 
potential of ABS in the fractionation of PEGylated proteins, under batch 
and continuous regime. In addition, in situ recovery of the PEGylated 
products through one-pot bioconjugation and ABS purification was 
successfully demonstrated for both enzymes studied. Although further 
research on scale-up is still required, the results presented show the 
relevance of ABS platforms for the development of separation 
processes of PEGylated proteins. 
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K₂HPO₄; ( ) KH₂PO₄; (▲); K3PO4 and (■) K₂HPO₄/ KH₂PO; at 25ºC. The lines represent the 
Merchuk fit through Eq. 1. 
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Fig. 2.17. Phase diagrams of the copolymer Pluronic L-35 + potassium phosphate buffer 
(pH = 6.6), without the addition of surfactant (▬); and with the addition of 1 wt% of 
Triton X-100 (■); and Triton X-114 (♦), at 25ºC. The lines represent the Merchuk fit 
through Eq.1. 
Fig. 2.18. Phase diagrams obtained for the copolymers: Pluronic 17R4 (●); Pluronic 10R5 
(▲); and Pluronic L-35 (■) + potassium phosphate buffer (pH = 6.6), at 25ºC. The lines 
represent the Merchuk fit through Eq.1. 
Fig. 2.19. Coexistence curves for the ternary systems with potassium phosphate buffer 
+ water + Pluronic 17R4 (♦); Pluronic 10R5 (●); and Pluronic L-35 (▲); and for the 
quaternary system composed of potassium phosphate buffer + Pluronic L-35 + water + 
1 wt% of Triton X-114 (--■--). 
Fig. 2.20. Recovery data obtained for the three proteins regarding top/copolymer-rich 
phase (%Rec Top) and bottom/salt-rich phase (%Rec Bottom) and respective standard 
deviations () by using the different ATPS: cytochrome c, Cyt c (■); azocasein, Azo (■); 
and ovalbumin, Ova (■). For each system studied the selectivity results are reported.  
Fig. 2.21. Recovery values obtained for the surfactant-rich phase (%Rec Top) and 
surfactant-poor phase (%Rec Bottom), with the respective standard deviations () by 
applying AMTPS to separate azocasein (■); and ovalbumin (■). For each system studied 
the selectivity results are presented.  
Fig. 2.22. Diagram of the integrated process to selectively separate cytochrome c (Cyt 
c), ovalbumin (Ova) and azoasein (Azo). The proposed strategy includes two steps of 
purification using, respectively, ATPS and AMTPS based on Pluronic L-35 and potassium 
phosphate buffer - PB (pH = 6.6). The purity (Px) and recovery (Rx) of each step is 
provided in the present diagram. An ultrafiltration was applied to improve the 
separation of Cyt c and Ova and an acid precipitation was applied to isolate the Azo from 
Pluronic L35. The potassium phosphate buffer was maintained in the Azo-rich phase as 
a stabilizing solution. 
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Fig. 3.1. Reaction conditions to produce monoPEGylated L-asparaginase (monoPEG-
ASNase). (A) Electrophoresis (SDS-PAGE) showing the influence of PBS buffer ionic 
strength on N-terminal PEGylation with pH 7.5 (PEG:ASNase ratio of 25:1, 2 kDa mPEG-
NHS): Column 1- ASNase (control), column 2- reaction in 10 mM PBS, column 3- reaction 
in 100 mM of PBS, column 4- reaction in 200 mM PBS, and column 5- Molecular weight 
(BioRad). (B) Percentage of PEGylation at different PEG:ASNase ratios, 25:1 and 50:1, in 
100 mM of PBS pH 7.5, 30 min of time reaction. (C) Percentage of PEGylation at different 
pH values (6.0, 6.5, 7.0, 7.5 or 8.0) in 100 mM of PBS, PEG:ASNase ratio of 25:1 and 30 
min of reaction time. (D) Percentage of PEGylation on different reaction times (15 to 90 
minutes) in 100 mM of PBS, pH 7.5, PEG:ASNase ratio of 25:1. Grey bars - polypegylated 
ASNase, white bars - monoPEGylated ASNase, dotted bars - free ASNase. Percentage of 
PEGylation was based on gel analysis by band intensity. 
Fig. 3.2. Enzymatic behavior of monoPEG-ASNase compared to ASNase (control) and 
polyPEGylated form. (A) Enzymatic kinetics of ASNase. (B) Enzymatic kinetics of 
monoPEG-ASNase. (C) Enzymatic kinetics of polyPEG-ASNase. Data analysis and 
statistical analysis (F-test) were done using GraphPad Prism 5.0 software. All trials were 
in triplicates and error bars represent the standard deviation 
Fig. 3.3. PEG attachment influence on native enzyme. (A) Enzymatic activity versus 
storage time at 4 °C for ASNase control, monoPEG-ASNase and polyPEG-ASNase. (B) 
Dynamic light scattering profiles of unreacted ASNase, mono and polyPEGylated 
ASNase. The hydrodynamic radius were 7.53 nm, 9.85 nm and 11.75 nm, respectively.   
Fig. 3.4. MALDI-TOF of free ASNAse and monoPEG-ASNase (with 2 kDa and 10 kDa PEG). 
(A) N-terminal peptide LPNITILATGGTIAGGGDSATK.(S) at m/z 2028.1809 and (B) lysine 
peptide SVNYGPLGYIHNGK.(I), at m/z 1518.7. Samples were acquired in duplicate. 
ASNase; blue line (spectrum 4), monoPEG-ASNase 2 kDa light and dark green line 
(spectrum 6 and 2), and monoPEG-ASNase 10 kDa; light blue line and orange (spectrum 
5 and 1).  
Fig. 3.5. Electrophoresis gel (native-PAGE) showing the proteolytic degradation 
/resistance of native ASNase and PEGylated forms. ASNase, monoPEG-ASNase and 
polyPEG-ASNase in presence of asparagine endopeptidase (AEP) and cathepsin B (CTSB) 
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after 84 h at 37 °C, stained with CBB (top gel) and stained with ferric chloride (bottom 
gel). Column 1- Protease-free ASNase, column 2- ASNase with CTSB, column 3- ASNase 
with AEP, column 4- protease-free monoPEG-ASNase, column 5- monoPEG-ASNase with 
CTSB, column 6- monoPEG-ASNase with AEP, 7- protease-free polyPEG-ASNase, column 
8- polyPEG-ASNase with CTSB and column 9- polyPEG-ASNase with AEP. 
Fig. 3.6. Cytotoxicity of monoPEG-ASNase in MOLT-4 and REH cells. Assays performed at 
48 h and 72 h, with cells alone (control), without enzyme (PBS) and at different 
concentrations of enzymatic activity (0.01, 0.05, 0.1, 0.3 or 0.6 U.mL-1). Grey bars - free 
ASNase and white bars - monoPEGylated ASNase. Error bars represent the standard 
deviation. Likelihood of significance less than 0.05 (*), less than 0.01 (**) and less than 
0.001 (***) when compared with the control. 
Fig. 3.7. Schematic overview of PEGylation reaction. 
Fig. 3.8. Molecular visualization of theoretical lysine residues (LYS) of cytochrome c (Cyt-
c, PDB code 1HRC) PEGylated, using the Software PyMOL. (A) Four residues of 
conjugation are highlighted: LYS - 22, 25, 27 and 39, resulting in Cyt-c-PEG-4. (B) Eight 
residues of conjugation are defined i.e. LYS - 22, 25, 27, 39, 55, 79, 86 and 87 resulting 
in Cyt-c-PEG-8. 
Fig. 3.9. Effect of pH on Cyt-c PEGylation yields. The PEGylation reaction was performed 
in 0.1 M phosphate buffer (at different pHs), 1:25 molar proportion (protein:mPEG-NHS, 
5 KDa), at room temperature, for 30 minutes, and with a constant stirring of 400 rpm. 
Different letters indicate significant differences (P < 0.05) between conditions (A-E). 
Fig. 3.10. SDS-PAGE for the mixture obtained after PEGylation of Cyt-c with mPEG-NHS, 
at different pH values. Lane 1: molecular weight marker, Lane 2: Cyt-c. The protein 
mixtures obtained after PEGylation of Cyt-c were: Lane 3: pH = 7, Lane 4: pH = 8, Lane 5: 
pH = 9; Lane 6: pH = 10, Lane 7: pH = 11, Lane 8: pH = 12. 
Fig. 3.11. Effect of molar ratio (protein:mPEG-NHS) on Cyt-c PEGylation yields. The 
PEGylation reaction was performed in 0.1 M phosphate buffer (pH = 7), at room 
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temperature, for 30 minutes, and with a constant stirring of 400 rpm. Different letters 
indicate significant differences (P < 0.05) between conditions (A-C). 
Fig. 3.12. SDS-PAGE for the mixture obtained after PEGylation of Cyt-c at different molar 
proportions (protein:mPEG-NHS). Lane 1: molecular weight marker, Lane 2: 1:5, Lane 3: 
1:10, Lane 4: 1:25, Lane 5: 1:35. 
Fig. 3.13. Effect of reaction time on Cyt-c PEGylation yields. Effect of molar ratio 
(protein:mPEG-NHS) on Cyt-c PEGylation yields. The PEGylation reaction was performed 
in 0.1 M phosphate buffer (pH = 7), 1:25 molar proportion (protein:mPEG-NHS, 5 KDa), 
at room temperature, and with a constant stirring of 400 rpm. Different letters indicate 
significant differences (P < 0.05) between conditions (A-C). 
Fig. 3.14. SDS-PAGE for the mixture obtained after PEGylation of Cyt-c with mPEG-NHS 
at different reaction times. Lane 1: molecular weight marker, Lane 2: 15 min, Lane 3: 30 
min, Lane 4: 45 min. 
Fig. 3.15. Near-UV CD spectra of Cyt-c (▬), Cyt-c-PEG-4 (▬) and Cyt-c-PEG-8 (▬) in 0.01 
M sodium phosphate buffer (0.14 M NaCl, pH = 7.4) in the region reflecting the protein 
tertiary structure. 
Fig. 3.16. Far-UV CD spectra of Cyt-c (▬), Cyt-c-PEG-4 (▬) and Cyt-c-PEG-8 (▬) in 0.01 
M sodium phosphate buffer (0.14 M NaCl, pH = 7.4) in the region reflecting the protein 
secondary structure. 
Fig. 3.17. Plot of the residual activity of Cyt-c and PEGylated protein forms (Cyt-c-PEG-4 
and Cyt-c-PEG-8) determined during 60 days at 4oC (A) and room temperature of 25oC 
(B). 
Fig. 3.18. (A) Far-UV and (B) Near-UV circular dichroism spectra of equine heart 
cytochrome c either in native form (Cyt-c, ▬) or PEGylated with 4 (Cyt-c-PEG-4, ▬) or 8 
(Cyt-c-PEG-8, ▬) PEGs. Experiments were carried out with 13-15 µM of Cyt-c/Cyt-c-PEG-
4/Cyt-c-PEG-8 in 0.01 M phosphate buffer (0.14 M NaCl, pH = 7.4) at room temperature 
(251°C). (C) Thermal stability curves of unfolding () and refolding (▬) processes of 
the same enzyme preparations. 
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Fig. 3.19. Arrhenius-type plots of initial activity of Cyt-c and PEGylated conjugates with 
4 (Cyt-c-PEG-4) or 8 (Cyt-c-PEG-8) PEGs attached, using 0.300 mM ABTS as a substrate. 
Fig. 3.20. Semi-log plots of the first-order denaturation constant (kd) vs. the reciprocal 
temperature (1/T). The slopes of the resulting straight lines used were used to estimate 
the activation energies (E*d) of irreversible inactivation (denaturation) of native 
cytochrome c (Cyt-c) and PEGylated conjugated with 4 (Cyt-c-PEG-4) or 8 (Cyt-c-PEG-8) 
PEGs attached. 
Fig. 4.1. Effect of polymer MW on log(K) of Cyt-c and PEGylated forms (Cyt-c-PEG-4 and 
Cyt-c-PEG-8) in PEG-phosphate buffer ABS (pH = 7). The PEG MW 300, 600, 1000, 1500, 
2000, 4000, 6000 and 8000 g.mol-1 were studied in a fixed mixture point 15 wt% PEG + 
20 wt% phosphate buffer. 
Fig. 4.2. Phase diagram () and respective tie-lines; TLs defined for the ABS composed 
of PEG 1500 + potassium phosphate buffer (pH = 7). The TLs were calculated considering 
the following mixture points (potassium phosphate buffer; PEG 1500 wt%):  (15; 15 
wt%),  (17.5; 15 wt%), (20; 15 wt%),  (22.5; 15 wt%),  (25; 15 wt%). 
Fig. 4.3. Effect of water content in the top-phase on log(K) of Cyt-c and PEGylated forms 
(Cyt-c-PEG-4 and Cyt-c-PEG-8) in PEG 1500 + phosphate buffer ABS (pH = 7). The studied 
mixture points were: (15; 15 wt%), (17.5; 15 wt%), (20; 15 wt%), (22.5; 15 wt%) (25; 15 
wt%) phosphate buffer; PEG 1500 wt%. 
Fig. 4.4. Diagram of multistep process to fractionate selectively the unreacted 
cytochrome c and each one of the PEGylated conjugates (Cyt-c-PEG-4 and Cyt-c-PEG-8). 
The proposed strategy includes three steps of purification using ABS, namely considering 
the ABS I and ABS II composed of PEG 8000 + potassium phosphate buffer (pH = 7) to 
separate Cyt-c-PEG-8 and ABS III using PEG 1500 + potassium phosphate buffer (pH = 7) 
to fractionate the unreacted Cyt-c from the Cyt-c-PEG-4 conjugate. The recovery yield 
of each step is also provided in the present diagram. The recycle and reuse of the 
unreacted Cyt-c in a new PEGylation cycle after recovery in the last step is also 
demonstrated. 
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Fig. 4.5. SEC-FPLC chromatogram of (A) unreacted Cyt-c concentrated in the bottom-
phase used directly in a new cycle of PEGylation; (B) unreacted Cyt-c used in a new cycle 
of PEGylation but after its isolation from the bottom phase through precipitation with 
cold acetone. (C) SDS-PAGE showing the successful use of the recycled Cyt-c in a new 
cycle of PEGylation: Lane M – Molecular Marker, Lane 1 – commercial equine heart Cyt-
c, Lane 2 – PEGylation mixture obtained after a new cycle of PEGylation using the 
purified Cyt-c. 
Fig. 4.6. Far-UV CD spectra of Cyt-c control (▬) and Cyt-c purified through aqueous 
biphasic system (▬). Cyt-c concentrations used are 15 and 13 µM for the control and 
purified forms, respectively. 
Fig. 4.7. Logarithm of K of both native (light grey bars) and PEGylated proteins (dark grey 
bars) in the one-step approach under development PEG-Prot + citrate (pH = 7) ABS [1.0 
wt% Protein (condition 2) + 12.5 wt% Prot-PEG/PEG + 12.5 wt% citrate buffer].  The 
selectivity of each system (S) is presented in red. Pictures of each ABS prepared are 
depicted for each system. 
Fig. 4.8. FTIR-ATR spectrum of ABS (1.0 wt% Protein + 12.5 wt% Prot-PEG/PEG + 12.5 
wt% citrate buffer) top-phase (---) bottom-phase (•••), pure Cyt-c (▬) and PEG (▬). 
Fig. 4.9. Schematic diagram of the integrated process combining bioconjugation 
reaction and separation with the polishing step and solvent recycling process for a 
complete PEGylation reaction. The dashed line represents steps that were not 
experimentally developed. 
Fig. 4.10. Schematic diagram of the integrated process combining bioconjugation 
reaction and separation with the polishing step and solvent recycling process for an 
incomplete PEGylation reaction. The dashed line represents steps that were not 
experimentally developed. 
Fig. 5.1. Chromatogram of FCPC purification of Cyt-c and Cyt-c-PEG performed 
employing ABS comprising 15 wt% of PEG (1000, 1500 and 2000) + 20 wt% of potassium 
phosphate buffer, at pH 7.0.  
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Fig. 5.2. HPLC chromatogram of the Cyt-c, Cyt-c PEGylation reaction media, purified Cyt-
c and purified Cyt-c-PEG. 
Fig. 5.3. Process diagram of the integrated process of purification in continuous regime 
applying FCPC without (A) and with the recycle of unreacted Cyt-c (B). 
Fig. 5.4. Chromatogram of FCPC representing the separation of unreacted Cyt-c and Cyt-
c-PEG, obtained after two-steps of PEGylation + fractionation using FCPC and the ABS 
comprising 15 wt% of PEG 2000 + 20 wt% of potassium phosphate buffer, at pH 7.0. 
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Chapter 1. General Introduction1 
1.1. Protein PEGylation technology 
Proteins are considered one of the most versatile biotechnological materials due to their 
ubiquitous nature allied with their wide range of applications. In this context, great 
technological and scientific efforts have been made to find ways to exploit the potential 
of biological functions that proteins exert in vivo. These efforts have culminated in an 
extensive diversity of products that include biopharmaceuticals, detergents, industrial 
biocatalysts, biosensors, among others. Albeit, the biological origin of the proteins gives 
them specific limitations, which must be taken into account to not compromise their 
properties and final application. In this sense, the development of novel techniques that 
seek to preserve, ensure, and even enhance the protein functionality are desired. These 
techniques include protein engineering,1,2 and chemical modifications of the protein.3–8 
The first technique takes advantage of the DNA technology and consists in the changing 
of specific amino-acid or sequences from the original protein structure in order to design 
a protein with improved characteristics.2 The chemical modifications of the protein can 
be achieved through protein crosslinking8 or by chemical binding of specific polymers to 
the protein.3 These proteins are modified intentionally for structure-function 
relationship studies or for development of new and improved products. PEGylation is a 
technique in which at least one chain of polyethylene glycol (PEG) is grafted onto the 
structure of the protein.9 PEGylation technology was first reported in 1977 by 
Abuchowski et al.10 for the modification of albumin and catalase. Depending on the 
number, molecular weight and location of the attached PEG chains, this covalent 
modification can enhance the physicochemical properties of the protein, without 
compromising the secondary structure.11  
 
1.1.1.  PEGylation reaction design  
Selecting the appropriate chemistry in the design of PEGylated conjugates is the first 
step to a successful process.5,6 PEGylation reactions have been extensively reviewed in 
                                                          
1 This chapter is based on the following article: Santos, J. H. P. M., Torres-Obreque, K. M., Pastore, G. M., Amaro, B. 
P. & Rangel-Yagui, C. O. Protein PEGylation for the design of biobetters: from reaction to purification processes. 
Brazilian J. Pharm. Sci. 54, (2018). 
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literature.3,5,6,12,13 The selection of the PEG derivative (the reactive PEG used in the 
PEGylation reaction) is fundamental, since it depends strongly on the location and 
number of amino-acids that are able to be PEGylated.14,15 Generally, the reactive groups 
in proteins involved in covalent binding to PEG molecules are nucleophiles,14,16 with the 
following moieties ranked in decreasing order of reactivity: thiol, α-amino, ɛ-amino, 
carboxyl, and hydroxyl.11 Moreover, the number and local reactivity of the available 
PEGylation sites (nucleophilic groups of the amino-acids), the experimental conditions 
of PEGylation reaction (i.e. pH, temperature, reaction time and molar ratio between PEG 
derivative and protein), and reactivity of the PEG derivative will have a noticeable 
influence on the composition of the PEGylated products.11 Thus, PEG coupling may 
result in heterogeneous mixtures, formed by different PEGylated conjugates with 
several degrees of PEGylation. Nevertheless, by the optimization of experimental 
reaction conditions, it is possible to direct the PEGylation reaction towards the 
formation of site-specific PEGylated conjugates and enhance the efficiency of 
PEGylation.15–17 It should be noticed that the PEGylation reactions are preferably 
conducted in single-step unidirectional batch system to guarantee the batch-to-batch 
control and the formation of all products in equal conditions. In this sense, validation, 
reproducibility, and optimization of the reaction are easier. Additionally, it allows to 
easily trace the potential formation of undesirable products (i.e. PEGylation adducts).11  
The maximization of the PEGylation yield and specificity of every reaction is required, 
whereas minimizing the costs. Therefore, some challenges in the PEGylation reaction 
still need to be addressed, namely (i) the design of site-specific PEGylation reactions to 
avoid a heterogeneity of PEGylated conjugates; (ii) to enhance the PEGylation reaction 
yield, through the use of liquid biocompatible solvents that guarantee the structure 
integrity of the proteins in alternative to aqueous buffer solutions; (iii) to allow 
shortened-time reactions to increase the PEGylation productivity; (iv) to decrease the 
amount of reactive PEG used in PEGylation reactions and the overall cost of the process.   
PEGylation of therapeutic proteins is commonly performed using reactive mono-
methoxy PEG (mPEG), approved for the use in pharmaceutical preparations by FDA and 
EMA. It has one of the hydroxyl groups methylated and the other linked to a specific 
group to react with the protein. This strategy avoids the formation of undesirable 
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byproducts, e.g. crossed linked products.3,18 One of the most used mPEG is the N-
hydroxylsuccinimide (NHS) functionalized polyethylene glycol (PEG-NHS). This amino (-
NH2) reactive PEG derivative can be used to modify proteins, peptides or any other 
surface by covalent bond to available amino groups; NHS esters react with primary 
amine groups at pH 7-8.5 to form stable amide bonds.19 Compared to other PEG NHS 
ester derivatives, the succinimidyl carbonate (SC) functionalized mPEG-NHS offers 
superior reactivity and higher stability in aqueous solution. 
 
1.2. Current advances in the purification of PEGylated conjugates 
PEGylation reactions commonly result in heterogeneous mixtures of unreacted protein, 
PEGylated conjugates and undesired PEGamers.20,21 Furthermore, the PEGylated 
conjugates formed are dissimilar among themselves, varying in the number of grafted 
chains and attaching sites. Therefore, efficient downstream strategies are needed to 
purify these complex mixtures for commercial approval.21 The purification of PEGylated 
conjugates consists in removing from the obtained mixture all species that do not 
present adequate characteristics. This implies three main challenges: (i) isolation and 
recycling of the unreacted protein from the PEGylated conjugates, (ii) isolation of each 
PEGylated protein form from the reaction media (e.g. PEG derivate, undesired 
PEGamers and hydroxylamine), and (iii) fractionation of PEGylated conjugates according 
to their degree of PEGylation. These multifaceted challenges are not easy to overcome, 
due to the fact that  the hybrid PEG-protein conjugate is structurally similar to the 
originator protein.11 Therefore, a combination of chromatographic20 and/or non-
chromatographic22 techniques can be used and designed for each PEGylation process, 
exploiting the physicochemical properties of the target biomolecules present in the 
mixture. In the last years, chromatographic fractionation platforms have been 
commonly used in downstream processes of protein PEGylation, as shown in Fig. 1.1. 
However, this tendency to prefer chromatographic techniques is related to the vast 
empirical knowledge obtained from several studies with a large spectrum of 
proteins.20,23–26 Non-chromatographic techniques have been used as alternatives to 
chromatographic strategies in the recent years, however, these are not fully 
characterized for the fractionation and analysis of PEGylated conjugates.22 
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Nevertheless, these later techniques are considered attractive downstream processes, 
since they exhibit several advantages: high versatility, ease of scale-up, biocompatible 
character, and low overall cost and time of processing.27 Non-chromatographic 
techniques are believed to offer the characteristics needed for higher selectivity and 
purity in the fractionation of PEGylated conjugates at low operating costs. Currently, 
efforts are being made to fully characterize those purification platforms and optimize 
them for a larger spectrum of PEGylated proteins.22,28 
 
Fig. 1.1. Distribution of the publications/papers reported in the last years (> 2010) dealing with the 
chromatographic and non-chromatographic techniques for the separation of PEGylated proteins. SEC – 
size exclusion chromatography, IEX – ion exchange chromatography, HIC – hydrophobic interaction 
chromatography. 
 
1.2.1. Chromatographic fractionation processes 
Currently, most purification processes for PEGylated proteins are based on 
chromatographic techniques, especially size exclusion chromatography (SEC)29–32 and 
ion exchange chromatography (IEX).17,26,33,34 SEC is a chromatographic method in which 
molecules in solution are separated by their molecular weight (MW). It is well 
recognized that SEC can be used to separate PEGylated species from unreacted protein 
and other components, but the effectiveness will greatly depend upon the molecular 
size of the species involved.29 For instance, the conjugation of a single PEG polymer with 
a protein with the same MW increases the protein molecular radius more than doubling, 
due to the conformation and high degree of hydration of PEG chains.35 Therefore, native 
and mono-PEGylated proteins should be readily separable by SEC.29–32 For protein 
conjugates with MW significantly different than the originator protein, SEC will be an 
effective purification platform, but the resolution among chromatographic peaks will be 
expected to diminish as PEGylation extent increases, due to the presence of more 
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PEGylated conjugates.31,32 However, SEC is not able to purify with great selectivity the 
positional isomers of PEGylated conjugates, due to the minimal differences among these 
protein species.35 For its part, IEX is capable of separating these proteins, because for 
each PEG molecule attached to an amino group, for example, a PEGylated protein has 
one less positive charge and this chromatographic technique separates the protein 
depending on net surface charge.35 By choosing the optimal ion exchanger and 
separation conditions, higher resolution can be obtained. This step must be achieved 
case-by-case depending on the specific protein and type of PEGylation.35 In the recent 
years, IEX has been the most used downstream technique for the separation of 
PEGylated conjugates17,26,33,34 (Fig. 1.1.). However, some drawbacks are observed due 
to the fact that PEG chains sterically interfere in the interaction of the charged residues 
of the protein and the ionic exchange support, producing a masking effect of the 
charges.35 Hydrophobic interaction chromatography (HIC) is also being applied in the 
fractionation of PEGylated proteins,20,24,25 although not so extensively as IEX and SEC. 
HIC takes advantage of the hydrophobicity changes through PEGylation process, 
separating PEGylated conjugates based on the relatively hydrophobicity/hydrophilicity 
of these protein species.35 Nonetheless, HIC has low capacity and poor resolution 
between adjacent peaks. To date it is not possible to conclude which type of 
chromatographic technique is the best option to fractionate PEGylated conjugates. 
Furthermore, there is no generalized chromatographic protocols to purify PEGylated 
conjugates among themselves, making it necessary to describe empirically the 
separation strategies on a case-by-case basis.22,35   
 
1.2.2. Non-chromatographic fractionation processes 
The non-chromatographic fractionation platforms applied in the purification of the 
PEGylated conjugates are: capillary electrophoresis (CE), membrane separation 
techniques (ultrafiltration, diafiltration and dialysis), aqueous biphasic systems (ABS) 
and microfluidics devices.22  Membrane separation processes are the simplest among all 
non-chromatographic platforms currently used and are based on the molecular weight 
and hydrodynamic radius. The main results show that PEGylated species can be 
fractionated and recovered efficiently using ultrafiltration and diafiltration, thus 
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achieving high yields and purification factors.36,37 Albeit, ultrafiltration methods may 
generate high product losses, particularly when using membranes with pores 
considerably smaller than the PEGylated protein hydrodynamic radius.38 Even though 
membrane separation techniques are not able to separate conjugates according to their 
positional isomerism, these unit operations seem to present certain advantages over 
SEC and IEX, where proteins of the same molecular size but different polymer lengths 
and number of attaching sites cannot be separated or fully resolved.39 Capillary 
electrophoresis (CE) has been used in the analysis and small-scale purification of 
PEGylated proteins.40–42 CE proved to be a powerful tool for the high resolution 
separation of different PEGylated products. The major advantages of this technique are 
automation capability, low sample consumption and short-time of the downstream 
process.42–44 CE is not adequate for industrial implementation due to technique scale-
up incapability.  
The design of novel microfluidic devices for rapid separation, concentration, and 
recovery of PEGylated proteins in a one-step operation is a current trend in the non-
chromatographic downstream processes.21,45,46 The application of aqueous biphasic 
systems, due to their great importance and advantages in the purification of PEGylated 
proteins are well-described in the Section 1.2.2.1. Moreover, it is important to highlight 
that those aqueous downstream platforms are focus of interest in the experimental 
work of this thesis, due to their versatile character and boundless potentiality in this 
field. 
 
1.2.2.1. Aqueous biphasic systems (ABS) 
Aqueous biphasic systems (ABS) were originally proposed by Albertsson47 as cleaner 
liquid-liquid extraction processes that could be used as potential substitutes for the 
conventional ones. This is mainly due to the fact that ABS are not based on hazardous 
volatile organic solvents and present abundant water content, providing milder and 
more biocompatible conditions for bioseparation/downstream processes.48,49 In fact, 
ABS are able to maintain the native conformation and biological activity of diverse 
biomolecules, while allowing high yields and purity levels. Evidences of their successful 
application are well-documented for a wide array of compounds, namely proteins50–52 
 General Introduction 
CHAPTER 1  
 
7 
 
including enzymes,53–55 cells,56,57 and antibiotics.58,59 Apart from their environmentally 
benign status, ABS are full of flexibility related with the countless types of chemical 
compounds that can be combined to create them, e.g. polymer + polymer,60–62 polymer 
+ salt,63–65 or salt + salt.66–68 More recently, the use of ionic liquids (ILs) as either phase 
forming agents,54,69–71 electrolytes72,73 or adjuvants74–76 emerged. Remarkably, the 
introduction of such ionic compounds in polymer-based ABS significantly increases the 
polarity differences between the phases.67 ILs are salts in the liquid state below a stated 
temperature of 100oC, conventionally composed of a large organic cation and an anion 
of either inorganic or organic nature.77 They present unique characteristics such as 
insignificant vapour pressure and flammability, being these the main reasons why ILs 
are labelled as greener solvents. Moreover, they possess high chemical78 and thermal79 
stabilities and outstanding capability of solvating compounds from a wide spectrum of 
polarities.80,81 These characteristics have contributed for the recognition of ILs as 
important phase forming agents in ABS. Furthermore, the ILs’ status of designer 
solvents,82 i.e. (almost) immeasurable cation/anion possible combinations, brings the 
possibility to manipulate ABS phases’ polarities and to develop tailor-made systems with 
specific affinities for certain biomolecules and applications. 
Several works addressed the application of ABS as purification tools to be used in the 
separation of PEGylated proteins.28,83–86 Table 1.1. presents information regarding the 
reports about the fractionation, recovery and partial purification of the PEGylated 
conjugates using ABS. Delgado et al.85,86 used PEG/dextran ABS as a feasible technique 
to characterize the degree of PEGylation (n) in PEGylated bovine serum albumin and 
PEGylated granulocyte-macrophage colony stimulating factor in mixtures of PEG-
protein conjugates. These authors determined the relationship between the increase in 
partition coefficient (K) of the PEGylated conjugate, considering the ratio of the 
concentration of the target protein in both top and bottom phases, with the degree of 
PEGylation of the protein species present in the resulting mixtures. González-Valdez et 
al.83 studied other type of ABS, in this case, PEG/salt-based ABS and evaluated the effect 
of PEG MW, tie-line length (TLL) and volume ratio (Vr) on the partition of native RNase 
A and lactoalbumin and their respective PEGylated conjugates. The results presented by 
the authors showed the potential of ABS for the fractionation of PEGylated proteins 
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from their unreacted proteins, however the sub-fractionation of PEGylated proteins 
among themselves (depending on their degree of PEGylation) was not achieved. The 
extended application of ABS was achieved by other authors, with the combination of 
this technique with continuous scale-up platforms, such as the counter current 
distribution ABS (CCD-ABS). This technique uses ABS to purify in continuous regime, as 
described in detail in Section 1.2.2.2. The application of CCD-ABS was already performed 
for the fractionation of PEGylated forms of lysozyme and RNase.28,87 From the reported 
results using ABS as purification platforms, it is necessary to fully characterize the 
behaviour of protein-polymer conjugates in ABS based operations, either for batch or 
continuous processing.  
 
Table 1.1. ABS applied in the separation of PEGylated proteins. 
 GM-CSF, granulocyte macrophage colony-stimulating factor; BSA, bovine serum albumin; IgG, 
immunoglobulin G; RNase A, ribonuclease A. 
 
Despite the advances reported, there is still much that needs to be address regarding 
the improvement of the purification of PEGylated conjugates with different degrees of 
PEGylation. Actually, it seems urgent the application of other types of ABS, such as 
PEG/polyacrylate (with or without electrolytes present), PEG/IL, copolymer/salt, just to 
Protein 
PEGylation 
degree 
(n) 
Polymer ABS used Goal Reference 
GM-CSF 0-2.5 
4.75% PEG + 4.75% 
Dextran T-500 + 0.15 M 
NaCl buffered with sodium 
phosphate, pH 6.8 
Correlation between log K vs 
n and purification of protein-
conjugates from unreacted 
protein and PEG 
85,86 
BSA 0-46 
NaCl-enriched ABS 
containing Dextran T-500 
and PEG 8000 or 6000 
Use of NaCl enriched ABS to 
purify protein-conjugates 
86 
IgG 0-43 
NaCl-enriched ABS 
containing Dextran T-500 
and PEG 8000 or 6000 
 
Separation of conjugates 
from the unreacted protein 
 
Use of  countercurrent 
distribution (CCD) with ABS 
for the separation of 
PEGylated conjugates with 
different degrees of 
PEGylation (i.e. mono- and 
di-PEGylated RNase A) 
 
86 
 
 
 
83 
 
 
28,83,84 
α-
Lactalbumin 
0-2 
PEG 400/1000/3350/8000 
+ potassium phosphate 
 
RNase A 0-2 
PEG 400/1000/3350/8000 
+ potassium phosphate 
Lysozyme 0-2 
19.36% PEG 3400 + 
14.68% potassium 
phosphate (pH=7) 
Fractionation of unmodified 
lysozyme,(PEG)1-lysozyme 
and (PEG)2-lysozyme using 
countercurrent distribution 
(CCD) and ABS 
 
87 
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mention a few. In situ product recovery through use of ABS in continuous regime and 
the application of other approaches regarding the continuous flow purification, namely 
the centrifugal partition chromatography (CPC), should also be focused in the near 
future.22  
 
1.2.2.2. Use of ABS to separate PEGylated proteins and their application in 
Centrifugal Partition Chromatography (CPC) 
Centrifugal Partition Chromatography (CPC) is a type of liquid-liquid chromatography 
requiring two immiscible liquid phases, one of which remaining stationary in the 
machine while the other acts as the mobile phase.88 The lack of a solid support 
distinguishes this technique from commonly used chromatographic methods, like high-
performance liquid chromatography (HPLC), where a column with an adsorbent material 
is usually utilized.89 While the basis of this technique is indeed common to other liquid-
liquid chromatographic methods - the partition of solutes between the two phases 
formed, the notable difference between them and CPC is the use of a centrifugal force 
by the later, in order to hold the stationary liquid phase in place.88 The concept of CPC 
was introduced in 1982 by Murayama et al.,90 stemming from an already established 
technique developed in 1944 by Lyman Craig,91 the counter current distribution (CCD), 
with the first functional CPC instrument being manufactured by Sanki Engineering.92 The 
main advantage of using CPC comes from the liquid-liquid nature of this process, making 
it unnecessary to use solid chromatographic supports, guaranteeing therefore almost 
100 % of compound recovery and an easy recyclability of the solvents, thus minimizing 
environmental problems and process costs,88 while also avoiding the need to buy, 
maintain and clean high-cost solid columns.93 The high volume of the stationary phase 
that can be loaded into the CPC is also a significant advantage, making this technique 
suitable for industrial application.94 While this adaptability is seen as an advantage in 
terms of potential applications, a careful choice of the solvents/phases is needed and 
defined according to the following criteria: easy phase separation; high capacity to be 
retained by the CPC; and separation/purification effectiveness.94 Even though the 
selection of a solvent system for use in CPC can be in many ways similar to other 
chromatographic methods, when it comes to criteria such as polarity, charge and 
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complexation, one also has to take into account the partition coefficients of the sample 
in that particular system.88 While classical chloroform/methanol/water or n-
hexane/ethyl acetate/methanol systems can be a good starting point, allowing for some 
manipulation of the system’s polarity to achieve the required sample distribution,88 
there has been a major interest in utilizing ABS in CPC. This increase in interest is not 
only due to ABSs already outlined advantages in terms of tunability,64 an essential 
characteristic for the development of a worthy CPC separation protocols, but also 
because of the highly biocompatible environment that ABS can provide, especially when 
compared to common organic solvents that, in many cases, induce significant 
conformational changes in proteins.49,95  
 
1.3. Applications of protein PEGylation 
1.3.1. Design of novel biobetters: PEGylation in biopharmaceutical field 
Therapies based on biopharmaceuticals were a revolutionary innovation in the 
pharmaceutical field due to the success to reach medical needs previously unmet, such 
as haemophilia, diabetes, arthritis and diseases of the immune system. Because of 
patent protections and the high market price of biopharmaceuticals, the holding 
companies of innovative molecules generated considerable revenue. Only six companies 
were responsible for the marketing of the ten best-selling biopharmaceuticals in 2011, 
about 37.6 % of total sales and reached a value of US $ 142 billion.96 However, some 
drawbacks upsurge, which are mainly related to the immunogenicity and low plasma 
half-life of these molecules. The immunogenicity is a concern in the production of anti-
drug antibodies (ADA – Anti-drug Antibodies) that may reduce the clinical efficacy by 
neutralization of the biological activity, the responses of hypersensitivity, anaphylactic 
reactions, among others.97,98 The lower biological half-life of biopharmaceuticals leads 
to more recurrent administrations to achieve the desired clinical effect in patients.99 
Another concern related to biopharmaceuticals available in the pharmaceutical market 
is of economic nature and is called "Patent Cliff”, a market phenomenon well described 
and known to the chemical drugs, that is approaching for biopharmaceuticals.96 This 
term refers to a sharp drop in sales of blockbusters when approaching the end of their 
patent protection. This drop in sales can impact negatively or positively the main 
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participants in the biological drug industry depending on the marketing strategies 
adopted.96 
Taking into account the economic need to remain competitive in the market and the 
necessity to solve the inherent problems of biopharmaceuticals, a new generation of 
protein-based medicines emerge: the follow-on biologics. This new generation of 
biopharmaceuticals is divided in two main groups: the biosimilars96,98  and biobetters.98–
100 Both are variants of an original protein-based medicine. However biosimilars, as the 
term suggests, aim to establish similarity to a known biological, while biobetters seek 
superiority in one or various aspects of their clinical profile.18 In this sense, biosimilars 
are close copies of marketed originator biotherapeutics, which must have the same 
safety, purity and efficacy profile as the originator compound.101 On the other hand, by 
definition, a biobetter is a biopharmaceutical changed through chemical or molecular 
modifications from an originator protein-based medicine, with functional changes that 
include increased half-life, reduced toxicity, reduced immunogenicity, and enhanced 
pharmacodynamic effects.18,101  
The biobetters represent an opportunity for innovation with reduced risk and increased 
sales for manufacturers, since the mechanism of action of the starting material molecule 
is already known. At the same time, these promote an improved treatment for patients 
and the reduction of the costs for health systems. One of the principal tools used for the 
development of biobetters is the PEGylation technique. After the first report of protein 
PEGylation in the 1970s,9 many proteins and peptides have been covalently conjugated 
with PEG.  
To date, 14 biobetters (PEGylated proteins, peptides, antibody fragments, and 
oligonucleotides) have been approved by FDA and are currently on the market (Table 
1.2.). From these 14 biobetters, 12 are PEGylated proteins, presented in 
biopharmaceutical market with a total market value of over US $ 8 billion per year and 
many others are in clinical trials.13 
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Table 1.2. FDA-approved PEGylated drugs in United and States and/or Europe. 
 
1.3.2. Design of novel biosensors: PEGylation in the biosensing field 
A biosensor is an analytical device, used for the detection of an analyte, which combines 
a biological component with a physicochemical detector.102,103 The sensitive element is 
a biologically derived material or biomimetic component that interacts (binds or 
recognizes) with the analyte under study (e.g. tissues, microorganisms, organelles, cell 
receptors, enzymes, antibodies, nucleic acids, etc).103,104 Biocatalysts can be widely 
applied in the biosensing field.105–108 However, enzyme-based biosensors suffer from the 
fact that proteins have a fragile conformation, being affected by several exogenous 
conditions (i.e.  pH, salt concentration, presence of proteases, temperature, among 
Brand name Company PEG size 
(Da) 
Indication(s) Year of 
approval 
Adagen® Enzon 5000 Severe combined 
immunodeficiency diseases 
(SCID) 
1990 
Oncaspar® Enzon 5000 Acute lymphoblastic leukemia 
(ALL) 
1994 
PEG-INTRON® Schering-Plough 12,000 Hepatitis C 2000 
PEGASYS® Hoffman-La Roche 40,000 Hepatitis C 2001 
Neulasta® Amgen 20,000 Neutropenia 2002 
Somavert® Pfizer 5000 Acromegaly 2003 
Macugen® Pfizer 40,000 Age-related macular 
degeneration 
2004 
Mircera® Hoffman-La Roche 30,000 Anemia associated with chronic 
renal failure 
2007 
Cimzia® UCB 40,000 Chronic, moderate to severe RA, 
Crohn’s disease, axial 
spondyloarthritis and psoriatic 
arthritis 
2008 
Puricase1® Savient 10,000 Chronic gout 2010 
Sylatron® Merck 12,000 Melanoma 2011 
Omontys® Affymax/Takeda 40,000 Anemia associated with chronic 
kidney disease 
2012 
Plegridy® Biogen 20,000 Multiple sclerosis 2014 
Adynovate® Baxalta 20,000 Hemophilia A 2015 
 General Introduction 
CHAPTER 1  
 
13 
 
others).105,109 Moreover, the exposure of redox enzymes to electrode materials often 
leads to unfolding and, subsequently, to irreversible inactivation.110 In general, long-
term stability and thermal stability are the two main drawbacks related to the potential 
application of enzyme-based biosensors. In order to overcome those drawbacks, 
chemical modification of the enzyme is frequently employed.8,111 As mentioned before, 
the chemical modification of proteins with polyethylene glycol (PEG) improves multiple 
properties: biocompatibility, long-term stability, enhanced thermal stability, and 
solubility in organic solvents.12 It is therefore not surprising that PEGylation has been 
employed to stabilize several biocatalysts with peroxidase-like activity, such as: 
cytochrome c,14,105,111,112 hemoglobin,113 myoglobin,114 and horseradish peroxidase.115 
 
1.4. Scopes and objectives 
This thesis has as main objective the development of PEGylation strategies to the 
creation of novel analytical and therapeutic proteins. The biopharmaceutical chosen for 
this purpose was the L-asparaginase (ASNase), an enzyme used in the treatment of 
Acute Lymphoblastic Leukemia (ALL). The PEGylation of this biopharmaceutical 
increases the half-life time of the enzyme in the human blood, protects the 
biopharmaceutical against proteolytic attack, and reduces the immunological reactions 
and protein aggregation. For the analytical part, a protein-based biosensor, namely the 
cytochrome c (Cyt-c), was selected to be studied in this thesis. This biocatalyst has 
peroxidase-like activity and can be applied as biosensor, however due to its problems 
related to long-term and thermal stability, the PEGylation will also be applied to 
overcome those drawbacks. This thesis is divided in the following Chapters: 
Chapter 2 shows the development and implementation of ABS as new purification 
platforms for the recovery of L-asparaginase (ASNase) from fermentation medium and 
cytochrome-c (Cyt-c) from a complex protein mixture. Chapter 3 reports a new strategy 
regarding the development of site-specific PEGylation reactions for the two studied 
proteins: ASNase (therapeutic enzyme) and Cyt-c (biosensor).  
After identifying the more efficient PEGylation reactions for Cyt-c and ASNase, Chapter 
4 shows the use of ABS to optimize an efficient downstream process to purify and obtain 
pure PEGylated forms of each protein under study.  
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Considering the necessity of exploring the purification strategies in continuous flow, in 
Chapter 5, the development of continuous purification processes, capable of 
contributing to purify different site-specific PEGylated proteins between each other and 
these form the unreacted proteins. 
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2.1. Heterologous expression and purification of active L-asparaginase I of 
Saccharomyces cerevisiae in Escherichia coli host 
Santos, J. H. P. M., Costa, I. M., Molino, J. V. D., Leite, M. S. M., Pimenta, M. V., Coutinho, 
J. A. P., Pessoa. A. J., Ventura, S. P. M., Lopes, A. M. & Monteiro, G. Biotechnology 
Progress, 2017, 33, 416-424.2 
 
Abstract  
L-asparaginase (ASNase) is a biopharmaceutical widely used to treat child leukemia. 
However, it presents some side effects, and in order to provide an alternative 
biopharmaceutical, in this work, the genes encoding ASNase from Saccharomyces 
cerevisiae (Sc_ASNaseI and Sc_ASNaseII) were cloned in the prokaryotic expression 
system Escherichia coli. In the 93 different expression conditions tested, the Sc_ASNaseII 
protein was always obtained as an insoluble and inactive form. However, the Sc_ASNaseI 
(His)6-tagged recombinant protein was produced in large amounts in the soluble fraction 
of the protein extract. Affinity chromatography was performed on a Fast Protein Liquid 
Chromatography (FPLC) system using Ni2+-charged, HiTrap Immobilized Metal ion 
Affinity Chromatography (IMAC) FF in order to purify active Sc_ASNaseI recombinant 
protein. The results suggest that the strategy for the expression and purification of this 
potential new biopharmaceutical protein with lower side effects was efficient since high 
amounts of soluble Sc_ASNaseI with high specific activity (110.1 ± 0.3 U.mg-1) were 
obtained. In addition, the use of FPLC-IMAC proved to be an efficient tool in the 
purification of this enzyme, since a good recovery (40.50 ± 0.01%) was achieved with a 
purification factor of 17-fold.  
 
Keywords: Biopharmaceutical; Fast Protein Liquid Chromatography (FPLC); Purification; 
Recombinant DNA; Enzyme technology. 
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1. Introduction 
The L-asparaginase (ASNase), L-asparagine amidohydrolase [EC 3.5.1.1] is an enzyme 
which catalyzes the hydrolysis of the amino group of L-asparagine, forming L-aspartic 
acid and ammonia. The discovery of this enzyme started with Kidd’s1 remarkable 
observation that Guinea pig serum had anti-tumor activity against several types of 
lymphoma in mice. Broome2 elucidated this anti-leukemic activity attributing it to 
ASNase action. Nevertheless, only in 1967, the ASNase was isolated in enough quantity 
to prove its anti-tumoral activity in clinical trials.3 Since then, the demand for the proper 
and efficient isolation and purification techniques for ASNase has increased, due to its 
pharmacological importance and proved application. 
ASNase was shown to be very useful in treating acute lymphocytic leukemia (ALL),4–6 
acute myeloid leukemia7 and lymphomas.8 ALL is a blood and bone marrow-related 
cancer whose prevalence is higher in childhood9,10. Nowadays, ASNase based drugs are 
available in different preparations/formulations as described in Table 2.1..11–16  
Table 2.1. Commercially approved ASNase.11–16 
Drug Name 
Production 
Source 
Type Manufacteur 
Elspar® Escherichia coli Native enzyme Lundbeck Inc 
Kidrolase® Escherichia coli Native enzyme EUSA Pharma S.A. 
Oncaspar® 
(PEG-asparaginase) 
Escherichia coli PEGylated native 
enzyme 
Sigma Tau Pharmaceuticals 
Graspa® Escherichia coli Native enzyme 
encapsulated in 
erythrocytes 
ERYTECH Pharma 
Leunase® Escherichia coli Modified E.coli HAP 
strain 
Kyowa Hakko Kirin Co. Ltd. 
Spectrila® Escherichia coli Recombinant Enzyme Medac Gesellschaft fuer 
klinische Spezialpraeparate 
mbH 
Erwinase® Erwinia 
chrysanthemi 
Native enzyme EUSA Pharma 
Crisantaspase® Erwinia 
chrysanthemi 
Native enzyme Ohara Pharmaceutical 
 
However, there are some factors limiting its use as a chemotherapeutic agent, namely 
i) the daily dose demand (10-200 U.kg-1 per day), for different periods of time, which 
may last for 21 days, and ii) the toxic side effects that can occur during therapy, i.e. 
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hyperglycemia, decreased serum albumin, lipoproteins and fibrinogen, increased liver 
fat and some mild brain dysfunctions6,11,17–20 and iii) the development of hypersensitivity 
to treatment. The hypersensitivity reactions ranging from a small allergy in the drug 
injection area, bronchospasm and even anaphylactic shock, occurs in 5 to 50% of the 
treated patients. Nowadays, the researchers are focused in the partial or total 
elimination of these problems, regarding some protein structural modification 
approaches, through genetic engineering, gene enhancement and/or by ASNase 
conjugation with biopolymers (e.g. polyethylene glycol (PEG), dextran, albumin and 
heparin)5,11,21–23 or by changing the expression host systems.24 
In this work, the genes codifying ASNase were isolated from the Saccharomyces 
cerevisiae BY4741 (Invitrogen), a microorganism able to synthesize two distinct forms of 
ASNase: Sc_ASNaseI, an intracellular constitutive enzyme and Sc_ASNaseII, a 
periplasmic enzyme which is secreted when the microorganism is exposed to some 
stress conditions, in particular to nitrogen starvation. Both enzymes are poorly 
characterized; Ferrara et al.25 obtained a better endogenous amount of Sc_ASNaseII 
using the double mutant strain ure2dal80. However, the posterior yield of 
Sc_ASNaseII heterologous expression in Pichia pastoris was 7-fold higher than in the 
mutant S. cerevisiae26 and the protein has been successfully expressed and purified in 
its active form, using this host cell.27 In this work, the intention was to analyze the 
expression of the Sc_ASNases, eukaryotic forms of the biopharmaceutical ASNase, by 
applying the well-characterized, simple, fast and cheap host heterologous E. coli 
expression system. In order to access this system capacity, a bioinformatics analysis was 
conducted to evaluate both enzymes requirements as for its post-translational 
modifications in the native host, followed by the expression of the enzymes and 
evaluation of their activities. Moreover, the Fast Protein Liquid Chromatography (FPLC) 
purification of Sc_ASNaseI was applied as a downstream methodology platform. 
Actually, the use of the FPLC purification in proteins has been previously explored,28–30 
thus being considered a well-established technique in different biotechnological 
industries. 
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2. Materials and methods 
2.1. E. coli expression vector construction 
In order to amplify the ASP1 and ASP3 genes, the genomic DNA of S. cerevisiae extracted 
with PureLink® Genomic DNA Purification Kit (Invitrogen®, Carlsbad, CA, USA) was used. 
Also, the ASP3 synthetic gene with optimized codons to express protein in E. coli was 
purchased from GenScript Corporation. Primers to amplify the target yeast genes were 
commissioned to the company Exxtend (Paulínea, SP, Brazil) (sequences described in 
Table 2.2.). Sc_ASNase genes were cloned into expression vectors described in Table 
2.3.. Restriction enzymes NdeI, BamHI and XhoI were purchased from New England 
Biolabs (NEB, Ipswich, UK). T4 DNA ligase was obtained from Promega (Madison, WI, 
USA). The bacteria transformation was carried out by electroporation in a MicroPulser 
Electroporator (BioRad®, Hercules, CA, USA). Luria Bertani – L.B. (0.5% NaCl, 0.5% yeast 
extract, and 1% triptone) solid medium (2% agar added) with added carbenicillin (50 
µg.µL-1) was used to select transformants which contain pET15b or pET22b vectors or 
added of kanamycin (15 µg.µL-1) to select transformants with pET28a+SUMO 
construction. The recovery of the plasmids from bacteria was performed using a 
QIAprep Spin Miniprep Kit (Qiagen®, Hilden, Germany), according to the manufacturer's 
instructions. The correct insert of Sc_ASNase genes into the pET vectors were confirmed 
by DNA sequencing, for all expression vectors described in Table 2.3. 
 
Table 2.2. Sequence of primers used to carry out the constructions of the Sc_ASNases overexpression 
vectors. 
Primer name   Sequence (5’ 3’) 
Restriction 
enzyme site 
ASP1-fw GGGAATTCCATATGAAAAGCGATTCAGTTGAAATCA NdeI 
ASP1-rv CGCGGATCCTCACCACCATAGAC BamHI 
ASP3-1-fw GGGAATTCCATATGAGATCTTTAAATACCC NdeI 
ASP3-26-fw CGGGATCCGAAGAGAAGAATTCTTC BamHI 
ASP3-32-fw GGGAATTCCATATGTTGCCATCAATCAAAATTTTTGG NdeI 
ASP3-26opt-fw GGGAATTCCATATGGAAGAAAAAAATAGCTC NdeI 
ASP3-BamHI-rv CGGGATCCTTAACCACCGTAGACG BamHI 
ASP3-XhoI –rv CCGCTCGAGACCACCGTAG XhoI 
ASP3-opt-rv CATTGGATCCTCAACCGCC BamHI 
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Table 2.3. Description of the primers combination, type of DNA templates and expression vectors used in 
this work. 
Forward 
primer 
Reverse Primer DNA template Vector Final construction 
ASP1-fw ASP1-rv 
S. cerevisiae 
genomic DNA 
pET15b ASP1+pET15b 
ASP3-1-fw ASP3-BamHI-rv 
S. cerevisiae 
genomic DNA 
pET15b ASP3_1-362+pET15bA 
ASP3-32-fw ASP3-BamHI-rv 
S. cerevisiae 
genomic DNA 
pET15b ASP3_32-362+pET15bB 
ASP3-26-fw ASP3-XhoI –rv 
S. cerevisiae 
genomic DNA 
pET22b ASP3_26-362+pET22bC 
ASP3-26opt-
fw 
ASP3-opt-rv 
ASP3 
optimized 
gene 
pET15b 
ASP3opt_26-
362_pET15bD 
ASP3-26-fw ASP3-XhoI –rv 
S. cerevisiae 
genomic DNA 
pET28b+SUMO 
ASP3_26-362+ 
pET28b+SUMOE 
A Complete Sc_ASNaseII fused with N-terminal His6-tag and expressed in cytoplasm in E. coli. 
B Sc_ASNaseII without the first 32 amino acids – sequence of protein that aligns with bacterial 
Ec_ASNaseII- fused with N-terminal His6-tag and expressed in cytoplasm in E. coli. 
C Mature Sc_ASNaseII without the 26 first amino acids involved in the intermembrane signalling secretion 
in yeast S. cerevisiae. Protein fused with C-terminal His6-tag and expressed in periplasmic space in E. coli. 
D Mature Sc_ASNaseII without the 26 first amino acids involved in the intermembrane signalling secretion 
in yeast S. cerevisiae. The gene was synthesised with optimal codons to express in E. coli; expressed with 
N-terminal His6-tag and in cytoplasm. 
E Mature Sc_ASNaseII without the 26 first amino acids involved in the intermembrane signalling secretion 
in yeast S. cerevisiae fused with N-terminal high solubilizing protein SUMO, expressed in cytoplasm. 
 
2.2. Heterologous expression of Sc_ASNaseI  
The E. coli BL21 (DE3) strain was grown in LB liquid media, supplemented with the 
appropriate antibiotics, at 37°C until OD600nm = 0.6-0.7. When the bacteria were in the 
log-phase, 1 mM of isopropylthio-β-D-galactoside (IPTG) was added, and the solution 
was incubated for 3 h at 37°C to induce the transcription and, consequently, to allow 
the production of Sc_ASNaseI. The sample pre-treatment was conducted by a chemical 
lysis procedure; herein cell pellets from genetically transformed E. coli BL21 (DE3) were 
suspended in 10 mL of BugBuster Master Mix (Merck-Millipore™, Billerica, MA, USA) per 
g of cell, mixed gently for 20 min and centrifuged at 16,000 x g for 20 min at 4°C; the 
pellet was discarded and the supernatant was subjected to vacuum filter membrane 
(0.45 μm, Merck-Millipore); to the filtered sample, the final concentration of 20 mM 
imidazole was added. 
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The affinity chromatography was performed on a FPLC™ System (ÄKTA purifier, GE 
Healthcare) using a Ni2+-charged, 5 mL HiTrap IMAC FF column (GE Healthcare). A linear 
gradient, running from 0-500 mM of imidazole at 5.0 mL.min-1 was carried in order to 
be possible to identify the lowest imidazole concentration of the elution buffer required 
to extract the highest amount of the purified Sc_ASNaseI. This concentration range was 
further used in an imidazole gradient step, in which two-step concentrations of 
imidazole (160 and 272 mM) were applied. The initial sample volume applied was 5.0 
mL. A binding buffer (20 mM sodium phosphate buffer at pH 8.0 and 500 mM NaCl) and 
an elution buffer (20 mM sodium phosphate buffer at pH 8.0, 500 mM NaCl and 500 mM 
imidazole) were used in the purification process. The samples were previously 
centrifuged 4,000 x g for 20 min at 4°C and desalted through an exclusion 
chromatography step in a PD-10 column (GE Healthcare Life Sciences) with Tris-HCl 
buffer (20 mM) at pH 8.6. 
 
2.3. Screening of conditions for Sc_ASNaseII expression 
The E. coli strains (Table A.1 at Appendix A) were genetically transformed with the 
chosen construction containing the ASP3 gene (Table 2.3). The screening of conditions 
for Sc_ASNaseII protein expression was carried out in 10 mL of LB medium plus the 
selective antibiotic medium, starting with a cell optical density of OD600nm = 0.2, at 37°C 
and 180 rpm until a cell density of OD600nm = 0.6-0.7. At this point, an IPTG solution was 
added at the described concentrations (0.01, 0.1, 0.5 and 1.0 mM) and incubated for 3 
h at 37°C or overnight at 20°C to induce the production of Sc_ASNaseII using the 
conditions, vectors and gene combinations described in Table A.2 at Appendix A. At the 
end of this procedure, the cells were pelleted, the supernatant discarded and 1.5 mL of 
BugBuster Master Mix (Merck-Millipore) was added, gently mixed for 20 min and 
centrifuged at 16,000 x g for 20 min. The pellet containing the cellular debris and 
inclusion bodies (containing insoluble proteins), was separated from the supernatant 
(with the soluble proteins) and both were analyzed by SDS-PAGE 12%, under reducing 
conditions, in accordance with the Laemmli’ method31. The electrophoresis was 
performed at 120 V using a vertical BioRad® system. The protein markers of different 
molecular weights were acquired from BioRad®. The volume of the samples added to 
the gel was 10 µL with a protein concentration ranging from 0.01 to 3 mg.mL-1. The gels 
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were silver stained for the protein bands detection, using the Silver Staining Kit 
(Amersham Pharmacia Biotech®) and following the manufacturer's instructions. 
 
2.4. Nessler activity assay and purification parameters calculation 
The determination of the enzymatic activity was performed by the Nessler activity assay 
(expressed in U.mL-1).32 The sample volume of 0.1 mL was incubated at 37°C for 30 min 
in Tris-HCl buffer (50 mM, pH 8.6) with L-asparagine (9 mM). Then, the reaction was 
stopped with the addition of trichloroacetic acid (TCA). The Nessler reagent (Merck) was 
mixed by inversion for 1 min and then the reactions were measured in a microplate 
reader at λ436nm (Spectramax Plus384, Molecular Devices). A standard curve was 
prepared using ammonium sulfate. In order to remove the possible interferences of 
quantification, two blanks composed by Tris buffer + L-asparagine + TCA were made for 
each sample. Moreover, at least three samples of each enzymatic activity measurement 
were prepared, being the results described, the average of the three replicas. 
The total protein concentration was measured through absorbance assay, measuring 
the absorbance at λ280nm, by UV-Vis spectroscopy. A calibration curve with bovine serum 
albumin (BSA) (lyophilized powder, ≥ 96 wt%, Sigma-Aldrich, St. Louis, MO, USA) was 
used to determine the protein concentration in each sample. 
2.5. Computational analysis of recombinant Sc_ASNases 
The possible N-glycosylation sites were predicted using NetNGlyc 1.0 program.33 The 
presence and location of signal peptide cleavage sites in the amino acid sequence was 
determined using the SignalP 4.1 program.34 The method incorporates a prediction of 
cleavage sites and a signal peptide/non-signal peptide prediction based on a 
combination of several artificial neural networks and hidden Markov models. 
 
3. Results and discussion 
3.1. Bioinformatics analysis of Sc_ASNases 
A computational analysis of the Sc_ASNases using bioinformatics tools was carried out. 
This analysis included the prediction of glycosylation sites using sequence information 
(NetNGlyc 1.0) and the presence, prediction and location of signal peptide cleavage sites 
in the ASNase amino acid sequences (SignalP 4.1). 
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The bioinformatics results obtained predicted that the Sc_ASNaseI could be expressed 
in its active form in E. coli, despite its prokaryotic expression nature. These data 
(NetNGlyc 1.0 and SignalP 4.1) resulted in three possible glycosylation sites (Fig. 2.1.A), 
even in the absence of a signal peptide (Fig. 2.2.A). This observation suggests that the 
glycosylation, if present in its native host, is not essential for the enzyme activity, which 
is supported by the high value of the enzyme specific activity (SA) found for the purified 
Sc_ASNaseI (see below). This is an important result, since E. coli is a robust expression 
system, largely adopted by biopharmaceutical companies due its high titers outcomes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  2.1. Prediction results of N-glycosylation in the Sc_ASNaseI (A) and Sc_ASNaseII (B), using the 
NetNGlyc 1.0 software. The sequence position represents the protein amino-acids position. The graph 
depicts the possible sites of N-glycosylation in the Sc_ASNases sequence (- blue lines), represented by the 
blue bars that rise vertically and pass the program threshold (- red line). 
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Fig. 2.2. Presence and location predictions of signal peptide and signal peptide cleavage sites in the 
Sc_ASNaseI (A) and Sc_ASNaseII (B) sequences by the SignalP-4.1 software. C-score represents the raw 
cleavage site score generated by the software. S-score: signal peptide score generated by the software. 
Y-score: combined cleavage site score generated by the software. If a signal peptide cleavage site is 
predicted, a C-score above the threshold (dashed purple line) would be present for some of the amino-
acids. In our specific case, a signal peptide cleavage site and signal peptide itself is not predicted. 
 
In contrast, Sc_ASNaseII presents 3 possible glycosylation sites (Fig. 2.1.B) and a signal 
peptide to direct this protein to the endoplasmic reticulum (Fig. 2.2.B); therefore, it is 
highly probable that this protein undergoes glycosylation. In fact, endogenously 
produced Sc_ASNaseII was observed with a high molecular weight due to 
hypermannosylation.35 Moreover, Castro-Girão et al.27 have described that 
heterologous produced Sc_ASNaseII produced by P. pastoris undergoes glycosylation, 
since after the purification process, two bands were observed by electrophoresis, which 
were then turned into one, just after treatment of Sc_ASNaseII with PNGase F (a 
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deglycosylation protein). In addition, as previously discussed, these authors observed 
the specific activity of Sc_ASNaseII produced by P. pastoris in the soluble fraction. 
Summing up, glycosylation seems to play an essential role for this enzyme activity and a 
prokaryotic system might be inappropriate to produce Sc_ASNaseII. 
 
3.2. Expression and purification of Sc_ASNaseI  
Recombinant protein expression in industrial scale demands careful evaluation of all 
process production steps. The choice of an appropriate host lies as a major step to this 
goal, moreover in the production of biopharmaceuticals. The proper protein folding, 
activity, purity and yield are dependent on the host ability to translate, fold and keep 
high amounts of the desirable protein in its soluble form. Sajitha et al.24 successfully 
expressed the ASNase from E. coli into the eukaryotic host P. pastoris. The authors 
obtained a soluble and active ASNase in the supernatant and speculate that this protein 
might undergo eukaryotic glycosylation conferring more stability to the protein and 
fewer side effects. In an attempt to obtain a cost effective, fast and efficient Sc_ASNase 
expression system, the gene ASP1 was cloned into pET15b between NdeI and BamHI 
restriction sites, which results in a Sc_ASNaseI N-terminal His-tag fusion protein. The 
native protein is predicted to present a molecular weight of 41,385.6 Da, but the 
recombinant protein with His-tag and thrombin recognition site, presents a molecular 
weight of 43,139.0 Da. As depicted in Fig. 2.3., the prokaryotic E. coli cell was able to 
express high amounts of soluble Sc_ASNaseI. However, the protein obtained in this first 
test presented a considerable number of contaminant proteins, especially in the fraction 
of higher Sc_ASNaseI concentration (Fig. 2.3., lane 6).  
Taking into account that the administration of this biopharmaceutical (ASNase) will be 
potentially carried by its direct injection into the human blood, the high purity of ASNase 
is certainly a crucial demand for it to be considered as a promising therapeutic 
alternative. In this sense, an FPLC purification was performed considering two main 
tasks; the first one using a linear gradient of imidazole in order to identify the lowest 
imidazole concentration able to elute the highest amount of Sc_ASNaseI, and the second 
one using the optimized imidazole concentration to develop a purification protocol in 
which the same buffer was used to perform a two-step purification procedure. 
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Fig. 2.3. SDS-PAGE stained with Comassie-Blue representing the first attempt of Sc_ASNaseI purification 
by IMAC. In the left are indicated the molecular protein weights of the highlight bands of the BenchMark 
protein ladder (lane 1). Lanes 2-6: sequential eluted Sc_ASNaseI from a nickel column purification. 
 
Both approaches were applied and from the general results (Table 2.4.), it was 
concluded that, while fractions 4-5 contain the expression of host contaminant proteins 
resulting in a very low specific Sc_ASNaseI activity (0.02 ± 0.01 U.mg-1), the purified 
fractions 20-31 exhibited the highest specific activity (6.61 ± 0.08 U.mg-1). Considering 
the results obtained, the imidazole concentrations chosen for the stepwise purification 
were 160 and 272 mM, which correspond to fractions 23 and 30, respectively. Table 2.5. 
summarizes the results obtained, correlating the fractions collected with the respective 
Sc_ASNaseI activity results, along with the protein concentration, enzymatic activity 
(EA), specific activity (SA), purification factor (PF), and recovery (%Rec) parameters. 
From the set of results obtained (Fig. 2.4. and Table 2.5.), we conclude that the most 
pure fraction exhibited a SA of 110.1 U.mg-1 comparable to the commercially available 
ASNase formulations, like Erwinaze® (from E. chrysanthemi) and Elspar® (from 
recombinant E. coli) containing 225 U.mg-1 (information displayed in the Product 
Datasheet - Active Asparaginase full-length protein ab73439). In what concerns the 
application of the purification step (FPLC purification), even higher specific activities 
would be reached, these similar to the values described for the commercial ASNase. 
Moreover, not only the enzyme activity is maintained but also the yields of purification 
of ASNase obtained were considerable (enzyme yield circa 1,001 U.g cell-1). It should be 
highlighted that Sc_ASNaseI was remarkably purified at 15 wt% of total cell dry weight, 
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which is a sizable piece of total cellular protein. Taking into account the results obtained 
and the demands of future applications, further optimization studies should be 
performed to the FPLC purification protocol, namely evaluating the effect of the fraction 
volume, pump pressure, initial volume injected, elution and binding buffer formulations 
in order to further improve the purifying yields. Other authors have reported some 
attempts to purify Sc_ASNaseI in the same line of work, namely Dunlop and 
collaborators.35 These authors used several steps of purification to obtain the 
endogenous Sc_ASNaseI from S. cerevisiae; being the best specific activity found around 
5 U.mg-1, which is almost 20-fold lower than the obtained in the present work. In 
addition, the same authors commented on the difficulty to separate both isoforms 
endogenously expressed Sc_ASNaseI from Sc_ASNaseII,35 a difficulty surpassed in this 
work by the use of an heterologous strategy and just one chromatographic purification 
step, which allowed the purification of Sc_ASNaseI resulting in a much higher specific 
activity than that obtained from endogenous expression. For a method/process to be of 
industrial relevance, the polishing of the target macromolecule being produced and 
purified is a crucial step. In this case, and considering the potential application of the 
biopharmaceutical in the ALL treatment, the elimination of the (His)6-tag from the 
biopharmaceutical36 can be achieved through the use of the aminopeptidase dipeptidyl 
peptidase I (DPPI), either alone or in combination with glutamine cyclotransferase (GCT) 
and pyroglutamyl aminopeptidase (PGAP). In both cases, the (His)6-tag is cleaved off by 
DPPI, which catalyses a stepwise excision of a wide range of dipeptides from the N-
terminus of a peptide chain.37 Other major concern considering the potential use of the 
biopharmaceutical in the ALL treatment is related to metal leaching from the column 
during purification.38 Although additional costs may be inserted for validation, new 
technologies have been developed in a lab scale in this context, in particular the 
treatment of the final sample with EDTA (GE Healthcare’s excel39 and Roche’s 
cOmplete40). Albeit, large-scale application of this system still needs to be fully 
evaluated. 
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Table 2.4. FPLC purification with an imidazole linear gradient (0-500 mM) step at 5.0 mL.min-1. Fractions 
eluted with Sc_ASNaseI activity are shown, along with the protein concentration (mg.mL-1), enzymatic 
activity (U.mL-1) and specific activity (U.mg-1) values. 
Sample 
Protein concentration 
(mg.mL
-1
) 
EA 
 (U.mL
-1
) 
SA  
(U.mg
-1
) 
Fractions 4-5 3.52 ± 0.03 0.06 ± 0.01 0.02 ± 0.01 
Fractions 14-18 0.05 ± 0.01 0.03 ± 0.01 0.49 ± 0.01 
Fractions 20-31 0.02 ± 0.01 0.11 ± 0.01 6.61 ± 0.08 
 
 
 
Fig. 2.4. Polyacrylamide gel electrophoresis combined with silver staining, showing the purified samples 
from the two-step FPLC purification. The brown box stresses the (His)6-tagged ASNase bands (~45.0 kDa). 
The different lanes represented the eluted fractions (5, 6 and 7: washout unbound proteins; 26-40: 
purified Sc_ASNase I and 48-57: non-purified Sc_ASNase I) and PM means Unstained Protein Molecular 
weight marker. 
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Table 2.5. FPLC purification with the two-step concentration methodology of the initial imidazole 
concentration (160 and 272 mM), applied at 5.0 mL.min-1. Fractions eluted with Sc_ASNaseI activity are 
shown, along with protein concentration (mg.mL-1), enzymatic activity (U.mL-1), specific activity (U.mg-1), 
purification factor (fold) and recovery (%) parameters.  
Sample 
Protein 
concentration 
(mg.mL
-1
) 
EA 
 (U.mL
-1
) 
SA  
(U.mg
-1
) 
PF (fold) 
Recovery 
activity    
(%) 
Cell extract 0.38 ± 0.01 2.50 ± 0.01 6.52 ± 0.01 1.00 100.00 
Stepwise FPLC 
purification 
(Fractions 38-
42) 
0.02 ± 0.01 2.017 ± 0.01 110.06 ± 0.34 16.88 40.50 
 
3.3. Expression and purification of Sc_ASNaseII 
Initially, the same expression and purification procedures described for Sc_ASNaseI 
were applied to express Sc_ASNaseII. Fig. 2.5. depicts the high level of Sc_ASNaseII 
expression in the E. coli host cells. However, the protein was completely concentrated 
in the insoluble fraction of the cell lysate (Fig. 2.5., lane 2). From the results of the lower 
growth temperature test, the conclusion was that this test was not improving the 
insoluble fraction presence as suggested elsewhere.41 In this context, several growth 
conditions including temperature of induction, concentration of (the inductor) IPTG and 
the time of induction were tested, since the optimization of these parameters is being 
recognized as a good strategy to overexpress soluble recombinant proteins in bacterial 
cells (as reviewed by Papaneophytou and Kontopidis42). None of these conditions were 
able to produce soluble Sc_ASNaseII in the E. coli host cell. It was hypothesized that the 
native gene from the amino-acids 1 to 362, i.e. with the yeast periplasmic signal, should 
enhance the solubility of the protein; however, this expression also resulted in an 
insoluble protein. Then, several genetic attempts to obtain soluble Sc_ASNaseII were 
carried out, namely (i) the synthetic ASP3 gene was expressed with optimized codons to 
the E. coli host, (ii) by changing the expression vector modifying the position of His-tag 
from the N- to C-terminal, and (iii) constructing a vector that expresses Sc_ASNaseII in 
fusion with the SUMO protein (a highly soluble protein). Moreover, eight different types 
of E. coli strains were also tested (Table A.1 in Appendix A). In conclusion, 93 different 
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expression conditions (described in Table A.2 in Appendix A) were tested without any 
success in the production of soluble Sc_ASNaseII. The only condition that resulted in low 
amounts of soluble Sc_ASNaseII (described briefly in Fig. 2.6.) produced a protein with 
a low specific activity (3.8 U.mg-1 of protein) after the Immobilized Metal ion Affinity 
Chromatography (IMAC) purification step. These results are in accordance with the 
bioinformatics analysis, since Sc_ASNaseII was predicted to be glycosylated in the native 
host. The absence of glycosylation, caused by E. coli lack of glycosylation machinery, 
seems to be a key factor in the Sc_ASNaseII activity. Dunlop et al.35 also purified 
Sc_ASNaseII endogenously produced in S. cerevisiae; the authors obtained a maximum 
SA of 60 U.mg-1 of protein. However, this protein was characterized as 
hypermannosylated, which means that endogenous obtained Sc_ASNaseII is highly 
immunogenic and cannot be used as a biopharmaceutical from this source, because 
human immune system cells possess a receptor for mannose.43 In addition, Sc_ASNaseII 
has been described as possessing 204 U.mg-1 of protein, when expressed in P. pastoris 
host, a 3-fold higher activity than the endogenous source.27 From the main results, it is 
suggested that, in contrast with Sc_ASNaseI, which is soluble and active when expressed 
in E. coli host cells, the Sc_ASNaseII cannot be properly produced in this host cell, 
independent of the growth conditions used. 
 
Fig. 2.5. SDS-PAGE stained with Comassie-blue representing the expression of Sc_ASNaseII in the insoluble 
fraction of the E. coli cell lysateThe construction pET15b+ASP3_32-362 expressed in the bacterial host 
strain CodonPlus (DE3) (Merck™); cells were pre inoculated in LB media overnight at a 37oC and 250 rpm. 
The inoculum was initially diluted to OD600nm 0.2 in fresh culture media, grown at the same conditions 
until OD600nm 0.4 when 0.1mM of IPTG was added and culture temperature was changed to 12oC. This 
Sc_ASNaseII induction was performed for 24 hours. In this expression vector construction, the protein 
starts at the amino-acid residue number 32, without the predicted yeast periplasmic signal.  - Lane 1: 
BenchMark™ Protein Ladder; Lane 2: insoluble fraction pelleted after clarification of the cell lysate by 
centrifugation. Lane 3: supernatant of cell lysate, representing the protein soluble fraction. 
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Fig. 2.6. SDS-PAGE stained with Comassie-blue representing the expression of Sc_ASNaseII in the soluble 
fraction of the E. coli cell lysate and the specific activity of this protein.  Fractions of nickel affinity 
purification. Lane 1: Total supernatant after cell lysis; Lane 2: BenchMark™ Protein Ladder; Lanes 3 and 4: 
Fractions from column elution with 500 mM of imidazole.  
 
4. Conclusions 
The optimized two-step FPLC purification method allowed the successful purification of 
Sc_ASNaseI from S. cerevisiae expressed in E. coli BL21 (DE3). Moreover, the 
bioinformatics analysis together with the enzyme activity results obtained suggested 
that N-glycosylation is not essential for Sc_ASNaseI activity. Antitumor activity and 
biochemical characterization of Sc_ASNaseI are being now conducted to evaluate the 
potential of this enzyme in acute lymphocytic leukemia treatment. By contrast, the 
results suggest that Sc_ASNaseII requires glycosylation, and therefore a eukaryotic 
expression host system to produce soluble and active enzyme. 
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2.2. In situ purification of periplasmatic L-asparaginase by aqueous two 
phase systems with ionic liquids (ILs) as adjuvants 
Santos, J. H. P. M., Santos, J. C. F., Meneguetti, G. P., Rangel-Yagui, C. O., Coutinho, J. A. 
P., Vitolo, M., Ventura, S. P. M. & Pessoa, A. J. Journal of Chemical Technology & 
Biotechnology, 2018, 93, 1871-1880.3  
Abstract 
Bacterial L-asparaginase is an important biopharmaceutical used in the treatment of 
acute lymphoblastic leukemia (ALL) and lymphosarcoma. Taking into account its main 
application in cancer therapy, the most important request for the L-asparaginase 
production is the need for a highly pure biopharmaceutical obtained in the final of the 
downstream process, which is considered as the crucial step in the production of this 
enzyme. In this ambit, this work proposes the use of polymer-salt aqueous two phase 
systems (ATPS) based on polyethylene glycol and citrate buffer, with ionic liquids (ILs) as 
adjuvants, combined with the permeabilization of cell membrane using n-dodecane and 
glycine for the in-situ purification of periplasmatic L-asparaginase from Escherichia coli 
(E. coli) cells. The process proposed was optimized in terms of polymer molecular 
weight, pH, tie-line length/mixture point, presence and nature of the adjuvant and its 
concentration. The results show that L-asparaginase preferentially partitions to the 
polymer-rich phase, due to hydrophobic interactions between both the PEG and 
enzyme. Remarkably, the addition of 5 wt% of 1-butyl-3-methylimidazolium 
methanesulfonate, [C4mim][CH3SO3] as adjuvant lead to high recoveries and purification 
factors, i.e. %RecTop = 87.94 ± 0.03 (%) and PF = 20.09 ± 0.35, and a final specific activity 
SA = 3.61 ± 0.38 U.mg-1 protein, from a crude enzyme extract with a SA = 0.18 ± 0.05 
U.mg-1 protein. Moreover, better results were achieved when a pre-purification step 
consisting of an ammonium sulfate precipitation was combined with the optimized ABS. 
It is here shown that the integration of pre-purification step with the ATPS further 
increased the specific activity and purification factor of this biopharmaceutical to SA = 
22.01 ± 1.36 U.mg-1 protein and PF = 173.8 ± 10.7, without compromising the enzyme 
structural integrity. Summing up, a novel integrated downstream process was 
successfully implemented for the in-situ purification of a high-cost biopharmaceutical 
from fermentation broth.  
 
Keywords: Therapeutic enzyme; L-asparaginase, aqueous two-phase systems; ionic 
liquids as adjuvants; integrated in-situ purification process. 
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1. Introduction 
L-asparaginase, L-asparagine amidohydrolase, EC.3.5.1.1 (ASNase) is a 
biopharmaceutical produced mostly by E.coli1,2 that has been widely studied as a 
therapeutic agent in the treatment of specific tumour types, including acute 
lymphoblastic leukemia (ALL)3–5 in humans and canine lymphosarcoma.6,7 ASNase was 
approved for medical use in the United States in 19788 and, since then it is on the World 
Health Organization's List of Essential Medicines.9 The underlying principle behind the 
ASNase anti-cancer mechanism of action is the deprivation of the essential amino acid 
L-asparagine for leukemic cells, which require exogenous sources of this amino acid for 
their survival.10 ASNase catalyses the conversion of L-asparagine to aspartic acid and 
ammonia.2 Its commercial manufacture conventionally uses downstream processes 
such as unit chemical lysis,11 protein precipitation,12–15 centrifugation,16 filtration,13,17 
fluidised bed chromatography,11 and other chromatographic techniques12,15,16,18–20 (e.g. 
ion-exchange, gel filtration and immobilized metal affinity chromatography - IMAC). 
Recently, new strategies were developed regarding the purification of ASNase, namely 
those based in Aqueous Two-Phase Extraction (ATPE) via Aqueous Two-Phase Systems 
(ATPS) and Aqueous Micellar Two-Phase Systems (AMTPS).17,21 The in situ ATPE 
strategies are combining different cell disruption approaches with the use of ATPS, 
resulting in higher product yields and lower costs associated to the enzyme purification. 
Moreover, it can also increase the productivity of the downstream process22–26 by the 
elimination of antagonists (including proteases or other product-degrading agents). 
Actually, through the differential partition behaviour of the target product and 
antagonists, or the so-called contaminants also present in the bulk after the cell 
disruption, the product hydrolysis/denaturation is also reduced.17,27 Furthermore, the 
industrial scale-up in continuous flow of these integrated processes based in the 
combination of efficient cell disruption and ATPS is simpler and faster and more 
productive than the batch operations.17,26,28  
In this ambit, the first AMTPS described for ASNase purification was composed of Triton 
X-100 and potassium phosphate (K2HPO4).21 However, this system leads to enzyme 
inactivation by antagonists (e.g. proteases and carbohydrases), high ionic strength, and 
protein interactions with cell debris, resulting in product loss. Moreover, one of the 
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major drawbacks of AMTPS is the difficulty to remove the surfactant (approximately 15 
w/v%) from the enzyme solution. In the same line, Zhu et al.17 proposed ATPS and 
AMTPS composed by phosphate buffer (KH2PO4/K2HPO4) and polyethylene glycol (PEG) 
or poloxamers (poly(propylene glycol) block with poly(ethylene glycol), PEG-PPG-PEG). 
The purification factors obtained with these systems were quite low, from 0.75-3.37, 
probably due to the high salting-out ability of phosphate salts resulting in the proteins 
(target and contaminants) preferential partition to the polymer-rich phase. Moreover, 
this work was mainly focused in the application of AMTPS being the PEG/salt-based ATPS 
poorly optimized. Conditions, like PEG molecular weight (MW), tie-line length (TLL), pH 
and mixture point, normally resulting in big effects were completely neglected in this 
work. In addition, the phosphate buffer has great interference with the methods of 
ASNase quantification (Nessler29 and aspartate hydroxamate30 assays) used in this work, 
which is another factor explaining the lower values of purification obtained. Due to the 
low purification data obtained and the higher purity required to apply ASNase as a 
biopharmaceutical, it would be important to develop novel and more efficient in situ 
downstream integrated processes. 
Ionic liquids (ILs) are salts in which the ions are poorly coordinated, which results in 
these compounds being liquid below 100°C.31 Moreover, these liquid salts exhibit 
tunable physicochemical properties related to their designer solvent character, through 
the manipulation of a large range of cations and anions. Most ILs are soluble in water 
and have been used as phase forming compounds in ATPS.32 Recently, ILs have been 
applied as additives in the ATPS formation, as adjuvants33–35 and electrolytes36,37 in 
polymer-based ATPS, showing outstanding results in the purification of biomolecules. In 
this way, the presence of ILs in small amounts was proved to potentiate significantly the 
purification performance of ATPS, when compared to the systems with no adjuvant.33–
35  
In this work, novel polymer-salt ATPS based on polyethylene glycol (PEG) and the 
biodegradable and nontoxic organic salt citrate buffer with ILs as adjuvants for the in-
situ purification of periplasmatic ASNase from Escherichia coli, were investigated. The 
conditions, polymer molecular weight, pH, TLL/mixture point, presence and nature of 
adjuvant and its concentration, were extensively investigated to optimize the ATPS 
purification performance. For the most promising in situ ATPS, an additional step of pre-
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purification consisting in the enzyme precipitation with ammonium sulfate was applied 
in order to further enhance the productivity and purification of ASNase. The integrated 
process of purification and isolation of ASNase will be proposed.  
 
2. Materials and methods 
2.1.  Materials 
The polyethylene oxide polymers, PEG 2000, 4000, 6000, 8000, as well as the potassium 
citrate, citric acid and ammonium sulphate (> 95 wt%) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). The ILs used in this work as adjuvants were 1-butyl-3-
methylimidazolium chloride ([C4mim]Cl), 1-butyl-3-methylimidazolium dimethyl 
phosphate ([C4mim][DMP]), 1-butyl-3-methylimidazolium methanesulfonate 
([C4mim][CH3SO3]) and 1-butyl-3-methylimidazolium triflate [C4mim][CF3SO3]. The ILs 
were purchased from Iolitec (Heilbronn, Deutschland), with purity > 97 wt%. The water 
content of ILs was measured and taken into account in the preparation of the ATPS.  
Ultrapure water by reverse-osmosis (Millipore Co. Ltd.) was used in all experiments. All 
chemicals used in upstream process of ASNase, and protein and activity assays were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). 
 
2.2. Preparation of crude enzyme extract 
E. coli BL21 (DE3) (Novagen, WI, USA) harbouring vector (pET15b+ansB) and ampicillin 
resistance gene as selection marker was grown in Luria Bertani (LB) agar plate 
containing: tryptone (10 g.L-1), yeast extract (5 g.L-1), NaCl (10 g.L-1), agar 15% w/v and 
ampicillin (100 µg.mL-1) at pH 7.0; 37 °C for 24 h. Five isolated colonies were inoculated 
in 8 mL of LB (Difco, Detroit MI, USA) containing tryptone (10 g.L-1), yeast extract (5 g.L- 
1), NaCl (10 g.L-1) and ampicillin (100 µg.L-1); which was incubated in a shaker Excella® 
E24 (New Brunswick, New Jersey, USA), at 37 °C and 250 rpm for 8 h. For stock cultures, 
samples were withdrawn and glycerol was added to a final concentration of 15% (v/v) 
under sterile conditions and stored at - 80 °C. The inoculum was prepared from 0.25 mL 
of the stock culture in 25 mL of LB (1:10, medium volume:flask volume ratio), at 37 °C 
and 250 rpm for 12 h. Culture for periplasmatic ASNase production was prepared from 
0.5 mL of the inoculum in 25 mL (1:10, medium volume:flask volume ratio) of modified 
LB (addition of 0.1 M of potassium phosphate buffer pH 7.0; 5.0 g.L-1 of glucose;  0.5 g.L-
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1 of MgSO4.7H2O; 0.05 g.L-1 of CaCl2.2H2O; 0.1 mg.L-1 of H3BO4; 0.1 mg.L-1 of CoCl2.6H2O; 
25 mg.L-1 of ZnSO4.7H2O; 4 mg.L-1 of MnCl2.4H2O; 0.1 mg.L-1 of NaMoO4.2H2O; 1.8 mg.L-
1 of CuSO4.5H2O; 20 mg.L-1 of FeSO4.7H2O; 0.1 mg.L-1 of NiSO4.6H2O; 0.8% w/v of glycine 
and 6% v/v of n-dodecane) in shaker at 37 °C and 250 rpm. After 4 h of growth, culture 
was induced for 24 h by 0.1 mM of isopropyl β-D-thiogalactopyranoside (IPTG). A crude 
enzyme extract (cell-free supernatant) was obtained by centrifugation (10000 xg, 4 °C 
and 5 min) and stored at -20°C for further purification experiments. The crude enzyme 
extract presented protein concentrations of 4.3 ± 1.5 mg.mL-1 and specific activity of 
0.18 ± 0.05 U.mg-1 protein. 
 
2.3. Pre-purification step: enzyme precipitation by ammonium sulfate 
A crude enzyme extract volume of 0.3 mL and 0.7 mL of saturated ammonium sulfate 
(70 wt%) was mixed for 2 min in a vortex mixer. Precipitated proteins were then 
removed by centrifugation (15000 xg, 15 min, 4°C); the supernatant was discarded and 
the protein pellet was dissolved in 0.3 mL of distilled water. 
  
2.4. Tie-lines (TLs) determined for the polymer-salt ATPS 
Before the purification assays, tie-lines (TLs) for the polymer-salt ATPS were determined. 
The ternary phase diagram of PEG 6000/citrate system at pH = 7 was obtained from 
literature,34 and it was correlated using the Merchuk equation38 (Eq. 1): 
          (1) 
where 𝑤𝑃𝐸𝐺 and 𝑤𝐶𝑖𝑡 are, respectively, the polymer and inorganic salt weight 
percentages (wt%), and A, B and C are the Merchuk parameters. 
The TLs were determined by a gravimetric method originally proposed by Merchuk et 
al.38 to calculate the composition of the two-phases in equilibrium. The TLs were 
calculated for the system based in PEG 6000/citrate buffer at pH = 7, and considering 
the following extraction points (PEG/salt – wt%): 15/15; 17.5/17.5; 20/20 and 22.5/22.5. 
The weight compositions of both phase formers (PEG and citrate) in the top and bottom 
phases ( 𝑤𝑃𝐸𝐺
𝑇𝑜𝑝,  𝑤𝐶𝐼𝑡
𝑇𝑜𝑝,  𝑤𝑃𝐸𝐺
𝐵𝑜𝑡 ,  𝑤𝐶𝑖𝑡
𝐵𝑜𝑡 ) were obtained by solving the following system of 
four equations and four unknown variables: 
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 𝑤𝑃𝐸𝐺
𝑇𝑜𝑝 = 𝐴 exp[(𝐵.  𝑤𝐶𝑖𝑡
𝑇𝑜𝑝0.5) − (𝐶.   𝑤𝐶𝑖𝑡
𝑇𝑜𝑝3)      (2) 
 𝑤𝑃𝐸𝐺
𝐵𝑜𝑡 = 𝐴 exp[(𝐵.  𝑤𝐶𝑖𝑡
𝐵𝑜𝑡0.5) − (𝐶.   𝑤𝐶𝑖𝑡
𝑇𝑜𝑝3)      (3) 
       (4) 
       (5) 
The superscripts Top and Bot designate the PEG 6000-rich and citrate-rich phases, 
respectively, and M represents the initial mixture point composition. The parameter α 
is the ratio between the top weight and total weight of the mixture. The solution of the 
referred system gives the concentration of the polymer and salt in the top and bottom 
phases. The tie-line length (TLL) is defined as: 
TLL = √(𝑤𝐶𝑖𝑡
𝑇𝑜𝑝 − 𝑤𝐶𝑖𝑡
𝐵𝑜𝑡)
2
+ (𝑤𝑃𝐸𝐺
𝑇𝑜𝑝 − 𝑤𝑃𝐸𝐺
𝐵𝑜𝑡 )
2
         (6) 
 
2.5. ASNase partition in ATPS 
Polymer-salt ATPS composed of PEG and citrate, with and without the addition of ILs as 
adjuvants were prepared. In the studied ATPS, the top phase corresponds to the PEG-
rich phase, while the bottom phase is mainly composed of the buffered salt. The ternary 
mixture compositions for ASNase purification were chosen based on the phase 
diagrams34 constituted by PEGs with different molecular weights (2000, 4000, 6000 and 
8000 g.mol-1) and the citrate buffer at different pHs (5, 6, 7 and 8). All phase formers 
were added into an Eppendorf flask as a dry powder or stock solution, along with 0.4 mL 
of crude extract of ASNase, resulting in a 2.0 g system. Each mixture was then stirred in 
a vortex mixer and left to equilibrate for 120 minutes (a period of time established in 
previous optimization experiments) at 4°C in order to achieve the complete partition of 
ASNase between both phases. The volume of each phase, as well as ASNase activity and 
total protein concentration, were the parameters to determine. All experiments were 
carried out in triplicate and the interference of the buffer and PEG ascertained with the 
use of blank control samples, these prepared without the addition of ASNase crude 
extract. The partition coefficient of total proteins (KP) was calculated as the ratio 
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between the protein concentration in top and bottom phases, respectively, [P]t and [P]b 
according to Eq 7: 
𝐾𝑝 =  
[𝑃]𝑡
[𝑃]𝑏
          (7) 
The partition coefficient of ASNase (KA) was calculated as the ratio between the 
volumetric activity of ASNase (U.mL-1) in the top (At) and bottom phases (Ab), according 
to Eq 8: 
𝐾𝐴 =  
𝐴𝑡
𝐴𝑏
          (8) 
The recovery yields of total proteins (%Rec P) and ASNase (%Rec A) into to PEG-rich 
phase were defined based on the partition coefficients of total proteins and ASNase, 
respectively, and the volume ratio (Vr), according to Eq. 9: 
%𝑅𝑒𝑐𝑃 𝑜𝑟 𝐴 =  
100
(1+(
1
𝑉𝑟× 𝐾𝑝 𝑜𝑟 𝐴
))
                    (9) 
The purification factor (PF) is given by the ratio between the specific activity of the top 
phase (SAt) and the specific activity of the initial crude enzyme extract (SAi), according 
to Eq. 10: 
𝑃𝐹 =  
𝑆𝐴𝑡
𝑆𝐴𝑖
          (10) 
 
2.6. In situ extraction of ASNase: pre-purification and purification steps 
The in situ extraction of ASNase from E. coli was performed through cell 
permeabilization by glycine and n-dodecane, followed by the contaminant proteins’ 
precipitation with ammonium sulfate. After the precipitation step, ATPS (with and 
without ILs as adjuvants) were integrated as a final step of purification. The ATPS used 
in this downstream process were the PEG 6000/citrate buffer (15/15 wt%) at pH = 7 
without IL and PEG 6000/citrate buffer (15/15 wt%) with 5 wt% of [C4mim][CH3SO3] as 
adjuvant at pH = 7 for the ATPS supplemented with IL. 
 
 
2.7. Determination of ASNase activity  
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The ASNase activity was based on the protocol of Drainas and co-workers30 and 
expressed as U.mL-1. Briefly, 0.1 mL of sample, 0.7 mL of of Tris-HCl buffer (50 mM, pH 
8.6), 0.1 mL of L-asparagine (0.1 M) and 0.1 mL of hydroxylamine (1.0 M, pH 7.0) were 
incubated at 37°C for 30 min. The reaction was interrupted by adding 0.5 mL of 0.31 M 
of iron chloride reagent (dissolved in HCl 0.33 M and trichloroacetic acid 0.3 M solution). 
The reaction solution was centrifuged at 3220xg for 15 min and the iron chloride–
hydroxamic acid complex produced was quantified at 500 nm. The calibration curve was 
prepared from a -aspartohydroxamic solution (Sigma-Aldrich, MO, USA). In this work, 
one unit of ASNase activity is defined as the amount of enzyme that produces 1 μmol of 
-aspartohydroxamic acid per minute under the experiment conditions defined. The 
specific activity (U.mg-1) represents the ratio between the volumetric activity of ASNase 
(U.mL-1) and the total protein concentration (mg.mL-1). 
 
2.8. Determination of total protein concentration  
The protein concentration was determined with the Pierce BCA Protein Assay and Micro 
BCA Protein Assay (Thermo Scientific, Schwerte, Germany) according to the 
manufacture’s recommendations. Bovine serum albumin was used as standard protein.  
 
2.9. In silico analysis 
E. coli ASNase structure (code 3ECA)39 was retrieved from the Protein Data Bank (PDB)  
and converted into PQR files according to Dolinsky et al.40 using PARameters for 
Solvation Energy (PARSE) force field at different pH values (5, 6, 7 and 8). A PQR file is a 
PDB file with the temperature and occupancy columns replaced by columns containing 
the per-atom charge (Q) and radius (R). Electrostatic properties were calculated using 
automatically-configured sequential focusing multigrid calculation on Adaptive Poisson-
Boltzmann Solver (APBS). These systems can module the biomolecular solvation by 
solving the Poisson-Boltzmann equation (PBE). Moreover, these will also provide implicit 
solvent models of nonpolar solvation, which accurately account for both repulsive and 
attractive solute-solvent interactions. Hydrophobicity was estimated by the software 
ExPasy41 (adapted to red scale), which is based on amino acid scale from Eisenberg et 
al..42 All results were performed using PyMOL Molecular Graphics System, Version 1.8 
Schrödinger, LLC. 
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3. Results and discussion 
3.1. Preparation of the ASNase crude extract 
After the E. coli cultivation (see Materials and Methods Section) and ASNase expression, 
the cell disruption was promoted by using glycine and n-dodecane. From this procedure, 
the complete secretion of periplasmatic ASNase was achieved, however, other proteins 
were also released. Chemical permeabilization of outer cell membrane with detergents 
and salts, such as Triton X-100 and K2HPO4, is reported in literature for ASNase secretion 
from E. coli.21 However, this is the first time that glycine (for the disruption of the 
peptidoglycan layer)43 and n-dodecane (for the disruption of the outer cell membrane)44 
are employed together in an integrated purification process using ATPS. This 
permeabilization approach was previously studied and proved to be effective on the 
enzyme release, with 89% of ASNase secreted to fermentation broth.45 The final crude 
enzyme extract obtained has a protein concentration of 4.3 ± 1.5 mg.mL-1 and specific 
activity of 0.18 ± 0.05 U.mg-1 protein. 
 
3.2.  ASNase partition in polymer-salt ATPS 
Polymer-salt ATPS were studied in the purification of ASNase from the crude enzyme 
extract. The ternary phase diagrams described in literature34 were used to determine 
the extraction mixture compositions. Commonly, polymer/phosphate buffer-based 
ATPS are focused, however in this work, a citrate buffer-based salt was used, since this 
is more biocompatible and biodegradable. Additionally, this buffer is able to maintain 
the pH stable in a wider range and to create a larger biphasic region to work on, due to 
its stronger salting-out ability. Table 1 summarizes all ASNase partition results obtained 
by applying in situ polymer-salt ATPS, considering the study of several conditions. It 
should be stressed that no protein precipitation was observed in any experimental 
condition and the protein mass balance was acceptably in the range of 80-120%. Given 
the high number of systems and conditions tested, this work will be mainly discussed 
considering each one of the conditions individually.  
3.2.1. ASNase partition in PEG + citrate buffer-based ATPS 
Usually, the partition coefficient of proteins (KP) depends on several factors, such as the 
characteristics of the phase-forming polymer, the hydrophobic effect, charge and size 
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of proteins. The partition coefficient of the target protein (KA) is mostly dependent on 
the specific characteristics of the enzyme that could lead to interactions with the phase 
formers, e.g. hydrophobicity, hydrophilicity, charge or π-interacting groups. 
The recovery yields, %Rec A and %Rec P, and purification factors of ASNase in ATPS 
composed of PEGs with different molecular weight + citrate buffer (at pH = 7) are 
presented in Fig. 2.7.. All mixtures compositions used in this set of experiments 
correspond to the same extraction point composed of 15 wt% of polymer + 15 wt% of 
citrate buffer + 70 wt% of water. As can be seen, the ASNase partitions preferentially to 
the polymer-rich phase and this tendency increases with the polymer molecular weight. 
From the partition coefficient data, it is concluded that the ASNase partition is suffering 
the highest variations when different polymers molecular weights are tested, which is 
demonstrated by the greatest variation of KA (from 3.09 ± 0.15 to 25.59 ± 0.15) when 
compared with KP range (from 1.99 ± 0.03 to 2.96 ± 0.32). The ASNase partition results 
from the combined citrate salting-out effect and hydrophobic interactions between PEG 
and the hydrophobic parts of ASNase, already reported in literature by Sanches and 
collaborators.46 Additionally, recent studies identified the same partition trend for 
ASNase in PEG 1000, 3000, 6000/potassium dihydrogen phosphate ATPS.17 This can 
justify the increase of %Rec A (from 67.27 ± 1.05 to 93.86 ± 0.31 %) and KA (from 3.09 ± 
0.15 to 25.59 ± 0.15) by increasing the polymer molecular weight. In terms of total 
proteins, a different partition behaviour was observed, since PEGs of intermediate 
molecular mass (4000 and 6000) presented a lower tendency to concentrate 
contaminant proteins in PEG-top rich phase (Fig. 2.7. and Table 2.6.).  Nevertheless, the 
higher PF was observed for PEG 6000, resulting from the high KA (25.59 ± 0.15) and %Rec 
A (similar to PEG 8000-based ATPS) and one of the lowest KP (2.36 ± 0.14) and %Rec P 
values (%Rec P = 58.72 ± 0.16%). Taking into consideration the overall set of results 
obtained for the purification parameters of ASNase, the PEG 6000-based ATPS was 
selected for further studies. 
                                                               Production and purification of ASNase and Cyt-c 
CHAPTER 2  
55 
 
No. Polymer pH Phase composition (wt %) Adjuvant; Concentration (wt%) Kp Ka %Rec P %Rec A PF 
      PEG Citrate Water             
1 PEG 2000 7 15 15 70   2.40 ± 0.26 3.09 ± 0.15 61.37 ± 0.16 67.27 ± 1.05 2.14 ± 0.13 
2 PEG 4000 7 15 15 70 
 
1.99 ± 0.03 7.91 ± 0.15 54.60 ± 0.16 82.35 ± 2.07 4.76 ± 0.53 
3 PEG 6000 7 15 15 70 
 
2.36 ± 0.14 25.59 ± 0.15 58.72 ± 0.16 93.71 ± 1.05 13.45 ± 1.61 
4 PEG 8000 7 15 15 70 
 
2.96 ± 0.32 25.57 ± 3.15 63.80 ± 3.16 93.86 ± 0.31 8.73 ±  0.10 
5 PEG 6000 5 15 15 70 
 
2.28 ± 0.71 20.47 ± 1.32 59.24 ± 1.27 91.56 ± 1.25 12.55 ± 1.12 
6 PEG 6000 6 15 15 70 
 
2.24 ± 0.45  18.75 ± 0.45 58.26 ± 2.03 90.81 ± 0.32 12.68 ± 1.20 
7 PEG 6000 8 15 15 70 
 
4.09 ± 1.16 5.66 ± 1.16 70.19 ± 6.01 92.04 ± 2.64 6.42 ± 2.15 
8 PEG 6000 7 17.5 17.5 65 
 
2.36 ± 0.34 7.01 ± 1.00 56.27 ± 2.51 80.51 ± 2.25 7.37 ± 0.18  
9 PEG 6000 7 20 20 60 
 
6.56 ± 1.13 17.25 ± 5.60 81.51 ± 0.28 90.35 ± 2.86  6.87 ± 1.36 
10 PEG 6000 7 22.5 22.5 55 
 
9.74 ± 0.51 30.22 ± 9.92 85.36 ± 0.80 97.73 ± 0.30 9.67 ± 0.07 
11 PEG 6000 7 15 15 69 [C4mim]Cl; 1 wt% 2.43 ± 0.55 26.36 ± 0.25 60.95 ± 1.67 94.05 ± 0.24 13.86 ± 0.41 
12 PEG 6000 7 15 15 69 [C4mim][DMP]; 1 wt% 3.91 ± 0.49 18.37 ± 1.30 69.32 ± 3.26 91.65 ± 0.54 9.66 ± 0.68 
13 PEG 6000 7 15 15 69 [C4mim][CH3SO3]; 1 wt% 2.09 ± 0.18 32.06 ± 0.76 55.19 ± 0.43 95.06 ± 0.11 16.85 ± 0.40 
14 PEG 6000 7 15 15 69 [C4mim][CF3SO3]; 1 wt% 2.42 ± 0.01 31.02 ± 0.15 59.19 ± 0.16 94.90 ± 0.02 16.30 ± 0.08 
15 PEG 6000 7 15 15 67.5 [C4mim][CH3SO3]; 2.5 wt% 2.21 ± 0.43 24.78 ± 1.32 57.01 ± 1.39 91.94 ± 0.02 18.85 ± 1.02 
16 PEG 6000 7 15 15 65 [C4mim][CH3SO3]; 5 wt% 1.21 ± 0.12 22.08 ± 3.02 40.37 ± 1.14 87.94 ± 0.03 20.09 ± 0.35 
Table 2.6. Effect of polymer molecular mass, pH, phase composition and adjuvant concentration on the partition behaviour of ASNase through the use of in situ polymer-
citrate buffer ATPS. 
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Fig. 2.7. Recovery yield of total proteins (%Rec P) and ASNase (%Rec A) and purification factor of ASNase 
(PF) for the ATPS composed of PEG + citrate buffer (15 wt%/15 wt%) at pH 7. Errors bars correspond to 
standard deviations obtained from three replicates.  
The recovery yields, %Rec A and %Rec P and purification factors of ASNase in ATPS 
composed of PEG 6000/citrate buffer at different pH values are presented in Fig. 2.8.. It 
is observed that through the change of pH, the partition of ASNase continues to be 
mostly dominated by hydrophobic interactions, since high %Rec A are obtained towards 
the polymer-rich phase.17 In this sense, in silico studies performed to characterize the 
hydrophobic regions of ASNase, at different pH values, are presented in Fig. 2.9.A. The 
analysis of the solvent-accessible surface area (SASA) shows a significant hydrophobic 
region on ASNase surface that does not change significantly with pH. Compared with 
conventional hydrophilic proteins with a size similar to ASNase, human serum albumin 
(1BM0, HSA)47 - 57412.180 A2 and bovine serum albumin (4F5S, BSA)48 - 58218.199 A2, 
it is found that the low SASA values of ASNase confirm its hydrophobic character. 
Previous results17 reported an increase of the ASNase partition towards the PEG-rich 
phase at pH close to the pI (pI = 4.9)17-18 by the application of ABS based on 
PEG/phosphate-based ATPS, as a result of the electrostatic interactions reduction 
between cell debris and the product molecules. From the gather data, it was inferred 
that pH does not affect significantly the ASNase SASA values, nor its partition behaviour 
in PEG/citrate-based ATPS, reinforcing the hypothesis that hydrophobic interactions are 
the important driving-force in polymer/salt-based ATPS. However, in aqueous solution 
pH affects the electric charges of both ASNase (Fig. 2.9.B) and periplasmatic 
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(contaminant) proteins, thus influencing the protein partition between both phases. The 
recovery of total proteins (%Rec P) in the PEG-rich phase increased in alkaline pH values 
(pH = 8), therefore, leading to a decrease in PF. After the optimization of the pH, the 
system PEG 6000/citrate buffer at pH = 7 was considered as the most efficient and 
further used in the next studies, comprising the effect of the mixture point/TLL and the 
use of ILs as adjuvants. 
 
Fig. 2.8. Recovery yield of total proteins (%Rec P) and ASNase (%Rec A), and purification factor of ASNase 
(PF) for the ATPS composed of PEG 6000 + citrate buffer (15 wt%/15 wt%) at different pHs. Error bars 
correspond to standard deviations obtained from three replicates. 
 
Fig. 2.9. 3D structure of ASNase (PDB: 3ECA) (A) hydrophobicity surface using Eisenberg amino acid scale39 
and solvent-accessible surface area (SASA), calculated for pHs 5, 6, 7 and 8. Red-scale refers to less 
hydrophobic (white) to more hydrophobic (red) parts of ASNase; (B) electrostatic charge at the ASNase 
surface and solvent-accessible surface area (SASA) calculated for pHs 5 to 8. Red-white-blue scale refers 
to minimum (-5 kT/e, red) and maximum (5 kT/e, blue) surface potential.  
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Fig. 2.10. shows the results of four mixture points (15.0/15.0; 17.5/17.5; 20.0/20.0; 
22.5/22.5 wt% of polymer/salt) studied for the PEG 6000/citrate buffer system at pH 7. 
The composition of the top polymer-rich phase and bottom salt-rich phase, along with 
the parameter α and tie-line length (TLL) for each studied ATPS are presented in Table 
2.7.. From the results obtained, it is concluded that higher TLL were obtained for the 
systems with upper amounts of both phase formers. Moreover, the partition of the total 
proteins seems to be dependent on the TLL since there is an increase of KP (circa 4.1-
fold) and %Rec P (circa 20% higher) with the increase of TLL (Fig. 2.10.B and Tables 2.6-
2.7.). The citrate content present in the bottom rich-phase ranged from 20.26 to 33.50 
wt% (Table 2.7.), resulting in a stronger salting-out effect for higher TLL. These results 
show that while hydrophobic interactions are again dominating the partition of ASNase, 
for the more hydrophilic contaminant periplasmatic proteins, their partition is being 
dominated by the salting-out effects. It is thus possible to use these distinct driving-force 
mechanisms of partition of both ASNase and periplasmatic contaminant proteins to 
manipulate the purification of ASNase. After the optimization of the TLL effect, it was 
defined as the best condition the lowest TLL (TLL = 38.33), represented by the mixture 
point composed of 15 wt% of PEG 6000/15 wt% of citrate buffer at pH 7.0, with %Rec A 
> 80 %, KA > 7, and PF = 13.45 ± 1.61. This extraction point was then adopted to 
investigate the effect of ILs as adjuvants on the ASNase purification. 
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Fig. 2.10. (A) Ternary phase diagram of PEG 6000 + citrate buffer system at pH = 7 with representation of 
tie-lines (TL) for the following mixture points: PEG 6000 wt%/citrate buffer wt% = 15.0/15.0; 17.5/17.5; 
20.0/20.0; 22.5/22.5. (B) Recovery yields of total proteins (%Rec P) and ASNase (%Rec A) and purification 
factor (PF) for the PEG 6000 + citrate buffer ATPS at pH = 7, considering four distinct mixture points. Error 
bars correspond to standard deviations obtained from three replicates.  
 
Table 2.7. Composition of the initial mixture point (M), polymer-rich phase (Top) and salt-rich phase (Bot), 
along with the parameter α and the tie-line length (TLL). 
 
3.2.2. ASNase partition in PEG + citrate buffer + IL (as adjuvant)-based ATPS 
The study of the effect of the ILs as adjuvants in the purification of enzymes produced 
via fermentation was recently reported as being one of the most promising  approaches 
of purification49, which was also adopted in this work. Herein, four ILs were tested as 
adjuvants, on the ASNase partition, in concentrations of 1 wt% of the overall system 
weight. Four imidazolium-based ILs presenting the same cation ([C4mim]+) combined 
with the anions Cl-, [DMP]-, [CH3SO3]- and [CF3SO3]- were selected to evaluate the effect 
of their polarity on the partition of both ASNase and contaminant proteins. Firstly, all 
imidazolium-based ILs investigated have a preferential partition towards the top phase, 
as reported elsewhere,34 affecting the chemical and physical properties of the polymer-
[PEG]M  [Cit]M   [PEG]Top  [Cit]Top  [PEG]Bot  [Cit]Bot  α TLL 
15.0 15.0 37.36 6.15 1.72 20.26 0.373 38.33 
17.5 17.5 47.10 4.99 0.37 24.74 0.366 50.72 
20.0 20.0 55.25 4.24 0.061 28.91 0.361 60.45 
22.5 22.5 60.70 3.88 0.0042 33.50 0.371 66.94 
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rich phase. According to the results reported in Fig. 2.11., no significant differences were 
observed in %Rec A, independently of the IL used. However, the data suggest that the 
ILs have an influence on the partition of the periplasmatic proteins, thus resulting in 
%Rec P ranging from 55.19 ± 0.43 to 69.32 ± 3.26 %. The less polar anions, 
[C4mim][CH3SO3] and [C4mim][CF3SO3], by enhancing the hydrophobicity of the top 
phase, were found to effectively decrease the amount of contaminant proteins in the 
PEG 6000-rich phase, increasing the PF in approximately 20%. Moreover, the polar 
anions Cl- and [DMP]- seem to reduce the hydrophobicity of the polymer-rich phase 
enhancing the partition of the periplasmatic proteins to this phase, thus reducing the 
PF. Summing up, ILs with higher polarity decreased the PF, meaning that specific polar 
interactions between the periplasmatic proteins and ILs are promoted in the top phase, 
enhancing the partition of the contaminant proteins towards the polymer-rich phase. 
Contrastingly, both [C4mim][CH3SO3] and [C4mim][CF3SO3] display a lower hydrogen-
bond basicity and were better at enhancing the ASNase PF, through the decrease of IL-
contaminant proteins interactions. These results corroborate the importance of the IL 
anion in the partition of proteins, in this case, the contaminant periplasmatic proteins, 
thus allowing the increase of the purification performance of the polymeric ATPS. At this 
stage, the maximum purification achieved was around PF = 16.85 ± 0.40 for the 
[C4mim][CH3SO3]. In order to endorse this statement, and aiming at to increase even 
more the PF of ASNase, the effect of IL concentration was studied, specifically for the 
[C4mim][CH3SO3] (best system). The results (Fig. 2.12.) corroborated the tendency 
previously discussed; the increased concentration of this less polar IL is significantly 
suppressing the partition of contaminant proteins towards the PEG-rich phase, 
culminating in the highest PF = 20.09 ± 0.35 obtained for the ATPS with 5 wt% of IL. In 
summary, small IL amounts’ could enhance the ASNase partition and improve the 
purification performance of ATPS, which obviously brings additional advantages 
regarding the enzyme purity and the cost of the overall process of downstream.  
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Fig. 2.11. Recovery yield of total proteins (%Rec P) and ASNase (%Rec A), and purification factor (PF) in 
the ATPS composed of PEG 6000 + citrate buffer (15 wt%/15 wt%) at pH = 7 and with 1 wt% of [C4mim]-
based ILs as adjuvants. Error bars correspond to standard deviations obtained from three replicates. 
 
Fig. 2.12. Recovery yield of total proteins (%Rec P) and ASNase (%Rec A) and purification factor (PF) in the 
ATPS composed PEG of 6000 + citrate buffer (15 wt%/15 wt%) at pH = 7 and with [C4mim][CH3SO3] as 
adjuvant. Errors bars correspond to standard deviations obtained from three replicates. 
 
3.3. In situ extraction of ASNase by ATPS integrated with pre-purification step 
 
Despite the good results of PF obtained, these are not sufficient for the use of ASNase 
as a biopharmaceutical. In this sense, a new strategy of purification was defined, which 
consists in the integration of two steps of purification. In this ambit, a pre-purification 
step was included between the stages of production and purification using the most 
                                                               Production and purification of ASNase and Cyt-c 
CHAPTER 2  
62 
 
performant ATPS (15 wt% of PEG 6000 + 15 wt% of citrate buffer + 65 wt% of water + 5 
wt% of [C4mim][CH3SO3] at pH = 7). The pre-purification was thus defined by using an 
ammonium sulfate solution to precipitate as much as possible the contaminant proteins, 
a strategy recurrently applied in the purification of enzymes.49 The inclusion of a pre-
purification step can help eliminating: (i) the contaminant proteins partitioned to the 
same aqueous phase as ASNase; and (ii) the antagonists and cell debris that may affect 
the ASNase activity. Moreover, some other advantages could be defined, like the fact 
that the ammonium sulfate precipitation is a cost-effective and scalable purification 
approach that could increase the overall purity of ASNase. Taking these advantages into 
account, the different strategies/platforms were compared for the purification of 
ASNase (Fig. 2.13.). Analysing the results of Fig. 2.13., it is clear the advantage of using 
the integration of both pre-purification and purification processes (ammonium sulfate 
precipitation + [C4mim][CH3SO3]-based ATPS, respectively), an approach resulting in the 
highest purification performance. This integrated downstream process proved to be 
much more efficient with higher ASNase specific activity (22.0 ± 1.36 U.mg-1 protein) and 
purification factor (PF = 174 ± 11) than the isolated purification step by itself (ATPS or 
protein precipitation). Fig. 2.14. depicted the SDS-PAGE profile of the different steps of 
purification (Lane 5) and of the integrated downstream process (Lane 4) developed in 
this work. Through the main results it is concluded that a clear band of the ASNase 
subunit is obtained (≈ 35 kDa) for the integrated process (Lane 4), with the absence of 
contaminant proteins. Actually, with the pre-purification step, the elimination of a 
diversified plethora and high content of contaminant periplasmatic proteins,50 e.g. 
nucleotidases, β-lactamase, alkaline phosphatase, ribonuclease, endonuclease I, 
caboxypeptidase II, cytochrome c, hydrogenase and nitrite reductase, was possible, 
while maintaining the ASNase structural integrity and activity for further purification 
using ATPS.  
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Fig. 2.13. Comparison between pre-purification step, IL-free ATPS, ATPS with IL, IL-free ATPS integrated 
with pre-purification step and ATPS with IL integrated with pre-purification step for the extraction and 
purification of periplasmatic L-asparaginase from E.coli cell paste. 
 
Fig. 2.14. SDS-PAGE of commercial ASNase from E.coli (1) Precipitated proteins from fermentation broth 
(2) Fermentation broth (3) Top-phase of the optimized ATPS, the PEG 6000/citrate with 5 wt% 
[C4mim][CH3SO3] (as adjuvant) with pre-purification (4) Top-phase of the optimized ATPS, the PEG 
6000/citrate with 5 wt% [C4mim][CH3SO3] (as adjuvant) without pre-purification (5). Molar masses 
reference Precision Plus Protein (BIORAD, CA, US) (M). 
 
Since the main aim of this work is the optimization of the ASNase purification from the 
fermentation broth, the integrated downstream process envisaged was schematically 
represented as Fig. 2.15.. This comprises the purification step, the cell disruption to 
release the ASNase, the pre-purification step to eliminate part of the contaminant 
proteins, the IL-ATPS to refine the purification of the biopharmaceutical, and the 
isolation of ASNase. As depicted, the best ATPS and conditions selected are represented, 
as well as the isolation methods defined for the polishing of ASNase and contaminant 
proteins from both phases by using an ultrafiltration, culminating in the sequent reuse 
of the phases in new cycles of purification.   
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Fig. 2.15. Schematic representation of the in situ purification process of periplasmatic ASNase by using 
polymer-based ATPS with [C4mim][CH3SO3] as adjuvant. The isolation of ASNase and the recycling of both 
aqueous phases are also represented. 
 
4. Conclusions 
In this work, an efficient integrated downstream process combining cell 
permeabilization (applying glycine and n-dodecane) with the purification of ASNase by 
using IL-ATPS was here demonstrated. In this ambit, polymer-based ATPS using ILs as 
adjuvants showed, one more time, to be efficient in the purification of enzymes, i.e. 
ASNase. Actually, our results reveal a high affinity of ASNase for the polymer rich-phase 
of the ATPS, justified by the hydrophobic interactions established between the enzyme 
and the polymer. Moreover, it was demonstrated the high purification performance of 
the ATPS using 5 wt% of a [C4mim][CH3SO3] as adjuvant (when compared with the 
common polymeric system), attaining a PF = 20.09 ± 0.35 and SA = 3.33 ± 0.38 U/mg 
protein. Moreover, and taking into account other purification schemes, an ammonium 
precipitation pre-purification step was tested, demonstrating again clear advantages in 
terms of downstream process efficiency over discrete and sequential operations, 
attaining a purification factor of 173.8 ± 10.7. Actually, it was proven that low amounts 
of ILs in the formulation of ATPS are shown to be enough to achieve complete 
extractions of ASNase (%Rec ASNase ≈ 90%) with high purity. The system with high 
purification performance was then used in the design of an integrated process 
comprising the steps of production, cell disruption, and purification with an ammonium 
sulfate precipitation followed by the application of ATPS with IL as adjuvant, and 
culminating in the ASNase isolation and phases reuse. 
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2.3. Integration of Aqueous (Micellar) Two-Phase Systems on the proteins 
separation 
Vicente, F. A.,* Santos, J. H. P. M.,* Pereira, I. M. M., Gonçalves, C. V. M., Dias, A. C. R. 
V., Coutinho, J. A. P. & Ventura, S. P. M., BMC Chemical Engineering, 2019, 
https://doi.org/10.1186/s42480-019-0004-x.4 
* Both authors contributed equally to this work. 
Abstract 
A two-step approach combining an aqueous two-phase system (ATPS) and an aqueous 
micellar two-phase system (AMTPS), both based on the thermo-responsive copolymer 
Pluronic L-35, is here proposed for the purification of proteins and tested on the 
sequential separation of three model proteins, cytochrome c, ovalbumin and azocasein. 
Phase diagrams were established for the ATPS, as well as co-existence curves for the 
AMTPS. Then, by scanning and choosing the most promising systems, the separation of 
the three model proteins was performed. The aqueous systems based on Pluronic L-35 
and potassium phosphate buffer (pH = 6.6) proved to be the most selective platform to 
separate the proteins (SAzo/Cyt = 1667; SOva/Cyt = 5.33 e SAzo/Ova = 1676). The consecutive 
fractionation of these proteins as well as their isolation from the aqueous phases was 
proposed, envisaging the industrial application of this downstream strategy. The 
environmental impact of this downstream process was studied, considering the carbon 
footprint as the final output. The main contribution to the total carbon footprint comes 
from the ultrafiltration (~49%) and the acid precipitation (~33%) due to the energy 
consumption in the centrifugation. The ATPS step contributes to ~17% while the AMTPS 
only accounts for 0.30% of the total carbon footprint. 
 
 
Keywords: aqueous (micellar) two-phase systems; downstream process; thermo-
responsive copolymers; proteins; carbon footprint. 
                                                          
4 Contributions: JS, IP and FV acquired the experimental data. The environmental data was acquired by IG and CD. JS, 
FV, SV and JC interpreted the experimental data. SV and JC conceived and directed this work. The manuscript was 
mainly written by JS and FV with significant contributions from the remaining authors. 
                                                              Production and purification of ASNase and Cyt-c 
CHAPTER 2  
 
71 
 
1. Introduction 
In the past few years, there has been an increased interest and effort focused the 
extraction and separation of proteins, not only those produced via fermentation, but 
also proteins recovered from different raw materials and biomass matrices. Most 
fermentative processes result in a product that is a complex combination of proteins 
and other metabolites or cell debris. However, in this protein rich-pool, it is quite 
difficult to achieve a good separation and purification of the target protein from all the 
other contaminants. Bioprocesses require efficient purification platforms for the 
isolation of the desired components and the elimination of the by-products. These are 
still the main challenge for the industrial applications,1 and responsible for up to 80% of 
the production costs.2 Recently, with the increased attention given to the valorisation 
of new products from emergent raw materials and biomass, such as algae3 and 
cyanobacteria,4 the development of improved downstream approaches is of high 
interest and value.  
Conventional downstream processes to purify proteins are based on chromatographic 
techniques, namely size exclusion chromatography, ion exchange chromatography and 
hydrophobic chromatography.5,6 These methods are easy to validate and implement in 
batch and larger scale, however they are quite expensive. Among the non-
chromatographic methods, ultrafiltration 7,8 and precipitation 9,10 appear as the main 
approaches used in protein separation, though, these methods are ineffective in the 
separation of similar proteins, since they only act based on protein size and 
hydrophilicity, respectively. Over the last years, aqueous two-phase systems (ATPS) 
emerged as an alternative platform for protein separation, considering their intrinsic 
versatility, in some cases leading to an enhanced purification performance.11  
ATPS are a particular type of biphasic system used in liquid-liquid extraction as a primary 
recovery step for the product isolation and purification by partially separating it from 
impurities or substrates, hence reducing the subsequent downstream processing 
volume. One of the most important advantages of ATPS is the high-water content in 
both phases, which turns the microenvironment of the system more biocompatible for 
proteins and other biomolecules. This downstream platform is interesting since it can 
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combine several steps into a single operation, namely clarification, extraction, isolation, 
purification and concentration of the compound.12 In chemical industry, two-phase 
systems are employed due to its simplicity, low costs, low viscosity, short phase 
separation time and easier scale-up.11,12 ATPS have been widely applied on the 
purification and recovery of biological products, such as proteins, genetic material, 
organelles and bionanoparticles.12 For that purpose there are some physicochemical 
properties of the biomolecules (isoelectric point, surface hydrophobicity and molar 
mass) as well as of the ATPS components 11 ((co)polymers, salts, surfactants and ionic 
liquids 13) and process conditions selected (such as the system temperature, or pH 6,14) 
that must be taken into account and optimized. 
Pluronic triblock copolymers are non-ionic surfactants from the polyoxyethylene alkyl 
ether family being composed by units of polyethylene glycol (PEG) and polypropylene 
glycol (PPG). By changing the number of PEG units in the copolymer, its hydrophilicity 
can be controlled. The copolymers critical micelle concentration (CMC) and surface 
activity are much more sensitive to temperature than those for the conventional 
surfactants due to their composition,15 making them more versatile. Among others they 
are thermo-responsive, being able to form two macroscopic phases when submitted to 
a temperature above their cloud point, and are commonly known as aqueous micellar 
two-phase systems (AMTPS).11 In 2000, Persson et.al.16 proposed a copolymer-starch 
ATPS as part of an integrated process, in which they managed to purify apolipoprotein 
A-1 from an E. coli fermentation broth and from human plasma.  
An integrated platform for the purification of a model protein mixture, composed of 
cytochrome c, ovalbumin and azocasein, is here proposed. Besides the need to improve 
the processes efficiency and reduce their cost, there is a growing concern to evaluate 
their environmental impact. Here, an environmental evaluation of the new two-step 
approach proposed was carried using the carbon footprint as indicator. 
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2. Material and Methods  
2.1. Materials 
Three phosphate-based salts were used, namely monopotassium phosphate (K₂HPO₄) 
acquired on Panreac (99 wt% purity), dipotassium phosphate (KH₂PO₄) obtained from 
Sigma (99.5 wt% purity) and tripotassium phosphate (K₃PO₄) attained from Acros 
Organic (97 wt% purify). A phosphate-buffer solution (K₂HPO₄/KH₂PO₄) was also used at 
pH = 6.6. The copolymers employed in this work were Pluronic L-35, Pluronic 10R5 and 
Pluronic 17R4, all acquired at Sigma-Aldrich. As co-surfactants, Triton X-114 and Triton 
X-100 (purity > 95 wt%) purchased from Acros Organic, were tested. Cytochrome c 
(purity > 95 wt%) from equine heart and azocasein (99 wt% purity) were acquired from 
Sigma-Aldrich, whereas albumin from hen egg white (97 wt% purity) was supplied by 
Fluka, BioChemika. 
2.2. Measurement of phase diagrams and tie-lines for ATPS 
The binodal curves of the ATPS with different compositions were determined using the 
cloud-point titration method17 at 25 (±1)ºC, at atmospheric pressure. This technology is 
based on the dropwise addition of a salt solution to a polymer aqueous solution, both 
with known concentrations, until the mixture becomes turbid (representing the biphasic 
system). Then, a known mass of water was added to clear the solution (corresponding 
to the monophasic system). This procedure was repeated to obtain enough data for the 
design of the respective binodal curves. The phase diagram data were correlated using 
the Merchuk equation,18 as described in Eq.1: 
[𝐶𝑜𝑝𝑜𝑙𝑦𝑚𝑒𝑟] = 𝐴 × exp[(𝐵[𝑆𝑎𝑙𝑡]0.5) − (𝐶𝑋3)]                                                        (1) 
where [Copolymer] and [Salt] are respectively the copolymer and inorganic salt weight 
percentages (wt%). Three different studies were attained for the phase diagrams design: 
the inorganic salt type, the copolymer type and the presence of adjuvants (Triton X-100 
and Triton X-114). In this sense, for the inorganic salt type study, four salts were used: 
K₂HPO₄, KH₂PO₄, K₃PO₄ and K₂HPO₄/KH₂PO₄, being the Pluronic L-35 and Triton X-100 
maintained constant. For the second study, different copolymers (Pluronic L-35, Pluronic 
10R5, and Pluronic 17R4) were studied while the potassium phosphate buffer 
(K2HPO4/KH2PO4, pH = 6.6) was kept constant. Finally, the impact of small amounts of 
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Triton X-114 (1 wt%) was studied for the system constituted by Pluronic L-35 and the 
potassium phosphate buffer (pH = 6.6).  
The TLs were determined by the gravimetric method originally proposed by Merchuk et 
al.18, for the extraction points presented in Table A.9 at Appendix A, to calculate the 
composition of the two-phases in equilibrium. The compositions of copolymer and salt 
in the top and bottom phases were obtained as well as the TLL,19 being the data 
presented in Figure A.8 and Table A.7 at Appendix A 
 
2.3. Measurement of the AMTPS cloud point curves  
The AMTPS cloud point curves were carried out by the cloud point method.20 Herein, 
the AMTPS corresponds to the ATPS top phase, which was composed of potassium 
phosphate buffer (K₂HPO₄ /KH₂PO₄) at pH = 6.6 or water and a different copolymer 
(Pluronic L-35, Pluronic 10R5 or Pluronic 17R4). For the AMTPS using Triton X-114 as 
adjuvant, the ATPS top phase also displayed this component. Basically, this procedure 
consists on a visual identification, while raising the temperature, of the point at which a 
mixture with known compositions becomes turbid (biphasic system), indicating the 
system cloud point. The experimental curves were obtained by plotting the cloud point 
versus the copolymer mass concentration. These curves represent the boundary 
between the conditions at which the system presents a single phase (below/outside the 
curve) or two macroscopic phases (above/inside the curve). Once the cloud point curves 
were measured, a mixture point for each system in the biphasic region on both the ATPS 
and AMTPS was selected, at the lowest possible polymer concentration and 
temperature. The experimental mixture in the ATPS was selected with 23 wt% of 
copolymer and 6 wt% of potassium phosphate buffer (pH = 6.6), for a final volume of 5 
mL. It should be noted that the copolymers concentration in the cloud point curves are 
not identical for all the studied systems since for Pluronics 10R5 and L-35, there is not a 
biphasic region for concentrations lower than 22 wt%. 
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2.4. ATPS coupled with AMTPS to separate model proteins – single protein 
purification 
Two pseudo-ternary systems composed of 23 wt% of Pluronic 10R5 or L-35 + 6 wt% of 
potassium phosphate buffer + 71 wt% of proteins solution and one quaternary system 
composed of 23 wt% of Pluronic L-35 + 6 wt% of potassium phosphate buffer + 1 wt% 
of Triton X-114 + 70 wt% of proteins solution were studied as the purification platforms 
for three model proteins: cytochrome c (0.5 g.L-1), azocasein (0.3 g.L-1) and ovalbumin 
(1.59 g.L-1). 
On the first step of purification (ATPS), the systems were homogenised for 2 h at 25ºC 
and then these were centrifuged for 10 min, at 25 ºC, and 251.55 g. These conditions 
allow the two phases formation and equilibrium, after which both phases were 
collected, their volumes and weights determined, and the proteins quantified by UV-Vis 
spectroscopy, as described below. For the second step of purification, the 
top/copolymer-rich-phase was used to the AMTPS formation, being the systems 
composed of Pluronic 10R5, Pluronic L-35 and Pluronic L-35 + Triton X-114 left at 39ºC, 
44ºC and 40ºC overnight, respectively. Both phases were then collected, their volumes 
and weights determined, and the proteins quantified by UV-Vis spectroscopy, at a 
wavelength of 280 nm for ovalbumin, and 409 nm for cytochrome c. Azocasein has three 
characteristic peaks, namely at 215 nm, 342 nm, and 440 nm. However, in this work the 
wavelength of 342 nm was selected since it represents the maximum absorbance 
experimentally found. Calibration curves were performed for each model protein. The 
analytical quantification was performed at least in triplicate, and to prevent possible 
interferences, blanks were routinely applied. For both steps of purification (ATPS and 
AMTPS), several parameters were determined. The partition coefficient (K) for each 
model protein was calculated as the ratio between the equilibrium concentrations of 
the protein in the top phase ([Prot]T) and the protein in the bottom phase ([Prot]B). To 
facilitate the analysis, the K results were normalized through their logarithmic function, 
as described by Eq.2: 
log(𝐾) = log (
[Prot]T
[Prot]B
)                                                                                               (2) 
The recovery parameter of each protein towards the top (%Rec Top) and the bottom 
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(%Rec Bottom) phases was determined by the ratio among the protein mass on top or 
bottom phases, respectively, and the initial protein mass applied in the system (Eqs. 3 
and 4): 
%𝑅𝑒𝑐 𝑇𝑜𝑝 =
VT[Prot]T
VT[Prot]T+VB[Prot]B
× 100                                                                    (3) 
%𝑅𝑒𝑐 𝐵𝑜𝑡𝑡𝑜𝑚 =
VB[Prot]B
VT[Prot]T+VB[Prot]B
× 100                                                              (4) 
Since the main intention was to measure the selective partition of the proteins (e.g. 
protein A and protein B), the selectivity (S) parameter was analysed through Eq. 5: 
𝑆 =
𝐾Prot A
𝐾Prot B
                                                                                                                     (5) 
 
2.5. Integrated ATPS and AMTPS - complex purification mixture  
In order to mimic a real system, the three model proteins were simultaneously 
separated. The most selective integrated system identified, i.e. 23 wt% Pluronic L 35 + 6 
wt% potassium phosphate buffer (pH = 6.6) ATPS + AMTPS, was applied for the 
separation of the proteins from the complex mixture. 
The quantification of the proteins was performed using size exclusion chromatography 
(SEC-FPLC). The top and bottom phases upon separation were injected into an AKTA™ 
purifier system (GE Healthcare) size exclusion chromatographer equipped with a 
Superdex 200 Increase 10/300 GL chromatographic column prepacked with crosslinked 
agarose-dextran high resolution resin (GE Healthcare) to quantify the three model 
proteins. Moreover, through these measurements, the purity and purification yield (%) 
were also calculated. The column was equilibrated with 0.01 M of potassium phosphate 
buffer (0.14 M NaCl, pH = 7.4) and eluted with the same buffer at the flow of 0.75 
mL.min-1. The quantification of each proteins was carried out at 280 nm by FPLC/UV size-
exclusion method. The purification performance of the integrated process was 
evaluated based on the recovery yield (Rx %) and purity (Px %) for the three proteins as 
it can be seen at Eqs. 6 and 7.  
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𝑅𝑥 (%) =  
𝑚 (𝑃𝑟𝑜𝑡𝑒𝑖𝑛𝑝𝑢𝑟𝑖𝑓𝑖𝑒𝑑 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛)
𝑚(𝑃𝑟𝑜𝑡𝑒𝑖𝑛𝑖𝑛𝑖𝑡𝑖𝑎𝑙)
𝑥100       (6) 
𝑃𝑥 (%) =  wt% 𝑃𝑟𝑜𝑡𝑒𝑖𝑛𝑥        (7) 
The recovery yield was calculated by dividing the protein weight in the purified fraction 
by the initial protein weight (before purification). The purity was calculated by the 
weight percentage of the desirable protein (either Ova, Cyt c, or Azo) present in the 
purified fraction. 
 
2.6. Isolation of model proteins 
The polishing step was performed for the purified protein phases envisioning the 
industrial applicability of this integrated approach. The acid precipitation of azocasein 
was performed from the top phase of AMTPS, using 0.1 M of trichloroacetic acid (TCA), 
being the pellet dissolved in 0.1 M of NaOH (Fig. A5 of Appendix A). The copolymer 
recovery through azocasein precipitation was also confirmed by 1H NMR and ATR-FTIR. 
The recovery of both cytochrome c and ovalbumin in the bottom phase of ATPS was 
achieved through ultrafiltration using a 30 kDa cut-off membrane, through Amicon 
Ultra-15 Centrifugal Filter Units. 
 
2.7. Environmental assessment 
The environmental evaluation of the downstream process developed in this work, was 
carried by the estimation of its carbon footprint for the most performant separation 
system [Pluronic L-35 triblock + potassium phosphate buffer (K₂HPO₄/KH₂PO₄)]. The 
analysis of the carbon footprint was done considering the application of both (i) ATPS 
and (ii) AMTPS platforms, the proteins fractionation using ultrafiltration (iii) as well as 
for the polishing step using acid precipitation (iv). The carbon footprint is the sum of 
greenhouse gas (GHG) emissions, associated with the system tested, expressed as mass 
of carbon dioxide equivalent (CO2 eq.) from a life cycle perspective.  
The production of all the solvents (potassium phosphate buffer, Pluronic L-35 triblock 
copolymer, TCA, NaOH, distilled water), and the electricity consumed during the 
operation of the equipment was included in this assessment. Data on the amounts of 
solvents, distilled water and equipment operating time were obtained during the 
                                                              Production and purification of ASNase and Cyt-c 
CHAPTER 2  
 
78 
 
experiment, while equipment power was taken from equipment catalogues (Table A.10 
at Appendix A). Data on GHG emissions from the production of all solvents and 
electricity were sourced from Ecoinvent database version 3.4, being presented in Table 
A.11 at Appendix A.21 The GHG emissions for the production of distilled water were 
calculated based on GHG emissions from tap water production22 and GHG emissions 
from electricity consumption during the distillation process. The carbon footprint was 
calculated for 1 kg of the aqueous system. 
 
3.  Results and Discussion 
3.1. Design and characterization of the separation process 
The present work reports a novel approach for the separation of proteins. This is divided 
into two sequential liquid-liquid extraction steps, a first step based in ATPS and a second 
step based in AMTPS. 
3.1.1. Measurement of the ATPS phase diagrams and tie-lines 
The ATPS were characterized through the measurement of the phase diagrams and tie-
lines (TLs), aiming at understanding the effect of different inorganic salts and the 
copolymer nature along with the influence of surfactants used as adjuvants on their 
formation. The phase diagrams were determined for all the ATPS studied, as depicted in 
Figs 2.16, 2.17, and 2.18. All curves were determined using the cloud-point titration 
method at 25 ± 1ºC and atmospheric pressure. The experimental points were correlated 
using the Merchuk equation.18 Its parameters (A, B and C) used on the description of the 
experimental binodal data as well as the experimental data for the phase diagrams are 
reported in Tables A.3-6 at Appendix A. The experimental TLs, along with their 
respective length (tie-line length, TLLs), are reported in Table A.7 at Appendix A. The 
TLL is a numerical indicator of the difference between the compositions of the two 
phases and it is generally used to correlate trends in the partition of solutes between 
both phases. The mixtures with total compositions along a specific TL have different 
mass or volume ratios from those of the two coexisting phases, though the composition 
of each phase is maintained.23 
                                                              Production and purification of ASNase and Cyt-c 
CHAPTER 2  
 
79 
 
Regarding the effect of inorganic salts in the ATPS formation, their aptitude to promote 
the phase separation was studied for potassium phosphate salts, namely K₂HPO₄, 
KH₂PO₄, K₃PO₄ and K₂HPO₄/KH₂PO₄. The study of inorganic salt nature has been 
performed on ATPS composed of Pluronic L-35 as the phase former in presence of small 
amounts of Triton X-100 (circa of 1 wt%) – Fig. 2.16. Herein, the ability to promote the 
two-phase formation follows the order: K₃PO₄ > K₂HPO₄/KH₂PO4 ≈ K₂HPO₄ > KH₂PO₄. In 
general, the potassium phosphate salts with higher salting-out strength exhibit a wider 
biphasic region. This observation corroborates the qualitative trend on the salt cations 
ability to induce the salting-out nature of the copolymer, which follows closely the 
Hofmeister series24 with KH2PO4 and K3PO4 being the weakest and strongest salting-out 
agents, respectively. Considering the buffer capacity of the potassium phosphate buffer 
(K₂HPO₄/KH₂PO₄), a very attractive aspect for the proteins separation, along with its 
larger biphasic region, this system was adopted in the following studies. 
 
Fig. 2.16. Phase diagrams of the copolymer Pluronic L-35 and inorganic salts - (♦) K₂HPO₄; ( ) KH₂PO₄; 
(▲); K3PO4 and (■) K₂HPO₄/ KH₂PO; at 25ºC. The lines represent the Merchuk fit through Eq. 1. 
The presence of a surfactant as adjuvant was evaluated in terms of its ability to promote 
the two-phase formation by using small amounts (circa of 1 wt%) of two non-ionic 
surfactants, namely Triton X-114 and Triton X-100. These surfactants possess a similar 
chemical structure, varying only in the number of ethoxylate groups forming the 
surfactant’s crown and thus, its hydrophilicity (cf. the hydrophilic-lipophilic balance 
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(HLB) of the surfactants is presented in Table A.12 at Appendix A). The surfactants’ 
influence was analysed in a Pluronic L-35 + potassium phosphate buffer-based ATPS and 
compared with the conventional system (without any adjuvant present) – Fig. 2.17.. The 
results show that the use of these co-surfactants does not significantly affects the 
binodal curves, and thus the phases separation in this system. 
 
Fig. 2.17. Phase diagrams of the copolymer Pluronic L-35 + potassium phosphate buffer (pH = 6.6), without 
the addition of surfactant (▬); and with the addition of 1 wt% of Triton X-100 (■); and Triton X-114 (♦), 
at 25ºC. The lines represent the Merchuk fit through Eq.1. 
The copolymer nature (normal versus reverse) and composition (weight percentage of 
PEG units, cf. Table A.7 at Appendix A) were two other aspects explored on the phase 
diagrams. Three different copolymers were selected, namely Pluronics 17R4, 10R5 and 
L-35 and studied using a pseudo-ternary system composed of potassium phosphate 
buffer (pH = 6.6). The respective phase diagrams are present in Fig. 2.18., where a 
tendency can clearly be established, considering their capacity to form two phases, as 
Pluronic 17R4 > Pluronic 10R5 > Pluronic L-35.  Herein, Pluronic 17R4 holds the wider 
biphasic region, due to its more hydrophobic nature, considering the 60 wt% of PPG in 
its composition compared with the 50 wt% in the remaining copolymers. In contrast, 
Pluronic L-35 displays the narrowest biphasic region, though with only a small difference 
for Pluronic 10R5. This difference is a result of the copolymer structural rearrangement, 
i.e. Pluronic L-35 is composed of repetitive units of PEG-PPG-PEG, while Pluronic 10R5 
presents sequences of PPG-PEG-PPG. Therefore, the normal copolymer evidences a 
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higher hydrophilicity owing to the two PEG units, resulting in a lower ability to form the 
two-phases.  
 
Fig. 2.18. Phase diagrams obtained for the copolymers: Pluronic 17R4 (●); Pluronic 10R5 (▲); and Pluronic 
L-35 (■) + potassium phosphate buffer (pH = 6.6), at 25ºC. The lines represent the Merchuk fit through 
Eq.1. 
3.1.2. Measurement of the AMTPS coexisting curves  
As thermo-responsive copolymers, these systems can be induced to form two-phases 
using temperature as the driving force. The cloud points were determined, and the 
phase diagrams are presented in Fig. 2.19. These results show that the copolymer nature 
and composition display a major effect on the AMTPS formation, namely upon the cloud 
points. Once again, the ability of the copolymers to form the biphasic region follows the 
tendency of Pluronic 14R4 > Pluronic 10R5 > Pluronic L-35. The main difference is that 
now, there is the formation of an AMTPS instead of a simpler ATPS, which means that 
the phase separation occurs due to the micelles coalescence in one phase and is not a 
result of the copolymer being salted-out by the salt. Herein, there is a complex balance 
of distinct interactions (electrostatic interactions, hydrophobic associations, hydrogen 
bonds and van der Waals forces), which in turn affects both solute-solute and solute-
solvent interactions.25 Moreover, it is well known that the addition of a co-surfactant 
can, not only reduce the system cloud points, but also improve the system extractive 
performance.25,26 This is the best option in terms of the cloud point extraction of labile 
proteins, and thus, the quaternary system composed of Pluronic L-35 + potassium 
phosphate buffer (+ water) + Triton X-114 was also characterized and depicted in Fig. 
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2.19. (dashed line and square symbol).  
 
Fig. 2.19. Coexistence curves for the ternary systems with potassium phosphate buffer + water + Pluronic 
17R4 (♦); Pluronic 10R5 (●); and Pluronic L-35 (▲); and for the quaternary system composed of potassium 
phosphate buffer + Pluronic L-35 + water + 1 wt% of Triton X-114 (--■--). 
 
Through these results, it is visible a slight reduction of the cloud point temperatures of 
this system in comparison with the pseudo-ternary system composed of Pluronic L-35, 
but in absence of Triton X-114 as co-surfactant. Since both Pluronic L-35 and Triton X-
114 are non-ionic surfactants above their CMC, non-ionic mixed micelles are formed. 
Nevertheless, it seems that there is a dominance of the copolymer in the aggregate’s 
formation, since it is present in higher concentration.  
3.2. Optimization of the proteins partition applying ATPS and AMTPS 
Once the phase diagrams had been characterized, a mixture point was selected, 
considering two criteria, the water content, and an appropriate temperature, above the 
system cloud point, but not too high to maintain the proteins thermal stability. As 
previously mentioned, cytochrome c, azocasein and ovalbumin were the model proteins 
selected (cf.  properties in Table A.8 at Appendix A). The ternary system composed of 
Pluronic 17R4 was not used due to experimental restrictions imposed by its very low 
cloud point (25ºC).  
Thus, the systems studied in the partition of proteins were the ones constituted by 
Pluronic L-35 and Pluronic 10R5 and the quaternary system composed of Pluronic L-35 
+ potassium phosphate buffer + water + Triton X-114. The ATPS and AMTPS prepared to 
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perform the partition tests are exemplified by the case of Pluronic L-35 as presented in 
Fig. A.1 of Appendix A.  
The recovery and partition coefficient data obtained for each model protein in both (top 
and bottom) phases of the ATPS and AMTPS were determined, and the results presented 
in Figs 2.20., 2.21., A.2 and A.3 (Appendix A). From the Recovery results displayed in 
Figs 2.20. and 2.21. and corroborated by the partition coefficient data (Figs A.2 and A.3 
of Appendix A), it is clear the cytochrome c (red bars) preferential partition to the 
bottom/salt-rich phase whereas azocasein (blue bars) was completely recovered in the 
top/copolymer-rich phase. Contrarily, the ovalbumin (green bars) partition was found 
to be dependent on the system, since for Pluronic L-35-based AMTPS, ovalbumin is 
mainly recovered in the top phase, while for Pluronic 10R5, this protein partitions 
preferably for the bottom-phase of the ATPS.  
 
Fig. 2.20. Recovery data obtained for the three proteins regarding top/copolymer-rich phase (%Rec Top) 
and bottom/salt-rich phase (%Rec Bottom) and respective standard deviations () by using the different 
ATPS: cytochrome c, Cyt c (■); azocasein, Azo (■); and ovalbumin, Ova (■). For each system studied the 
selectivity results are reported.  
 
The cytochrome c preferential partition to the salt-rich phase can be improved by the 
proper choice of the copolymer, being this partition more pronounced for Pluronic 10R5 
(%Rec Bottom = 95 ± 5 %). It is also clear that electrostatic interactions between proteins 
and the buffer are not the only parameter influencing the proteins’ partition behaviour 
since both cytochrome c and ovalbumin partition varies with the copolymer applied. For 
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instance, when the normal is replaced by the reverse Pluronic, the ovalbumin partition 
tendency completely changed with around 60% of this protein being concentrated not 
in the polymeric phase but in the salt-rich phase. This leads to the conclusion that some 
more specific interactions between the copolymers and ovalbumin should be occurring 
and dictating its partition. Likewise, cytochrome c recovery is also improved with this 
copolymer replacement, suggesting that the more hydrophobic character of Pluronic 
10R5 might be forcing more cytochrome c to migrate towards the more hydrophilic 
phase.  
Regarding the presence of Triton X-114 as co-surfactant, it was found that the ovalbumin 
recovery is enhanced by 20% to the copolymer-rich phase. This reinforces the notion 
that some specific interactions between the system phase formers and the proteins 
contribute to their partition. 
To further elucidate the ability of these systems to separate the proteins, the ATPS 
selectivity was also determined. As expected, higher selectivity values were obtained for 
the Pluronic L-35 in the partition of ovalbumin and cytochrome c. Even though the 
presence of Triton X-114 affects the partition of proteins, a negligible effect is observed 
when the proteins selectivity (especially SOva/Cyt c) is investigated. Nevertheless, 
outstanding selectivity values were obtained for the partition of azocasein and 
cytochrome c in all the studied systems (S > 1250). 
Sequentially, the ATPS top phase was submitted to a temperature above the cloud point 
of each system and allowed it to separate into two macroscopic phases, aiming at 
separating ovalbumin and azocasein in the end. Once again, azocasein migrated 
completely towards the top/surfactant-rich phase while ovalbumin partitioned mostly 
to the bottom/surfactant-poor phase. The ability to fractionate both model proteins in 
the AMTPS is described by the trend: Pluronic 10R5 < Pluronic L-35 + 1 wt% Triton X-114 
< Pluronic L-35. The differential partition between the two proteins can be explained by 
their molecular weights and hydrophobic/hydrophilic character.26,27 The smallest and 
more hydrophobic protein, in this case azocasein, is recovered inside the micelles, while 
ovalbumin, due to its higher molecular weight and more hydrophilic character, is 
excluded to the most hydrophilic phase, the surfactant-poor phase. As far as the pseudo-
ternary and quaternary systems with Pluronic L-35 are concerned, it can be assumed 
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that the micelle complexity of the quaternary AMTPS hinders the partition of ovalbumin 
towards the surfactant-rich phase. Therefore, the addition of a co-surfactant is not so 
selective as it was in the first separation step, probably by the nature of the mixed 
micelles created.26 Taking these results into account, the system with Pluronic L-35 was 
identified as the most selective system for the two fractionation steps. 
 
Fig. 2.21. Recovery values obtained for the surfactant-rich phase (%Rec Top) and surfactant-poor phase 
(%Rec Bottom), with the respective standard deviations () by applying AMTPS to separate azocasein (■); 
and ovalbumin (■). For each system studied the selectivity results are presented.  
 
3.3. Sequential fractionation of the protein mixture 
The separation of the three proteins present in a single mixture was performed for the 
most selective system composed of Pluronic L-35 + potassium phosphate buffer + water. 
The isolation of each protein from the phase formers was a step also investigated in this 
work and corroborated by distinct techniques. Herein, two different parameters were 
considered to analyse the proteins purification owing to the use of a complex protein 
mixture, namely the proteins recovery (Rx) in each phase and their purity (Px). This data 
is presented in Figs 2.22. and A.4 (of Appendix A). As expected, the protein partition of 
ovalbumin, azocasein and cytochrome c maintained almost the same partition profile as 
previously observed for each protein when individually tested (section 2.2 of this work). 
Herein, cytochrome c was completely recovered in the salt-rich phase of the ATPS (RCyt 
c = 100% and PCyt c = 14%), which was an improvement compared to the results previously 
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obtained for each protein tested individually. However, ovalbumin partitioned almost 
completely to the salt-rich phase contrarily to the expected (ROva= 96% and POva = 86%), 
being the remaining concentration separated from azocasein in the second fractionation 
step, applying the AMTPS. In this case, azocasein was completely recovered in the 
surfactant-rich phase (RAzo = 100% and PAzo = 100%), whereas the ovalbumin still present 
in the system was totally concentrated in the surfactant-poor phase (ROva= 4% and POva 
= 100%). In the end, an ultrafiltration step was applied to isolate cytochrome c and 
ovalbumin, obtaining a cytochrome c recovery of 89% with a 74% purity and recovering 
97% of an almost pure (99%) ovalbumin. Aiming at the industrial potential of the 
integrated process developed, an isolation step was considered in this integrated 
process enabling the reuse of copolymer for additional cycles of purification. For this 
step, an acid precipitation of Azo was carried using TCA (0.1 M at pH 3-4) to promote 
the azocasein isolation from Pluronic L-35, as represented in Figure A.5 of Appendix A. 
After Azo precipitation, the pellet was microfuged at maximum speed and the 
supernatant was discharged, being applied a solution of NaOH (0.1 M) to further dissolve 
the precipitated protein. Both the azocasein isolation and copolymer recovery were 
confirmed through 1H NMR and FTIR, as shown in Figs A.6 and A.7 of Appendix A, 
respectively. The NMR data seems identical before and after the polishing step, Fig. A.6, 
however, the FT-IR spectra were different. In Fig. A.7, the main differences between the 
aqueous copolymer solution (black line) and the supernatant (red line) presenting 
essentially Pluronic L-35 correspond to the amount of water present in the solutions (cf. 
1625 cm-1: water H-O-H bend and 3400-3200 cm-1: water O-H stretch). The potassium 
phosphate buffer was not recovered since it is a common media used to stabilize 
proteins. 
Overall, high purities (> 74 %) were obtained for the four distinct polished streams: iv), 
v), vii) and ix), as presented in Fig. 2.22. It should be stressed that circa of 5 wt% of 
Pluronic L-35 is still present in stream ix); yet, this copolymer concentration is at an 
acceptable concentration approved by FDA.28 Summing up, a high-performance 
separation process was here developed by the sequential application of ATPS and 
AMTPS to separate ovalbumin (maximum yield and purity of 97% and 99%, respectively), 
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azocasein (maximum yield and purity of 100%) and cytochrome c (maximum yield and 
purity of 89% and 74%, respectively).     
 
Fig. 2.22. Diagram of the integrated process to selectively separate cytochrome c (Cyt c), ovalbumin (Ova) 
and azoasein (Azo). The proposed strategy includes two steps of purification using, respectively, ATPS and 
AMTPS based on Pluronic L-35 and potassium phosphate buffer - PB (pH = 6.6). The purity (Px) and 
recovery (Rx) of each step is provided in the present diagram. An ultrafiltration was applied to improve 
the separation of Cyt c and Ova and an acid precipitation was applied to isolate the Azo from Pluronic L35. 
The potassium phosphate buffer was maintained in the Azo-rich phase as a stabilizing solution. 
 
3.4. Environmental assessment 
Fig. 2.23. shows the results of the carbon footprint of the novel purification platform of 
proteins complex matrices per 1 kg of aqueous system. The total carbon footprint is 
equal to 117 kg CO2 eq. The contribution of the fractionation process (79 kg CO2 eq.), which 
includes the ATPS, AMTPS and ultrafiltration steps, represents ~67% of the total carbon 
footprint, is dominated by the ultrafiltration step (~49%). The proteins isolation process 
contributes with 39 kg CO2 eq. This process encompasses the acid precipitation step, 
representing ~33% of the total carbon footprint. The main contribution to the carbon 
footprint comes from the electricity consumption, more precisely, the electricity 
consumption in the centrifugation processes of the ultrafiltration and acid precipitation 
steps (representing a contribution of 99.6 % and 99.9 % of the carbon footprint for each 
step, respectively). The carbon footprint of the ATPS step is also dominated by electricity 
consumption, mainly by the centrifuge, contributing to 95 % of the carbon footprint.  
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However, it should be noted that the energy consumption of some equipment should 
be reviewed in view of the system industrial implementation. 
 
Fig. 2.23. Carbon footprint for the two scenarios proposed for 1 kg of aqueous system. 
 
4. Conclusions 
An integrated purification platform composed of ATPS and AMTPS was here proposed 
for the fractionation of different biomolecules present in complex matrices. Both the 
ATPS and AMTPS were first characterized, and then applied in the fractionation of a 
mixture of three model proteins, namely cytochrome c, azocasein and ovalbumin. The 
results herein obtained showed that the ternary system composed of Pluronic L-35 (23 
wt%) + potassium phosphate buffer (6 wt%) was the most selective system as proved by 
the selectivity values achieved: SAzo/Cyt=1667, SOva/Cyt=5.33 and SAzo/Ova=1676. The 
combination of these two liquid-liquid extraction units emerged as an attractive 
platform to improve the extraction and purification of proteins, with a final fractionation 
of cytochrome c and ovalbumin being achieved through ultrafiltration and an acid 
precipitation carried out to isolate azocasein from the copolymer. Finally, the carbon 
footprint was evaluated to better understand the environmental impacts of this new 
protein purification process. The main contribution to the total carbon footprint of the 
system comes from the ultrafiltration (~49%) and acid precipitation (~33%) steps mainly 
due to their energy consumption. 
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3.1. Novel biobetter of monoPEGylated ASNase for the treatment of acute 
lymphoblastic leukemia 
Meneguetti, G. P., Santos, J. H. P. M., Obreque, K. M. T., Barbosa, C. M. V., Monteiro, 
G., Farsky, S. H. P., Oliveira, A. M., Angeli, C. B., Palmisano, G., Ventura, S. P. M., Junior, 
A. P. & Rangel-Yagui, C. O. Plos One, 2019, 14(2): e0211951. 
https://doi.org/10.1371/journal.pone.0211951.5 
 
Abstract 
L-asparaginase (ASNase) from Escherichia coli is currently used in some countries in its 
PEGylated form (ONCASPAR®, pegaspargase) to treat acute lymphoblastic leukemia 
(ALL). PEGylation refers to the covalent attachment of poly(ethylene) glycol to the 
protein drug and it not only reduces the immune system activation but also decreases 
degradation by plasmatic proteases. However, pegaspargase is randomly PEGylated 
and, consequently, with a high degree of polydispersity in its final formulation. In this 
work we developed a site-specific N-terminus PEGylation protocol for ASNase. The 
monoPEG-ASNase was purified by anionic followed by size exclusion chromatography to 
a final purity of 99%. The highest yield of monoPEG-ASNase of 42% was obtained by the 
protein reaction with methoxy polyethylene glycol-carboxymethyl N-
hydroxysuccinimidyl ester (10 kDa) in 100 mM PBS at pH 7.5 and PEG:ASNase ratio of 
25:1. The monoPEG-ASNase was found to maintain enzymatic stability for more days 
than ASNase, also was resistant to the plasma proteases like asparaginyl endopeptidase 
and cathepsin B. Additionally, monoPEG-ASNase was found to be potent against 
leukemic cell lines (MOLT-4 and REH) in vitro like polyPEG-ASNase. MonoPEG-ASNase 
demonstrates its potential as a novel option for ALL treatment, being an inventive 
novelty that maintains the benefits of the current enzyme and solves challenges. 
 
 
Keywords: N-terminal PEGylation, biobetters, biopharmaceutics, therapeutic enzymes, 
acute lymphoblastic leukemia. 
                                                          
5 Contributions: GM, JS, KO, CB, CA and GP acquired the experimental data. The conceptualization of this work was 
done by CY. The manuscript was mainly written by GM and JS, with contributions from all the authors. 
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1. Introduction 
PEGylation is one of the most effective approaches to solve intrinsic problems of protein 
drugs, such as immunogenicity and short half-life. It refers to the covalent attachment 
of polyethylene glycol (PEG) on the protein surface.1 PEG is a highly water-soluble 
polymer, with low immunogenicity and approved by the US Agency for Food and Drug 
Administration (FDA). PEG-protein conjugates have several advantages as increased 
solubility and stability, prolonged half-life in the body and decreased metabolic 
degradation by enzymes.2 Thus, PEGylation has become a well-established technology, 
increasing the therapeutic potential of biopharmaceutics like the L-asparaginase 
(ASNase).3 
L-asparaginase (L-asparagine amidohydrolase) is an enzyme used on chemotherapy 
schemes to treat acute lymphocytic leukemia (ALL). More than 95% complete remission 
is observed within 4 to 6 weeks of treatment of children with ALL.4 More recently, 
researchers also showed that treatment with ASNase or dietary asparagine restriction 
reduces metastasis of breast cancer, what improves the potential uses of this drug.5 
However, hypersensitivity due to anti-ASNase antibodies is frequent with the use of the 
native enzyme from Escherichia coli. One available option to minimize hypersensitivity 
is pegaspargase (Oncaspar®), the PEGylated form of the enzyme. Pegaspargase also 
presents longer biological half-life than the native enzyme.6 The FDA approval for 
pegaspargase to treat patients with hypersensitivity to the native form of the enzyme 
was granted in 1994 and in 2006, it was approved as treatment for children and adults 
with newly diagnosed ALL.7 Nonetheless, only in 2015 the European Medicine Agency 
(EMA) granted a marketing authorization for the drug.8 The method used for 
pegaspargase production is the conjugation of PEG to free amines, typically at lysine 
residues and at N-terminus. An important limitation of this approach is that proteins 
typically contain many lysine residues and, therefore, PEGylation is random, leading to 
a high degree of polydispersity on the resulting preparations.9 Approximately 69-82 
molecules of 5 kDa methoxylated PEG are conjugated to ASNase.4 The main concern 
related to random PEGylation is that different PEGylated species often have different 
pharmacokinetic profiles and possibly different intrinsic biological activities.10 One 
strategy to tackle the problem of random PEGylation is N-terminal site-specific 
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PEGylation (Fig. B.1 at Appendix B). It involves the conjugation of one PEG molecule to 
protein N-terminus, taking advantage of lower pKa of N-terminal α-amino group (7.5 to 
8.5) compared with that of the ε-amino group in lysine (pK ≈ 10.5).2 Therefore, at pH 
values between 7.0 and 8.5 the lysine amine residues are predominantly protonated and 
thus unreactive to PEG. A considerable fraction of N-terminus, in turn, is unprotonated 
and available for conjugation with PEG, resulting in monoPEGylated protein.11 
In this work, an optimized protocol to synthesize an N-terminus PEGylated ASNase was 
developed. The monoPEG-ASNase produced is more stable over the time and in vitro 
resistant to plasma proteases than the non-PEGylated enzyme, while keeping the same 
activity against leukemic cell lines. 
 
2. Materials and methods 
2.1. Materials 
E.C.3.5.1.1 L-asparaginase enzyme was commercially obtained from ProSpec Tany 
(Ness-Ziona, Central District, ISR). The reactive PEG polymers, methoxy polyethylene 
glycol-carboxymethyl N-hydroxysuccinimidyl ester 2, 5 and 10 kDa (mPEG-NHS) were 
purchased from NANOCS (New York, NY). All buffer solutions (phosphate buffered 
saline, PBS and tris(hydroxymethyl)aminomethane hydrochloride, Tris-HCl) were 
prepared with purified water from a Millipore Milli-Q system (Bedford, MA) and pH 
adjusted at room temperature (22 to 25 °C). All other reagents used were of analytical 
grade. Proteases asparagine endopeptidase (AEP) and a cathepsin B (CTSB) were 
purchased from Abcam (Cambrigde, Cambridgeshire, ENG). Leukemia cell lines, acute T-
cell lymphoblastic leukemia (MOLT-4) and B-cell lines (REH), and healthy cell line, Human 
Umbilical Vein Endothelial Cells (HUVEC), were obtained from Rio de Janeiro (Brazil) cell 
bank.  
 
2.2. ASNase PEGylation 
The influence of the buffer ionic strength (10, 100 or 200 mM of PBS), PEG:ASNase molar 
ratio (25:1 or 50:1) and pH (6.0, 6.5, 7.0, 7.5 or 8.0) on site-specific PEGylation of ASNase 
was first investigated using a 2 kDa of mPEG-NHS. This molecular size presents a smaller 
hydrodynamic volume than the market attached 5 kDa mPEG-NHS, facilitating PEG 
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conjugation and initial understanding of how PEGylation happens. Nonetheless, PRG 
MW does not influence reaction conditions. The initial use of 2 kDa mPEG was a proof 
of concept, since this reactive PEG is relatively cheaper.  Additionally, a significant excess 
of mPEG-NHS was used due to its susceptibility to suffer hydrolysis in aqueous solutions; 
these values of molar ratio are in accordance with previous works.12-14 Each system, at 
selected conditions, was kept under mechanical stirring at room temperature (22 to 25 
°C) for 30 minutes. After that, 20 mM hydroxylamine was added to cleave any unstable 
PEGylation site formed. All samples were analyzed by electrophoresis (SDS-PAGE). 
Reaction yields were obtained based on electrophoresis band intensity using the ImageJ 
software.15  
After defining the best ionic strength, PEG:ASNase ratio and pH for N-terminal 
PEGylation, an experiment was carried out to define the reaction time for higher yields 
of monoPEG-ASNase. Considering that time is very important parameter for the 
PEGylation reaction, the same protocol described above was employed at the best 
conditions and just changing time reaction. The samples were withdrawn every 15 
minutes until 90 minutes, and PEG-ASNase concentration quantified based on 
electrophoresis band intensity. Subsequently, ultrafiltration (Amicon Ultra-15, 30 kDa 
MWCO) was used for buffer exchange, concentration of samples and removal of 
hydroxylamine and unreacted PEG from reaction. The final protocol was also applied to 
ASNase PEGylation with 10 kDa mPEG-NHS.   
A similar pegaspargase (polyPEGylated ASNase) was also synthesized as a reference, by 
a random PEGylation protocol. Briefly, 5 kDa of mPEG-NHS and ASNase at 50:1 ratio 
were reacted for 1 h in 100 mM of PBS at pH 10.0, under magnetic stirring. Then, the 
reaction was stopped with 20 mM of hydroxylamine as described above.  
 
2.3. Electrophoresis in polyacrylamide gel  
Samples from PEGylation reactions were analyzed by SDS-PAGE16 and to observe the 
enzymatic integrity of ASNase, the samples after the purification process were analyzed 
by native-PAGE. Proteins were stained with Coomassie Brilliant Blue, CBB17 or silver.18 
Electrophoretic gel for separation was prepared with 522 mM of Tris-HCl (pH 8.8), 6%, 
10% or 12% of acrylamide/bis-acrylamide, 0.09% (w/v) of ammonium persulphate (PSA), 
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and 0.19% (v/v) of tetramethylethylenediamine (TEMED). The packing gel was prepared 
with 116 mM of Tris-HCl (pH 6.8), 5% of acrylamide/bis-acrylamide, 0.14% (w/v) of PSA, 
and 0.29% (v/v) of TEMED. For SDS-PAGE, 0.1% (w/v) of sodium dodecyl sulfate (SDS) 
was added to the gels. Samples were prepared with 4x of protein buffer and 25 mM of 
dithiothreitol (DTT) for SDS-PAGE. The running buffer was Tris-Glycine/SDS 1x (pH 8.3) 
for SDS-PAGE and the gel was kept under 80 mA at room temperature (22 to 25 ºC). For 
native-PAGE, the buffer was Tris-Glycine 1x (pH 8.8) and the gel was kept under 100 mA 
at 4 ºC. 
 
2.4. Purification of PEGylated ASNase 
Purification was performed on a Fast Protein Liquid Chromatography GE Healthcare 
AKTA Explorer 100. The monoPEG-ASNase was purified with an anionic column Resource 
Q 6 mL (GE Healthcare Life Science, Marlborough/USA), equilibrated with buffer A (Tris-
HCl, 20 mM at pH 7.0) and eluted with buffer B (Tris-HCl, 20 mM at pH 7.0, with 1 M of 
NaCl). The running protocol corresponded to 12 column volumes up to 170 mM of NaCl 
of linear gradient at a flow rate of 3 mL.min−1. The protein elution profile was monitored 
by UV absorbance at 280 nm. Size exclusion chromatography (SEC), Superdex 200 
Increase 10/300 GL (GE Life Sciences), was performed as a polishing step and also to 
estimate the monoPEG-ASNase molecular mass. This purification protocol 
corresponded to an isocratic elution with 50 mM of Tris-HCl (pH 8.6) buffer at a flow 
rate of 0.5 mL.min-1.  
Reference sample (polyPEG-ASNase) was also purified by SEC in isocratic elution with a 
flow rate of 0.5 mL.min-1, but with 100 mM of PBS (pH 7.0) + 0.9% of NaCl buffer. Four 
standards from GE Healthcare Life Sciences were used: ferritin (440 kDa), conalbumine 
(75 kDa), carbonic anhydrase (29 kDa) and ribonuclease A (13.7 kDa). Dead column 
volume was determined by blue dextran 2000. 
 
2.5. Determination of protein concentration 
ASNase concentration was determined by the bicinchoninic acid (BCA) kit method 
(Merck-Sigma, Darmstadt, Germany), which is based on the detection of a purple copper 
complex that absorbs at 562 nm.19 Spectrophotometric measurements were performed 
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in a Biophotometer Plus (Eppendorf) spectrophotometer. Samples were incubated with 
the BCA reagent for 30 minutes at 37 °C. Total protein concentration was obtained by 
interpolating the values of absorbance on a calibration curve of bovine serum albumin 
(BSA). 
 
2.6. Determination of enzymatic activity of ASNase 
Enzymatic activity of ASNase was determined by the Nessler method.20 The method is 
based on the release of ammonium by ASNase enzymatic cleavage, which interacts with 
the Nessler's reagent giving rise to a brown colored compound (maximum absorption at 
436 nm). One enzyme unit (U) is defined as the amount of enzyme required to produce 
1 μmol of ammonia per minute, at pH 7.3 and 37 °C. The reaction system was composed 
of 24 mM of Tris-HCl buffer (pH 8.6), 9 mM of L-asparagine and the sample. The system 
was kept in a water bath at 37 °C for 30 minutes; the reaction was stopped with 68 mM 
of trichloroacetic acid (TCA). All experiments were performed in triplicate. Specific 
activity (U.mg−1 of protein) was calculated based on protein concentration and ASNase 
activity determinations at the same day. 
 
2.7. Kinetic analysis 
The kinetic parameters of ASNase samples were determined by means of the NADH-
coupled method.21 The β-NADH oxidation was measured spectrophotometrically at 
340 nm (εβ-NADH = 6.1 μmol−1·cm−1) and 37 °C. Assays were performed in 96-well 
microplates. Each well received, final concentration, 50 mM of Tris–HCl, pH 8.6; L-
asparagine at different concentrations (0.07, 0.1, 0.3, 0.5, 0.7, 1.5, 2.0 and 2.5 mM); 0.13 
mM of β-NADH, 1 mM of α-ketoglutarate, 0.5 U of glutamate dehydrogenase (diluted in 
50 mM of PBS, pH 7.4; 50% of glycerol) and 1.8 ± 0.2 U of the enzyme sample (ASNase, 
monoPEG-ASNase or polyPEG-ASNase), 30 minutes reaction time. Data analysis and 
statistical analysis (F-test) were done using the GraphPad Prism 5.0 program (La Jolla, 
California/USA).  
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2.8. Determination of PEGylated ASNase activity over time 
Samples of monoPEG-ASNase, polyPEG-ASNase and free ASNase were maintained at 
4 °C for 21 days to verify activity over storage time by quantifying protein concentration 
and enzymatic activity. Measurements were done in triplicate and a non-linear 
regression was fit using GraphPad Prism 5.0. 
 
2.9. Dynamic light scattering - DLS 
Dynamic light scattering (DLS) was used to determine the hydrodynamic radius of the 
conjugate samples. All measurements were performed on a Zetasizer Nano ZS, a DLS 
instrument, using non-invasive backscatter (NIBS) detection. The protein samples were 
at 1.0 mg.mL-1 in saline buffer (50 mM of Tris-HCl, pH 8.6) where, for each protein, no 
subunit dissociation is expected. All samples were filtered before measurement using 
0.22 μm or smaller pore size to remove large aggregates and the quantification of 
number size distributions was performed for each sample at 25ºC.  
 
2.10. MALDI-TOF mass spectrometry 
Matrix-assisted laser desorption/ionization (MALDI) coupled to time of flight (TOF) was 
used to determine the position of PEGylation. The proteins samples with and without 
PEG of 2 kDa and 10 kDa were treated initially with 10mM DTT to reduce disulfide bonds 
and alkylated with 55mM iodoacetamide to block the reduced thiols. Subsequently, 
trypsin was added to each protein sample in a 1:50 enzyme:protein ratio. The enzymatic 
reaction was blocked with 1%TFA and the tryptic peptides were desalted using R3 micro-
columns as previously reported.22 The tryptic digests were co-crystallized with α-Cyano-
4-hydroxycinnamic acid matrix dissolved in 30:70 (v/v) (acetonitrile : 0.1% TFA in water) 
at a concentration of 10 mg.mL-1. The MS spectra were acquired in reflectron positive 
ion mode in a 700-4000 m/z range. External calibration was performed for all spectra. 
The mzXML files were processed using Mass-Up.23 The MALDI-TOF MS spectra were 
processed using baseline subtraction and smoothing. Subsequently, MS spectra were 
overlaid in order to evaluate the signal intensity of the tryptic peptides obtained from 
ASNase without PEG and with PEG 2 kDa and 10 kDa.  
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2.11. Evaluation of ASNase resistance to plasmatic proteases 
The evaluation of resistance to proteolytic cleavage by asparaginyl endopeptidase (AEP) 
and cathepsin B (CTSB) was based on an adaptation of Patel et al. method.24 Briefly, 4 μg 
of sample was added to 2 μg of CTSB or 1.8 μg AEP in 20 μL of Tris-HCl buffer (50 mM, 
pH 8.8) and kept under bath stirring at 37 °C for 84 hours. After, a Native-PAGE 
electrophoresis was performed. Zymography was also performed to detect enzyme 
activity.25 After the Native-PAGE running, the gel was submerged in an enzyme reaction 
medium (30 mM of Tris-HCl, 38 mM of L-asparagine and 0.2 M of hydroxylamine 
hydrochloride at pH 7.0) and incubated at 37 °C for 30 minutes. Subsequently, the gel 
was washed with ultra-pure water and revealed with chromogenic iron chloride solution 
(FeCl3, 10%, and TCA, 3.3 % (w/v), in 0.7 M of HCl). After 24 h the gel was flushed with 
CBB.  
 
2.12. In vitro cytotoxicity assays 
Mitochondrial viability (hence cell viability) was quantified by the reduction of MTT (3-
(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazoline bromide) by the enzyme succinate 
dehydrogenase present in the mitochondrial membrane, resulting in crystals of 
formazan, whose production is proportional to the number of metabolically active 
cells.26 The assay was performed as described by Costa et al.27with acute T-cell 
lymphoblastic leukemia (MOLT-4) and B-cell lines (REH), and healthy human umbilical 
vein endothelial cell line (HUVEC). The cell lines were maintained in the Roswell Park 
Memorial Institute medium (RPMI 1640) with 10% of fetal bovine serum (v/v), L-
glutamine and sodium pyruvate, incubated at 37 °C in a 5% of CO2. Cells were pealed 
after reaching a high cell density, confluence greater than 90%. HUVEC line had its cells 
trypsinized with 0.05 mL.cm2 of Trypsin/EDTA solution, ressuspended in fresh medium. 
After reaching confluence, cell lineages were centrifuged at 600 xg at 4 °C for 10 min 
and suspended in fresh RPMI medium. The visualization of cell viability was done with 
Trypan blue (Sigma-Aldrich, Darmstadt, Hessen, GER). Cells were counted in Neubauer's 
chamber. MOLT-4 or REH, at 1.0 x 104 cells/well and HUVEC, at 2.0 x 104 cells/well, were 
incubated in 96-well microplates with 0.01, 0.05, 0.1, 0.3 and 0.6 U.mL-1 of ASNase 
samples (free, monoPEGylated and polyPEGylated) in 20 mM sodium phosphate buffer 
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pH 7.4. Ultrafiltration method (Amicon Ultra-30 kDa MWCO) was used for buffer SEC 
elution exchange and samples were filtered with 0.22 µm steric filter. MOLT-4 and REH 
were tested at the same plate. Control cells were RPMI medium and protein buffer 
(50 mM of Tris–HCl, pH 8.8) without enzyme. Then, 48 or 72 h later (at 37 °C in a 5% CO2 
incubator) a 0.25 mg.mL-1 MTT solution was added. After 4 h, 1% of SDS was added and 
cells were incubated under the same conditions for more 24 h. The optical density 
reading was performed in a spectrophotometer at the wavelength of 540 nm. The 
results were expressed as a percentage of MTT reduction, having as parameter the 
control group, for which 100% reduction was attributed. The assays were done in 
triplicate and data analysis was carried with the program GraphPad Prism 5.0. 
 
3. Results  
3.1. ASNase PEGylation 
Site-specific PEGylation at N-terminal region is highly influenced by pH, temperature, 
reaction time and ionic strength.11 The latest is mainly determined by the ions dissolved 
and, therefore, the total concentration of electrolytes in solution.28 Buffer ionic strength 
effect on conjugation of PEG to ASNase was investigated by varying molarity of PBS (pH 
7.5): 10, 100 and 200 mM were investigated. Results presented in Fig 3.1.A show that 
best PEGylation yields were obtained with 100 mM of PBS. Regarding PEG:ASNase ratio, 
similar yields (42-45%) were observed for both 25:1 and 50:1 molar ratios (Fig 3.1.B). 
Nonetheless, at a PEG:ASNase ratio of 25:1, less polyPEGylated species were formed in 
comparison to 50:1 (7% and 19%, respectively).  
After defining the best PBS molarity (ionic strength) and PEG:ASNase ratio, we 
investigated the effect of pH on PEGylation yields. Since ASNase N-terminal has a pKaLEU 
of 7.6 (Table B.1 at Appendix B), we investigated the PEGylation reaction at a pH range 
from 6.5 to 8.0 and found that PEGylation increases with pH (Fig 3.1.C, Fig. B.2 at 
Appendix B). However, at pH 8.0 the monoPEGylation yield decreased with the 
concomitant increase of polyPEGylation. According to the results, PEGylation at pH 7.5 
provides better yields with less than 10% of polyPEGylated species. 
The effect of different reaction times from 0 to 90 minutes (Fig 3.1.D, Fig. B.3 at 
Appendix B) was also evaluated, and a maximum yield of 41% was observed in 
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monoPEGylated ASNase after 30 minutes of reaction, compared to 28% at 15 minutes 
and 40% at 45 minutes. Although the reaction time of 45 minutes showed similar yields 
to 30 minutes, the concentration of polyPEGylated species, in other words the 
polydispersity, was higher (13 and 17%, respectively). Additionally, the polydispersity 
increased with time and reached a maximum of 30% at 75 minutes of reaction time. At 
30 minutes, polyPEGylation rate (13%) was nearly a half of the value observed at 90 
minutes.   
The best conditions for ASNase monoPEGylation were defined as 100 mM of PBS, pH 7.5, 
PEG:ASNase ratio 25:1 and reaction time of 30 min. This protocol was applied for ASNase 
PEGylation with 10 kDa of mPEG-NHS resulting in about 40% of monoPEG-ASNase yields. 
Moreover, a polyPEGylated ASNase was also prepared as previously described, to be the 
reference of the commercially available drug pegaspargase.  
 
Fig 3.1. Reaction conditions to produce monoPEGylated L-asparaginase (monoPEG-ASNase). (A) 
Electrophoresis (SDS-PAGE) showing the influence of PBS buffer ionic strength on N-terminal PEGylation 
with pH 7.5 (PEG:ASNase ratio of 25:1, 2 kDa mPEG-NHS): Column 1- ASNase (control), column 2- reaction 
in 10 mM PBS, column 3- reaction in 100 mM of PBS, column 4- reaction in 200 mM PBS, and column 5- 
Molecular weight (BioRad). (B) Percentage of PEGylation at different PEG:ASNase ratios, 25:1 and 50:1, in 
100 mM of PBS pH 7.5, 30 min of time reaction. (C) Percentage of PEGylation at different pH values (6.0, 
6.5, 7.0, 7.5 or 8.0) in 100 mM of PBS, PEG:ASNase ratio of 25:1 and 30 min of reaction time. (D) 
Percentage of PEGylation on different reaction times (15 to 90 minutes) in 100 mM of PBS, pH 7.5, 
PEG:ASNase ratio of 25:1. Grey bars - polypegylated ASNase, white bars - monoPEGylated ASNase, dotted 
bars - free ASNase. Percentage of PEGylation was based on gel analysis by band intensity. 
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3.2. Purification of PEGylated ASNase 
A strong anion exchange column (Resource Q, GE Healthcare) was used to purify the 
monoPEG-ASNase. At this stage of the purification, all different forms of protein present 
in the reaction medium were separated: free enzyme (unreacted ASNase) with 92 mM 
of NaCl, monoPEGylated enzyme (78 mM of NaCl) and polyPEGylated forms of the 
enzyme with 67 mM of NaCl (Fig. B.4 at Appendix B). Anion exchange chromatography 
resulted in monoPEG-ASNase with 70% of purity and 57% of yield. To confirm the 
molecular mass of the monoPEG-ASNase and to refine purification, the fractions eluted 
with 78 mM of NaCl were subjected to size exclusion chromatography (Fig. B.5 at 
Appendix B). MonoPEG-ASNase was eluted at 10.65 mL, while free ASNase (pure 
enzyme) was eluted at 11.39 mL, corresponding to 187 ± 10 kDa and 146 ± 6 kDa, 
respectively. Therefore, we obtained 99% of purity monoPEG-ASNase with 45% of yield. 
Only SEC was necessary for polyPEG-ASNase, once size difference between unreacted 
and polydisperse ASNase is high.4 PolyPEGylated ASNase sample was eluted at 8.28 mL 
to 9.61 mL (Fig. B.6 at Appendix B), corresponding to a polydispersity range weight from 
264 ± 3 to 410 ± 9 kDa and 28 to 57 units of PEG 5 kDa. 
 
3.3. Determination of kinetic parameters  
The kinetics of an enzyme allows to elucidate its catalytic mechanism, its role in 
metabolism and how its activity in the cell is controlled. The mathematical model of 
Michaelis-Menten24 was used to determine the kinetic parameters. Different 
concentrations of the substrate L-asparagine (5 to 1,470 μM) and respective rates of 
saturation of ASNase fractions were studied (Fig. 3.2.). 
The kinetic parameters obtained for ASNase, monoPEG-ASNase and polyPEG-ASNase 
are shown in Table 3.1.. All samples presented Michaelian behavior with similar Km 
values of 20 μM, 35 μM and 65 μM respectively (Table 3.1.). In fact, the turnover values 
were similar to those described in literature for ASNase.27 
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Fig 3.2. Enzymatic behavior of monoPEG-ASNase compared to ASNase (control) and polyPEGylated form. 
(A) Enzymatic kinetics of ASNase. (B) Enzymatic kinetics of monoPEG-ASNase. (C) Enzymatic kinetics of 
polyPEG-ASNase. Data analysis and statistical analysis (F-test) were done using GraphPad Prism 5.0 
software. All trials were in triplicates and error bars represent the standard deviation. 
 
Table 3.1. Kinetic parameters of L-asparaginase (ASNase), monoPEG-ASNase and own produced 
pegaspargase reference (polyPEG-ASNase).a 
Enzyme Km (μM) vmax (μmol.min-1) 
ASNase 19.58 ± 0.003 2.36 ± 0.015 
monoPEG-ASNase 34.67 ± 0.005 3.34 ± 0.007 
polyPEG-ASNase 65.21 ± 0.005 8.36 ± 0.065 
a All experiments were done in triplicate and error bars represent the standard deviation. The 
kinetic parameters were calculated by non-linear regression analysis using GraphPad Prism 5.0 
software.  
 
3.4. PEGylated ASNase activity over time   
Enzymatic activity of polyPEG-ASNase, monoPEG-ASNase and free ASNase over time 
was studied for 21 days (Fig. 3.3.A). After purification, the monoPEG-ASNase maintained 
its initial specific activity (233 ± 8.1 U.mg-1). However, the excess of PEG units randomly 
conjugated to ASNase, in polyPEG-ASNase similarly to pegaspargase, decreased the 
specific activity to 21% of the pure enzyme activity, getting 50 ± 0.6 U.mg-1. After seven 
days, pure ASNase (control) lost 53% of specific activity. On the other hand, the 
monoPEG-ASNase and polyPEG-ASNase remained stable up to 21 days (p-
value = 0.005).  
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Fig 3.3. PEG attachment influence on native enzyme. (A) Enzymatic activity versus storage time at 4 °C for 
ASNase control, monoPEG-ASNase and polyPEG-ASNase. (B) Dynamic light scattering profiles of 
unreacted ASNase, mono and polyPEGylated ASNase. The hydrodynamic radius were 7.53 nm, 9.85 nm 
and 11.75 nm, respectively.   
 
3.5. Dynamic light scattering 
The PEGylation of ASNase caused an increase in the hydrodynamic diameter of the 
protein, through the binding of the PEG structure to the protein (Fig 3.3.B), an effect 
well-described in literature.30-31 The hydrodynamic radius values are 7.53 nm, 9.85 nm, 
and 11.75 nm for ASNase, monoPEG-ASNase and polyPEG-ASNase, respectively. 
Comparing both PEGylated proteins, the polyPEG-ASNase has the highest hydrodynamic 
diameter, related to the higher amount of PEG attached to the protein.  
 
3.6. MALDI-TOF mass spectrometry 
To confirm site-specific PEGylation, the signal intensity of MS peak corresponding to the 
N-terminal and internal peptides were compared between the PEGylated and not 
PEGylated protein. Fig. 3.4.A, represents the first peak at 2028.1809 corresponding to 
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the N-terminal peptide LPNITILATGGTIAGGGDSATK.(S) and Fig 3.4.B represents MS peak 
corresponding to peptide SVFDTLATAAK.(T) at m/z 1123.6, an internal peptide that 
contains a lysine residue.  
 
Fig 3.4. MALDI-TOF of free ASNAse and monoPEG-ASNase (with 2 kDa and 10 kDa PEG). (A) N-terminal 
peptide LPNITILATGGTIAGGGDSATK.(S) at m/z 2028.1809 and (B) lysine peptide SVNYGPLGYIHNGK.(I), at 
m/z 1518.7. Samples were acquired in duplicate. ASNase; blue line (spectrum 4), monoPEG-ASNase 2 kDa  
light and dark green line (spectrum 6 and 2), and monoPEG-ASNase 10 kDa; light blue line and orange 
(spectrum 5 and 1).  
 
The MS signal of the N-terminal peptide derived from free ASNase is higher than the 
others samples (PEGylated forms), Fig. 3.4.A, indicating that this peptide sequence has 
been modified during PEGylation. It should be noted, that all the intensities were 
normalized to avoid sample loading bias. In order to prove that this reduction was not 
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due to other factors, we analyzed other MS peaks (Fig. 3.4.B) corresponding to internal 
peptides with lysine residues since the PEG reacts with lysine. The MS signal intensity of 
all peptides were equal between the different conditions showing that PEGylation was 
site-specific to ASNase N-terminal.   
 
3.7. Proteolytic degradation 
Fig. 3.5. presents the electrophoretic profile of ASNase samples after exposition to two 
human blood proteases related to the decrease in ASNase plasma half-life, AEP and 
CTSB.32 AEP specifically cleaves asparagine and aspartate residues.25 To date, the 
proteolytic sites for CTSB have not been defined, but it is known that this enzyme can 
recognize a wide range of residues combinations.28 
 
 
Fig 3.5.  Electrophoresis gel (native-PAGE) showing the proteolytic degradation /resistance of native 
ASNase and PEGylated forms. ASNase, monoPEG-ASNase and polyPEG-ASNase in presence of asparagine 
endopeptidase (AEP) and cathepsin B (CTSB) after 84 h at 37 °C, stained with CBB (top gel) and stained 
with ferric chloride (bottom gel). Column 1- Protease-free ASNase, column 2- ASNase with CTSB, column 
3- ASNase with AEP, column 4- protease-free monoPEG-ASNase, column 5- monoPEG-ASNase with CTSB, 
column 6- monoPEG-ASNase with AEP, 7- protease-free polyPEG-ASNase, column 8- polyPEG-ASNase with 
CTSB and column 9- polyPEG-ASNase with AEP. 
 
The polyethylene glycol chain is known to protect protein sites susceptible to proteolytic 
degradation.34 This protective effect was present for PEGylated forms, either as mono 
or polyPEGylated, when incubated with both tested proteases since no shifts were 
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observed in the electrophoretic bands. Conversely, the native ASNase presented 
degradation in the presence of the proteases and electrophoretic shifts were observed 
corresponding to smaller protein structures. Activity staining also showed that ASNase 
activity decreased more with AEP cleavage than CTSB, while no activity change was 
observed for monoPEG-ASNase and polyPEG-ASNase in presence of both proteases. 
 
3.8. Cytotoxicity 
In vitro assays using MOLT-4 (T lymphocytes) and REH (B lymphocytes) ALL cell lines 
were performed to test the cytotoxic potential of monoPEG-ASNase (Fig. 3.6.). REH line 
is considered to be resistant to ASNase, since it expresses considerable levels of 
asparagine synthetase35 and MOLT-4 is described as an ASNase-sensitive strain.36 As a 
control, HUVEC cells were used (Fig. B.7 at Appendix B). 
 
Fig 3.6. Cytotoxicity of monoPEG-ASNase in MOLT-4 and REH cells. Assays performed at 48 h and 72 h, 
with cells alone (control), without enzyme (PBS) and at different concentrations of enzymatic activity 
(0.01, 0.05, 0.1, 0.3 or 0.6 U.mL-1). Grey bars - free ASNase and white bars - monoPEGylated ASNase. Error 
bars represent the standard deviation. Likelihood of significance less than 0.05 (*), less than 0.01 (**) and 
less than 0.001 (***) when compared with the control. 
 
All ASNase samples (PEGylated or native) presented similar cytotoxicity to leukemic 
cells. For the sensitive strain MOLT-4 treated with monoPEG-ASNase, we detected 
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reductions of 48% and 62% in cell viability after 48 h and 72 h, respectively. PolyPEG-
ASNase reduced 55% and 68% of cell viability after 48 h and 72 h. Additionally, no 
statistically significant differences were observed in cytotoxicity among PEGylated 
species and free enzyme. Reductions around 23% to 26% in REH cell viability were 
observed after 48 h for ASNase and monoPEG- ASNase, while polyPEG-ASNase reduced 
35% of REH cell viability. For 72 h reaction, the reduction was approximately 33% - 39% 
for all the samples tested. Therefore, PEGylation preserved ASNase cytotoxic activity 
against leukemic lines. Moreover, both ASNase and monoPEG-ASNase were not toxic to 
healthy HUVEC cells (Fig. B.7 at Appendix B). 
 
4. Discussion  
In this work we developed a site-specific N-terminal PEGylation protocol for E. coli 
ASNase, currently employed in the treatment of ALL, to overcome the high degree of 
polydispersity of the commercial pegaspargase. According to our results, the increase of 
the ionic strength from 10 to 100 mM provided counter ions that contributed to 
protonation of protein residues stabilizing them and favoring PEGylation at 
unprotonated N-terminal amino acid.28 At higher molarity (200 mM), PEGylation rate 
was lower probably due to mPEG-NHS instability. Usually, an excess molar ratio of 
reactive PEG over the protein amount is added to increase PEGylation and overcome 
reactive PEG hydrolysis.37 However, the PEG:enzyme ratio of 25:1 resulted in less 
polyPEGylated forms when compared to ratio 50:1 (7% and 19%, respectively). 
An adequate pH value is crucial for PEGylation as it determines the nucleophiles 
reactivity. Nucleophilic attack occurs at pH values closer or higher than the pKa value of 
the amino acid residue, because they will be predominantly deprotonated.38 Since all 
lysine residues of ASNase present pKa ≥ 10.5, while N-terminal pK ≈ 7.6, the best pH 
value for ASNase PEGylation was 7.5. By increasing pH values around 7.5, the reaction 
gradually lost specificity, since other amine residues were PEGylated.  
Hydrolysis of mPEG-NHS, i.e. the half-life of succinimidyl group hydrolysis by nucleophilic 
attack on the ester group depends directly on its molecular structure and the ester-
binding site on the structural chain.39 The hydrolysis half-life of the PEG with an aliphatic 
C4 ester linkage (such as the one used in the present work) is around 44 minutes, 
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whereas for PEG with a C2 ester linkage it is around 3 minutes, at pH 8.0.40 Therefore, 
the best conditions to favor ASNase monoPEGylation were defined as 100 mM of PBS 
(pH 7.5), PEG:protein ratio of 25:1 and reaction time of 30 min. 
Even with the N-terminal site-specific PEGylation protocol, multiple PEGylated enzyme 
structures can be produced and must be removed of the final preparation.41  A common 
purification technique is size exclusion chromatography (SEC).42-43 However, to obtain 
high chromatographic resolution, samples species must have at least 20% of difference 
in size.44 PEGylation also alters the isoelectric point (pI) of the protein. The change in 
charge depends on the size of the protein, the number of conjugated PEG molecules and 
the residues to which PEG chains bind.45  
Pabst et al.46 purified PEGylated bovine serum albumin (monoPEG-BSA) by anion 
exchange chromatography with a yield of 50% and Subramanian47 purified 
monoPEGylated α-lactalbumin from the reaction mixture by SEC with 56% of yield and 
93% of purity. For polyPEG-ASNase, we obtained 58% of yield and purity of 98% by 
applying a one-step purification using SEC and considering desired polydispersity in the 
final sample. On the other hand, when the PEGylated and nonpegylated proteins are 
close in molecular mass (such as ASNase and monoPEG-ASNase) another purification 
step is required. In this sense, we used strong anion exchange chromatography (55% 
yield) followed by size exclusion chromatography (45% yield) to a final preparation with 
99% of purity of monoPEG-ASNase. The confirmation of N-terminal PEGylation was also 
determined by the significant reduction in the MS signal intensity for the N-terminal 
peak, compared to other lysine containing peptides that do not change after PEGylation, 
indicating that the PEG was added to the N-terminal residue. 
Data on SEC usually presents good size correlations for globular proteins, regarding the 
molecular mass. Based on SEC, we obtained 146 ± 6 kDa for ASNase molecular mass, 
corroborating the literature data that describes this enzyme with 136 to 150 kDa.9,48 
When flexible linear chains of PEG are attached to a protein, the SEC power of prediction 
decreases and usually size is underestimated. MonoPEG-ASNase was estimated to have 
187 ± 10 kDa, what is consistent with the attachment of four 10 kDa PEG chains to the 
protein (one at each monomer N-terminal). PolyPEG-ASNase was estimated to present 
a range of 264 ± 3 kDa to 410 ± 9 kDa, what is below the expected considering that 69 
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to 82 units of 5 kDa PEG should be attached to the protein.4 One possibility for such a 
difference is that, as explained, the high number of linear PEG chains attached, and the 
fact that the PEG chains are shorter (10 kDa for monoPEG-ASNase and 5 kDa for 
polyPEG-ASNase) resulted in a stronger influence in protein elution and the 
underestimation of polyPEG-ASNase size by SEC.  
The kinetic properties of the purified monoPEG-ASNase were determined to investigate 
whether N-terminal PEGylation would result in significant differences in ASNase activity. 
Kinetic properties as the maximum saturation velocity (Vmax) and the Michaelis constant 
(Km), allows not only the formulation of hypotheses on the enzyme behavior in a cellular 
environment, but also to predict on how ASNase will respond to changes in 
environmental conditions.49 ASNase is described as a Michaelian enzyme with high 
affinity for the substrate. In this work, a Km of 20 μM for ASNase was obtained, which is 
in agreement with the values defined in literature, from 12.5 to 22 μM.50-51 For 
monoPEG-ASNase, as expected, a higher Km (35 μM) was obtained since the PEG 
moieties may hinder substrate access to the enzyme and also difficult enzyme-substrate 
molecular interactions. The same effect occured with polyPEG-ASNase presenting a 
higher Km of 65 μM. Previous studies report a Km of 12 to 40 μM for pegaspargase.6,52 
The N-terminal site-specific PEGylation significantly preserved ASNase affinity for the 
substrate, since the Km of monoPEG-ASNase was still in the micromolar range and lower 
than the value observed for polyPEG-ASNase.  
One of the main concerns about the site-specific N-terminal PEGylation was if the lower 
number of PEG moieties would be enough to provide protein stability. Our results 
showed that both monoPEG-ASNase and polyPEG-ASNase remained stable for 21 days, 
while free ASNase lost approximately 50-70% of its activity in just one week. However, 
the large number of PEG molecules conjugated to ASNase in random PEGylation 
significantly decreased the enzymatic activity of polyPEG-ASNase in 79%. Pegaspargase 
is marketed with at least 85 U.mg-1, that is, 65% smaller than the nonpegylated form. 
Therefore, site specific N-terminal PEGylation indicates enzymatic stability to further 
studies with longer storage times, once that commercially available pegaspargase in 
buffer saline solution is valid for 8 months when stored at 2 to 8 °C.53 
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The commercially available pegaspargase has a longer plasma half-life than the free 
ASNase due to steric hindrance of PEG to proteases. Therefore, the determination of 
monoPEG-ASNase stability to proteases degradation is pivotal. Our results confirmed 
ASNase cleavage by the proteases, but cleavage by CTSB did not completely inactivate 
the enzyme. Nonetheless, CTSB cleavage is intracellular, after enzyme capturing by 
phagocytic cells.33 Proteolytic degradation by AEP, on the other hand, resulted in a 
significant loss of ASNase activity by the protease mechanism of action that involves 
interaction with Asn248 and Asp90 residues of ASNase active site.50 MonoPEG-ASNase 
was found to be stable in presence of both AEP and CTSB cells, demonstrating that the 
binding of four PEG moieties to the enzyme was enough to provide plasma stability. This 
study also suggests that monoPEG-ASNase may be less immunogenic, as degradation by 
proteases may lead to the exposition of epitopes that activate the immune response.24 
Besides stability in solution and resistance to proteases cleavage, monoPEG-ASNase 
presented similar in vitro cytotoxicity against leukemic cell lines (MOLT-4 and REH) in 
comparison to polyPEG-ASNase and free enzyme. Costa et al.27 demonstrated that 
10 U.mL-1 of ASNase reduced almost 100% of MOLT-4 cells and 20% of REH cells viability 
in 72 h of incubation. The ASNase activity of a therapeutic dose must be at least 0.1 to 
0.2 U.mL-1 and,6,52 in this sense, the range of 0.01 to 0.6 U.mL-1 was tested in the present 
work. MonoPEG-ASNase resulted in 62% and 33% viability reduction of MOLT-4 and REH 
cells, respectively, considering 72 h of incubation. Cytotoxicity against healthy cell lines 
(HUVEC) was also investigated and monoPEG-ASNase was found to be safe with no 
cytotoxic effect. HUVEC cells were used as control since they are highly metabolic cells 
covering the vessels wall and, consequently, in contact with circulating substances. 
Hence, we showed that any physical or metabolic alteration that could lead to cell death 
was caused by the enzymes. 
In conclusion, it was developed an optimized protocol for site-specific N-terminal 
PEGylation of ASNase to produce a novel enzyme variant, monoPEG-ASNase, with 
similar yield of monoPEGylation as literature,46-47 with reaction time of 30 minutes which 
represent a great industrial production time and also less cost with raw material since 
the reaction needs less PEG than unspecific PEGylation.  Also this novel enzyme variant 
promote a kinetic profile and activity towards leukemic cell lines in comparison to the 
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free and polyPEGylated enzyme. The N-terminal site-specific PEGylation provides batch-
to-batch control over pegaspargase (commercially available ASNase) and an enhanced 
long-term stability, being considered a better biobetter than the polyPEGylated form. In 
addition, monoPEG-ASNase is at least three-times more stable than native ASNase and 
resistant to cleavage by serum proteases. This monoPEG-ASNase can be considered as 
a potential novel biopharmaceutical to treat ALL, as well as possibly other types of 
cancer.  
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3.2. Site-specific PEGylated cytochrome c as biosensor: PEGylation reaction 
to enhance its long-term stability 
Santos, J. H. P. M., Meneguetti, G. P., Carreto, G., Coutinho, J. A. P., Ventura, S. P. M. & 
Rangel-Yagui, C. O. 2019 (manuscript in preparation).6 
 
Abstract 
Cytochrome c (Cyt-c) has been currently employed in bioelectrochemical applications 
for redox sensing due to its peroxidase-like activity. Nevertheless, its potential as a 
biosensor is significantly reduced due to low long-term and thermal stability, generally 
attributed to the fragile conformation of proteins. To overcome these drawbacks, in this 
work, a site-specific PEGylation protocol for Cyt-c was developed. The PEG derivative 
used was a 5kDa methoxy polyethylene glycol succinimidyl NHS ester (mPEG-NHS) and 
a site-directed PEGylation at the lysine amino-acids was performed. In this case, the aim 
was to establish an optimized protocol to control the number of PEGylated amino acid 
residues at specific sites. The effects of reactional medium pH, molar proportion (Cyt-
c:mPEG-NHS) and reaction time were evaluated. The best conditions were defined as 
pH 7, 1:25 Cyt-c:mPEG-NHS and 15 min reaction time resulting in PEGylation yields of 
45% for the attachment of 4 PEG molecules (Cyt-c-PEG-4) and 34% for the binding of 8 
PEG molecules (Cyt-c-PEG-8). Circular dichroism spectra demonstrated that Cyt-c 
PEGylation did not cause significant changes to the secondary and tertiary structures of 
the PEGylated forms. The long-term stability of free and PEGylated Cyt-c was also 
investigated in terms of catalytic activity of ABTS oxidation by hydrogen peroxidase. The 
main results demonstrate that both Cyt-c-PEG-4 and Cyt-c-PEG-8 were found to be more 
stable than the free protein. In particular, Cyt-c-PEG-8 presented great potential as a 
biosensor, since its structure and activity was found to be three times higher than that 
defined for the free protein over 60-days of storage, at distinct temperatures of 4 oC and 
25 oC. 
 
 
 
Keywords: cytochrome c; PEGylation; lysine amino-acid residues; stability; biosensor. 
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1. Introduction 
Cytochrome c (Cyt-c) is a small protein with 104 amino acids and about 12 kDa molecular 
weight. It is is a heme protein involved in mitochondrial electron transfer, even though 
not considered as an enzyme in nature, it catalyzes several chemical reactions including 
the hydrogen peroxide reduction, aromatic oxidation, hydroxylation, epoxidation and 
N-demethylation.2 Based on the broad heterogeneity obtained in biotransformation 
reactions catalyzed by Cyt-c, along side with the high reactivity towards different 
substrates and the electron transfer capability, this protein has been recently explored 
as a biosensor of hydrogen peroxide, nitric oxide and polycyclic aromatic hydrocarbon.2–
4 However, the potential biosensing applications of Cyt-c are compromised by 
irreversible denaturation, aggregation and/or precipitation. This short-term stability 
condition results from the fragile conformation shared by most proteins, where Cyt-c is 
also included.  
The stability of biosensors during storage is crucial to guarantee reproducibility and 
feasibility of biochemical measurements. Generally, long-term stability of protein-based 
sensors is the major problem associated with their potential application.5 In this sense, 
chemical modifications in proteins are a key solution to overcome these drawbacks. 
PEGylation is one of the most common chemical modifications applied in protein-based 
biosensing field, mostly due to the advantages it may bring to proteins.3 Chemical 
bonding of poly(ethylene glycol) (PEG) to the protein enhances the protein solubility in 
water and some organic solvents, confers long-term stability while reduces 
denaturation, aggregation, and precipitation, as well as prevents immunogenicity and 
proteolytic degradation due to the PEG shielding effect.6–8 Literature shows that many 
redox proteins with sensing applications have already been PEGylated to improve 
stability, e.g. horseradish peroxidase,9 hemoglobin,10 myoglobin.11 Recent studies 
showed that PEGylation could kinetically stabilize the Cyt-c structure through the 
maintenance of the heme group, while decreasing the unfolding rate.3,4,12 However, 
most of the PEGylation reactions presented in literature included in the field of 
biosensors are not site-specific, resulting in the random production of PEGylated 
conjugates with increased polydispersity.4,13 This unspecific reaction leads to a 
decreased bioactivity and lack of batch to batch control, resulting in a mixture of protein-
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based biosensors with differential biosensing activity.6,14 To overcome this problem, we 
developed a site-specific PEGylation protocol for Cyt-c through the conjugation of 
methoxy PEG succinimidyl NHS ester (mPEG-NHS). This functionalized PEG is attached 
to the protein through a nucleophilic attack of primary protein amine groups forming an 
ester bond and releasing an NHS group. Reaction conditions such as pH, molar 
proportion of protein:mPEG-NHS and reaction time were studied to obtain an enhanced 
yield of site-specific PEGylated conjugates. Furthermore, the effect of PEGylation on Cyt-
c chemical structure, function and stability over the time was also examined. The main 
results obtained identified the Cyt-c-PEG-8 (with eight PEG molecules attached) as the 
conjugate with the highest stability, proving that this chemical alteration is actually 
preserving the protein structure and function.  
 
2. Materials and methods 
2.1.  Materials 
Horse heart cytochrome c (Cyt-c, ≥ 95% purity), 2,2′-azino-di-(3-ethylbenzthiazoline 
sulfonic acid) (ABTS, ≥ 95% purity), hydrogen peroxide (99% purity), hydroxylammonium 
chloride (99% purity) were obtained from Sigma-Aldrich. The methoxy PEG N-
hydroxysuccinimide ester (mPEG-NHS, 5 kDa) was acquired from Nanocs with high 
purity. The aqueous buffer used in PEGylation reaction was the potassium phosphate 
buffer (100 mM). All other reagents were of analytical grade. The water used was double 
distilled, passed by a reverse osmosis system and further treated with a Milli-Q plus 185 
water purification apparatus. 
2.2. Cyt-c PEGylation 
The PEGylation reaction was carried following the method provided by the PEG 
derivative supplier.16 Briefly, Cyt-c was dissolved in 0.1 M of sodium phosphate buffer 
and allow to react with mPEG-NHS at room temperature and constant magnetic stirring 
of 400 rpm. Several parameters were optimized, namely the pH (7 - 12), protein:mPEG-
NHS molar proportion (1:5, 1:10, 1:25 and 1:35) and reaction time (15, 30 and 45 min).  
At the end, 2 M of hydroxylamine (1:10 v/v) was added to stop the reaction as well as 
to avoid the production of undesirable and unstable products (such as ester 
conjugation). 
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2.3. Purification of PEGylated conjugates 
PEGylation reaction mixtures were purified by size exclusion chromatography (SEC), 
using a Superdex 200 Increase 10/300 GL column (crosslinked agarose-dextran resin) 
(GE Healthcare) in an AKTA™ purifier system (GE Healthcare). The column was 
equilibrated with 0.01 M phosphate buffer (0.14 M NaCl, pH 7.4) and eluted with the 
same buffer at the flow of 0.75 mL min-1. The protein fractions (determined by U.V. at 
280 nm), corresponding to the unreacted Cyt-c and modified proteins Cyt-c-PEG-4 
(protein with 4 PEG molecules attached) and Cyt-c-PEG-8 (protein with 8 PEG molecules 
attached)  were stored at -20oC for further studies. The determination of Cyt-c 
concentration was carried out by the use of a calibration curve established in the SEC-
FPLC at the conditions described before. The retention time of Cyt-c (confirmed with the 
commercial and pure sample) was found to be ca. 24 min within an analysis time of 40 
min. The percentage yield of Cyt-c and Cyt-c modified conjugates was calculated dividing 
the FPLC peak area corresponding to the target protein by the total area of all peaks 
corresponding to all proteins and conjugates present in the sample. 
 
2.4. Determination of PEGylation degree of Cyt-c conjugates by SEC 
The PEGylation degree of the Cyt-c conjugates was determined by SEC.17,18 The 
determination of the molecular weight (MW) of protein conjugates and, consequently, 
the degree of PEGylation can be accomplished by the column calibration with several 
proteins with a known molecular weight. The column (Superdex 200 Increase 10/300 
GL) was calibrated using several proteins as MW markers: thyroglobulin 669 kDa, ferritin 
450 kDa, catalase 232 kDa, lactate dehydrogenase 136. 7 kDa, bovine serum albumin 67 
kDa, ovalbumin 45 kDa, carbonic anhydrase 31 kDa, soybean trypsin inhibitor 20.1 kDa, 
α-lactalbumin 14.4 kDa, cytochrome c 12.2 kDa, and the void volume (V0) was 
determined using blue dextran 2000. All standards were used from GE Healthcare. The 
standard proteins were run at the same conditions assayed for the SEC purification of 
Cyt-c conjugates, 0.01 M phosphate buffer (0.14 M NaCl, pH 7.4), at 0.75 mL min-1 of 
flow rate. The MW of the protein conjugates was determined by the linear relationship 
obtained by plotting the Kav value of the proteins calculated by the equation 1, and the 
logarithms of their MW. The calibration curve is presented in Fig. B.8 at Appendix B. 
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𝐾𝑎𝑣 =  
(𝑉𝑒−𝑉0)
(𝑉𝑇−𝑉0)
               (1) 
The elution volume (Ve) is the amount of eluent collected from the start of loading the 
sample to the point of its maximal elution; the (VT) corresponds to the total volume of 
the column. 
Nevertheless, the MW derived by this technique with globular proteins seems to be 
accurate to about ± 10%, resulting in uncertainty in the average number of PEG’s per 
Cyt-c inferior to ± 1. An example of each chromatogram corresponding to a specific 
PEGylation condition is depicted in Fig. B.9 at Appendix B. 
 
2.5. Circular dichroism (CD) spectroscopy 
CD spectra of Cyt-c and its modified forms were obtained in a Jasco J-720 
Spectropolarimeter (Tokyo, Japan). The final spectra were the average of six scans with 
subtraction of the buffer spectrum (0.01 M phosphate buffer, 0.14 M NaCl, pH 7.4). CD 
spectra were obtained in the far (190-260 nm) and near (250-350 nm) UV ranges. Far-
UV samples were placed in 1 mm optical length quartz cells with concentration ranging 
from 6 to 15 µM. Near-UV samples, with concentration ranging from 14 to 41 µM, were 
placed in 5 mm optical length quartz cells. Spectra intensities (θ, mdeg) were converted 
to residual molar ellipticity ([θ], deg.cm2.dmol-1) based on equation 2:  
[θ] =                (2) 
where (C) is the protein concentration in mol L-1, (l) is the optical length in cm and (n) 
is the number of residues in the protein, in this case, 104 residues. 
2.6. Determination of Cyt-c long-term stability 
Long-term stability was performed for both storage conditions, namely room (~25 oC) 
and refrigerated (4 oC) temperature. The peroxidase activity was measured during 60 
days and the residual activity (%) calculated taking into consideration the activity on day 
1 as 100%. The enzymatic activity of Cyt-c was determined by the catalytic oxidation of 
50 µM ABTS in the presence of 0.5 mM hydrogen peroxide.15 The concentration of non-
PEGylated and PEGylated Cyt-c was 10 µM in 0.01 M phosphate buffer (0.14 M NaCl, pH 
7.4). The reaction was initiated by the addition of hydrogen peroxide and the increase 
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in absorbance at 418 nm was measured in a SpectraMax plus 384 (Molecular Devices) 
spectrophotometer.  
2.7. SDS-PAGE  
Protein samples with 20 µL of volume were applied to a 12% polyacrylamide gel (10 x 
10.5 cm x 0.75 mm thick) under reducing conditions in accordance with Laemmli 
method.19 The electrophoretic run was performed by applying a 120 V potential 
difference for approximately 1h 30 min using vertical Mini Protean™ system (Bio-Rad, 
Hercules, CA, USA). Protein marker Precision Plus Protein was used (Bio-Rad). Gels were 
stained with Coomassie Brilliant Blue R-250 for visualization of protein bands.  
 
2.8. In silico studies: Molecular visualization of PEGylation 
The pKa of N-terminal and lysine residues based on Cyt-c crystal structure (PDB code, 
1HRC) and using the software H++ were determined to understand the location of PEG 
attachment in Cyt-c. Additionally, molecular models of Cyt-c were constructed using 
PyMOL (Molecular Graphics System, version 1.3, Schrödinger, LLC) based on the protein 
crystal structure. The in silico conjugation of four and eight molecules of mPEG (5 kDa) 
in lysine residues of Cyt-c to form Cyt-c-PEG-4 (LYS 22, 25, 27 and 39) and Cyt-c-PEG-8 
(LYS 22, 25, 27, 39, 55, 79, 86 and 87), was respectively performed. All PEG chains were 
auto-sculpted to adjust the proper molecular conformation.  
 
2.9. Statistical analysis 
PEGylation yields were experimentally quantified in triplicate for the three parameters 
under study, namely the pH, molar ratio and reaction time (each set of three 
determinations was used to calculate the average and respective standard deviations). 
Statistical data analysis was performed using one-way Analysis of Variance (ANOVA) and 
Tukey’s post-test, at a 5% level of significance. 
 
3. Results and discussion 
3.1.  Cyt-c PEGylation 
The selection of an appropriate PEGylation reaction in the design of site-specific 
polymer-protein conjugates to be applied in the biosensing field is the first step to obtain 
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a successful PEGylated product. Several of the final properties of the conjugate are 
directly related to the physical and chemical features of the selected PEG 
derivative.8,20,21 Moreover, the number and local reactivity of available attachment sites 
in the amino acid sequence of the target protein are important criteria to choose the 
type of PEGylation reaction.20 Therefore, the reaction design must be tailored to the 
protein of interest, depending on its physicochemical properties, amino acid sequence 
and final application.7,22 Taking this into account, the amino (-NH2) reactive PEGylation, 
using N-hydroxysuccinimide (NHS) functionalized poly(ethylene glycol) (mPEG-NHS) was 
selected, due to its inherent advantages. In this kind of PEGylation, the PEG polymer is 
generally attached to the ɛ amino group of lysine by a nucleophilic attack of the amine 
group to the ester carbonyl of the reactive PEG, releasing NHS as a byproduct (Fig. 
3.7.).16,23,24 Compared to other PEG-NHS ester derivatives, succinimidyl carbonate (SC) 
functionalized mPEG-NHS offers superior reactivity and higher stability in aqueous 
solution.16 
 
Fig. 3.7. Schematic overview of PEGylation reaction. 
 
The PEGylation of Cyt-c by reacting it with mPEG-NHS, resulted in three different 
degrees of polymer conjugation, these representing the attachment of four PEG 
molecules (Cyt-c-PEG-4), eight PEG molecules (Cyt-c-PEG-8), and a poly-PEGylated form 
(Cyt-c-Poly-PEG). In order to understand the location of PEGylation in Cyt-c, 
bioinformatics studies were conducted to determine the pKa of the amino acids that can 
be PEGylated (Table 3.2.) and to construct the molecular scheme of the Cyt-c PEGylated 
forms (Fig. 3.8.).  
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Fig. 3.8. Molecular visualization of theoretical lysine residues (LYS) of cytochrome c (Cyt-c, PDB code 1HRC) 
PEGylated, using the Software PyMOL. (A) Four residues of conjugation are highlighted: LYS - 22, 25, 27 
and 39, resulting in Cyt-c-PEG-4. (B) Eight residues of conjugation are defined i.e. LYS - 22, 25, 27, 39, 55, 
79, 86 and 87 resulting in Cyt-c-PEG-8. 
 
Primary amines exist at the N-terminus of each polypeptide chain and in the side-chain 
of lysine (Lys, K) amino acid residues.  PEGylation in amine groups preferentially takes 
place in deprotonated primary amines, in which the lone pair of electrons is freely 
available for the nucleophilic attack; therefore it deppends on the pKa of the residues. 
The location in the polypeptide chain is also important, since amino acids more exposed 
to the solvent and located in flexible regions of the protein are more likely to be 
PEGylated. Cyt-c contains 19 Lys residues and one N-terminal residue that can be 
potentially modified by PEG covalent binding. Of these, six are part of loop regions (four 
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in the largest loop more accessible to PEG and two in an intermediate loop), three are 
in the alpha-helix transition and the remaining are located in the alpha-helix 
composition (Table 3.2.). According to previous studies, the lysines more available for 
PEG attachment are Lys22, Lys25, Lys27, and Lys39, all located in the flexible region (Ω 
loop) of Cyt-c polypeptide chain. In this sense, the site-specific PEGylated form Cyt-c-
PEG-4 refers to PEG attachment to those amino acid residues. Regarding the other four 
lysines covalently bound to PEG in Cyt-c-PEG-8, Lys55, Lys60, Lys79, and Lys86 are the 
most probable binding sites. These lysines are present in flexible regions of the protein 
(Ω loop and alpha-helix transition). The N-terminal group cannot be PEGylated at neutral 
pH due to the extremely high pKa (Table 3.2.) that makes it preferentially protonated at 
most pH values and, therefore, enabling the occurrence of the nucleophilic attack. 
  
Table 3.2. pKa and location of the lysines (Lys) and N-terminal residue of Cyt-c (1HRC, PDB code). 
Residue pKa Location 
NT 11.8 N terminal 
Lys5 >12 alpha-helix 
Lys7 10.9 alpha-helix 
Lys8 9.7 alpha-helix 
Lys13 10.8 alpha-helix 
Lys22 9.9 Ω loop 
Lys25 11.2 Ω loop 
Lys27 10.9 Ω loop 
Lys39 10.3 Ω loop 
Lys53 10.7 alpha-helix 
Lys55 10.4 alpha-helix transition 
Lys60 10.4 alpha-helix transition 
Lys72 8.6 alpha-helix 
Lys73 11.0 alpha-helix 
Lys79 10.4 Ω loop 
Lys86 10.3 Ω loop 
Lys87 10.7 alpha-helix transition 
Lys88 10.4 alpha-helix 
Lys99 >12 alpha-helix 
Lys100 10.7 alpha-helix 
 
3.1.1. Effect of pH in the PEGylation of Cyt-c 
PEGylation reactions are mostly conducted in single-step unidirectional batch systems 
to guarantee that all products have followed the same procedure, enhancing validation, 
reproducibility, and optimization of the reaction. One of the key parameters to design a 
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site-specific PEGylation reaction is the pH. By the control of pH, PEGylation can be 
directed to produce specific conjugates, an essential feature to promote batch-to-batch 
control. The effect of pH in Cyt-c PEGylation is presented in Fig. 3.9. and, as can be seen, 
the number of PEGylated forms increases with the pH due to the higher probability of 
lysines to react with PEG derivative since in pH > pKa they are deprotonated. The 
unreacted protein quantity is also decreased in more alkaline pH as a result of a higher 
degree of PEGylation. An opposite trend is observed for pH > 10; the degree of 
PEGylation decreases and the concentration of unreacted protein increases to 66% at 
pH 12. This behavior could be explained due to the higher hydrolysis rate of the PEG 
derivate used when in alkaline solution, leading to lower concentrations of reactive PEG 
and consequently decreasing the yields of PEGylation. The highest yields of Cyt-c-PEG-4 
(38%) and Cyt-c-PEG-8 (26%) were both observed at pH 7, defined as the optimal pH in 
this specifc case.  
 
Note: All experiments were carried in triplicate. 
 
Fig. 3.9. Effect of pH on Cyt-c PEGylation yields. The PEGylation reaction was performed in 0.1 M 
phosphate buffer (at different pHs), 1:25 molar proportion (protein:mPEG-NHS, 5 KDa), at room 
temperature, for 30 minutes, and with a constant stirring of 400 rpm. Different letters indicate significant 
differences (P < 0.05) between conditions (A-E). 
pH 
Percentage of 
unreacted Cyt-c ± 
std (%) 
Percentage of  
Cyt-c-PEG-4 ± std 
(%) 
Percentage of  
Cyt-c-PEG-8 ± std 
(%) 
Percentage of  
Cyt-c-Poly-PEG ± std 
(%) 
7 23.63 ± 0.55 B 37.54 ± 0.47 A 26.48 ± 0.55 A 12.35 ± 0.63 D 
8 1.63 ± 0.04 DE 6.16 ± 0.38 D 14.18 ± 0.01 C 78.03 ± 0.41 B 
9 0.83 ± 0.26 E 2.40 ± 0.06 E 0 E 96.77 ±0.32 A 
10 4.39 ± 0.79 D 0.99 ± 0.05 E 0 E 94.62 ± 0.84 A 
11 13.18 ± 0.52 C 13.25 ± 0.32 C 20.86 ± 1.13 B 52.71 ± 1.33 C 
12 65.60 ± 1.83 A 26.06 ± 1.51 B 8.34 ± 0.32 D 0 E 
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Fig. 3.10. shows the electrophoretic profile (SDS-PAGE) of PEGylation reaction of Cyt-c 
at different pH values. The results depicted in this figure seem to corroborate the 
PEGylation yield data previously shown with each band representing one site-specific 
Cyt-c-PEGylated form. The bands presenting higher intensity correpond to pH 7 - 12, in 
opposition to those obtained for pH range between 8 and 10, in which the most intense 
bands are identifying the poly-PEGylated forms.   
 
Fig. 3.10. SDS-PAGE for the mixture obtained after PEGylation of Cyt-c with mPEG-NHS, at different pH 
values. Lane 1: molecular weight marker, Lane 2: Cyt-c. The protein mixtures obtained after PEGylation of 
Cyt-c were: Lane 3: pH = 7, Lane 4: pH = 8, Lane 5: pH = 9; Lane 6: pH = 10, Lane 7: pH = 11, Lane 8: pH = 
12. 
 
3.1.2. Effect of PEG derivative concentration in the PEGylation of Cyt-c 
The effect of PEG derivative concentration is a very important parameter to evaluate in 
order to attain a site-specific PEGylation. The effect of PEG derivate concentration on 
the PEGylation yield is depicted in Fig. 3.11. and Fig. 3.12. corresponds to the 
representative SDS-PAGE image of the reaction results. The lowest molar ratio values, 
specifically 1:5 and 1:10, resulted in less PEGylation extents and higher quantities of 
unreacted protein present. In addition, no band of poly-PEGylated forms was obtained 
at those experimental conditions. The optimal result was obtained at molar ratio 1:25 
corresponding to higher yields of site-specific Cyt-c-PEGylated forms. The upper molar 
ratio (1:35) promoted polydispersity of the PEGylated products due to the excess of PEG-
derivate.   
                                                                                                                PEGylation reaction 
CHAPTER 3  
 
129 
 
 
 
*All experiments were carried in triplicate. 
Fig. 3.11. Effect of molar ratio (protein:mPEG-NHS) on Cyt-c PEGylation yields. The PEGylation reaction 
was performed in 0.1 M phosphate buffer (pH = 7), at room temperature, for 30 minutes, and with a 
constant stirring of 400 rpm. Different letters indicate significant differences (P < 0.05) between 
conditions (A-C). 
 
 
 
Fig. 3.12. SDS-PAGE for the mixture obtained after PEGylation of Cyt-c at different molar proportions 
(protein:mPEG-NHS). Lane 1: molecular weight marker, Lane 2: 1:5, Lane 3: 1:10, Lane 4: 1:25, Lane 5: 
1:35. 
 
Molar ratio 
(protein:mPEG -
NHS) 
Percentage of 
unreacted Cyt-c ± 
std (%) 
Percentage of  
Cyt-c-PEG-4 ± std 
(%) 
Percentage of  
Cyt-c-PEG-8 ± std 
(%) 
Percentage of  
Cyt-c-Poly-PEG ± 
std (%) 
1:5 79.65 ± 0.41 A 17.80 ± 0.65 B 2.55 ± 0.25 C 0  C 
1:10 77.21 ± 4.42 A 20.04 ± 3.62 B 2.75 ± 0.80 C 0 C 
1:25 23.63 ± 0.55 B 37.54 ± 0.47 A 26.48 ± 0.55 B 12.35 ± 0.63 B 
1:35 9.44 ± 0.11 C 17.00 ± 0.06 B 32.10 ± 0.41 A 41.46 ± 0.59 A 
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3.1.3. Effect of time of reaction in the PEGylation of Cyt-c 
The reaction time for Cyt-c PEGylation was also investigated during 15, 30 and 45 min 
(Figs. 3.13. and 3.14.). Results showed that the poly-PEGylation yield increases with the 
reaction time. Therefore, higher yields of Cyt-c-PEG-4 (45%) and Cyt-c-PEG-8 (32%) were 
obtained in the shortest time of 15 min, with no poly-PEGylated forms produced, what 
could facilitate the purification process. Furthermore, the shorter times required in this 
process will translate into economic advantage. 
 
*All experiments were carried in triplicate. 
Fig. 3.13. Effect of reaction time on Cyt-c PEGylation yields. Effect of molar ratio (protein:mPEG-NHS) on 
Cyt-c PEGylation yields. The PEGylation reaction was performed in 0.1 M phosphate buffer (pH = 7), 1:25 
molar proportion (protein:mPEG-NHS, 5 KDa), at room temperature, and with a constant stirring of 400 
rpm. Different letters indicate significant differences (P < 0.05) between conditions (A-C). 
 
 In summary, a designed and tailor-made PEGylation reaction was developed and the 
best experimental conditions were set as pH 7, 1:25 molar ratio (Cyt-c:mPEG-NHS) and 
15 min reaction time. At these conditions we obtained two forms of site-specific 
PEGylated Cyt-c with no undesirable poly-PEGylated forms. Those PEGylated Cyt-c forms 
were then isolated through SEC-FPLC and then further applied in spectroscopic studies 
to understand the effect of PEGylation on the Cyt-c structure, as well as in the long-term 
stability of the conjugates.  
 
Reaction time 
(min) 
Percentage of 
unreacted Cyt-c ± 
std (%) 
Percentage of  
Cyt-c-PEG-4 ± std 
(%) 
Percentage of  
Cyt-c-PEG-8 ± std 
(%) 
Percentage of  
Cyt-c-Poly-PEG ± 
std (%) 
15 23.37 ± 1.93 A 44.70 ± 1.43 A 31.93 ± 0.51 A 0 C 
30 23.63 ± 0.55 A 37.54 ± 0.47 B 26.48 ± 0.55 B 12.35 ± 0.63 B 
45 11.42 ± 0.79 B 12.47 ± 0.13 C 26.13 ± 0.68 B 49.98 ± 1.34 A 
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Fig. 3.14. SDS-PAGE for the mixture obtained after PEGylation of Cyt-c with mPEG-NHS at different 
reaction times. Lane 1: molecular weight marker, Lane 2: 15 min, Lane 3: 30 min, Lane 4: 45 min. 
 
3.2. Effect of PEGylation on Cyt-c structure 
To verify the effect of PEGylation on Cyt-c secondary and tertiary structures, CD 
measurements were performed. The UV CD spectra (Fig. 3.15. and 3.16.) showed the 
characteristic tertiary and secondary structural fingerprints of Cyt-c. The spectrum 
shows a peak at around 330 nm with a small peak at 290 nm, characteristic of Trp. 
Between 280 and 290 nm, the Tyr peaks can be observed and at around the 255–270 
nm a weak peak of Phe is present. PEGylation of Cyt-c caused no significant spectral 
changes demonstrating that PEGylation did not disrupt Cyt-c tertiary structure (Fig. 
3.15.).  Similarly, no spectral changes were found by observation of the far-UV CD 
spectra upon PEGylation (Fig. 3.16.); the different proteinic forms exhibited negative 
intensity bands centered at 208 and 222 nm and a positive peak at the 195-200 nm 
region of the spectrum, characteristic of a predominant α-helical secondary structure. 
Our results corroborate with previous studies,12 in which other types of Cyt-c PEGylation 
also did not compromise the protein stability.  
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Fig. 3.15. Near-UV CD spectra of Cyt-c (▬), Cyt-c-PEG-4 (▬) and Cyt-c-PEG-8 (▬) in 0.01 M sodium 
phosphate buffer (0.14 M NaCl, pH = 7.4) in the region reflecting the protein tertiary structure. 
 
Fig. 3.16. Far-UV CD spectra of Cyt-c (▬), Cyt-c-PEG-4 (▬) and Cyt-c-PEG-8 (▬) in 0.01 M sodium 
phosphate buffer (0.14 M NaCl, pH = 7.4) in the region reflecting the protein secondary structure. 
 
3.3. Effect of PEGylation on the long-term stability of native and PEGylated forms 
To study the Cyt-c long-term stability in its native and PEGylated forms (in solution), it 
was measured the residual Cyt-c activity using the ABTS oxidation procedure during 60 
days at different temperatures (Fig. 3.17.). Both Cyt-c PEGylated conjugates showed 
higher residual activity than free Cyt-c from room and refrigirated temperatures. When 
stored for 60 days at 4 oC, Cyt-c-PEG-8 retained 80% of its activity and Cyt-c-PEG-4 
retained 63%, while the free Cyt-c retained only 30% of its activity. As expected, Cyt-c 
(free and PEGylated forms) was more stable at lower temperature. At room 
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temperature storage (25 oC) the free Cyt-c residual activity was only 22% contrasting 
with ≥53% for both Cyt-c PEGylated forms. The Cyt-c with higher mPEG content (Cyt-c-
PEG-8) presented superior stability than Cyt-c-PEG-4, particularly at low temperature. 
These results demonstrate that the site-specific PEGylation is a valuable strategy to 
increase Cyt-c stability during storage.  
 
Fig. 3.17. Plot of the residual activity of Cyt-c and PEGylated protein forms (Cyt-c-PEG-4 and Cyt-
c-PEG-8) determined during 60 days at 4oC (A) and room temperature of 25oC (B). 
 
4. Conclusions 
In this work, Cyt-c PEGylated conjugates, namely Cyt-c-PEG-4 and Cyt-c-PEG-8 were 
produced, and their potential demonstrated as biosensors. The optimal PEGylation 
conditions for site-specific reaction were optimized; pH 7, 1:25 molar ratio (Cyt-c:mPEG-
NHS) and 15 min of reaction, resulting in yields of 45% for Cyt-c-PEG-4 and 32% for Cyt-
c-PEG-8. The Cyt-c PEGylation caused no significant structural changes, which was 
evaluated through CD analysis, demonstrating that PEGylation did not compromise the 
protein conformation. Additionally, Cyt-c-PEGylated forms were found to be 
significantly more stable over the time than the free protein, with the higher stability 
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observed for the Cyt-c-PEG-8. The improved stability of PEGylated Cyt-c conjugates 
clearly brings advantages for its use as a biosensor by the possibility of extending its 
product half-life time.  
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3.3. PEGylation as an efficient tool to enhance protein thermostability: a 
kinetic and thermodynamic study on cytochrome c 
 
Santos, J. H. P. M., Carretero, G., Coutinho, J. A. P., Ventura, S. P. M., Converti, A. & 
Rangel-Yagui, C. O. International Journal of Biological Macromolecules, 2019, 
submitted.7 
Abstract  
Cytochrome-c from equine heart was kinetically and thermodynamically investigated 
either in its native (Cyt-c) and PEGylated forms. In this work, two Cyt-c-PEG conjugates 
with different PEGylation degrees, namely 4 and 8, represented by Cyt-c-PEG-4 and Cyt-
c-PEG-8, were tested. The main results exhibited maximum activities at 80◦C, and their 
irreversible deactivation was well described by a first-order kinetic. The results of 
activity collected at different temperatures (T = 30-100◦C) were then used to estimate 
the activation energy of the catalysed Cyt-c reaction (E* = 10.22, 7.51 and 8.87 kJ.mol-1 
for Cyt-c, Cyt-c-PEG-4 and Cyt-c-PEG-8) and the standard enthalpy variation of enzyme 
unfolding (ΔHoU = 33.82, 109.44 and 58.43 kJ.mol-1 for Cyt-c, Cyt-c-PEG-4 and Cyt-c-PEG-
8, respectively). When temperature increased in the range of temperatures 70-95 ◦C, 
the deactivation rate constant (kd) increased from 0.17 to 0.59 h−1, while the half-life 
(t1/2) decreased from 4.00 to 1.18 h for unreacted Cyt-c. However, for the PEGylated 
conjugates, the kd was reduced in the whole range of temperatures, while the t1/2 was 
doubled for Cyt-c-PEG-8 and increased 1.1-1.7-fold for Cyt-c-PEG-4. The results of 
residual activity tests carried in the temperature range 70–95 ◦C allowed to estimate the 
activation energy (E*d = 50.51, 72.63 and 63.36 kJ.mol-1 for Cyt-c, Cyt-c-PEG-4 and Cyt-
c-PEG-8), enthalpy (ΔH*d), entropy (ΔS*d) and Gibbs free energy (ΔG*d) of the enzyme 
irreversible denaturation. The higher enthalpic contributions of PEGylated conjugates in 
addition to the increase in ΔG*d, compared to the native protein, indorsed the protective 
role of PEGylation. Negative values of ΔS*d suggest the occurrence of aggregation 
phenomenon by increasing the temperature, further confirmed by thermal studies with 
circular dichroism where the change on the conformational protein structure was 
shown. The thermodynamic parameters determined suggest that the PEGylated Cyt-c 
has an enhanced thermostability, being this important for industrial biosensing 
applications.  
 
 
Keywords: Thermodynamics; thermostability; cytochrome c; protein PEGylation; 
bioconjugation; enzyme unfolding. 
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1. Introduction 
Horse heart cytochrome c (Cyt-c) is a heme protein involved in mitochondrial electron 
transfer with bio-electrochemical applications for hydrogen peroxide, polycyclic 
aromatic hydrocarbons (PAHs), and nitric oxide biosensing.1 Cyt-c is recurrently applied 
on the catalysis of several chemical reactions including hydrogen peroxide reduction,1 
lipid peroxidation,2 oxidation3 and hydroxylation4 of aromatic compounds. The 
peroxidase-like activity of Cyt-c has been demonstrated by the oxidation of various 
electron donors, among which are the 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic 
acid) (ABTS) and PAHs.5 This enzyme is considered an important redox biocatalyst since 
it is resistant to catalysis in organic solvents due to the covalent binding of the heme 
prosthetic group to the protein, it is stable in a wide range of pH (from 2 to 11), and of 
low cost. However, there is a need to improve its thermostability to increase the 
spectrum of applicability of Cyt-c as a biocatalyst and biosensor. One of the approaches 
followed to improve the thermostability of proteins is related with their chemical 
modification by bioconjugation.6–8 This process is carried by the covalent link of a 
protective polymer to the biomolecule being thermostabilized. The poly(N-(2-
hydroxypropyl) methacrylamide) (PHPMA), poly(oligoethylene glycol methyl ether 
methacrylate) (POEGMA), poly(D,L-lacticco-glycolic acid) (PLGA), poly(glutamic acid) 
(PGA), poly(N-isopropyl acrylamide) (PNIPAM), poly(N,N'-diethyl acrylamide) (PDEAM), 
polystyrene, and poly(ethylene glycol) (PEG), are some examples of polymers of 
biological and synthetic origin used for this purpose. PEG is a biocompatible polymer, 
with low immunogenicity, antigenicity and toxicity, it is soluble in water and other 
organic solvents. It has a high mobility in solution, making it one of the polymers most 
used for bioconjugation.9 In addition, PEG is, among the few synthetic polymers, 
considered safe by the Food and Drug Administration (FDA) and European Medicine 
Agency (EMA).10 The concept of protein PEGylation has been applied to several 
enzymes, leading to a new era of polymeric conjugate biocatalysts with improved 
properties. In the particular case of Cyt-c, PEGylation appears to be the first line option 
to enhance its thermostability.11 Behind the improvement of the thermostability, 
PEGylation improves several other properties, including its long-term stability, solubility 
in water, resistance to organic solvents and biocompatibility.10,12 These conditions are 
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exceptionally important taking into account that Cyt-c is used as a model biocatalyst in 
the biosensing field. The Cyt-c PEGylation was shown to kinetically stabilize the protein 
tertiary structure7, with the additional advantage of preserving the catalytic activity of 
enzymes at high temperatures.8 Nevertheless, a thermostability study on the effect of 
PEGylation on this specific redox enzyme has never been reported.  
The thermodynamic and kinetic studies can provide valuable information about the 
thermostability of enzymes at the operating temperature. Concerning the kinetic 
modelling of thermostability, a first-order deactivation reaction is usually adopted, 
describing its irreversible inactivation (denaturation), whose kinetics is usually 
expressed in terms of enzyme half-life (t1/2).13 On the other hand, the activation energy 
and the changes in the Gibbs free energy, enthalpy and entropy of irreversible 
inactivation are important parameters widely reported in literature to describe the 
thermodynamic behaviour of the enzyme denaturation phenomenon.14 
In this work, the kinetic and thermodynamic parameters of the activity and 
thermostability of two PEGylated conjugates, Cyt-c-PEG-4 and Cyt-c-PEG-8, were 
investigated and compared with the behaviour of the native protein. 
 
2. Materials and Methods 
2.1. Materials 
Horse heart cytochrome c (Cyt-c, ≥ 95% purity), 2,2′-azino-di-(3-ethylbenzthiazoline 
sulfonic acid) (ABTS, ≥ 95% purity), hydrogen peroxide (99% purity), and 
hydroxylammonium chloride (99% purity) were obtained from Sigma-Aldrich/Merck 
(Darmstadt, Germany). High-purity methoxy poly(ethyleneglycol) N-hydroxysuccinimide 
ester (mPEG-NHS, 5 kDa) was acquired from Nanocs (New York, USA). The aqueous 
medium used to perform the PEGylation reaction is composed of potassium phosphate 
buffer at 100 mM. All other reagents were of analytical grade. All solutions were 
prepared using double distilled water, passed through a reverse osmosis system and 
further treated with a Milli-Q plus 185 water purification apparatus (Millipore/Merck, 
Darmstadt, Germany).   
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2.2. PEGylation reaction and purification of PEGylated products 
The PEGylation reaction was carried according to the PEG derivative supplier.15 Briefly, 
Cyt-c was dissolved in 0.1 M of sodium phosphate buffer and allowed to react with 
mPEG-NHS at room temperature (25  1°C) and constant magnetic stirring of 400 rpm. 
The experimental conditions of the reaction were pH = 7.0, 1:25 protein:mPEG-NHS 
molar proportion and reaction time of 15 min.  At the end, 2.0 M of a hydroxylamine 
solution (1:10 v/v) was added to stop the reaction as well as to avoid the formation of 
undesirable and unstable byproducts like conjugated esters.  
After PEGylation and considering that the reaction is not complete, a complex media 
was obtained, composed of native Cyt-c, and two PEGylated forms, the Cyt-c-PEG-4 and 
Cyt-c-PEG-8. The PEGylated forms and unreacted Cyt-c were then separated by fast 
protein size exclusion liquid chromatography (SEC-FPLC), For that, a Superdex 200 
Increase 10/300 GL column filled with crosslinked agarose-dextran resin (GE Healthcare 
Life Sciences, Chicago, USA), in an AKTA™ purifier system (GE Healthcare) was used. The 
column was equilibrated with 0.01 M of potassium phosphate buffer (0.14 M of NaCl, 
pH 7.4) and eluted with the same buffer at a flow rate of 0.75 mL.min-1. Protein fractions 
with UV absorption at 280 nm, corresponding to the unreacted Cyt-c and PEGylated 
proteins were stored at -20oC for further studies. Concentrations of Cyt-c and Cyt-c-PEG 
conjugates were determined using a calibration curve established in the SEC-FPLC under 
the conditions previously described. The PEGylation degree of Cyt-c conjugates was 
determined by SEC and eletrophoresis.16 The determination of the molecular weights of 
the protein conjugates and, consequently, the degree of PEGylation was based on a 
calibration curve with several proteins with known molecular weights. 
 
2.3. Cyt-c activity assay 
The enzymatic activity of Cyt-c was determined by the catalytic oxidation of 50 µM of 
2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) in presence of 0.5 mM of 
hydrogen peroxide.5,6 The concentration of non-PEGylated and PEGylated forms was 10 
µM in 0.01 M of potassium phosphate buffer (0.14 M of NaCl, pH 7.4). The reaction was 
started by the addition of hydrogen peroxide and followed by the absorbance’ increase 
at 418 nm.  
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2.4. Circular dichroism spectroscopy 
Circular dichroism (CD) spectra of Cyt-c and PEGylated conjugates were acquired either 
in far-UV (190-260 nm) or near-UV (250-350 nm) range using a spectropolarimeter, 
model Jasco J-720 (Jasco, Tokyo, Japan). The final spectra were the average of 6 scans, 
followed by subtraction of the spectrum of 0.01 M of potassium phosphate buffer (0.14 
M of NaCl, pH = 7.4) obtained under the same conditions. Samples were placed in 1.00 
mm optical length quartz cells with concentrations ranging from 13 to 15 µM. the 
spectra intensities (θ, mdeg) were converted to residual molar ellipticity ([θ], 
deg.cm2.dmol-1) by the following expression: 
[θ] =
θ
10.C.l.n
                                                                                                                                 (1) 
where C is the protein concentration expressed in M, l is the optical length expressed in 
cm and n is the number of amino acid residues in the protein (104 in this case). 
The thermal stability of Cyt-c and its modified forms was also investigated by CD. 
Temperature was scanned from 30 to 90°C, at a rate of 1°C.min-1, and back from 90 to 
30°C to study, respectively, the unfolding and refolding processes suffered by the 
enzyme. Samples with concentrations ranging from 2 to 4 µM were placed in 5.00 mm 
optical length quartz cells, and the intensities of ellipticity at 222 nm (θ222, mdeg) were 
recorded throughout the experiment. Intensities of ellipticity were then converted to 
residual molar ellipticity ([θ]222, deg.cm2.dmol-1). 
 
2.5. Determination of kinetic parameters 
The Michaelis constant (Km) and the maximum rate (vmax) of the enzyme-catalyzed 
reaction were determined through a double reciprocal (Lineweaver–Burk) plot of Cyt-c 
activity versus ABTS concentrations (0.025-0.300 mM). The turnover number (kcat), 
defined as the maximum number of chemical conversions of substrate molecules per 
second that a single catalytic site executes at a given enzyme concentration, was 
calculated for Cyt-c and both PEGylated conjugates. The kinetic parameters were 
measured in triplicate and expressed as means  standard deviations. All experimental 
data were analysed using the Prism 6.0 software (Graphpad Software, San Diego, CA, 
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USA) for non-linear regression applied to Michaelis-Menten equation, and the 
determination coefficient (R2) was used to compare the fitting performance. The 
Michaelis-Menten curves of Cyt-c, Cyt-c-PEG-4 and Cyt-c-PEG-8 are provided in Fig. B.10 
at Appendix B. 
 
2.6. Thermodynamic study 
As described by Converti et al.,17 the thermal inactivation of enzymes can be described 
by an enzyme unfolding equilibrium: 
E  Eu 
where E and Eu are the folded and unfolded forms of the enzyme, respectively, with 
equilibrium constant KU, coupled with a time-dependent irreversible denaturation, 
characterized by a first-order rate constant (kd). At temperatures below the optimum 
temperature (T < Topt), the equilibrium is shifted to the left side favouring the native, 
folded form of the enzyme, being the rate constant of the enzyme-catalysed reaction 
(k0) described by the Arrhenius model. Conversely, when T > Topt, the equilibrium is 
shifted to the right side favouring the unfolded form18 and leading, after substitution of 
enzyme material balance in the KU definition and Michaelis-Menten equation, to Eq. (2): 
k0 =
A exp(-E*/RT)
1+ B exp(- ΔHU
o /RT)
              (2) 
where E* is the activation energy of Cyt-c-catalyzed reaction, R the ideal gas constant 
(8.314 J.K−1.mol−1), A and B, the Arrhenius and an additional pre-exponential factors, and 
ΔHoU the standard enthalpy variation of the inactivation equilibrium previously 
described. If the unfolded form of the enzyme becomes predominant, what is observed 
while raising the temperature, Eq. (2) may be simplified originating Eq. (3): 
k0 =
A
B
exp (
ΔHU
o -E*
RT
)               (3) 
For the protein conjugates Cyt-c-PEG-4 and Cyt-c-PEG-8, the calculation of k0 values is a 
challenge. Therefore, the proportionality existing between this parameter and the initial 
enzyme activity (v0) was adopted. The E* and ΔHoU were then estimated, either for 
                                                                                                                PEGylation reaction 
CHAPTER 3  
 
142 
 
native or PEGylated forms of Cyt-c, from the slopes of the straight lines of lnv0 vs. 1/T, 
according to the Arrhenius equation and Eq. (3), respectively.  
A different approach was used for the enzyme irreversible thermo-inactivation 
(denaturation), which was described by a first-order reaction kinetics – Eq. (4): 
vd = kdE                (4) 
where vd is the rate of enzyme denaturation and E represents the concentration of its 
active form. Introducing the activity coefficient (ѱ), defined as the ratio between E and 
the enzyme concentration before exposition to different temperatures (E0), kd was 
estimated at each temperature from the slope of the straight line of lnѱ vs. time. The 
activation energy of irreversible enzyme denaturation (E*d) was then estimated from 
the slope of the straight line of lnkd vs. 1/T. The activation enthalpy (ΔH*d), Gibbs free 
energy (ΔG*d) and entropy (ΔS*d) of denaturation either for the native or PEGylated 
forms of Cyt-c were finally estimated, as described by Melikoglu et al.,19 and through 
Eqs. (5) to (7): 
ΔHd
* =  Ed
* -RT              (5) 
ΔGd
* = -RT ln [
kd h
kB T
]              (6) 
ΔSd
* =  
ΔHd
* -ΔGd
*
T
                 (7) 
where kB and h are the Boltzmann and Planck constants, respectively.  
The enzyme half-life (t1/2) was defined as the time of exposure at a given temperature 
to reduce E to one half of E0 and calculated by Eq. (8):19 
t1/2 =  
ln2
kd
                (8) 
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3. Results and discussion 
3.1. Structural effects of Cyt-c PEGylation 
Cyt-c was modified with mPEG-NHS (5 kDa) forming a heterogeneous mixture of 
unreacted protein, two PEGylated conjugates with different PEGylation degrees 
(number of grafted polymer chains) and PEGylation by-products (e.g. salts and PEG 
derivative). Fast protein size exclusion liquid chromatography was applied in the 
separation of the different PEGylated forms as well as on the determination of the 
PEGylation degree, i.e. the number of PEG chains attached to Cyt-c. In particular, the 
PEGylation reaction led to two purified fractions with four and eight mPEG chains per 
Cyt-c molecule (on average), similarly to other PEGylated conjugates previously 
reported in literature for this enzyme.6,20 
To determine the effect of PEGylation on the Cyt-c secondary and tertiary structures, 
circular dichroism spectroscopy was employed. The far-UV and near-UV circular 
dichroism spectra of unreacted Cyt-c and both PEGylated conjugates were evaluated 
being the main results depicted in Figs. 3.18.A and 1B. In these figures, the characteristic 
secondary and tertiary structural fingerprints of Cyt-c are identified. The peak around 
330 nm and the small peak at 300 nm are characteristic of tryptophan (Trp), those 
between 280 and 290 nm representative of tyrosine (Tyr) and the ones around 255–270 
nm typical of phenylalanine (Phe). However, as previously observed by other authors,7,20 
the PEGylation reaction did not cause any significant spectral change either in the far 
(Fig. 3.18.A) or the near (Fig. 3.18.B) UV region, thus proving that the protein tertiary 
structure was maintained (Fig. 3.18.B). Moreover, the different protein forms exhibited 
negative intensity bands centred at 208 and 222 nm and a positive peak in the 195-200 
nm region of the spectrum, which are characteristic of a predominant α-helical 
secondary structure. 
The Cyt-c thermal stability (folding/unfolding) was also investigated through circular 
dichroism (Fig. 3.18.C). The unfolding curves showed similar behaviour between the 
three Cyt-c forms. In this case, the proteins were found to be stable up to 75°C and 
unfolded above this temperature. Nevertheless, the results demonstrated that the 
unreacted Cyt-c has refolded more efficiently than Cyt-c-PEG-4, followed by Cyt-c-PEG-
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8, suggesting that the PEG chain interferes with the refolding process, probably by steric 
hindrance of the unfolded protein chain during refolding.21 
 
Fig. 3.18. (A) Far-UV and (B) Near-UV circular dichroism spectra of equine heart cytochrome c either in 
native form (Cyt-c, ▬) or PEGylated with 4 (Cyt-c-PEG-4, ▬) or 8 (Cyt-c-PEG-8, ▬) PEGs. Experiments 
were carried out with 13-15 µM of Cyt-c/Cyt-c-PEG-4/Cyt-c-PEG-8 in 0.01 M phosphate buffer (0.14 M 
NaCl, pH = 7.4) at room temperature (251°C). (C) Thermal stability curves of unfolding () and refolding 
(▬) processes of the same enzyme preparations. 
 
3.2. Kinetic parameters 
To demonstrate the influence of PEGylation on the kinetics of enzyme-catalysed 
reaction, the activity of unreacted Cyt-c and the PEGylated conjugates was evaluated in 
terms of their capacity to oxidize ABTS in presence of 0.25 mM of hydrogen peroxide 
(Table 3.3.). The main kinetic parameters of this reaction, namely the Michaelis constant 
(Km), the turnover number (kcat) and the maximum reaction rate (vmax), were calculated 
from the experimental results of activity carried by varying the initial substrate 
concentration (S0) from 0.025 to 0.300 mM. The nonlinear regression of the 
experimental data of reaction rate vs. the ABTS concentration revealed that all the three 
enzyme preparations presented, with good correlation (R2 > 0.95), a Michaelis-Menten 
kinetics. The kinetic parameters estimated for the three preparations varied in the 
ranges of 36.00 ± 6.24 µM < Km < 85.21 ± 11.23 µM, 0.34 ± 0.03 min-1 < kcat < 0.91 ± 0.05 
min-1 and 0.41 ± 0.02 nmol.min-1 < vmax < 1.09 ± 0.05 µmol.min-1. The slight decrease of 
kcat and vmax, along with the increase in Km observed for PEGylated conjugates in 
                                                                                                                PEGylation reaction 
CHAPTER 3  
 
145 
 
comparison with the native protein, indicate the negative effect of the PEGylation on 
the Cyt-c catalytic performance. This effect was confirmed by the improvement of the 
catalytic activity by decreasing the PEGylation degree, in which Cyt-c-PEG-8 presented 
lower kcat and higher Km than Cyt-c-PEG-4. This behaviour was already observed in 
previous works, where the decrease of the activity of several enzymes after PEGylation 
was reported.22,23 Moreover, the PEGylation ability to stabilize the enzymes structure, 
even at high temperatures, compensates the decay of the kinetic parameters (i.e. kcat/Km 
ratio).22,24,25 Laccase is an example where the PEGylation was shown to reduce the 
kcat/Km ratio for the ABTS oxidation.24 Since in the present study the circular dichroism 
data excluded significant structural alterations of Cyt-c induced by PEGylation, these 
variations in the kinetic parameters may be attributed to (i) minor structural alterations 
in the heme environment7 and/or (ii) to the loss of enzyme structural flexibility caused 
by the polymer binding26. In terms of oxidation of polyaromatic hydrocarbons (PAHs), 
the effect of Cyt-c PEGylation was different from that observed for other electron 
donors. For instance, in the specific case of tetrahydrofuran, the Cyt-c PEGylation was 
reported to induce a positive effect on the kinetics parameters, with an increase in the 
kcat/Km ratio from 4.1 min-1.mM-1 to 132 min-1.mM-1.8,27 Nevertheless, the oxidation of 
electron donors such as ABTS by Cyt-c-PEGylated proteins would still be advantageous 
taking into consideration the various beneficial effects of attaching PEG to the protein 
structure, for example its improved thermostability. 
 
Table 3.3. Kinetic parameters of Cyt-c-catalysed reaction for the native cytochrome c (Cyt-c) or PEGylated 
conjugates, the Cyt-c-PEG-4 and Cyt-c-PEG-8. The catalytic oxidation of ABTS was performed in the 
presence of 0.5 mM of H2O2, at 251°C and pH 7.4. 
aMichaelis constant. 
bMaximum reaction rate. 
cTurnover number. 
Protein 
Km 
(µM)a 
vmax 
(nmol.min-1)b 
kcat 
(min-1)c 
kcat/Km 
(min-1.mM-1) 
R2 
Cyt-c 36.00 ± 6.24 
 
1.09 ± 0.05 
 
0.91 ± 0.05 25.30 0.956 
Cyt-c-PEG-4 73.24 ± 6.40 
 
0.73 ± 0.04 
 
0.61 ± 0.03 8.33 0.958 
Cyt-c-PEG-8 85.21 ± 11.23 0.41 ± 0.02 0.34 ± 0.03 4.04 0.975 
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3.3. Thermodynamic study 
Thermodynamic studies are important to understand the role of temperature on the 
enzymes activity. Here, the effect of the Cyt-c PEGylation degree on the protein 
reversible unfolding and long-term thermostability was investigated. 
3.3.1. Thermal inactivation – Enzyme unfolding 
The optimum temperature in terms of Cyt-c activity was identified by performing activity 
tests varying the temperature (T) from 30 to 100 ◦C. To minimize the influence of the 
irreversible denaturation on the activity of Cyt-c, only the initial values of enzyme 
activity (v0) were taken into account. Cyt-c and Cyt-c-PEG conjugates proved to be active 
on the range of temperatures from 30 to 80 ◦C, with an optimum temperature at 80 ◦C, 
in accordance with literature.1  
The semi-log plot of lnv0 vs. 1/T showed two tendencies. At temperatures below 80◦C, a 
linear decrease was found (Fig. 3.19.B), following the typical Arrenhius-type behaviour. 
Contrariwise, beyond 80°C, the opposite trend was observed (Fig. 3.19.A), suggesting 
temperature-driven enzyme unfolding. That being the case, from the slopes of the 
straight lines in the temperature ranges 30-80◦C (T < Topt) and 80-100◦C (T > Topt), the 
activation energies of the enzyme-catalysed reaction (E*) and the standard enthalpy 
changes of enzyme unfolding (ΔHoU) were estimated for the native and PEGylated forms 
with satisfactory correlations (R2 > 0.84 and > 0.97, respectively) (Table 3.4.). E* was 15-
36% higher for the native protein (10.22 kJ.mol-1) than the value estimated for the 
PEGylated conjugates, suggesting the reduction of the energy of the transition state 
promoted by the PEGylation. The very low E* values estimated for all preparations 
indicate that little energy was required to form the transition state of ABTS oxidation, 
thus highlighting an effective oxidation capacity. Apparently, they seem to be 
inconsistent with the lower catalytic performance at mild temperatures (T < Topt) of 
PEGylated conjugates, denoted by lower vmax and higher Km values, compared to the 
native enzyme. This apparent inconsistency may be the result of (i) enzyme unfolding 
and/or irreversible denaturation interference (see the following section) on the starting 
activity, (ii) insufficient predominance of enzyme unfolding at T > Topt, thereby making 
simplification of Eq. (1) to Eq. (2) not fully applicable.  
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Fig. 3.19. Arrhenius-type plots of initial activity of Cyt-c and PEGylated conjugates with 4 (Cyt-c-PEG-4) or 
8 (Cyt-c-PEG-8) PEGs attached, using 0.300 mM ABTS as a substrate. 
 
Table 3.4. Thermodynamic parameters of Cyt-c-catalyzed reaction and reversible unfolding of native Cyt-
c, Cyt-c-PEG-4 and Cyt-c-PEG-8 estimated according to the Arrhenius equation. The concentration of non-
PEGylated and PEGylated Cyt-c was 10 µM in 0.01 M of potassium phosphate buffer (0.14 M of NaCl, pH 
7.4). The catalytic oxidation of the substrate ABTS was performed in the range of T = 30 – 100 oC (ΔT = 10 
oC). 
 
 
 
 
 
 
Note: Activation energy of Cyt-c constant. 
 
PEGylation also increased the ΔHoU of thermal inactivation from 33.82 kJ.mol-1 for the 
native protein up to 109.44 kJ.mol-1 for Cyt-c-PEG-4. These results suggest the enzyme 
stabilization against unfolding at T > Topt. Additionally, the higher ΔHoU value for Cyt-c-
Protein 
E*  
(kJ.mol-1) 
ΔHoU  
(kJ.mol-1) 
Cyt-c 10.22 33.82 
Cyt-c-PEG-4 7.51 109.44 
Cyt-c-PEG-8 8.87 58.43 
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PEG-4 compared with Cyt-c-PEG-8 makes reasonable the hypothesis that excess 
PEGylation partially reduced this benefit. As suggested by Gaertner and Puigserver,28 
the entropic penalty related to the restricted motion of some amino acid groups on the 
protein surface due to the shell-like structure formed by coiled PEG chains influences 
protein stability.  
3.3.2. Thermostability – Irreversible enzyme denaturation 
Long-term residual activity tests were carried in the temperature range 70–95 ◦C, being 
the results in terms of residual activity coefficient (ψ) illustrated in the semi-log plots of 
Fig. B.11 at Appendix B. The residual activities of Cyt-c and PEGylated conjugates 
followed the typical first-order decay due to denaturation already observed for other 
oxidoreductases.29 For biosensors, the enzyme half-life (t1/2) is a key parameter in terms 
of economic feasibility and resistance to thermal inactivation, that has become a 
required property for industrial applications of catalysts.30,31  
The thermodynamic and kinetic parameters of the irreversible denaturation process are 
summarized in Table 3.5.. As can be seen, t1/2 progressively decreased and the rate of 
the first-order Cyt-c thermo-inactivation (kd) progressively increased with the increase 
in temperature, which means that its irreversible denaturation is more extensive. 
Regarding the effect of PEGylation, the protective role of PEG conjugation is confirmed, 
since both Cyt-c-PEG-4 and Cyt-c-PEG-8 exhibited higher t1/2 compared to the native 
protein. Additionally, the number of PEGs grafted to the protein greatly enhanced the 
enzyme long-term thermostability. Indeed, the higher the PEGylation degree, the longer 
the t1/2 (about twice and 1.1-1.7-fold that of Cyt-c than the values obtained for Cyt-c-
PEG-8 and Cyt-c-PEG-4, respectively).  
Semi-log plot of lnkd vs. 1/T allowed estimating, with good correlation (R2 > 0.96), the 
activation energies of denaturation (E*d) (Fig. 3.20.). In this case, 50.51 kJ.mol-1, 72.63 
kJ.mol-1 and 63.36 kJ.mol-1 were the data obtained for Cyt-c, Cyt-c-PEG-4 and Cyt-c-PEG-
8, respectively. The higher values of E*d obtained for the PEGylated conjugates when 
compared to the one found for the native protein confirmed the thermostability 
promoted by PEGylation. Moreover, the higher E*d value for Cyt-c-PEG-4 compared to 
Cyt-c-PEG-8 indicated that excess PEGylation has a negative impact, not only for enzyme 
unfolding, as previously discussed, but also on the conjugates thermostability. The 
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comparison of E*d data with the values found in literature is challenging, mainly due to 
the large variability resulting from the source and purity of the enzymes, as well as, the 
substrates used in the thermostability assays.30,32,33 
 
Fig. 3.20. Semi-log plots of the first-order denaturation constant (kd) vs. the reciprocal temperature (1/T). 
The slopes of the resulting straight lines used were used to estimate the activation energies (E*d) of 
irreversible inactivation (denaturation) of native cytochrome c (Cyt-c) and PEGylated conjugated with 4 
(Cyt-c-PEG-4) or 8 (Cyt-c-PEG-8) PEGs attached. 
 
Applying Eqs. (5–7), it was possible to calculate the activation enthalpy (ΔH*d), Gibbs free 
energy (ΔG*d) and entropy (ΔS*d) of denaturation for Cyt-c and PEGylated conjugates 
(Table 3.5.). These results indicate that the enzyme denaturation process is (i) 
exothermic (ΔH*d > 0), (ii) not spontaneous (ΔG*d > 0), and (iii) implies, at all tested 
temperatures (T = 70-95 ◦C), a transition state with an unexpected more rigid structure 
than the reacting system (ΔS*d < 0), either for native or PEGylated forms. In particular, 
the ΔH*d is an important thermodynamic parameter to consider, since it expresses the 
total amount of energy required to promote the enzyme denaturation,13 which is 
accompanied by the disruption of non-covalent linkages, including hydrophobic 
interactions, hydrogen bonds, and van der Waals forces.19 Lower ΔH*d values at higher 
operating temperatures indicate that enzyme thermo-inactivation is boosted at higher 
temperatures. So, the higher enthalpic contributions of PEGylated conjugates compared 
to the native protein mean that higher energy is needed to denature the PEGylated 
conjugates, thereby endorsing the protective role of PEG coupling. The extent of the 
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enzyme thermostability also depends on the ΔS*d, which expresses the amount of 
energy per temperature degree involved in the transition from a native to a denatured 
state.13 Negative values of ΔS*d, like those estimated in this study, suggest the 
occurrence of an aggregation process in which a few inter- and/intra-molecular bonds 
are formed.34 Thermal circular dichroism studies (Fig. 3.18.C) revealed a change in the 
protein conformation at temperatures at circa 75°C, suggesting that steric hindrance 
may have influenced the entropic variations. When an enzyme proceeds to the 
aggregated complex, the state of order of the system increases (ΔS*d < 0), reducing the 
consequent randomness degree of such a transition. Negative values of ΔS*d were also 
found for other redox enzymes29, hydrolases35 and proteases36,37 at high temperatures. 
Finally, the ΔG*d combines both enthalpic and entropic contributions.13 When ΔS*d < 0 
and ΔH*d > 0, the denaturation process is not spontaneous (ΔG*d > 0), as it was found in 
this work. A negative value of ΔG*d is associated with a spontaneous process, meaning 
that the protein is less thermostable. An increase in ΔG*d, on the contrary, can be 
understood as an increase in the enzyme’ resistance to denaturation, i.e. increased 
thermostability. Even though the ΔG*d values listed in Table 3.5. are similar for the three 
enzyme preparations, the highest ΔG*d data were obtained for the PEGylated conjugates 
in the entire range of temperatures, and especially for Cyt-c-PEG-8, which is consistent 
with the thermoprotective role of PEG previously discussed. However, contrary to what 
was observed for reversible unfolding, no negative impact of excess PEGylation was 
detected for irreversible thermo-inactivation of the enzyme.  
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Table 3.5. Thermodynamic and kinetic parameters of the irreversible thermal deactivation (denaturation) of native Cyt-c, Cyt-c-PEG-4 and Cyt-c-PEG-8
Cyt-c Cyt-c-PEG-4 Cyt-c-PEG-8 
T  
(oC) 
kd  
(h-1) 
t1/2  
(h) 
ΔH*d 
(kJ/mol) 
ΔG*d 
(kJ/mol) 
ΔS*d 
(J/mol.K) 
kd  
(h-1) 
t1/2  
(h) 
ΔH*d 
(kJ/mol) 
ΔG*d 
(kJ/mol) 
ΔS*d 
(J/mol.K) 
kd  
(h-1) 
t1/2  
(h) 
ΔH*d 
(kJ/mol) 
ΔG*d 
(kJ/mol) 
ΔS*d 
(J/mol.K) 
70 0.173 4.00 47.65 101.13 -155.83 0.101 6.84 69.78 102.66 -95.82 0.077 9.05 60.50 103.46 -125.18 
75 0.219 3.17 47.61 101.97 -156.13 0.154 4.49 69.74 102.98 -95.48 0.111 6.26 60.46 103.94 -124.89 
80 0.339 2.05 47.57 102.19 -154.67 0.157 4.41 69.69 104.45 -98.41 0.116 5.97 60.42 105.33 -127.18 
85 0.369 1.88 47.53 103.43 -156.08 0.295 2.35 69.65 104.09 -96.16 0.165 4.19 60.38 105.82 -126.87 
90 0.459 1.51 47.49 104.25 -156.31 0.422 1.64 69.61 104.50 -96.09 0.264 2.63 60.34 105.92 -125.53 
95 0.587 1.18 47.45 104.98 -156.28 0.551 1.26 69.57 105.17 -96.70 0.352 1.97 60.30 106.55 -125.63 
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4. Conclusions 
In this work, the kinetic and thermodynamic properties of PEGylated Cyt-c, a model 
redox protein, were determined. A maximum activity was observed at 80 ◦C for Cyt-c 
and both PEGylated forms, Cyt-c-PEG-4 and Cyt-c-PEG-8. The half-life for PEGylated 
conjugates, as well as the thermodynamic parameters of the enzyme denaturation were 
estimated based on tests of the residual activity. The Gibbs free energy and activation 
enthalpy was higher for PEGylated conjugates showing the protective role of this 
polymer, more pronounced at higher temperatures. Our results highlight the improved 
thermostability of the PEGylated forms of Cyt-c that could be profitably exploited for 
future industrial applications, especially in the biosensing and pharmaceutical sectors. 
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4.1. Multistep purification of cytochrome c PEGylated forms using polymer-
based aqueous biphasic systems 
Santos, J. H. P. M., Carretero, G., Coutinho, J. A. P.,  Rangel-Yagui, C. O. & Ventura, S. P. 
M. Green Chemistry, 2017, 19, 5800-5808.8 
Abstract 
Chemical PEGylation of proteins has been used to improve their physicochemical 
properties and kinetics. However, the PEGylation reactions lead to a heterogeneous 
mixture of PEGylated conjugates and unreacted protein, which is a challenge for the 
design of an efficient downstream process. The purification of PEGylated proteins 
should address the two main issues: the separation of PEGylated conjugates from the 
unreacted protein and the fractionation of the PEGylated conjugates on the basis of 
their degree of PEGylation. The present study aims at the development of liquid-liquid 
extraction processes for the purification of PEGylated conjugates. An initial study of the 
partition behavior of cytochrome c and their PEGylated conjugates (Cyt-c-PEG-4 and Cyt-
c-PEG-8) on polyethylene-glycol (PEG) + potassium phosphate buffer (pH = 7) aqueous 
biphasic systems (ABS) shows that PEGs with intermediate molecular weights  (PEG MW 
= 1000-2000) allow the separation of the PEGylated conjugates from the unreacted 
protein in a single step. It is further shown that the PEGylated conjugates can be 
efficiently separated using ABS based in PEGs with high molecular weight (PEG MW = 
6000-8000) and a study of the proteins stability after purification was carried using 
circular dichroism. A downstream process to separate Cyt-c, Cyt-c-PEG-4 and Cyt-c-PEG-
8 with high purities (96.5% Cyt-c, 85.8% Cyt-c-PEG-4, and 99.0% Cyt-c-PEG-8) was 
developed. The process proposed addresses not only the efficient separation of each of 
the protein forms but also the recycle of the unreacted protein purified and the ABS 
phases, which was successfully used in a new step of PEGylation. 
 
Keywords: Multi-stage aqueous biphasic systems; cytochrome c; PEGylation; PEGylated 
proteins; fractionation. 
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1. Introduction 
The use of PEGylation as a drug delivery technology was firstly proposed by Abuchowski 
et al.1 It consists in the covalent attachment of polyethylene glycol (PEG) chains to 
proteins. This approach can be used for drug delivery of biopharmaceuticals, its success 
depending on the characteristics of the PEGylated conjugates obtained, namely its 
enhanced pharmacokinetics properties, increased blood residence time and reduced 
immunological response and proteolytic degradation.2–4 This protein modification 
technique can enhance the “green” character of the final product, by preserving the 
efficacy of the function, while decreasing its toxicity,5 and thus their impact to the user 
and the environment. Through PEGylation, novel biobetters6,7 have been developed and 
commercialized. Pegadamase (Adagen), a PEGylated form of the enzyme adenosine 
deaminase8 used in the treatment of severe combined immunodeficiency disease 
(SCID),9 and Pegaspargase (Oncaspar), a PEGylated form of the enzyme asparaginase10 
used for the treatment of childhood acute lymphoblastic leukemia (ALL)11 are just two 
examples. In the field of biosensors, the PEGylation also showed to be a promising 
approach to enhance the thermal and long-term stability of the protein-based 
bionsensors.12–14  
Given the interest of the applications of protein PEGylation, the downstream processing 
of the PEGylated conjugates remains a bottleneck to its widespread use.15 The 
PEGylation reaction normally results in a heterogeneous mixture of unreacted protein 
with a variety of PEGylated conjugates with different degrees of PEGylation.16 The 
purification of the PEGylated conjugates implies thus three main challenges: (i) the 
isolation and recycling of the unreacted protein from the PEGylated conjugates, (ii) the 
fractionation of PEGylated conjugates according to their degrees of PEGylation , and (iii) 
the isolation of each protein form from the reaction products (e.g. PEG derivate, 
hydroxylamine and buffer).17 Nowadays, the downstream processes most used to 
fractionate the PEGylated conjugates are based on size exclusion chromatography 
(SEC)18,19 and ion exchange chromatography (IEX).20–22 Recently, non-chromatographic 
techniques such as capillary electrophoresis,23,24 ultrafiltration25–28 and aqueous 
biphasic systems (ABS)29,30 have been proposed to selectively purify the PEGylated 
conjugates.  
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Aqueous biphasic systems (ABS) were originally proposed by Albertsson31 as a cleaner 
and more biocompatible alternative to conventional liquid-liquid extraction processes 
that often use hazardous volatile organic solvents while ABS present a high water 
content, providing milder and more biocompatible conditions for bioseparations.32 ABS 
are designer processes, with a wide range of compounds that can be combined as phase 
formers, e.g. polymer + polymer,33–35 polymer + salt,36,37 salt + salt,38 among others.39–41 
This tailoring ability allows the design of specific downstream processes for a wide range 
of biomolecules.42–45 Furthermore, the scale-up of these systems is rather 
straightforward. 
The use of PEG + salt, PEG + polymer and PEG + polymer + salt (adjuvant) ABS for the 
separation of the PEGylated conjugates has been described for several proteins, e.g. 
bovine serum albumin,46 immunoglobulin G,46 α-lactalbumin,29 RNase A,29,47 lysozyme48 
and glycoproteins granulocyte-macrophage colony-stimulating factor (GM-CSF).30,46 
Delgado et al.30,46 reported a correlation between log K and the PEGylation degree of 
the conjugates that allowed the purification of protein conjugates from the unreacted 
protein. González-Valdez et al.29 proved that PEG + phosphate buffer ABS were able to 
efficiently fractionate the PEGylated conjugates from their unreacted precursors for two 
proteins: RNase A and α-lactalbumin. Nevertheless, the most remarkable application of 
ABS considering the downstream PEGylation process was attributed to Sookumnerd and 
Hsu,48 which used PEG + phosphate buffer countercurrent distribution in aqueous 
biphasic systems (CCD-ABS) to selectively fractionate the unmodified lysozyme, and its 
mono- and di-PEGylated forms. Galindo-López & Rito-Palomares47 also attempted the 
separation of mono-PEGylated and di-PEGylated RNase A, using CCD-ABS followed by 
an ultrafiltration. However, low selectivities (i.e. co-elution of mono-PEGylated RNase A 
and di-PEGylated RNase A in the purified fractions) were obtained and significant 
product loss (%Rec mono-PEGylated RNase A = 34% and %Rec di-PEGylated RNase A = 
45% of 50 kDa of PEG) occurred for both PEGylated conjugates. Despite the promising 
results of ABS in the fractionation of different protein PEGylated forms, their use is still 
compromised by the poor results obtained. While Cyt-c has been purified with ABS49,50 
and stabilized with ionic liquids,51,52 results for the purification of PEGylated cytochrome 
c (Cyt-c) with ABS are, to the best of our knowledge, previously inexistent. Cyt-c is a 
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biocatalyst53–56 used as a biosensor,12,57 and enzyme-based biosensors suffer from the 
fact that proteins have a fragile conformation, being affected by several exogenous 
conditions, namely pH, salt concentration, presence of proteases, and temperature, 
among others.12,58 In order to overcome those drawbacks, the chemical modification of 
proteins and enzymes is frequently employed.13,59 Actually, the chemical modification 
of protein-based biosensors through PEGylation improves their properties, like their 
biocompatibility, long-term stability, enhanced thermal stability, and solubility in 
organic solvents.2 In this context, some authors have already shown the potential of 
PEGylation in nanostructured Cyt-c biosensor, by improving its long-term stability even 
under accelerated conditions.12 However, there is a need to purify the PEGylated 
conjugates of Cyt-c in order to have a control batch-to-batch and guarantee that all 
purified conjugates have a similar biosensing activity. 
In this work, polymer-based ABS were used to develop an integrated process to 
fractionate different cytochrome c PEGylated forms and separate them from the 
unreacted protein. In the optimization of this integrated process, a multistep strategy 
was developed to separate firstly the unreacted protein from the conjugates and, 
secondly, the conjugates form each other. Aiming at the industrial application of the 
process, the recycling of the unreacted protein to a novel PEGylation cycle was also 
investigated, as well as the recycling and reuse of each phase former used in the ABS 
preparation.  
 
2.  Materials and Methods 
2.1. Materials 
Horse heart cytochrome c (Cyt-c) was acquired in Sigma-Aldrich with a purity of ≥ 95%. 
The PEG derivative used in the PEGylation reaction was the methoxyl polyethylene glycol 
succinimidyl NHS ester (mPEG-NHS or just mPEG), obtained from Nanocs (purity > 95%). 
Hydroxylammonium chloride acquired from Sigma-Aldrich was used to stop the 
PEGylation reaction and to avoid the formation of undesirable and instable products.  
The aqueous buffer used in the PEGylation reaction was 100 mM potassium phosphate 
buffer, being the pH adjusted using a solution of NaOH 2 M. The inorganic salts, K2HPO4 
and K2HPO4, were purchased from Sigma-Aldrich (purity of 95%). The phase formers 
used to prepare the different ABS were the polyethylene glycol (PEG) with different MW 
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(300, 600, 1000, 1500, 2000, 4000, 6000, and 8000), obtained from Sigma-Aldrich with 
high purity and the potassium phosphate buffer was prepared using K2HPO4 and K2HPO4.  
 
2.2. PEGylation reaction of Cyt-c 
The PEGylation reactions were conducted according to the literature.60 Briefly, 1 mL of 
a Cyt-c solution (0.5 mg.mL-1) in potassium phosphate buffer (100 mM, pH = 7) was 
added to a flask containing 5.2 mg mPEG with 5 kDa. The mixtures were stirred at 400 
rpm, for 15 min at room temperature with a magnetic stirrer, and then stored at -20oC 
for further use.   
 
2.3. Purification studies of unreacted Cyt-c and PEGylated forms using ABS 
Ternary mixtures of PEG + potassium phosphate buffer were used to study the 
fractionation of the unreacted Cyt-c and PEGylated forms. In these systems, the top 
phase corresponds to the PEG-rich phase while the bottom phase is mainly composed 
by potassium phosphate buffered salt. The mixture points used in the purification 
studies were chosen based on phase diagrams described in literature.61,62  
For the first screening, the effect of the PEG molecular weight was evaluated (PEG 300, 
600, 1000, 1500, 2000, 4000, 6000 and 8000 g.mol-1) considering a fixed mixture with 
15 wt% of PEG + 20 wt% of phosphate buffer (pH 7). Regarding the second set of 
experiments carried, in which the water content of the top phase was studied, the PEG 
1500 + potassium phosphate buffer (pH = 7) system was studied considering the mixture 
points: (15; 15 wt%), (17.5; 15 wt%), (20; 15 wt%), (22.5; 15 wt%), (25; 15 wt%), 
(potassium phosphate buffer; PEG 1500). The tie-lines (TLs) were calculated for all the 
mixture points aforementioned as previously reported.63,64  
For the study of the multistep ABS strategy three consecutive ABS were implemented: 
first step - ABS I using PEG 8000 + potassium phosphate buffer (pH = 7); second step - 
ABS II using PEG 8000 + potassium phosphate buffer (pH = 7); and third step - ABS III 
using PEG 1500 + potassium phosphate buffer (pH = 7). In the case of ABS II and ABS III 
the top-phase was recovered and used in the next step of purification. 
For the partition studies the preparation of ABS were carried in eppendorfs, with a total 
volume of 2 mL, being the aqueous mixture vigorously homogenised in vortex. After the 
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homogenisation, the systems were centrifuged for 15 min at 3500 rpm to induce the 
phase separation and both phases were carefully separated and weighted. After 
separation, both top and bottom phases were injected into an AKTA™ purifier system 
(GE Healthcare) size exclusion chromatographer equipped with a Superdex 200 Increase 
10/300 GL chromatographic column prepacked with crosslinked agarose-dextran high 
resolution resin (GE Healthcare) in order to separate and quantify each PEGylated 
conjugate and the unreacted protein. The column was equilibrated with 0.01 M of a 
sodium phosphate buffer solution (0.14 M NaCl, pH = 7.4) and eluted with the same 
buffer with a flow of 0.75 mL min-1. The quantification of the unreacted Cyt-c and each 
conjugate was carried at 280 nm by FPLC/UV size-exclusion method. 
All experiments were performed in triplicate, where the final absorbance was reported 
as the average of three independent assays with the respective standard deviations 
calculated. 
To assess the performance of the purification parameters for the different ABS, the 
partition coefficients in log scale (log K) of the unreacted Cyt-c and the PEGylated 
conjugates (Cyt-c-PEG-4 and Cyt-c-PEG-8), their recovery in the top (Rec Top - %) and 
bottom (Rec Bot - %) phases were determined (eqns. 1 to 3, respectively): 
log 𝐾 = log (
[𝑃𝑟𝑜𝑡]𝑡𝑜𝑝
[𝑃𝑟𝑜𝑡]𝑏𝑜𝑡
) 
(1) 
𝑅𝑒𝑐 𝑇𝑜𝑝 (%) =
100
1 + (
1
𝐾 × 𝑅𝑣)
 
(2) 
𝑅𝑒𝑐 𝐵𝑜𝑡 (%) =
100
1 + 𝑅𝑣 × 𝐾
 
 
(3) 
where [Prot]top and [Prot]bot represent the protein concentration in the top and bottom 
phases, respectively. Rv represents the volume ratio between the top and bottom phase 
volumes. The purity of the three Cyt-c proteins was calculated considering the ratio 
between the (SEC-FPLC) peak area representing the target protein and the peak area 
defined for the sum of all proteins present in the phase.65 The purification parameters 
were calculated for the unreacted Cyt-c and the PEGylated conjugates, respectively Cyt-
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c-PEG-4 and Cyt-c-PEG-8. The mass balance (MB) was calculated for the three Cyt-c 
based products, considering each separation unit, and the overall process (OMB). 
2.4. Recycling of unreacted Cyt-c and its application in a new cycle of PEGylation 
In order to prove the reuse of the unreacted protein in a subsequent cycle of PEGylation, 
after its recovery from the reactional mixture using the ABS two approaches were 
tested. The first strategy consists in adding directly to the reaction media the salt-rich 
phase with the unreacted Cyt-c. The second approach tested was the use of the 
unreacted Cyt-c free of the salt-rich phase, which was removed by precipitation using 
cold acetone. In this last approach, the unreacted protein was re-suspended in the same 
buffer used for the PEGylation reaction. For both cases, the quantification of the 
PEGylation conjugates and unreacted protein was performed by FPLC/UV SEC 
methodology. A SDS-PAGE of the samples was carried to evaluate the PEGylation yield. 
 
2.5. Circular Dichroism (CD) experiments  
CD spectra of Cyt-c before and after ABS purification were obtained in a Jasco J-720 
Spectropolarimeter (Jasco, Tokyo, Japan). The final spectra were the average of 6 scans, 
following subtraction of the spectrum representing 0.01 M of sodium phosphate buffer 
(0.14 M NaCl, pH = 7.4) obtained under the same conditions. CD spectra were obtained 
in the far-UV range (190-260 nm). Samples were placed in quartz cells (1.00 mm of 
optical length) with the concentration ranging from 13 to 15 µM. Spectra intensities (θ, 
mdeg) were converted to residual molar ellipticity ([θ], deg.cm2.dmol-1) by the following 
expression:  
[θ] =
θ
10.𝐶.𝑙.𝑛
                   (5) 
where C is the protein concentration in mol.L-1, l is the optical length in cm and n is the 
number of residues in the protein, that for this specific case is 104 residues. 
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3. Results and discussion 
3.1. Partition studies  
PEGylation is one of the most attractive strategies used to increase the half-life time of 
therapeutic proteins. Despite its high applicability, the efficiency of the PEGylation 
reaction is low, thus compromising the production of site-specific PEGylated proteins. 
In order to establish an efficient process to separate the PEGylated forms from the 
unreacted protein, polymer-based ABS composed of PEG and potassium phosphate 
buffer were investigated. The influence of the various process and system variables on 
the partition of these biomolecules was evaluated by using the heterogeneous mixture 
obtained after PEGylation. From the PEGylation reaction three forms were obtained, the 
unreacted Cyt-c, the Cyt-c PEGylated 4 times (Cyt-c-PEG-4) and the Cyt-c PEGylated 8 
times (Cyt-c-PEG-8). The recovery results at the ABS top and bottom phases are reported 
in Table C.1-2 at Appendix C. 
The effect of the PEG MW was the first variable studied. A fixed mixture point with 15 
wt% of PEG + 20 wt% of potassium phosphate buffer (pH = 7) was adopted and the 
partition of Cyt-c, Cyt-c-PEG-4 and Cyt-c-PEG-8 is shown in Fig. 4.1.. From the data it is 
possible to observe that the native/unreacted Cyt-c has a clear tendency to partition 
towards the salt rich (bottom) phase. This tendency is even more pronounced with the 
increase of the MW of PEG (i.e. PEG MW ≥ 1000), thus with the increased hydrophobicity 
of the PEG-rich phase. Since Cyt-c is a small (12 kDa) and highly hydrophilic heme 
protein,53 its higher affinity towards the most hydrophilic phase is thus expected. The 
PEGylated conjugates, by their turn, exhibited a different behaviour, their partition 
being dependent on the PEG MW. For PEGs with lower MW (i.e. PEG MW ≤ 2000) both 
conjugates partition towards the PEG-rich (top) phase, however for PEGs with higher 
MW the partition of the PEGylated forms towards the bottom phase becomes more 
significant. This is especially true for the form with lower degree of PEGylation (Cyt-c-
PEG-4) that exhibits a pronounced preference for the bottom phase in ABS with the 
heavier PEGs. The partition coefficients obtained for the different protein forms show 
that these ABS can be applied as purification platforms for (i) the separation of 
unreacted protein from the PEGylated conjugates using the ABS composed of PEG 
1000/1500 + potassium phosphate buffer (Rec BotCyt-c > 99% and Rec TopCyt-c-PEG-4 > 99% 
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and Rec TopCyt-c-PEG-8 > 99%) and (ii) the partial fractionation of the PEGylated conjugates 
according to their degree of PEGylation considering the use of ABS based in PEG 
6000/8000 + potassium phosphate buffer (Rec BotCyt-c > 99% and Rec BotCyt-c-PEG-4 > 99% 
and Rec TopCyt-c-PEG-8 ≈ 45%). 
 
Fig. 4.1. Effect of polymer MW on log(K) of Cyt-c and PEGylated forms (Cyt-c-PEG-4 and Cyt-c-PEG-8) in 
PEG-phosphate buffer ABS (pH = 7). The PEG MW 300, 600, 1000, 1500, 2000, 4000, 6000 and 8000 g.mol-
1 were studied in a fixed mixture point 15 wt% PEG + 20 wt% phosphate buffer. 
 
In order to fully explore the potential for the separation of the PEGylated forms, and 
aiming at increasing the selectivity of the systems previously studied towards the 
fractionation of these conjugates, different tie-lines were studied using mixture points 
with variable concentration of water. The ABS was chosen aiming at promoting the total 
partition of the PEGylated conjugates towards the top phase and the unreacted protein 
towards the opposite phase. The phase diagram and the respective tie-lines (TLs) of the 
selected ABS (PEG 1500 + potassium phosphate buffer, pH = 7) are depicted in Fig. 4.2.. 
The TLs were studied for the following mixture points: (15; 15 wt%), (17.5; 15 wt%), (20; 
15 wt%), (22.5; 15 wt%), (25; 15 wt%) potassium phosphate buffer; PEG 1500 wt%. The 
composition of the top phase was determined as described in Table C.3 at Appendix C. 
Table C.3 presents for the mixture points studied, their compositions, respective TLs and 
tie-line lengths (TLLs) obtained. As can be noticed from the results of Table 4.1., by 
increasing the tie-line length (TLL), the water content in the top phase decreases (from 
56.89 to 38.98 wt%). The partition behaviour of both unreacted Cyt-c and Cyt-c-PEG-8 
showed no significant dependency with the TLL as shown in Fig. 4.3.. On the other hand, 
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the partition of Cyt-c-PEG-4 is shown to decrease with the increase of the TLL. This could 
be explained by the fact that, when the concentration of water in the top phase 
decreases, these less PEGylated proteins, with intermediate hydrophobicity, start to be 
excluded from the most hydrophobic phase towards the bottom phase (decrease of 3 
fold on the log (K) from 3.42 to 1.40). The amount of water in top phase, has been 
described in literature as one of the driving-forces controlling the partition of PEGylated 
proteins.29 Analysing the results, it can observed that the effect of volume exclusion only 
affects the PEGylated conjugate with less degree of PEGylation, thus “PEG-PEG” 
interactions between the PEG phase forming agent and the PEG covalently bounded to 
the protein are most certainly occurring. Those specific “PEG-PEG” interactions were 
already observed by other authors.29 Previous PEGylated protein partition studies in 
PEG-dextran ABS showed partition coefficients to increase exponentially with the 
amount of PEG bound to the protein and a linear relationship between log K values and 
the number of grafted PEG chains.30 Other studies also assume that as the number of 
chains linked to the protein increase “PEG-PEG” interactions become an important 
driving-force for the partition on this ABS, since conjugates with a higher degree of 
PEGylation will have stronger interactions with the PEG-rich phase. Overall, in the 
polymer-salt studied ABS, the partition of the protein conjugates seems to be driven by 
“PEG-PEG” interactions, while the partition of the unreacted protein is dominated by its 
hydrophilic character, promoting hydrophilic interactions with the most polar phase. 
 
Fig. 4.2. Phase diagram () and respective tie-lines; TLs defined for the ABS composed of PEG 1500 + 
potassium phosphate buffer (pH = 7). The TLs were calculated considering the following mixture points 
(potassium phosphate buffer; PEG 1500 wt%):  (15; 15 wt%),  (17.5; 15 wt%), (20; 15 wt%),  (22.5; 
15 wt%),  (25; 15 wt%). 
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Fig. 4.3. Effect of water content in the top-phase on log(K) of Cyt-c and PEGylated forms (Cyt-c-PEG-4 and 
Cyt-c-PEG-8) in PEG 1500 + phosphate buffer ABS (pH = 7). The studied mixture points were: (15; 15 wt%), 
(17.5; 15 wt%), (20; 15 wt%), (22.5; 15 wt%) (25; 15 wt%) phosphate buffer; PEG 1500 wt%. 
 
3.2. Process design 
Considering the application of the various PEGylated forms, their use as both pure 
compounds or mixtures can be envisaged since PEGylated protein mixtures may result 
in a synergetic performance in terms of bioactivity, and for that reason in specific cases, 
e.g biosensing applications,17 the fractionation of PEGylated forms could not be 
necessary.  
If only the extraction of the PEGylated forms from the reaction mixture is required, a 
simplified process can be designed, as sketched in Fig. C.1 at Appendix C to achieve the 
separation of the unreacted protein from the PEGylated forms. Using this approach, the 
isolation and recycling of the unreacted protein from the PEGylated conjugates can be 
accomplished with recoveries higher than 99% for both the PEGylated forms, at the top, 
PEG 1500-rich phase, while more than 99% of the unreacted protein is recovered at the 
bottom, salt-rich phase. This means that, when the PEGylation reaction is not complete 
the reuse of the non-reacted proteins is possible, thus increasing the efficiency and 
sustainability of the overall process. To date, to the best of our knowledge, no studies 
were reported on the possibility of to purify and reuse the unreacted protein. 
The most important challenge in terms of purification is, however, the complete 
separation of each PEGylated conjugate obtained. The selective fractionation of each 
conjugate was achieved through a multistep strategy of purification sketched in Fig. 4.4. 
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In this process, two liquid-liquid separation units were applied, namely those based in 
PEG 8000 + potassium phosphate buffer (pH = 7) (ABS I and ABS II), representing two 
stages of  the same unit, and the second unit corresponding to ABS III, PEG 1500 + 
potassium phosphate buffer (pH = 7). The first unit was used in the separation of each 
PEGylated form, in which the conjugates were partially concentrated in opposite phases. 
The Cyt-c-PEG-4 was concentrated in the bottom phase, rich in salt, and Cyt-c-PEG-8 
preferentially partitions towards the most hydrophobic phase, rich in polymer. With the 
application of the first process unit, the complete separation of both PEGylated forms 
was achieved, as demonstrated by the recoveries reported in Fig. 4.4.. 
In the final of ABS II, the continuous removal of Cyt-c-PEG-8 was assessed and then, ABS 
III was applied to carry the final step of purification, in which the Cyt-c-PEG-4 was 
removed from the unreacted protein. From the results of log (K) for Cyt-c, Cyt-c-PEG-4 
and Cyt-c-PEG-8 showed in Table 4.1. it is possible to reinforce that the application of 
the multistep process is effectively contributing to efficiently fractionate and purify each 
PEGylated form and the unreacted protein with high selectivity.  High purities for each 
compound were obtained by applying this multistep approach as shown in Table 4.1., 
those being really appealing for the application of these biomolecules in the field of 
biosensors (purity of Cyt-c = 96.5%, purity of Cyt-c-PEG-4 = 85.8% and purity of Cyt-c-
PEG-8 = 99.0%). Additionally, the analysis of the overall mass balance (OMB) of the 
protein conjugate, shows that the protein losses during the multistep ABS are small. The 
detailed composition of the streams of the process are presented in Table C.4 at 
Appendix C. It should be taken in consideration that the water content contemplates 
the Cyt-c based products, since their quantity in terms of weight is comparatively smaller 
than the phase forming agents (initial Cyt-c solution = 0.5 mg.mL-1). This is the first report 
of a multistep approach using ABS in cascade being efficiently applied in the 
development of an effective downstream process to purify PEGylated conjugates 
according to their degree of PEGylation. 
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Fig. 4.4. Diagram of multistep process to fractionate selectively the unreacted cytochrome c and each one of the PEGylated conjugates (Cyt-c-PEG-4 and Cyt-c-PEG-8). The 
proposed strategy includes three steps of purification using ABS, namely considering the ABS I and ABS II composed of PEG 8000 + potassium phosphate buffer (pH = 7) to 
separate Cyt-c-PEG-8 and ABS III using PEG 1500 + potassium phosphate buffer (pH = 7) to fractionate the unreacted Cyt-c from the Cyt-c-PEG-4 conjugate. The recovery yield 
of each step is also provided in the present diagram. The recycle and reuse of the unreacted Cyt-c in a new PEGylation cycle after recovery in the last step is also demonstrated. 
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Table 4.1. Recoveries towards top and bottom phases, log (K), purities and mass balances (MB) obtained for the unreacted Cyt-c and for the PEGylated conjugates, respectively 
Cyt-c-PEG-4 and Cyt-c-PEG-8, in the integrated multistep process using polymer-based ABS as purification platforms, for the system using PEG (8000 and 1500) + potassium 
phosphate buffer (pH = 7). The overall mass balance (OMB) is also depicted in this table for unreacted and Cyt-c PEGylated forms. 
 Cyt-c Cyt-c-PEG-4 Cyt-c-PEG-8 
 Rec Top (%) Rec Bot (%) log(K) 
Purity 
 (%) 
MB  
(%) 
Rec Top (%) Rec Bot (%) log(K) 
Purity  
(%) 
MB 
 (%) 
Rec Top (%) Rec Bot (%) log(K) 
Purity  
(%) 
MB 
(%) 
ABS I 0.02 99.98 -3.48 70.0 90.65 0.05 99.95 -3.10 29.7 93.74 45.78 54.22 0.11 87.4 88.23 
ABS II 0.04 99.96 -3.13 85.2 92.59 0.13 99.87 -2.63 10.5 94.32 50.74 49.26 0.28 99.0 85.23 
ABS III 0.09 99.91 -2.80 96.5 84.78 99.56 0.44 2.63 85.8 85.62 21.79 78.21 -0.28 99.0 96.52 
OMB (%) 71.16 75.70 72.66 
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The development of recycling strategies aiming at the reuse of the recovered unreacted 
Cyt-c to be used in new cycles of PEGylation is required. For that reason, two different 
approaches were tested: (i) the direct PEGylation of the salt-rich aqueous phase in which 
the purified Cyt-c is concentrated and (ii) the use of an acetone precipitation step to 
isolate the purified Cyt-c from the salt-rich layer as represented in Fig. 4.5.. After the 
precipitation step the unreacted protein is ressuspended in the same buffer used in the 
PEGylation. The results obtained, presented in Fig. 4.5., show the first approach to be 
inefficient due to the absence of any PEGylation of the recycled Cyt-c as can be gauged 
from the chromatogram presented in Fig. 4.5.A, which could be due to the higher 
amounts of salt present. However, the approach based in the acetone precipitation 
proved to be efficient for the recovery of the Cyt-c for further PEGylation, as shown in 
the chromatogram presented in Fig. 4.5.B and Lane 2 of the SDS-PAGE in Fig. 4.5.C, thus 
increasing the viability of the overall process.  
Finally, the stability and integrity of the unreacted Cyt-c purified was accessed using far-
CD. Both the control and purified Cyt-c present a CD spectrum (Fig. 4.6.) characteristic 
of α-helical secondary structures, displaying negative intensity bands centred at 208 and 
222 nm and a positive peak at the 195-200 nm region of the spectrum, proving thus the 
structural integrity of the protein structure. Moreover, the PEGylated forms were also 
stable after the multistep downstream processing and confirmed by far-UV CD (Fig. C.2 
at Appendix C).  
The results reported highlight the potential of the downstream process here proposed 
for an efficient fractionation of the Cyt-c PEGylated conjugates and recovery of 
unreacted Cyt-c. 
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Fig. 4.5. SEC-FPLC chromatogram of (A) unreacted Cyt-c concentrated in the bottom-phase used directly 
in a new cycle of PEGylation; (B) unreacted Cyt-c used in a new cycle of PEGylation but after its isolation 
from the bottom phase through precipitation with cold acetone. (C) SDS-PAGE showing the successful use 
of the recycled Cyt-c in a new cycle of PEGylation: Lane M – Molecular Marker, Lane 1 – commercial equine 
heart Cyt-c, Lane 2 – PEGylation mixture obtained after a new cycle of PEGylation using the purified Cyt-
c. 
 
Fig. 4.6. Far-UV CD spectra of Cyt-c control (▬) and Cyt-c purified through aqueous biphasic system (▬). 
Cyt-c concentrations used are 15 and 13 µM for the control and purified forms, respectively. 
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4. Conclusions 
In order to overcome the difficulty to obtain pure site-specific PEGylated conjugates of 
Cyt-c-based biosensors, an alternative process of downstream was here proposed. For 
that, the use of consecutive steps of purification using polymeric-based ABS were 
applied on the separation of (i) the unreacted protein from the PEGylated forms and (ii) 
each PEGylated conjugate. From the main results obtained in the partition studies, it 
was assessed the impact of the molecular weight of PEG and water content composing 
the top phase enriched in PEG. These two conditions have a significant impact on the 
partition profile of the unreacted Cyt-c and the different PEGylated forms obtained in 
non-site-specific PEGylation reactions (in this case, specifically Cyt-c-PEG-4 and Cyt-c-
PEG-8) towards opposite phases. The different partition trend obtained for each class of 
proteins is actually explained by the presence of two major driving-forces occurring, 
namely the exclusion volume of the polymer-rich phase and “PEG-PEG” interactions. 
Considering thus the main applications of each PEGylated form and the unreacted 
protein, different processes of purification were defined to achieve different purposes. 
Thus, a single step process using the ABS composed of PEG 1500 was successfully 
developed for the isolation of the unreacted protein from the PEGylated conjugates. Rec 
Bot of 99.88 ± 0.05% of Cyt-c towards the bottom phase were achieved while in the top 
phase, Rec Top of 99.31 ± 0.62% and 99.87 ± 0.01% were obtained for Cyt-c-PEG-4 and 
Cyt-c-PEG-8. For the case when each PEGylated form is required in its purer form, a 
multistep process was developed by the conjugation of three different steps, all using 
the polymer-based ABS studied. This multi-step approach strategy was efficiently 
developed for the fractionation of the three protein species, namely Cyt-c, Cyt-c-PEG-4 
and Cyt-c-PEG-8, allowing recoveries higher than 99% of the unreacted Cyt-c and Cyt-c-
PEG-4 and more than 76.90% of recovery for Cyt-c-PEG-8 in the final of Step II. 
Envisaging the industrialization of these integrated processes, the recycling of the 
unreacted Cyt-c for a novel PEGylation reaction was successfully achieved by applying a 
precipitation step carried with cold acetone, in which it was proved the successfully 
reuse of the unreacted Cyt-c after purification, while maintaining the structural integrity 
of the protein. In this work, an efficient process of PEGylation and purification of 
different site-specific PEGylated forms was developed with high efficiency. 
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4.2. An integrated process combining the reaction and purification of PEGylated 
proteins 
Santos, J. H. P. M., Mendonça, C. M. N., Silva, A. R. P., Oliveira, R. P. S., Junior, A. P., 
Coutinho, J. A. P., Ventura, S. P. M. & Rangel-Yagui, C. O., 2019 (manuscript in 
preparation)9 
 
Abstract 
A downstream process combining PEGylation reaction and the use of enzyme conjugates acting 
as phase-forming components of aqueous biphasic systems (ABS) is here proposed. On this 
approach, the citrate buffer (pH = 7.0) was used simultaneously to stop the reaction (avoiding 
the use of hydroxylamine) and as phase forming agent inducing the phase separation of the 
PEGylated proteins. The partition of the bioconjugates was assessed using two model enzyme 
of small size [cytochrome c (Cyt-c) and lysozyme (LYS)], and two of large size [L-asparaginase 
(ASNase) and catalase (CAT)] as well as, reactive PEG of 5, 10, 20 and 40 kDa. The effect of the 
reaction time in the PEGylation and recovery steps was also evaluated. All reactive PEGs allowed 
high selectivity in the separation of PEGylated from native forms (S > 100). A positive effect of 
increasing the time of reaction was denoted. It allows the formation of greater amounts of 
PEGylated proteins, with an increase of the PEG-protein conjugated phase volume (top phase), 
with those of the higher reaction times allowing 100 % of recovery. More selective systems were 
obtained for Cyt-c and LYS (S > 100) than for ASNase and CAT (40 < S < 60), nevertheless for all, 
the native and PEGylated proteins had its biological activity preserved. Envisioning the industrial 
potential evaluation of the processes developed in this work, an integrated process diagram was 
defined combining the PEGylation reaction with the purification of the protein conjugates. Two 
different scenarios were investigated considering the PEGylation reaction performance. For 
both approaches (complete and incomplete PEGylation reaction), high recovery yields and 
purities were obtained for the PEGylated conjugates (92.1 ± 0.4% < %RecTCyt-c-PEG < 98.1 ± 0.1%; 
84.6% < purity < 100%) and for the unreacted enzyme (%RecBCyt-c = 81 ± 1%; purity = 97.7%), 
while maintaining their structural integrity. 
 
Keywords: PEGylation; bioconjugation; separation; aqueous biphasic systems; protein 
recovery. 
                                                          
9 Contributions: JS, CM and AS acquired the experimental data. JS, RO, SV, AP, JC and CY interpreted the 
experimental data. SV, JC and CY conceived and directed this work. The manuscript was mainly written by JS with 
contributions from the remaining authors.  
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1. Introduction 
Therapeutic biological products based on proteins and peptides are of increasing 
interest in the pharmaceutical field.1,2 This class of drugs is characterized by its high 
specificity, offering the possibility to treat complex diseases once considered 
untreatable. Nonetheless, protein drugs are usually associated to low solubility profiles, 
short shelf-lives, short circulating half-lives and susceptibility to cleavage by proteolytic 
enzymes.2,3 To date, several techniques have been implemented to increase solubility, 
improve molecular stabilization and enhance proteins pharmacokinetics.4–6 Most of 
those techniques focus in the bioconjugation of proteins with polymers, generating 
improved drugs, i.e. biobetters, which are superior when compared to the original 
biological.7,8 Among the large array of bioconjugation techniques, PEGylation is the most 
auspicious alternative. This strategy is FDA and EMA approved and it has been used in 
the development of several protein drugs currently in the market.7–9 Through careful 
selection of the reaction chemistry, one or more polyethylene glycol (PEG) molecules 
can be attached to the proteins, producing PEG-protein conjugated species with one or 
more grafted polymeric chains.10–13  
The biological stability and activity of PEGylated proteins are influenced by the chemical 
reaction used. Usually, PEGylation results in a complex mixture of proteins with varying 
number of PEG chains attached to amino acid residues, which can also vary on the 
location at the protein surface. A narrow number of site-specific modifications is 
available, such as the N-terminal PEGylation and cysteine PEGylation. Nonetheless, even 
site specific reactions still present some degree of polydispersity.9,12 The separation, sub 
fractionation and recovery of the target PEGamer among the different PEG-protein 
conjugated species is a crucial step in the PEGylation process.14 Moreover, aqueous 
biphasic systems (ABS) stands out as interesting alternatives not only for the separation 
of the PEGylated proteins from the other reaction products,15 but also for its sub-
fractionation according to the number of grafted chains among the produced 
conjugates.16–18 Aqueous biphasic systems (ABS) are clean alternatives for conventional 
organic-water solvent extraction systems. ABS are formed when either two polymers, 
one polymer and one kosmotropic salt, or two salts (one chaotropic salt and the other 
a kosmotropic salt) are mixed at appropriate concentrations.19 The two phases are 
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mostly composed of water and non-volatile components, thus eliminating volatile 
organic compounds. They have been used for a plethora of purifications in 
biotechnological field, due to their intrinsic benign and non-denaturing character.20,21 
The technical and economic advantages offered by ABS regarding issues like increase of 
protein recovery yields, decrease of processing time, scale-up feasibility, as well as 
absence of specialized equipment or highly-trained personnel, have been further 
supporting the hypothesis of an industrial substitution of chromatographic-based 
downstream processes by ABS platforms.22–24  
Despite the promising potential of ABS to separate PEGylated proteins, challenges like 
the recycling of phase-forming components and recovery of the target biological 
derivatives, have been pointed out as main limitations. Thus, novel insights into the 
development of innovative strategies to increase the industrial potential of ABS in 
PEGylation reactions still need to be explored. In this work, a novel integrated 
downstream process involving the simultaneous PEGylation reaction and ABS extraction 
of four model proteins (i.e. cytochrome-c, lysozyme, L-asparaginase and catalase) is 
proposed. In these systems, the PEG-protein conjugates are used as phase-forming 
components in ABS, together with citrate salt, allowing the formation of a biphasic 
system concurrently separating the PEGylated conjugates while simultaneously 
stopping the PEGylation reaction. Our results stand out as an attractive and simple in 
situ separation strategy for PEGylated proteins integrated with the bioconjugation 
reaction, without the need of toxic reagents to stop the reaction like hydroxylamine.10 
This research represents a pioneer study in the integration of PEGylation reaction and 
purification in a single step. By integrating the reaction and purification step by 
employing the PEGylated proteins as one of the ABS phase components, it was our 
intention to obtain a selective purification performance in the separation of the 
PEGylated conjugates from the unreacted proteins by a non-chromatographic and 
simple method. Following this approach, a successful integrated process was envisioned 
for a complete PEGylation reaction, but also for the most common scenario of an 
incomplete reaction (yield of reaction of 64 %). High recovery yields and purities were 
obtained for the PEGylated conjugates (92% < %RecTCyt-c-PEG < 98%; 85% < purity < 100%) 
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and for the unreacted enzyme (%RecBCyt-c = 81%; purity = 98%), thus increasing the 
overall sustainability of the process and meeting the principles of Green Chemistry. 
2. Materials and Methods  
2.1. Materials 
The four model proteins used were the horse heart cytochrome c (Cyt-c, ≈ 12 kDa, pI = 
10.0–10.5) with purity of ≥ 95% from Sigma-Aldrich (St. Louis, MO), lysozyme from 
chicken egg white (LYS, ≈ 14 kDa, pI = 11.35) with purity of ≥ 90% from Sigma-Aldrich, L-
asparaginase from Escherichia coli (ASNase, ≈ 130 kDa, pI = 4.9) 2500 IU with purity of ≥ 
95% from Prospec-Tany (Ness Ziona, Israel), and catalase from bovine liver (CAT, ≈ 240 
kDa, pI = 5.4) with a purity of ≥ 95% from Sigma-Aldrich.  
The PEG derivatives used in the PEGylation reaction were methoxy polyethylene glycol 
succinimidyl NHS ester of 5, 10, 20 and 40 kDa (mPEG-NHS, purity > 95%), obtained from 
Nanocs (New York, NY). The aqueous buffer used in the PEGylation reaction was the 
potassium phosphate buffer (100 mM), pH adjusted to 7 through drop-wise addition of 
NaOH 2 M. Potassium citrate buffer was used to stop the PEGylation reaction and to 
promote the formation of the biphasic system. The salts potassium phosphate dibasic 
(K2HPO4, 95% of purity), potassium phosphate monobasic (KH2PO4, 95% of purity), citric 
acid, (C6H8O7, purity ≥ 99%) and potassium citrate tribasic monohydrate (C6H5K3O7·H2O, 
purity ≥ 99%) were purchased from Sigma-Aldrich. Polyethylene glycols (PEG) and 
methoxy polyethylene glycol (mPEG) for phase diagrams determination were from 
Sigma-Aldrich with purity ≥ 95 %. 
For the chromatography mobile phase, sodium chloride, NaCl, (purity ≥ 99 %; Sigma-
Aldrich), sodium phosphate dibasic, Na2HPO4, (purity ≥ 99 %; Sigma-Aldrich), sodium 
phosphate monobasic, NaH2PO4, (purity ≥ 99 %; Sigma-Aldrich), and ultrapure water 
treated in a Mili-Q 185 water apparatus (Millipore, Bedford, MA) were used. Syringe 
filters (0.45 µm of pore size; Specanalitica, Portugal) and membrane filters (0.22 µm; 
Sartorius Stedim Biotech, Germany) were applied in the filtration steps. 
 
2.2. Phase diagrams of polyethylene glycol + citrate buffer ABS 
The experimental phase diagrams were determined gravimetrically, within an 
uncertainty of ± 10-4 g, using the cloud point titration method22,23 at (298 ± 1) K and 
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atmospheric pressure. The phase diagrams were constructed for PEG 2, 6, 10, and 20 
kDa + citrate buffer (pH = 7.0) and for mPEG 2 kDa + citrate buffer (pH = 7.0). Briefly, 
two stock solutions were prepared: 50 wt% of PEG and 50 wt% of citrate buffer, 
C6H5K3O7/ C6H8O7, pH = 7.0. Drop-wise addition of buffer was carried to the polymer 
solution until the visual detection of a turbid system (biphasic region). Subsequently, 
drop-wise addition of the milli-Q water was conducted until the system became clear 
(monophasic region). This procedure was repeated several times in order to obtain the 
binodal curve, being performed under constant stirring and controlled temperature. The 
experimental phase diagrams data were correlated using the Merchuk equation24 (Eq. 
1): 
[PEG] = 𝐴 exp[(𝐵 × [Citrate]0.5) − (𝐶 × [Citrate]3)             (1) 
where [PEG] and [Citrate] represent the weight percentages of PEG polymers and citrate 
buffer, respectively. A, B and C are constants obtained by the regression of the 
experimental data. The Merchuk equation was chosen since it has a low number of 
adjustable parameters to correlate these data and it is the most commonly applied.24 
2.3. Combined PEGylation reaction and recovery step 
The PEGylation reactions were conducted according to literature.28 Briefly, 300 μL of a 
protein solution (2 mg.mL-1, condition 1 and 4 mg.mL-1, condition 2) in potassium 
phosphate buffer (100 mM, pH = 7.0) was added to a flask containing 50 mg of mPEG-
NHS. The mixtures were magnetically stirred at 400 rpm for 7.5 min, at room 
temperature, and then the reaction was stopped through the drop-wise addition of 100 
μL of potassium citrate buffer (pH=7.0, 50 wt% C6H5K3O7/C6H8O7), consequently 
promoting the formation of two-phase systems composed by Prot-PEG-rich (top) phase 
and salt-rich (bottom) phase. The ABS applied were composed of 0.5 wt% of Prot + 12.5 
wt% of Prot-PEG/PEG + 12.5 wt% of C6H5K3O7/C6H8O7 (condition 1) and 1.0 wt% of Prot 
+ 12.5 wt% of Prot-PEG/PEG + 12.5 wt% of C6H5K3O7/C6H8O7 (condition 2). The two 
aqueous phases were carefully separated, and their volumes were measured.  
Three variables were studied to develop and optimize the integrated conjugation-
recovery process, namely the (i) mPEG-NHS molecular weight, (ii) reaction time and (iii) 
protein type. For the first study, four mPEG-NHS polymers of 5, 10, 20 and 40 kDa were 
conjugated with Cyt-c at 2 mg.mL-1 (condition 1) and 4 mg.mL-1 (condition 2). Following, 
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three reaction times were studied for Cyt-c PEGylation with mPEG-NHS of 20 kDa at 
condition 2, namely: 7.5, 15, and 30 min. Finally, to proof this one-step approach for 
more than one protein, different classes of proteins were tested: small proteins (Cyt-c 
and LYS, < 50 kDa) and large proteins (ASNase and CAT, > 100 kDa). In this step, the 
PEGylation reaction was performed with mPEG-NHS of 20 kDa, for 7.5 min at condition 
2 and the ABS formed by potassium citrate buffer addition. 
 
2.4. Quantification of PEGylated conjugates and unreacted protein: fractionation 
parameters 
The quantification of unreacted protein (Cyt-c, LYS, ASNase, and CAT) and each 
conjugate (Cyt-c-PEG, LYS-PEG, ASNase-PEG, and CAT-PEG) at both top and 
bottom phases was carried out by size-exclusion chromatography and detection 
at 280 nm,16 with a respective calibration curve for each protein and PEGylated 
conjugate. Samples of top and bottom phases were injected into an AKTA™ 
purifier system (GE Healthcare, United States) Fast Protein Liquid 
Chromatographer equipped with a Superdex 200 Increase 10/300 GL 
chromatographic column prepacked with crosslinked agarose-dextran high 
resolution resin (GE Healthcare). The column was equilibrated with 0.01 M of a 
sodium phosphate buffer solution (0.14 M NaCl, pH = 7.4) and eluted with the 
same buffer with a flow of 0.75 mL min-1. All experiments were performed in 
triplicate and the final concentration was reported as the average of three 
independent assays with the respective standard deviations calculated. 
The performance of the different ABS investigated was based on the following 
parameters: partition coefficients in log scale (log K) and recoveries in the top (Rec 
Top - %) and bottom (Rec Bot - %) phases of unreacted proteins and PEGylated 
conjugates, Eqs. 2 to 4, respectively: 
log 𝐾 = log (
[Prot]top
[Prot]bot
) 
(2) 
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where [Prot]top and [Prot]bot represent the protein concentration in the top and bottom 
phases, respectively. Rv represents the volume ratio between the top and bottom phase 
volumes.  
The selectivity (S) is a key parameter to be measured, since the fractionation of 
PEGylated conjugates from the unreacted protein is under study. Therefore, the 
selective partition of the proteins (i.e. PEGylated protein from unreacted protein), can 
be assessed through Eq. 5: 
𝑆 =
𝐾Prot−PEG
𝐾Prot
                                                                                                                      (5) 
2.5. Total protein concentration determination 
The protein concentration was determined with the Pierce BCA Protein Assay and Micro 
BCA Protein Assay (Thermo Scientific, Schwerte, Germany) according to the product 
recommendations. Bovine serum albumin (albumin standard ampules, Thermo 
Scientific, Schwerte, Germany) was used as standard protein. 
2.6. Protein activity assays  
The activity of the proteins was determined for the top and bottom phase, in order to 
guarantee that the ABS platforms are gentle and maintain biological activity. The specific 
activity, SA, (U.mg-1) represents the ratio between the volumetric activity of the 
respective protein (U.mL-1) and the total protein concentration (mg.mL-1) at a certain 
aqueous phase (top or bottom). Every sample was measured in triplicate and for 
calculation of reaction rate the average was used. 
 
2.6.1. Cyt-c activity 
The enzymatic activity of Cyt-c was determined by the catalytic oxidation of 50 µM of 
2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid), ABTS (Sigma–Aldrich, > 98%) in 
𝑅𝑒𝑐 𝑇𝑜𝑝 (%) =
100
1 + (
1
𝐾 × 𝑅v)
 
(3) 
 
 
𝑅𝑒𝑐 𝐵𝑜𝑡 (%) =
100
1 + 𝑅v × 𝐾
 
(4) 
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the presence of 0.5 mM of hydrogen peroxide (Sigma–Aldrich, solution 30 wt% in 
H2O).29,30 The samples of both top and bottom phases were diluted to obtain a protein 
concentration of 10 µM in 0.01 M of potassium phosphate buffer (0.14 M of NaCl, pH 
7.4). The reaction was started by adding hydrogen peroxide and followed by the 
absorbance increase at 418 nm. 
 
2.6.2. LYS activity 
The LYS activity was determined using Micrococcus lysodeikticus, M. lysodeikticus 
(Sigma–Aldrich) as substrate.31 The kinetic assay is based on the lysis of the bacterial 
cells by lysozyme resulting in a decrease of turbidity over time. The M. lysodeikticus cells 
(0.015% w/v) were suspended in 50 mM of sodium phosphate buffer at pH 6.24. For the 
diluted samples of top and bottom phases, a volume of 0.1 mL was mixed with 2.5 mL 
of substrate solution. Absorption measurements at 450 nm were performed for 10 min 
in 30 s intervals with orbital shaking in between the measurements. The diluted samples 
of protein from both phases contained 200 400 U.mL-1 of LYS. A blank consisting of 0.1 
mL of sodium phosphate buffer (50 mM, pH 6.24) mixed with 2.5 mL of substrate 
solution was measured likewise. The absorbance values of the protein samples were 
subtracted from the absorbance values of the M. lysodeikticus blank, resulting in a 
positive slope of the measured values over time. One unit is equal to a decrease in 
turbidity of 0.001 per minute at 450 nm, pH 6.24 and 25°C under the specified 
conditions. 
 
2.6.3. ASNase activity 
The ASNase activity was based on the protocol of Drainas and co-workers.32 
Briefly, 0.1 mL of diluted sample (top and bottom phase), 0.7 mL of Tris-HCl buffer 
(50 mM, pH 8.6), 0.1 mL of ASNase (0.1 M) and 0.1 mL of hydroxylamine (1.0 M, 
pH 7.0) were incubated at 37°C and 30 min. The reaction was interrupted by 
adding 0.5 mL of 0.31 M of iron chloride reagent (dissolved in HCl 0.33 M and 
trichloroacetic acid 0.3 M solution, Sigma–Aldrich, > 97%). The reaction solution 
was centrifuged at 3220xg for 15 min and the iron chloride–hydroxamic acid 
complex produced was quantified at 500 nm. The calibration curve was prepared 
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from a -aspartohydroxamic solution (Sigma-Aldrich, MO, USA, ≥ 98%). One unit 
of ASNase activity is defined as the amount of enzyme that produces 1 μmol of -
aspartohydroxamic acid per minute under the experiment conditions defined.  
 
2.6.4. CAT activity 
The CAT activity was quantified by the Iwase et al. method that measures the trapped 
oxygen gas generated by the catalase–hydrogen peroxide reaction, which is visualized 
as foam.33 Each CAT sample from top and bottom phases (100 μL) was added in a 
Pyrex tube (13 mm diameter × 100 mm height, borosilicate glass; Corning, USA). 
Subsequently, 100 μL of 1% Triton X-100 (Sigma–Aldrich, 98%) and 100 μL of undiluted 
hydrogen peroxide (Sigma–Aldrich, solution 30 wt% in H2O) were added to the CAT 
samples, mixed thoroughly and then incubated at room temperature. The CAT samples 
from top and bottom phases were diluted to stay in the linearity range of 20–300 units 
(U) of catalase activity. Following completion of the reaction, the height of O2-forming 
foam that remained constant for 15 min in the test tube was finally measured using a 
ruler and correlated to CAT concentration based on a calibration curve. 
2.7. FTIR-ATR spectra acquisition 
The Fourier Transform Infrared Spectroscopy (FTIR) profile of standards (Cyt-c, 
model protein and PEG) and top and bottom phases were recorded using the FT 
RAMAN BRUKER 100/S spectrometer (Bruker, Billerica, MA) in mid-IR mode, 
equipped with an Universal ATR (attenuated total reflectance) sampling device 
containing diamond/ZnSe crystal. For powdered samples, an extra accessory plate 
with a conic awl was used, requiring only a few milligrams, without any previous 
sample preparation. The pressure applied to squeeze the powdered sample 
towards the diamond was approximately 148 ± 1 N. The spectra were scanned at 
room temperature in absorbance mode over the wave number range of 4000 to 
50 cm-1, with a scan speed of 0.20 cm.s-1, and 30 accumulations at a resolution of 
4 cm-1. Triplicates of each sample were averaged to obtain an average spectrum. 
A background spectrum of air was scanned under the same instrumental 
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conditions before each series of measurements. The spectra acquired were 
processed with the Spectrum software version 6.3.2. 
3. Results and Discussion 
3.1. Phase diagrams and selection of mixture point for ABS preparation  
Novel ternary phase diagrams were determined for the systems used in the integrated 
step (polyethylene glycol + C6H5K3O7/C6H8O7 pH = 7 + water, 298 ± 1 K) to define a 
biphasic region and consequently, to choose a mixture point corresponding to phase 
separation on a top phase rich in PEG and a bottom one rich in salt. Citrate-based salts 
were chosen since they are biodegradable and nontoxic, with a strong salting-out 
ability.34 The detailed experimental weight fraction data, Merchuk correlation 
parameters (A, B and C) and graphical representations of phase diagrams in mass 
fraction are reported at Tables C.5-6 and Fig. C.3 at Appendix C. In the downstream 
process proposed to integrate the PEGylation reaction with the fractionation by ABS, 
the PEGylated protein is expected to work as one of the phase forming components. 
Since the grafted PEG groups are methoxylated and no previous reports on mPEG phase 
diagrams are available, novel experimental phase diagrams were mapped out. The 
phase diagrams for polyethylene glycol (PEG) and mPEG with the same molecular weight 
(2 kDa) + C6H5K3O7/C6H8O7 (pH = 7) were studied and similar binodal curves were 
obtained (Fig. C.3A at Appendix C). Therefore, the methoxy group of the polymer chain 
has a negligible effect regarding the two-phase formation capability, and for larger 
polymer sizes the equivalent trend should be observed. Based on this result, phase 
diagrams of PEG/citrate systems were mapped out for regular PEGs of 2, 6, 10, and 20 
kDa (Fig. C.3B at Appendix C). As extensively described in literature, for PEG/salt-based 
ABS, the increase of molecular weight contributes to a higher capacity to induce phase 
separation due to the hydrophobicity of the phase formed by longer polymeric PEG 
chains.35,36 Based on the phase diagrams, a biphasic mixture point was chosen to be 
applied in the PEGylation reaction media (12.5 wt% of PEG + 12.5 wt% C6H5K3O7/C6H8O7 
pH = 7). This mixture point corresponds to the biphasic region in all phase diagrams 
evaluated (PEGs 6-20 kDa). 
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3.2. Process optimization 
PEG/salt-based ABS are highlighted as promising for the recovery of PEGylated proteins, 
i.e. bovine serum albumin,37,38 Cyt-c,16 RNase A,17,18,39 lactoalbumin,17 LYS,40 
Immunoglobulin G,37 and granulocyte-macrophage colony stimulation factor.37,38 
Nevertheless, the direct application of this operation on reaction media has not been 
extensively studied. The only previous report refers to an in situ ABS strategy formed by 
adding 4 mol.L−1 of ammonium sulphate in 20 mmol.L−1 Tris–HCl (pH 7.0) to lysozyme 
PEGylation reactions.15 In this study, several polymers and salt solutions were tested as 
potential phase-forming agents with the further analysis of LYS-PEG and LYS partitioning 
behaviour. This manuscript showed some insights on the possibility to conceive a 
unidirectional and integrative process in the production of PEGylated proteins at large 
reaction volumes, which cannot be processed using packed bed or on-column 
PEGylation processes due to the limiting saturation capacities of the large columns. Yet, 
the need to deeply explore the in-situ potential of ABS in PEGylation reaction still 
demands to be addressed. Moreover, the idea of an integrative approach combining the 
bioconjugation reaction and ABS recovery, without the use of toxic reagents such as 
hydroxylamine to stop the reaction, neither the addition of more quantities of PEG to 
promote the phase separation is still a challenge. Given the well-established versatility 
of ABS regarding their integration capacity for chemical reactions in one-step and one-
pot processes,41,42 we investigated the full one-step potential of ABS combining 
PEGylation reaction and protein conjugates purification. The effect of the size of the 
reactive PEG on the integrated purification stage, the influence of the reaction time in 
the in-situ ABS for recovery of PEGylated proteins, and the proof of concept by 
investigating several proteins (with small and large sizes) were investigated.  
Initially, mPEG-NHS of different molecular weights (5, 10, 20, and 40 kDa) were used for 
the PEGylation of Cyt-c. After PEGylation, the addition of salt promoted the phase 
separation with the top phase rich in PEGylated proteins (phase-forming compound) and 
excess of mPEG, while the bottom phase is rich in potassium citrate salt, for which the 
unreacted proteins preferentially partitioned. Table 4.2. presents the values of volume 
ratio (VR) and recovery parameters for Cyt-c and Cyt-c-PEG, i.e. K, %RecT, %RecB, and S 
for both experimental conditions. Fig. 4.7. shows the data of S and the logarithm 
                                                   Development of novel purification platforms using ABS 
CHAPTER 4  
 
190 
 
function of K obtained after the study of two distinct protein concentrations (0.5 wt% 
and 1.0 wt% of protein, conditions 1 and 2, respectively) and different conditions of PEG 
MW, reaction time and type of protein. The positive values of log K depicted in Fig. 4.7. 
indicate the partition preference of the protein towards the top phase, while negative 
values indicate its preference for the bottom phase. S values above 1000 were 
represented as >1000, indicating the complete separation of PEGylated proteins from 
the unreacted protein. Our results show that VR tends to increase with the PEG MW (i.e. 
0.46 ≤ VR ≤ 0.81, condition 1) resulting on the increase of the upper volume of top phase 
rich in PEGylated protein. In the range of PEG MW studied (Table 4.2. and Fig. 4.7.A), 
higher selectivity values were obtained (S ≥ 61 and S ≥ 87, for conditions 1 and 2, 
respectively). In this sense, the unreacted protein partitioned preferentially to the 
bottom phase, predominantly in the systems with PEGs of smaller MW (%RecBCyt-c > 85% 
for mPEG 40 kDa, %RecBCyt-c = 100% for mPEG 5 kDa, condition 1). Moreover, the 
PEGylated protein migrates to the top phase, preferentially for systems with larger PEG 
MWs (%RecTCyt-c-PEG > 90% for mPEG 5 kDa, %RecTCyt-c-PEG > 97% for mPEG 40 kDa, 
condition 1). Indeed, the PEGylated Cyt-c is one of the main phase forming agents. 
Partition results were similar for both initial Cyt-c concentrations studied (conditions 1 
and 2, respectively). Nonetheless, PEGylation yields were higher for condition 1 as a 
consequence of the higher mPEG-NHS:protein molar ratio.  
The effect of PEGylation reaction tie was investigated for 1.0 wt% of Cyt-c (condition 2). 
As it can be seen in Fig. 4.7.B and Table 4.3., high selectivity values were observed for 
all reaction times. The increase of reaction time resulted in higher PEGylation yields, 
with 100% of Cyt-c-PEG for the longer time of reaction (t = 30 min). Herein, for the 
complete reaction, it is also demonstrated the ability of this system to concentrate the 
PEGylated conjugates in the aqueous phase. As a result, the top-phase volume increases 
with the reaction time (0.90 ≤ VR ≤ 2.80), as it can be seen by the photos depicted in Fig. 
4.7.. Likewise, the recovery yields are enhanced with the extension of the reaction 
(%RecTCyt-c-PEG = 98.5 ± 0.1% for 30 min, %RecTCyt-c-PEG = 93.6 ± 0.3% for 7.5 min). 
Additionally, the efficiency of adding potassium citrate to end the PEGylation reaction 
was proved, since different degrees of PEGylation were obtained after adding it at 
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distinct reaction times. Therefore, it represents a non-toxic and eco-friendly alternative 
to replace hydroxylamine as a reagent to stop PEGylation.   
Aiming at proving the transversal potential of integrating the PEGylation reaction and 
primary recovery as an alternative approach, three other enzymes were tested. In this 
sense, the mixture point (1.0 wt% of Protein + 12.5 wt% Prot-PEG + 12.5 wt% potassium 
citrate buffer, pH = 7.0) previously selected was tested for LYS, ASNase and CAT, using 
the PEG of 20 kDa (Table 4.4. and Fig. 4.7.C). Again, the preferential behaviour of native 
proteins towards the salt-rich phase and the PEGylated species to the top phase was 
observed with no exceptions. Nonetheless, a more selective performance was found for 
Cyt-c and LYS (smaller proteins), with S values of 123 and >1000, respectively. In the case 
of LYS, a complete separation was obtained (%RecBLYS = 100% and %RecTLYS-PEG = 100%) 
by our one-step in-situ approach. Regarding the larger enzymes, higher recovery yields 
were obtained for PEGylated conjugates towards the top phase, but recovery yields of 
the unreacted protein towards the opposite phase were lower (94 % > %RecTPROT-PEG > 
98%, 58% > %RecBPROT > 66%). This decrease of recovery yield of unreacted protein in 
salt-rich phase may be a result of its higher molecular weight and consequent protein 
partition to the top phase by a salting-out phenomena caused by the potassium citrate 
salt presence.43    
 
 
 
 
 
 
Fig. 4.7. Logarithm of K of both native (light grey bars) and PEGylated proteins (dark grey bars) in the one-
step approach under development PEG-Prot + citrate (pH = 7) ABS [1.0 wt% Protein (condition 2) + 12.5 
wt% Prot-PEG/PEG + 12.5 wt% citrate buffer].  The selectivity of each system (S) is presented in red. 
Pictures of each ABS prepared are depicted for each system. 
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Table 4.2. Effect of molecular weight (MW) of mPEG-NHS upon the volume ratio (VR) and partitioning behaviour, represented as the partition coefficient (K), top and bottom-
phase recoveries (%RecT and %RecB), and selectivity (S) of native and PEGylated Cyt-c in Cyt-c-PEG + potassium citrate buffer-based ABS. 
MW mPEG-NHS VR KCyt-c KCyt-c-PEG S %RecTCyt-c  %RecBCyt-c %RecTCyt-c-PEG %RecBCyt-c-PEG  
Condition 1: 0.5 wt% Cyt-c + 12.5 wt% Cyt-c-PEG + 12.5 wt% potassium citrate buffer 
mPEG 5 kDa 0.46 0.00072 ± 0.00004 4.5  ± 0.2 >1000 0% 100% 90.7 ± 0.5% 9.3 ± 0.5% 
mPEG 10 kDa 0.52 0.0051 ± 0.0003 2.2  ± 0.1 426 0.3 ± 0.1% 99.7 ± 0.1% 80.7 ± 1.0% 19.3 ± 1.0% 
mPEG 20 kDa 0.73 0.115 ± 0.06 7 ± 0.4 61 7.8 ± 0.7% 92.3 ± 0.7% 90.6 ± 0.5% 9.4 ± 0.5% 
mPEG 40 kDa 0.81 0.204 ± 0.01 31  ± 2 154 14.2 ± 0.7% 85.8 ± 0.7% 97.5 ± 0.1% 2.5 ± 0.1% 
Condition 2: 1.0 wt% Cyt-c + 12.5 wt% Cyt-c-PEG + 12.5 wt% potassium citrate buffer 
mPEG 5 kDa 0.52 0.038 ±  0.002 3.3 ± 0.2 87 1.9 ± 0.1% 98.1 ± 0.1% 86.4 ± 0.7% 13.6 ± 0.7% 
mPEG 10 kDa 0.58 0.090 ±  0.005 10.8 ± 0.5 119 5.0 ± 0.3% 95.0 ± .0.3% 94.9 ± 0.3% 5.1 ± 0.3% 
mPEG 20 kDa 0.90 0.108 ± 0.005 13.3 ± 0.7 123 8.9 ± 0.4% 91.1 ± 0.4% 93.6 ± 0.3% 6.4 ± 0.3% 
mPEG 40 kDa 2.17 0.109 ± 0.005 25 ± 1 233 19.1 ± 1.0% 80.9 ± 1.0% 92.1 ± 0.4% 7.9 ± 0.4% 
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Table 4.3. Effect of PEGylation reaction time on the volume ratio (VR) and partition behaviour, represented as the partition coefficient (K), top and bottom-phase recoveries 
(%RecT and %RecB), and selectivity (S) of native and PEGylated Cyt-c in ABS composed of 1.0 wt% Cyt-c + 12.5 wt% Cyt-c-PEG/PEG + 12.5 wt% potassium citrate buffer, at pH 
7.0. 
 
 
 
*Absence of unreacted Cyt-c since at 30 min the complete PEGylation reaction occurs. 
 
Table 4.4. Partition parameters for Cyt-c, LYS, ASNase, and CAT for the in-situ approach under development: Volume ratio (VR), partition coefficient (K), top and bottom-phase 
recoveries (%RecT and %RecB), and selectivity (S) of native and PEGylated enzyme conjugates in ABS composed of 1.0 wt% Protein + 12.5 wt% Prot-PEG/PEG + 12.5 wt% 
potassium citrate buffer.  
Proteins VR KPROT KPROT-PEG S %RecTPROT %RecBPROT %RecTPROT-PEG %RecBPROT-PEG 
Cyt-c 0.90 0.108 ± 0.005 13.3 ± 0.7 123 8.9 ± 0.4% 91.1 ± 0.4% 93.6 ± 0.3% 6.4 ± 0.3% 
LYS 0.73 0.0002 ± 0.0001 543 ± 27 >1000 0% 100% 100% 0% 
ASNase 0.90 0.79 ± 0.04 47.5 ± 2.4 60 41.6 ± 2.1% 58.4 ± 2.1% 98.1 ± 0.1% 1.9 ± 0.1% 
CAT 1.11 0.46 ± 0.02 18.8 ± 1.0 41 33.9 ± 1.7% 66.1 ± 1.7% 94.4 ± 0.3% 5.6 ± 0.3% 
 
Time (min) VR KCyt-c KCyt-c-PEG S %RecTCyt-c %RecBCyt-c %RecTCyt-c-PEG %RecBCyt-c-PEG 
7.5 0.90 0.108 ± 0.005 13.3 ± 0.7 123 8.9 ± 0.4% 91.1 ± 0.4% 93.6 ± 0.3% 6.4 ± 0.3% 
15 1.24 0.181 ± 0.009 43.3 ± 2.2 239 18.3 ± 0.9% 81.7 ± 0.9% 97.2 ± 0.1% 2.8 ± 0.1% 
30 2.80 * 180.8 ± 9.0 >1000 * * 98.5 ± 0.1% 1.5 ± 0.1% 
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While developing a strategy able to efficiently produce PEGylated enzymes and purify 
them from the respective unreacted protein, the ABS used in this work proved to be 
simultaneously able to maintain the activity and structural integrity of each model 
enzyme. The enzyme activity was evaluated in both top and bottom phases, to 
guarantee the biological activity of both PEGylated and unreacted enzyme, since we 
expected to increase the sustainability of the process by reintroducing the unreacted 
enzyme in new cycles of PEGylation reaction.16 Table 4.5. presents the specific activity 
(SA, U.mg-1) and the volumetric activity (A, U.mL-1) for each enzyme species 
concentrated in both top and bottom phases. In all cases, the enzyme activity was 
preserved, emphasizing the biocompatible and mild nature of the downstream process 
envisioned in this work. Moreover, and due to the enzymes’ sensibility to small changes 
in their secondary structure, Fourier transform infrared spectroscopy (FTIR) was also 
applied to investigate PEG-proteins bioconjugation and partition. Fig. 4.8. shows the 
FTIR spectra of pure PEG and Cyt-c together with ABS top and bottom phases after 
PEGylation and phase separation. As observed, the IR spectra present three main 
spectral regions resultant from a complex combination of vibration modes from 
different infrared-activate functional groups typical of PEG and Cyt-c IR fingerprints: 
3500-2700 cm−1, 1700-1500 cm−1 and 1500-1000 cm−1.44,45 The appearance of two bands 
at 2921 and 2883 cm−1 assigned to aliphatic C-H asymmetric and symmetric stretching 
of PEG methylene groups at the top Cyt-c confirms the success of the PEGylation 
reaction while also demonstrates the presence of Cyt-c-PEG as main component of top-
phase of ABS.46 This is further supported by the occurrence of a broad envelope with 
maximum intensity centered on 1085 cm−1, resultant of a band merging effect assigned 
to the combination of C–O, C–O–C stretches and C–O–H bending vibrations of the 
attached PEG.44 The amide I band presented at 1638 cm−1 representing the C-O 
stretching vibration of peptide group, the amide II band at 1578 cm−1 corresponding 
primarily to N-H bending and contributions of C-N stretching vibrations, as well as, 
amide III at 1388 cm−1 representing the N-H bending and C-N stretching vibrations, prove 
that Cyt-c keeps its secondary structure after PEGylation.47 Despite the fact that no 
changes are observed at the vibrational frequency of the studied proteins, an increase 
of intensity of amide I when compared with the amide II is observed for the ABS top 
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phase, and when compared with the data for both the pure Cyt-c and bottom phase of 
ABS. 
Table 4.5. Proof of concept for four model enzymes: Cyt-c, LYS, ASNase, and CAT of one-pot conjugation 
+ in situ ABS. The specific activity, SA, (units: U.mg-1), the volumetric activity of the respective protein 
(units: U.mL-1) and the total protein concentration (units: mg.mL-1) of top and bottom phases of Prot-PEG 
+ citrate ABS are depicted in this table. 
Proteins 
[P]T  
(mg.mL-1) 
[P]B  
(mg.mL-1) 
AT  
(U.mL-1) 
AB  
(U.mL-1) 
SAT  
(U.mg-1) 
SAB  
(U.mg-1) 
Cyt-c 0.352 0.070 1.11 0.17 3.15 2.40 
LYS 0.437 0.039 2.55E+03 5.52E+03 5.84E+03 1.43E+05 
ASNase 0.174 0.044 1.56E+01 2.78E+01 8.97E+01 6.28E+02 
CAT 0.182 0.064 6.84E+04 1.22E+04 3.76E+05 1.91E+05 
 
 
Fig. 4.8. FTIR-ATR spectrum of ABS (1.0 wt% Protein + 12.5 wt% Prot-PEG/PEG + 12.5 wt% citrate buffer) 
top-phase (---) bottom-phase (•••), pure Cyt-c (▬) and PEG (▬). 
 
3.3. Process optimization 
Three of the main criteria for the development of a sustainable process combining 
reaction and separation allied with the Green Chemistry principles, are the (i) need for 
a high yield of reaction, (ii) the possible recycle of main unreacted reagents and (iii) the 
possible recycle of the main solvents. In this work, a schematic diagram (Figs. 4.9. and 
4.10.) was defined combining the PEGylation reaction with the purification of the 
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protein conjugates. Here, two scenarios were considered. A first one were the 
PEGylation reaction is complete (1.0 wt% of Cyt-c + mPEG-NHS-20 kDa, 30 min), thus 
eliminating the need to recycle the unreacted enzyme (Fig. 4.9.). The second scenario 
(the worst but most common one) describes an incomplete PEGylation reaction (1.0 
wt% of Cyt-c + mPEG-NHS-40 kDa, 7.5 min) and for which, the recycling of the unreacted 
enzyme was contemplated in the approach (Fig. 4.10.). In both cases, the dual role of 
the citrate salt was verified, namely as a phase-forming solvent but firstly, as an agent 
acting to stop the PEGylation reaction, which is also contributing for the higher 
sustainability of the process. Moreover, for both scenarios, the yield of reaction, as well 
as the recovery yields of both enzyme conjugates and unreacted enzyme (for the 
incomplete reaction), are represented in the respective diagram for both top and 
bottom phases. When the complete reaction is evaluated (Fig. 4.9.), the process is 
simpler, since after the reaction (PEGylation yield of 100%) the only demand is for the 
separation of the enzyme bioconjugates by ABS, followed by the recycle of the phase-
forming solvents, which can be easily achieved by applying an ultrafiltration. Using this 
approach, the isolation of the citrate salt-rich phase from the PEGylated Cyt-c is 
accomplished with success. Since the presence of the Cyt-c conjugate is only residual 
(around 1.5%), the salt can be directly reintroduced in the process for new cycles of 
PEGylation + separation. Despite the good performance of this approach, the second 
scenario contemplating an incomplete reaction is the most common (Fig. 4.10.). Here, 
in addition to the recycle of the phase-forming solvents, the recycle and reuse of the 
unreacted enzyme in a new cycle of PEGylation was also contemplated. In this case, 
higher selectivity values were found for higher purity of both the PEGylated conjugates 
(purity = 84.6%) on the top phase and unreacted protein (purity = 97.7 %) on the bottom 
phase. Nevertheless, in both scenarios, the waste production was prevented by the 
addition of a recycling process using ultrafiltration, simultaneously allowing the reuse of 
(i) phase-forming components (citrate salt) in a consequent in-situ ABS purification, and 
(ii) unreacted protein for a novel PEGylation reaction, thus contributing for the higher 
sustainability and lower economic impact of the overall process. Allied with the good 
performance of the processes envisioned in this work, an enhanced capacity to improve 
the production of higher amounts of purified PEGylated proteins was obtained. The 
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strategy developed in this work combined the higher efficiency in the recovery of 
PEGylated proteins, with the possibility to re-use the unreacted protein and the phase 
former compounds (i.e. potassium citrate salt) to perform a second reaction.16 In the 
end, an advantageous integrated process, in comparison with chromatographic 
techniques was here demonstrated, since the saturation limitations, especially in large 
scale48 described for chromatography, were eliminated.  
 
Fig. 4.9. Schematic diagram of the integrated process combining bioconjugation reaction and separation 
with the polishing step and solvent recycling process for a complete PEGylation reaction. The dashed line 
represents steps that were not experimentally developed. 
 
Fig. 4.10. Schematic diagram of the integrated process combining bioconjugation reaction and separation 
with the polishing step and solvent recycling process for an incomplete PEGylation reaction. The dashed 
line represents steps that were not experimentally developed. 
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4. Conclusions 
In an era where the demand for more sustainable, cheap and “green” downstream 
processes is increasing, the need for improved downstream approaches is crucial. In this 
work, an alternative process was envisioned, by integrating the enzyme PEGylation with 
the separation of conjugates and unreacted enzyme. Aiming at simplifying the process, 
the PEGylated enzyme produced was used as one of the phase-forming agents, allowing 
the two-phase split after the direct addition of potassium citrate buffer. Despite the dual 
role of the enzyme conjugates as product of the reaction and phase forming agent, the 
citrate salt also acts as phase-forming agent, but firstly it is used to stop the PEGylation 
reaction, thus simplifying the process and avoiding the need for extra compounds on 
the reaction media. After optimization of the main conditions of reaction (time of 
reaction and PEG MW), an integrated process was successfully achieved for four model 
proteins, namely Cyt-c, LYS, ASNase and CAT.  
Envisioning the industrial potential of the processes developed in this work, the 
schematic representation of the process diagram was defined combining PEGylation 
reaction with purification. Two different scenarios were here contemplated, the first 
one representing a complete PEGylation reaction (1.0 wt% of Cyt-c + mPEG-NHS-20 kDa, 
30 min), and a second and most common, where an incomplete PEGylation reaction is 
represented (1.0 wt% of Cyt-c + mPEG-NHS-40 kDa, 7.5 min). For both approaches, high 
recovery yields and purities were obtained for the PEGylated conjugates (92.1 ± 0.4% < 
%RecTCyt-c-PEG < 98.1 ± 0.1%; 84.6% < purity < 100%) and for the unreacted enzyme 
(%RecBCyt-c = 81 ± 1%; purity = 97.7%), while maintaining their structural integrity. 
The findings reported here open a new path for application of integrated bioconjugation 
+ purification using ABS for the recovery of high-value biological products, like 
therapeutic biobetters and biosensors from larger reaction volumes, without 
compromising the success of the downstream process. 
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5.1. Continuous purification of PEG-Protein conjugates by fast centrifugal 
partition chromatography 
Santos, J. H. P. M., Ferreira. A. M., Almeida, M. R., Coutinho, J. A. P., Freire, M. G., 
Rangel-Yagui, C. O. & Ventura, S. P. M. Green Chemistry, 2019, submitted.10 
 
Abstract 
This work proposes the application of aqueous biphasic systems (ABS) in FCPC for the 
purification of PEGylated cytochrome c conjugates. After the proper optimization of the 
processual conditions, the ABS composed of PEG 2000 + potassium phosphate buffer (at 
pH 7) was selected as the most performant to be applied on FCPC to separate unreacted 
Cytochromec (Cyt-c) from the PEGylated conjugate in continuous flow. Yields of 
purification (Y% > 88%) and purity levels around 100% were obtained, even after the 
reuse of both the unreacted Cyt-c in a new cycle of PEGylation + FCPC purification and 
the phase former components (PEG 2000 and potassium phosphate buffer), 
contributing towards the development of a sustainable fractionation approach in 
continuous regime for bioconjugates. 
 
 
 
 
 
 
 
 
Keywords: cytochrome c; protein PEGylation; continuous purification regime; aqueous 
biphasic systems; fast centrifugal partition chromatography; countercurrent 
chromatography. 
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1. Introduction 
Protein PEGylation is widely used in the pharmaceutical industry,1–4 yet, it can also be 
used to obtain novel protein-based biosensors.5–8 PEGylated drugs are commonly 
classified as biobetters,2,4,9 since the PEG attachment on the protein normally results in 
pharmacokinetic and pharmacodynamic improvements.10,11 Generally, PEGylation 
enhances drug solubility and decreases immunogenicity.1 PEGylation also increases 
plasma half-life by reducing drug proteolysis and clearance, thereby follow-on in a 
reduced dosing frequency to the patient.2,12 Taking into consideration all these benefits, 
a wide variety of therapeutic proteins,13–15 peptides,16 and antibody fragments,11 as well 
as small molecule drugs,17 have been PEGylated. In terms of protein-based bionsensors, 
the PEGylation overcomes the crucial issue regarding the lack of long term stability of 
the protein since the PEGylated conjugate is more stable over extended periods of time 
while maintaining the biosensing aptitude.5 
The conjugation reaction between PEG and protein is carried out by addition of 
activated PEG (also known as PEG derivative) and protein under the proper conditions 
(i.e. pH, molar ration PEG:protein, time, temperature and agitation speed).18,19 The 
chemistry behind protein PEGylation is well-know, being extensively discussed in the 
literature.9,19,20 While the conjugation reaction is rather straightforward, the 
fractionation and separation of PEGylated conjugates is troublesome, especially for 
continuous regime and scale-up processing.21 Protein PEGylation results in a complex 
heterogeneous colloidal solution, consisting in residual polymer, native protein, reaction 
byproducts and in some cases different forms of the modified protein (i.e. different 
number of PEG molecules attached at different residues).19 Therefore, there is the need 
to separate the PEGylated conjugates from the rest of the chemicals presented in the 
reaction. 
Currently, purification processes of PEGylated proteins are based on chromatographic 
techniques, i.e. size exclusion chromatography (SEC)22,23 and ion exchange 
chromatography (IEX).24,25 Nonetheless, the separation of PEGylated proteins through 
conventional chromatographic based techniques showed to be, in a considerable 
number of cases, an unfeasible option, due to coelution of PEGylated products and 
native protein (i.e. poorer resolution at peak separation and peak overlapping).26,27 This 
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occurs because separations by size (SEC) and charge (IEX) are ineffective to discriminate 
the PEG-protein conjugates from unreacted protein when the differences of molecular 
weight and charge between PEGylated conjugates and native protein are small. 
Recently, an effort has been noticed to seek for alternative non-chromatographic 
processes to fractionate PEGylated conjugates, through several techniques: membrane 
separations, electrophoresis, capillary electrophoresis, and aqueous biphasic systems 
(ABS).28 In this way, the possibility to use aqueous biphasic systems principles in 
combination with chromatographic techniques, more specifically countercurrent 
chromatography (CCC), could be an interesting novel alternative for the separation of 
PEGylated proteins. Countercurrent chromatography consists in liquid–liquid 
chromatography which uses a support-free liquid stationary phase held in place by a 
simple centrifugal or complex centrifugal force field.29 Countercurrent chromatography 
in aqueous two phase systems has been proven to be highly selective for closely related 
proteins, which have only slight differences in partitioning behavior.29,30 In this case, it 
is studied the application of hydrostatic CCC columns, known as fast centrifugal partition 
chromatographs (FCPCs).30–32 Their two main characteristics are:   single axial rotation 
through a constant centrifugal field and enclosed geometrical volumes, tubes, channels, 
or locules that repeat themselves through connecting tubes forming a pattern.29  
In this paper we evaluated the potential application of FCPC, for the separation of 
PEGylated species, using cytochrome c as a model protein. A previous report by our 
research group proved the potential application of PEG-phosphate ABS to separate the 
PEGylated cytochrome c (Cyt-c) from the unmodified form.33 PEGylated Cyt-c forms are 
produced through an acylation reaction using NHS-PEG ester, which links to the protein 
in the amino groups.  The continuous regime of purification through FCPC was 
evaluated, through the proper selection of mobile and stationary phases (i.e. mixture 
point and phase components) and possibility of recycling the unreacted protein to a 
novel PEGylation reaction and consequent FCPC purification.  
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2. Materials and Methods 
2.1. Materials 
Cytochrome c (Cyt-c) from equine heart (purity ≥ 95%) was acquired from Merck. The 
PEG derivative used in the PEGylation reaction was the methoxyl polyethylene glycol 
succinimidyl NHS ester (mPEG-NHS), obtained from Nanocs (purity > 95%) with a 
molecular weight of 20 kDa. The salts used on the protein PEGylation step were the 
potassium phosphate monobasic (KH2PO4), potassium phosphate dibasic (K2HPO4), and 
hydroxylammonium chloride all acquired from Merck, with purity of 95%.  
For the FCPC separation process, the polyethylene glycol series (PEGs) used included 
PEG 600, 1000, 1500, 2000, and 4000. All these polymers were bought from Merck with 
high purity. The potassium phosphate buffer (PB) was prepared using the salts KH2PO4 
and K2HPO4.  
The mobile phase applied in the HPLC analysis was composed of acetonitrile (purity ≥ 
99.9 wt%), trichloroacetic acid (purity ≥ 99.5 wt%) from Acros organics, both HPLC grade, 
and ultra-pure water, double distilled and passed through a Milli-Q plus 185 water 
purification apparatus. Syringe filters (0.45 µm) acquired from GE Healthcare, Whatman, 
were used. 
 
2.2. PEGylation reaction of Cyt-c 
The PEGylation reactions were conducted following standard protocols described in  
literature.33,34 Briefly, 2 mL of a Cyt-c solution (0.5 mg.mL-1) in 100 mM of PB (pH = 7) 
was added to a flask containing 20.8 mg of mPEG-NHS with 20 kDa (protein:PEG molar 
ratio = 1:25). The mixtures were stirred at 400 rpm, for 30 min at room temperature 
with a magnetic stirrer. To stop the PEGylation reaction 10% (v/v) of hydroxylammonium 
chloride (1 M) was added. After, the samples were stored at -20oC for further use in 
FCPC. 
 
2.3. Fast Centrifugal Partition Chromatography Purification 
2.3.1. FCPC equipment 
A Fast Centrifugal Partition Chromatography (FCPC)® system, model FCPC-C, from 
Kromaton Rousselet-Robatel (Annonay, France), was used to investigate the continuous 
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separation of PEGylated and non-PEGylated proteins. The equipment used in this work 
is the same presented in our previous study, where phenolic compounds were purified 
in a continuous regime.35 In order to verify the PEG + potassium phosphate buffer ABS 
behaviour in the equipment, increase the stationary phase retention ratio and decrease 
the purification time, operating conditions, such as flow-rate and rotation speed were 
investigated (Table 5.1.). The best flow rate and rotation speed found were of 2.5 
mL.min-1 and 200 rpm with a Sf of 41.18%. The stationary phase retention, Sf, was 
calculated by the ratio of the stationary phase volume (VS) and the column volume (VC): 
Sf= VS/VC. 
 
Table 5.1. FCPC assays with PEG 1000 + phosphate buffer ABS, mixture points adopted, stationary phase 
retention (Sf) achieved and operating conditions. 
 
2.3.2. FCPC purification of PEGylated and non-PEGylated Cyt-c 
Ternary phase diagrams of PEG + potassium phosphate buffer were constructed through 
cloud point titration method36 to further study the fractionation of the unreacted Cyt-c 
and PEGylated forms. In these systems, the top phase corresponds to the PEG-rich phase 
while the bottom phase is mainly composed by potassium phosphate buffer. The 
mixture point composed of 15 wt% of PEG + 20 wt% of potassium phosphate buffer (pH 
= 7) using different PEG molecular weights (Table 2) was selected. This system was set 
to work in the descending mode. The rotor was entirely filled with the PEG-(top)-rich 
phase at 5 mL.min-1 and 600 rpm to achieve the homogeneous solvent re-equilibration 
PEG 
(g.mol-1) 
Potassium 
phosphate 
buffer 
Mixture point 
(PEG; buffer 
wt%) 
CPC Sf 
Flow rate          
(mL.min-1) Rotation 
speed (rpm) 
1000 pH 7 
15; 20 ✓ 11.76 3.0 2000 
15; 20 ✓ 9.31 3.0 2500 
15; 20 ✓ 16.67 2.5 2500 
15; 20 ✓ 41.18 2.5 2000 
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on the rotor. Then, the rotation was set up at the highest speed (2000 rpm), needed for 
the appropriate stationary phase retention. After the set-up of the working rotational 
speed, the potassium phosphate buffer-rich-(bottom) phase was pumped (2.5 mL.min-
1) through the stationary phase to reach the equilibrium, i.e. when only the mobile phase 
came out of the column and the signal baseline is stabilized. The stationary phase 
retention parameter for all the ABS applied was calculated, ranging from 38% to 46%, 
depending on the PEG molecular weight used (Table 5.2.). The sample loop was filled 
with 2 mL of the PEGylation Cyt-c samples (obtained by the method 2.2.). An elution-
extrusion countercurrent chromatography method was applied,37,38 composed by two 
main steps: first an elution with potassium phosphate buffer-rich phase and then an 
extrusion with water. The first 20 min of elution were performed using the bottom(salt)-
rich phase as mobile phase to extract the unreacted Cyt-c, then the PEGylated 
conjugates of Cyt-c were eluted with water by extrusion. By applying an elution-
extrusion process, full sample recovery can be achieved with high resolution of the 
peaks. 
 
2.3.4. Integrated process applying continuous purification by FCPC 
An integrated process was created to reuse the unreacted Cyt-c in a novel PEGylation 
reaction. This integrated process combines the PEGylation reaction, followed by FCPC 
purification and then the isolation of the purified fractions of Cyt-c by applying an 
ultrafiltration step. The purified Cyt-c fractions were filtrated through Amicon Ultra 
centrifugal filters (Merck) with a MWCO of 4 kDa to remove the mobile phase 
(composed of potassium phosphate buffer with small quantities of PEG). The 
ultrafiltration step consisted in three washes of 100 mM of potassium phosphate buffer 
(pH = 7) to change the solvent of the unreacted Cyt-c to the appropriate PEGylation 
medium. The polished Cyt-c fraction was then PEGylated with a molar ratio of 1:25 
(protein:PEG) and applying the same conditions of reaction time, temperature, and 
agitation speed, described in section 2.2. The yield of Cyt-c-PEG (Y%, corresponding to 
the weight of PEGylated protein in the purified fraction divided by the initial weight of 
PEGylated protein after bioconjugation reaction) was calculated for both the integrated 
and simple processes, meaning the process with and without recycling of Cyt-c. 
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2.4. Polishing of purified Cyt-c products (Cyt-c and Cyt-c-PEG) and recycling of phase 
components  
Both purified fractions containing the PEGylated sample and the unreacted protein were 
ultrafiltrated through Amicon Ultra centrifugal filters (Merck) with a MWCO of 4 kDa for 
the removal of phase components of the mobile phase. The recycling of the phase 
components from the fractions without protein was achieved in the integrated process. 
This additional step aims to decrease the environmental impact and to seek for the 
higher sustainability of the purification process proposed. 
 
2.5. Analytical procedures: HPLC quantification of Cyt-c and Cyt-c-PEG 
The quantification of purified fractions of PEGylated Cyt-c and unreacted protein from 
the FCPC was carried by HPLC-DAD (Shimadzu, model PROMINENCE). HPLC analyses 
were performed with an analytical C18 reversed-phase column (250 × 4.60 mm), kinetex 
5 μm C18 100 A, from Phenomenex. The mobile phase used was a gradient system of 
0.1% of trifluoracetic acid (TFA)-ultra-pure water (phase A) and 0.1% TFA-acetonitrile 
(phase B), previously degassed by ultrasonication. The separation was conducted using 
the following gradient mode, 0 min 25% of B, 42 min 42% of B, 45 min of B, and then 
returning to initial conditions during 20 min to ensure the column stabilization. The flow 
rate used was 0.8 mL.min-1 with an injection volume of 60 μL. DAD was set at 409 nm. 
Each sample was analysed at least in duplicate. The column oven and the autosampler 
operated at a controlled temperature of 25°C. Cyt-c and Cyt-c-PEG presented retention 
times of 16.5 and 19.3 minutes, respectively. 
The purification performance of FCPC process was evaluated based on the purification 
yield (Y%) and purity (%) determined for both Cyt-c and Cyt-c-PEG. The purification yield 
was calculated by dividing the protein weight in the purified fraction (either Cyt-c or Cyt-
c-PEG) by the initial protein weight (before purification). The purity (%) was calculated 
by the weight percentage of the desirable protein (either Cyt-c or Cyt-c-PEG) in the 
purified fraction. 
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3. Results and Discussion 
3.1. FCPC purification step 
The phase diagrams of the ABS formed by PEG and the potassium phosphate buffer 
solution were experimentally prepared under the scope of this work,36 being the results 
depicted in Fig. D.1 at Appendix D. A well-established behaviour was observed for 
PEG/salt-based ABS, which correlates the increase of PEG molecular weight with the 
ability to form two aqueous phases.39,40 The mixture point adopted to test the 
continuous purification using FCPC was 15 wt% of PEG + 20 wt% of potassium phosphate 
buffer (pH = 7), which represents a biphasic system (Fig. 5.1.). Furthermore, to better 
understand the separation of both proteins (unreacted and PEGylated conjugate) the 
partition of both protein structures, at lab scale, was determined, being the respective 
partition coefficients calculated for all the studied systems (Table D.1 at Appendix D). 
The results suggest the preferential partition of Cyt-c-PEG towards the PEG-rich phase 
and the unreacted protein towards the opposite phase (i.e. salt-rich phase), which 
results in high selectivity values, as previously shown in literature.33,41–44 Due to the 
different characteristics of the proteins in terms of their relative 
hydrophilicity/hydrophobicity nature, the application of this type of systems in a 
continuous regime using the FCPC was investigated. The same five ABS composed of 
PEGs with different molecular weights + potassium phosphate buffer were investigated. 
The manipulation of PEG molecular weight was evaluated (ranging from 600 to 4000 
g.mol-1), maintaining fixed the mixture point and the FCPC operational conditions (i.e. 
flow rate and rotation speed), being the stationary phase retention and the capability to 
perform the purification runs calculated (Table 5.2.).  
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Table 5.2. PEG + potassium phosphate buffer ABS tested in FCPC, mixture points adopted, stationary 
phase retention and operating conditions. 
 
The polymer-based ABS designed with PEG of higher molecular weight (i.e. PEG 4000) 
resulted in a highly viscous top-phase, preventing the application of FCPC due to the 
over-pressure troubleshooting. Moreover, the polymer-based ABS using the PEG with 
the lower molecular weight (i.e. PEG 600) exhibited a lower value of Sf, indicating the 
weak capacity to retain the stationary phase. Taking into account all the processual 
restrictions previously identified, the work developed employing the FCPC was done 
using PEGs with intermediate molecular weights, namely PEG 1000, PEG 1500, and PEG 
2000.   
After selecting the most appropriate ABS to apply on FCPC, the next step was to perform 
the PEGylation of Cyt-c. For that, a PEG derivative (mPEG-NHS) of 20 kDa was used to 
perform the PEGylation, then forming a complex reaction medium, containing a 
heterogeneous mixture of proteins (Cyt-c and Cyt-c-PEG) and salts (hydroxylamine and 
potassium phosphate buffer). The yield of PEGylation observed was at circa 43.5%, with 
only one PEGylated conjugate formed (Cyt-c-PEG). This yield is quite reasonable when 
compared to other PEGylation yields obtained for Cyt-c.5,6,45 Fig. 5.1. presents the 
chromatogram resulting from the batch injection of 2 mL of reaction medium, 
performed in the descending mode and with a mobile phase flow rate of 2.5 mL.min−1. 
PEG 
(g.mol-1) 
Potassium 
phosphate 
buffer 
Mixture point 
(PEG; buffer 
wt%) 
CPC Sf Operating conditions 
600 
pH 7 
15; 20 ✓ 38.73 
Flow: 2.5 mL.min-1; 
Rotation speed: 2000 
rpm 
1000 15; 20 ✓ 41.18 
1500 15; 20 ✓ 46.07 
2000 15; 20 ✓ 46.08 
4000 15; 20 ✕ -- 
Over-pressure 
Highly viscous top-
phase 
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The ascending mode was also tested resulting in lower fractionation performance, being 
for this reason discarded. The bottom potassium phosphate buffer-rich phase was used 
as mobile phase during the initial stage of elution (from 0 to 20 min).  
 
Fig. 5.1. Chromatogram of FCPC purification of Cyt-c and Cyt-c-PEG performed employing ABS comprising 
15 wt% of PEG (1000, 1500 and 2000) + 20 wt% of potassium phosphate buffer, at pH 7.0.  
 
Afterwards and, for the elution of unreacted Cyt-c, the mobile phase was changed to 
water and the extrusion method was applied37,38 to efficiently separate the 
bioconjugates (from 20 to 40 min). This change on the mobile phase was required to 
decrease the elution time of Cyt-c-PEG, since the PEGylated form has a higher affinity to 
the stationary phase used during the initial stage of elution, the PEG-rich phase. Previous 
studies33 and the partition tests here performed in lab scale for both proteins (Table D.1 
at Appendix D) demonstrated that Cyt-c exhibits a K < 1, resulting in its favourable 
interaction with the most hydrophilic phase. On the contrary, the PEGylated form was 
concentrated mostly in the top-rich phase (K > 1). This behaviour is probably justified by 
the preferential PEG-PEG interactions and by some hydrophobic effects occurring. In this 
sense, the FCPC results agreed with the previous lab-scale partition assays, meaning that 
the unreacted protein migrating preferentially to the mobile phase, was firstly 
separated, followed the PEGylated conjugate further eluted by extrusion.  No losses of 
stationary phase were observed during the separation run and the complete separation 
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of the two proteins was achieved with the Cyt-c elution observed in fractions 7-15, and 
the Cyt-c-PEG in fractions 35-39, depending on the PEG molecular weight used as phase 
component. After the removal of the phase components (PEG and potassium phosphate 
buffer) by ultrafiltration, using MWCO = 4 kDa Amicon centrifugal filter, both proteins 
were identified by HPLC (Fig. 5.2.), aiming at to prove the successful separation between 
the proteins and the solvents. 
 
Fig. 5.2. HPLC chromatogram of the Cyt-c, Cyt-c PEGylation reaction media, purified Cyt-c and purified 
Cyt-c-PEG. 
 
The results showed high yields and purities for both proteins (i.e. Y% > 96% and purity = 
100% for Cyt-c; Y% > 88% and purity = 100% for Cyt-c-PEG) in all systems applied in FCPC 
(cf. Table 5.3.). Nonetheless, PEG 2000 can be highlighted as the most promising system 
due to the highest values of Y% for both unreacted and PEGylated protein. Therefore, 
the experiments and results discussed before demonstrated the potential of these 
specific ABS allowing the development of versatile approaches for the separation of 
PEGylated conjugates using FCPC in a continuous regime. 
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Table 5.3. Purified fractions, yield (%) and purity of Cyt-c and Cyt-c-PEG obtained after FCPC purification. 
  Cyt-c 
 
Cyt-c-PEG 
 Fractions Y (%) Purity  Fractions Y (%) Purity 
PEG 1000 14-15 96.10% 100  39 88.23% 100 
PEG 1500 12-14 98.91% 100  38-39 90.62% 100 
PEG 2000 7-12 100.11% 100  35 99.18% 100 
 
3.2. Integrated purification process: recycling of Cyt-c and ABS phase-forming 
compounds  
Currently, the biopharmaceutical industries seek for the development of processes 
based on the principles of Green Chemistry and Sustainability, and in this sense, the 
profitability of the process has to be taken into account.46 Based on the recent trends in 
the design of novel protein PEGylated products, it is herein proposed a novel recycling 
strategy composed of two steps: (i) the reuse of purified unreacted Cyt-c for a new cycle 
of PEGylation reaction and purification, and (ii) the reutilization of the phase-former 
solvents (PEG 2000 and potassium phosphate buffer) for a consequent FCPC purification 
step. Fig. 5.3. shows the simplified process without any recycling step (Fig. 5.3.A) and 
the integrated process contemplating the recycling of both Cyt-c and phase-forming 
components (Fig. 5.3.B). It must be highlighted that the polishing step was achieved 
using an ultrafiltration step (section 3.1.), since this allows the recovery and appropriate 
application of the PEGylated conjugate recycled.  
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(A) 
 
(B)     
 
Fig. 5.3. Process diagram of the integrated process of purification in continuous regime applying FCPC 
without (A) and with the recycle of unreacted Cyt-c (B). 
 
After the “re-PEGylation” process of the purified Cyt-c, a subsequent FCPC purification 
step was performed using the PEG 2000 + potassium phosphate buffer system, which 
was providing the highest purification yield, applying the same methodology of elution-
extrusion CCC.37,38 Fig. 5.4. depicts the chromatogram of each protein after FCPC 
application, where it can be seen the complete separation of the two protein products, 
using PEG 2000 after recycling, without losses of the stationary phase. The Cyt-c eluted 
is represented by fractions 10-12, and the Cyt-c-PEG corresponds to fractions 36-37. 
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Furthermore, remarkable purities and yields of purification (Y%) were obtained in this 
subsequent FCPC purification step. Indeed, the purity of both proteins was kept around 
100% with minor losses of Y% (at circa 5% and 10% respectively for Cyt-c and Cyt-c-PEG, 
cf. Table 5.4.).  
 
Fig. 5.4. Chromatogram of FCPC representing the separation of unreacted Cyt-c and Cyt-c-PEG, obtained 
after two-steps of PEGylation + fractionation using FCPC and the ABS comprising 15 wt% of PEG 2000 + 
20 wt% of potassium phosphate buffer, at pH 7.0.  
 
Table 5.4. Purified fractions, yield (Y%) and purity (%) of Cyt-c and Cyt-c-PEG obtained after FCPC 
purification in both processes designed. 
  Cyt-c  Cyt-c-PEG 
 Fractions Y (%) Purity (%)  Fractions Y (%) Purity (%) 
PEG 2000 7-12 100.11 100  35 99.18 100 
PEG 2000 Recycled 10-12 95.95 100  36-37 90.85 100 
 
Literature shows the use of CCC in the purification of PEGylated RNAse A47 and 
lysozyme,48 using the technique of countercurrent distribution (CCD). In comparision 
with FCPC, CCD is a preparative CCC scale technique firstly developed, it uses gravity to 
maintain the liquid stationary phase, resulting in very long elution times, lower 
resolution, and highly laborious work (no-automation), currently being an outdated 
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option.49 Even so, Galindo-López et. al. attempted to purify mono and di-PEGylated 
products, applying PEG 8000 + PB ABS with CCD technology with ultrafiltration as 
polishing step. Accordingly, co-elution of both PEGylated forms was observed and lower 
yields were obtained when compared with FCPC results (Y% ranging from 38 to 60%).47 
Sookkumnerd et. al. also attempted to purify mono and di-PEGylated proteins, i.e. 
lysozyme, applying a PEG 3400 + PB ABS with CCD technology and showed difficulties in 
purifying PEGylated conjugates, resulting in lower purities in preparative scale and 
confirming  FCPC a as better option.48 In comparison with the results found in the 
literature, the newly designed centrifuges hydrostatic CCC columns (i.e. FCPC) allow 
greater yields and purity in the large scale purification of proteins, taking advantage of 
the several spotlights and commodities (Table 5.5.).29,50 Further studies should be 
applied using other types of CCC columns (i.e. hydrodynamic) such as high-speed 
countercurrent chromatography (HSCCC) which can support more viscous polymers 
(high molecular weight PEGs as phase components) and can reveal a great opportunity 
to efficiently  purify PEGylated conjugates with different degrees of functionalization.51 
In this work, with the integrated process (PEGylation reaction + separation of PEGylated 
products two times) contemplating the recycling of the phase forming compounds and 
unreacted Cyt-c, the overall cost of the PEGylation process was decreased, as a 
consequence of the high yields and purities obtained in the two consecutive purification 
steps studied. Overall, this findings opens up a novel path for engineering process in the 
developing of continuous purification steps that can easily be scaled-up through the 
combination of ABS and chromatography with CCC technology, in particular with 
hydrostatic columns (FCPC). 
 
4. Conclusions 
The present study reports two different strategies based upon aqueous two-phase 
systems and ultrafiltration for the potential separation of PEGylated conjugates of Cyt-
c. The systems proposed exploiting the principle of CCC-ABS and applying FCPC resulted 
in the complete fractionation of PEGylated from unreacted protein. The manipulation 
of phase components was studied to establish the best purification condition in 
continuous purification regime. The protein polishing step was achieved by 
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ultrafiltration, removing the polymer and salts from the purified fractions. Additionally, 
an integrated process contempling the Cyt-c and phase forming compounds recycling 
was proposed, resulting in higher purification yields and purities, while increasing the 
overall sustainability of the process. In conclusion, the findings reported here point to 
the fractionation efficiency of novel continuous non-chromatography downstream 
processes in PEGylated proteins purification. 
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Table 5.5. Comparison of several types of columns used in countercurrent chromatography (CCC) regime of purification. Highlights and challenges of CCC technique. 
Technology Type Advantages  Disadvantages  
Countercurrent 
distribution (CCD) 
Gravitational 
 
 Easy operation and intrinsic simplicity. 
 
 Highly laborious; 
 Preparative scale; 
 Long elution times (days); 
 Rudimentary technique; 
 Inefficient fractionation performance.  
Fast centrifugal 
partition 
chromatography 
(FCPC) 
Hydrostatic 
(constant 
centrifugal field, 
one axis of rotation) 
 Versatile to work at ascending and descending 
modes; 
 Scale-up technique. 
 
 Operational problems using solvents with 
medium and higher viscosity; 
 Maintenance, e.g. lubrication of rotating seals 
every 100 h; 
 Time-consuming purification method. 
 
High-speed 
countercurrent 
chromatography 
(HSCCC) 
Hydrodynamic 
(variable centrifugal 
field, two axes of 
rotation) 
 Higher efficiency and peak resolution; 
 Greater versatility of solvents that can be used 
as mobile and stationary phases. 
 Shorter operational times; works more rapidly; 
 Scale-up technique. 
 
 Possible noisy gear assembly;  
 Maintenance, e.g. connecting tube to change 
every 100 h. 
 
Countercurrent 
chromatography (CCC) 
Highlights 
 Quick (high throughput in preparative separation) 
 Inexpensive (contemplate only the cost of solvents, which are still 
significantly lower than the ones applied in HPLC) 
 Gentle and versatile, for separation of several compounds, with less 
chance of decomposition 
 Able to range from milligrams to tens of grams on the same 
instrument 
 Ability to switch between normal and reversed-phase 
 Free of irreversible adsorption to a solid support (recovery of sample 
at 100%) 
Challenges 
 Aqueous solvents are not commonly used, 
more studies should be attained. 
 Higher cost of equipment investment, when 
compared with other fractionation 
technologies.   
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Conclusions and future work 
This thesis is based on the development of site-specific protein PEGylation reactions and 
alternative purification platforms of PEGylated conjugates through the exploration of 
aqueous biphasic systems. For that reason two enzymes were studied under this scope: 
ASNase and Cyt-c, to produce, respectively, therapeutic and analytical proteins with 
enhanced properties. 
In Chapter 2. the upstream and downstream processing for the production of a 
pharmaceutical grade ASNase through chromatographic (Section 2.1.) and non-
chromatographic purification platforms was presented (Section 2.2).  The optimized 
two-step FPLC purification method allowed successful purification of ASNase from S. 
cerevisiae expressed in E. coli BL21 (DE3). Alternatively, the design of an integrated 
process comprising the steps of production, cell disruption, and purification with an 
ammonium sulfate precipitation followed by the application of ABS with IL as adjuvant, 
and culminating in the ASNase isolation and phases reuse was achieved. This integrated 
non-chromatographic process lead to purification factor 20 times higher than 
chromatographic method. In Section 2.3, an efficient integrated ABS platform was 
developed to fractionate and recover Cyt-c from a complex protein mixture. An 
integrated purification platform composed of ABS and micellar-based ABS (AMTPS) was 
first characterized, through the construction of phase diagrams and then applied in the 
fractionation of Cyt-c from a protein mixture. The obtained results showed that the 
ternary system composed of Pluronic L-35 (23 wt%) + potassium phosphate buffer (6 
wt%) was the most selective system, demonstrating the potential of combine these two 
liquid-liquid extraction units can lead to great selectivity performance. The carbon 
footprint was evaluated to better understand the environmental impacts of this novel 
protein purification process. 
After carrying out the development of processes of production and purification of the 
proteins under study, the PEGylation reaction of both ASNase and Cyt-c was evaluated 
(Chapter 3). An optimized protocol for site-specific N-terminal PEGylation of ASNase was 
successfully developed in Section 3.1., and adequate yields were obtained 
(monoPEGylation yield% = 41%). This novel biobetter, was produced in lower times 
(reaction time of 30 min), with less quantity of PEG reactive,  which represent a great 
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industrial production time and also less cost with raw material since the reaction needs 
less PEG than unspecific PEGylation.  Also this novel enzyme variant exhibited not only 
enhanced long-term stability, in comparison with to polyPEGylated form similar to the 
currently one on the market (ONCASPAR®), as well as higher protection to proteolytic 
activity in comparison with native ASNase. The kinetic profile and activity against 
leukemic cell lines were investigated and attested, this mono-PEG ASNase as a potential 
biobetter to treat acute lymphoblastic leukemia. In Section 3.2. a site-specific 
PEGylation reaction for Cyt-c was successfully developed. The best PEGylation 
conditions were pH 7, 1:25 Cyt-c:mPEG-NHS (molar ratio) and 15 min reaction time 
resulting in PEGylation yields of 45% for the attachment of 4 PEG molecules (Cyt-c-PEG-
4) and 34% for the binding of 8 PEG molecules (Cyt-c-PEG-8).  The PEGylated forms of 
Cyt-c exhibited enhanced long-term stability in terms of catalytic activity of ABTS 
oxidation by hydrogen peroxidase. Based on bioconjugation reaction engineering, the 
protective role of PEG considering the design of novel protein-based biosensors was 
demonstrated. The thermostability of PEG covalent conjugation of the protein-based 
biosensors were further evaluated in Section 3.3. From the thermodynamic parameters 
obtained, it was possible to conclude that PEGylation of Cyt-c enhanced its 
thermostability, proving to be an important tool for industrial biosensing applications. 
Such protection was even enhanced at higher temperatures. 
Taking into account that the protein PEGylation reactions are not complete, with the 
formation of heterogeneous mixtures, there is a need to investigate sustainable 
processes for the purification of PEGylated conjugates. In this sense, batch ABS based 
platforms for the fractionation of site-specific PEGylated conjugates were studied in 
Chapter 4. The separation of PEGylated conjugates from the unreacted protein and the 
sub-fractionation of the PEGylated conjugates among themselves on the basis of their 
degree of PEGylation was successfully achieved with the use of multistage ABS based on 
PEG + phosphate buffer (pH = 7),  the results are presented in Section 4.1.. This pioneer 
work, was the first to prove the possibility to fractionate site-specific PEGylated 
conjugates with the use of non-chromatographic ABS technology. Systems based on 
intermediate molecular weight (MW) PEGs showed to be promising platforms to 
selectively fractionate the PEGylated conjugates from the unreacted protein in a single 
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step, while ABS formed by higher MW PEGs exhibited higher selectivity in the 
purification of specific PEGylated conjugates. The two main driving-forces affecting the 
protein partitioning were the volume exclusion (of the polymer-rich phase) and the 
“PEG-PEG” interactions. In this sense, a multi-stage ABS strategy was developed to 
purify the three protein species, namely Cyt-c, Cyt-c-PEG-4 and Cyt-c-PEG-8 with high 
purities (96.5% Cyt-c, 85.8% Cyt-c-PEG-4, and 99.0% Cyt-c-PEG-8). Furthermore, an 
innovative recycling procedure of the purified Cyt-c for a novel PEGylation reaction was 
also achieved, increasing the feasibility and sustainability of the overall process (moving 
towards a circular economy). Within the ABS-based separation field, a novel one pot 
process designed with the integration of protein PEGylation reaction with the direct 
application of polymer + salt-based ABS on the reaction media was successfully 
developed for several model proteins: Cyt-c, LYS, ASNase, and CAT (Section 4.2.). The 
PEGylated protein was used as phase forming components, being concentrated and 
recovered in the top aqueous phase. The citrate buffer was applied not only to promote 
the formation of ABS through salting-out process, but also to stop the PEGylation 
reaction (a greener alternative to conventional reagents such as hydroxylamine, which 
exhibits high toxicity). The obtained results show high selectivies in the recovery of 
PEGylated Cyt-c from unreacted Cyt-c for several molecular weights reactive PEGs (5-40 
kDa) and reaction times (7.5-30 min). The findings reported here open a new pathway 
for the application of one-pot bioconjugation + ABS step for the recovery of high-value 
biological products, such as therapeutic biobetters modified with different PEG sizes 
from large reaction volumes.  
Looking for the need to transpose the efficient batch ABS-based separation units to a 
continuous purification regime, fast centrifugal partition chromatography (FCPC) 
applying ABS was investigated for the in situ fractionation of PEGylated protein 
conjugates (Chapter 5). In this sense, the application of PEG + phosphate buffer ABS in 
FCPC for the purification of PEGylated Cyt-c conjugates was effectively attained. The 
proportion of phase components in PEG + phosphate buffer ABS was evaluated in order 
to obtain the best purification yield and purity. An outstanding purification performance 
was obtained in the fractionation of Cyt-c from Cyt-c-PEG (Y% > 88% and purity = 100%). 
Furthermore, the recycling of unreacted Cyt-c for a novel PEGylation step and FCPC 
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purification was achieved, along with the reuse of phase components (PEG and 
phosphate buffer), towards the creation of a more sustainable process.  
From the current work developed in this thesis, it is clear the great potential of ABS in 
the fractionation of PEGylated proteins, under batch and continuous regime. Moreover 
in situ recovery of the PEGylated products through one-pot integration of 
bioconjugation and ABS purification was successfully proved for both enzymes studied.  
As future work and taking advantage of the results achieved and discussed above, it 
would be interesting to: 
 Optimize site-specific protein PEGylation reactions with improved yields, 
through the application of alternative solvents in bioconjugation reactions, such 
as ionic liquids (ILs). 
 Explore the potential of ionic liquids (ILs), deep eutectic solvents (DES), and 
copolymers as phase forming compounds of ABS to the purification of protein 
PEGylated conjugates. 
 Test other continuous purification regimes based on ABS technology to 
fractionate site-specific PEGylated conjugates (i.e. high-speed countercurrent 
chromatography, HSCCC and continuous tubular separator).  
 Use MALDI-TOF MS to do a better characterization of PEGylated Cyt-c conjugates 
(Cyt-c-PEG-4 and Cyt-c-PEG-8). 
 Apply the site-specific PEGylated Cyt-c conjugates in bioelectrochemical redox 
sensing in order to develop an enhanced biosensor with long-term stability.   
 Study the effect of PEGylation in thermal and kinetic stability of both ASNase and 
mono-PEGylated ASNase and other enzymes. 
 Evaluate the in vivo drug clearance of ASNAse vs mono-PEGylated ASNase, 
through in vivo localization of labelled native and PEGylated asparaginase 
performed in mice with further ex vivo biodistribution studies. 
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Table A.1. E. coli strains used in this work. 
E. coli strain Genotype 
Selection 
marker 
Manufacturer 
DH5α1 [deoR endA1 gyrA96 hsdR17 
Δ(lac)U169 recA1 relA1 supE44 thi-1 
(Φ 80 lacZΔM15)] 
- Novagen™ 
AD4942 [Δ(araABC-leu)7697 ΔlacX74 
ΔmalF3 ΔphoAPvuII phoR trxB ::Kanr 
F'[lacIqlacZΔM15proAB+] 
Kan Novagen™ 
BL21(DE3)3 [F– ompT hsdSB(rB–, mB–) gal 
dcm (DE3)] 
- 
Life 
Technologies™ 
BL21 
CodonPlus(DE3)4 
[RIPL: endA gal ompT hsdSB Dcm+ 
Hte Tetr (pACYC-RIL argU ileY leuW 
Cam]r (DE3) 
Cam and 
Strep 
Agilent 
Technologies 
Tuner™ (DE3) gal hsdSB lacY1 ompT  (DE3)  Novagen™ 
BL21pLyss(DE3)5 F–, ompT, hsdSB (rB–, mB–), dcm, 
gal, λ(DE3), pLysS, Cmr 
Cam Promega™ 
C43 (DE3)6 [F – ompT hsdSB (rB- mB-) gal dcm 
(DE3)] 
- Lucigen ™ 
Rosetta™(DE3)7 F– ompT hsdSB(rB – mB –) gal dcm 
(DE3) pRARE2 (CamR) 
Cam Novagen™ 
Origami(DE3)8 1∆(ara–leu)7697 ∆lacX74 ∆phoA 
PvuII phoR araD139 ahpC galE galK 
rpsL F'[lac+ lacI q pro] (DE3) 
gor522::Tn10 trxB 
Cam, Strep 
and Tetra 
Novagen™ 
- = no selective marker, Kan = kanamycin, Cam = chloramphenicol, Tetra = tetracycline, Strep = 
streptomycin. Main reason to use this strain: 1 Cloning vectors; 2 (trxB) mutants that enable disulfide bond 
formation in the E.coli cytoplasm expressed proteins; 3 Expression of cytoplasmic proteins and deficient 
in both lon and ompT proteases; 4 extra copies of genes that encode the tRNAs that most frequently limit 
translation of heterologous proteins in E. coli; 5 high-stringency expression host due to expression of T7 
lysozyme; 6 Effective in expressing toxic and membrane proteins; 7 Expresses six rare tRNAs that most 
frequently limit translation of heterologous proteins in E. coli; 8 trxB/gor mutant, greatly facilitates 
cytoplasmic disulfide bond formation. 
 
 
 
 
 
Table A.2. Screening of expression conditions. I = Insoluble, S = Soluble, 0 = Do not express, .= Not tested.                                                                                                                                                                       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A.3. Merchuk parameters (A, B and C) used on the description of the experimental binodal data by 
Merchuk Equation. 
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Pluronic L-35 
(1.0% Triton X-100) 
A ± 𝝈 B ± 𝝈 𝟏𝟎𝟓(C ± 𝝈) 
K₂HPO₄ 82.56 ± 5.73 -0.45 ± 0.05 101.51 ± 22.32 
KH₂PO₄ 154.70 ± 14.24 -0.64 ± 0.04 21.42 ± 5.29 
K₃PO₄ 102.49 ± 7.83 -0.59 ± 0.05 92.40 ± 21.19 
K₂HPO₄/KH₂PO₄ 108.03 ± 10.03 -0.62 ± 0.05 73.41 ± 16.07 
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Pluronic L-35 + 
K₂HPO₄/KH₂PO₄ 
A ± 𝝈 B ± 𝝈 𝟏𝟎𝟓(C ± 𝝈) 
Triton X-114 96.16 ± 1.97 -0.59 ± 0.01 40.19 ± 3.66 
Triton X-100 108.03 ± 10.03 -0.62 ± 0.05 73.41 ± 16.07 
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K₂HPO₄/KH₂PO₄ A ± 𝝈 B ± 𝝈 𝟏𝟎𝟓(C ± 𝝈) 
Pluronic L-35 109.62 ± 5.44 -0.67 ± 0.03 28.11 ± 9.74 
Pluronic 10R5 97.99 ± 7.87 -0.64 ± 0.05 51.81 ± 2.14 
Pluronic 17R4 137.31 ± 18.28 -0.95 ± 0.11 169.71 ± 1.42 
 
 
 
 
Table A.4. Weight fraction data (w) for the systems composed of Pluronic L-35 (1) + Phosphate salts - 
K₂HPO₄; KH₂PO₄; K3PO4 and K₂HPO₄/KH₂PO4 (2) + H2O (3) determined in the present work at 25ºC. 
 
Pluronic L-35 + K₂HPO₄ Pluronic L-35 + KH₂PO₄ Pluronic L-35 + K3PO4 
Pluronic L-35 + 
K₂HPO₄/KH₂PO4 
100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 
56.972 0.911 44.926 3.857 56.803 0.878 12.232 8.791 
51.969 0.831 44.048 3.782 33.111 2.520 12.170 8.747 
50.726 1.286 43.064 4.031 33.111 2.520 12.532 8.701 
48.245 1.223 42.257 3.955 29.936 2.954 12.755 8.665 
46.616 1.853 41.012 4.279 27.866 2.749 12.413 8.618 
44.727 1.778 40.453 4.221 25.855 3.830 13.142 8.493 
42.544 2.661 39.409 4.498 25.728 3.425 13.023 8.417 
39.373 2.463 39.037 4.455 25.193 3.954 13.486 8.374 
38.602 2.804 37.002 5.002 25.011 3.925 13.359 8.295 
38.049 2.764 36.753 4.968 24.427 4.098 14.353 8.068 
37.606 2.963 35.927 5.192 23.643 4.189 14.191 7.977 
36.622 2.886 35.426 5.120 23.449 4.298 14.816 7.896 
35.867 3.236 33.872 5.551 23.428 3.839 15.032 7.825 
35.344 3.188 33.689 5.521 23.335 4.277 14.653 7.809 
34.986 3.358 32.886 5.746 22.824 4.128 15.377 7.752 
34.079 3.270 32.562 5.689 22.299 4.518 15.215 7.671 
33.562 3.522 30.410 6.301 22.163 4.490 15.715 7.597 
32.893 3.452 30.235 6.265 21.596 4.300 16.018 7.465 
0.036 19.956 29.126 6.583 21.112 4.781 16.333 7.329 
0.021 11.847 28.959 6.545 20.479 4.590 16.238 7.287 
7.277 10.407 27.411 6.994 20.315 4.553 16.826 7.147 
6.767 9.678 27.298 6.966 20.085 4.671 16.651 7.073 
14.387 8.285 25.342 7.537 19.639 5.088 17.383 7.003 
13.823 7.960 25.229 7.504 19.553 4.722 17.041 6.977 
17.931 7.248 16.379 10.114 19.313 5.004 17.291 6.967 
17.592 7.111 16.279 10.052 19.248 4.779 17.684 6.962 
19.685 6.757 11.492 12.197 18.983 4.921 18.057 6.812 
19.362 6.646 11.395 12.094 18.972 5.173 17.938 6.767 
22.828 6.075 12.619 11.791 18.731 4.855 18.474 6.661 
22.135 5.891 12.417 11.602 17.681 5.144 18.766 6.585 
25.527 5.359 13.895 11.243 17.390 5.307 18.636 6.540 
25.001 5.248 13.634 11.032 17.261 5.268 19.197 6.477 
27.611 4.854 16.275 10.408 17.100 5.359 19.002 6.411 
26.979 4.742 15.884 10.158 16.648 5.495 19.600 6.183 
30.595 4.218 18.625 9.531 16.505 5.807 20.109 6.123 
29.640 4.086 18.332 9.380 16.341 5.551 19.957 6.077 
  20.460 8.904 16.001 5.630 20.461 6.014 
  19.914 8.667 15.545 5.641 20.834 5.916 
  22.299 8.155 15.266 5.974 20.666 5.869 
  22.138 8.096 15.125 5.737 21.535 5.761 
  23.696 7.765 14.972 6.246 22.287 5.564 
  23.369 7.658 14.861 5.900 21.947 5.479 
  25.283 7.261 14.756 5.858 23.148 5.363 
  24.978 7.173 14.328 5.959 22.733 5.266 
  27.839 6.592 14.114 6.095 24.627 5.023 
  27.288 6.461 13.966 6.031 23.896 4.874 
  34.449 5.059 13.680 6.426 27.827 4.298 
  33.544 4.926 13.266 6.300 26.964 4.165 
    12.755 6.432 30.458 3.807 
    12.754 6.934 28.988 3.623 
    12.446 6.767 32.624 3.215 
    11.974 6.633 31.705 3.124 
    11.833 6.555 33.141 2.941 
 
 
 
 
Table A.5. Weight fraction data (w) for the systems composed of Pluronic L-35 (1) + Phosphate Buffer - 
K₂HPO₄/KH₂PO4 (pH=6.6) (2) + H2O (3) with 1 wt% of adjuvant, determined in the present work at 25ºC. 
 
Pluronic L-35 + K₂HPO₄/KH₂PO4 +  
Triton X-100 
Pluronic L-35 + K₂HPO₄/KH₂PO4 +  
Triton X-114 
100 w1  100 w2 100 w1  100 w2 
56.901  1.206 57.611  0.809 
48.911  1.036 55.462  0.779 
45.641  2.336 52.969  1.655 
39.386  2.016 46.695  1.459 
37.048  3.112 42.470  2.114 
34.055  2.861 40.365  2.009 
32.273  3.783 39.375  2.457 
30.509  3.577 37.977  2.370 
29.778  3.982 36.559  2.614 
28.976  3.875 35.052  2.765 
27.042  4.266 34.672  2.955 
26.399  4.652 33.372  2.999 
26.070  4.594 32.640  3.148 
25.603  4.878 32.146  3.407 
24.967  4.757 31.499  3.338 
24.063  5.327 29.746  3.897 
23.433  5.187 28.718  4.122 
23.085  5.414 28.261  4.056 
22.459  5.267 26.966  4.454 
21.695  5.784 26.252  4.602 
21.107  5.628 25.982  4.555 
20.476  6.072 25.605  4.782 
20.117  5.966 24.411  4.927 
19.618  6.326 23.778  5.094 
19.215  6.196 23.452  5.302 
18.822  6.489 23.157  5.235 
18.506  6.380 21.956  5.735 
18.022  6.749 21.389  5.906 
17.701  6.629 21.233  5.863 
   20.581  6.161 
   20.016  6.360 
   19.503  6.498 
   19.288  6.426 
   18.581  6.656 
   18.227  6.798 
   18.056  6.925 
   17.930  6.876 
   17.289  7.118 
   17.126  7.242 
   16.736  7.374 
   16.169  7.475 
   15.952  7.646 
   15.857  7.601 
   15.522  7.666 
   14.876  7.998 
   14.140  8.242 
 
 
 
 
Table A.6. Weight fraction data (w) for the systems composed of copolymers (1) - Pluronic 17R4 or 10R5 
+ Phosphate Buffer- K₂HPO₄/KH₂PO4 (pH=6.6) (2) + H2O (3) determined in the present work at 25ºC.
  
Pluronic 17R4 + K₂HPO₄/KH₂PO4 Pluronic 10R5+ K₂HPO₄/KH₂PO4 
100 w1 100 w2 100 w1 100 w2 
57.328 0.922 65.656 1.326 
50.975 0.820 46.570 1.940 
49.678 1.320 37.390 2.018 
44.177 1.174 36.480 2.467 
43.518 1.462 33.338 2.820 
41.235 1.385 32.376 2.739 
40.363 1.789 31.698 3.111 
37.097 1.645 30.477 2.991 
36.165 2.118 29.565 3.515 
33.560 1.966 28.379 3.374 
32.647 2.470 27.662 3.806 
30.216 2.286 26.889 3.699 
29.724 2.582 26.484 3.952 
28.697 2.493 25.855 3.858 
28.465 2.638 25.065 4.065 
27.533 2.552 24.683 4.315 
27.230 2.749 24.263 4.242 
26.596 2.685 23.862 4.510 
26.382 2.828 23.416 4.426 
25.947 2.782 22.873 4.565 
25.753 2.914 22.559 4.784 
25.293 2.862 22.256 4.719 
25.011 3.059 21.964 4.926 
24.416 2.986 21.759 4.880 
24.110 3.206 21.484 5.077 
23.527 3.128 21.277 5.028 
23.290 3.303 20.986 5.239 
22.480 3.188 20.748 5.180 
21.922 3.618 20.523 5.346 
21.621 3.568 20.230 5.270 
21.437 3.712 19.978 5.459 
21.060 3.646 19.663 5.373 
20.882 3.788 19.272 5.674 
20.555 3.729 19.107 5.625 
20.426 3.834 18.981 5.723 
20.109 3.775 18.823 5.676 
 
 
 
 
Table A.7. Experimental data of TLs and TLLs of the studied ATPS. 
 
Weight fraction composition (𝒘t%) 
TLL 
[𝐂𝐨𝐩𝐨𝐥]𝐓𝐨𝐩 [𝐒𝐚𝐥𝐭]𝐓𝐨𝐩 [𝐂𝐨𝐩𝐨𝐥]𝐌 [𝐒𝐚𝐥𝐭]𝐌 [𝐂𝐨𝐩𝐨𝐥]𝐁𝐨𝐭 [𝐒𝐚𝐥𝐭]𝐁𝐨𝐭 
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30.28 3.66 22.96 6.00 9.43 10.35 21.90 
34.83 2.93 26.04 6.02 4.79 13.47 31.84 
39.35 2.35 29.28 5.85 3.32 14.89 38.15 
43.33 1.94 32.02 6.00 1.87 16.84 44.06 
48.79 1.48 35.60 5.95 1.49 17.52 49.94 
50.37 1.36 37.98 6.00 0.59 20.00 53.15 
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33.91 2.82 23.01 6.00 2.01 12.13 33.24 
39.97 2.32 25.98 5.99 1.87 12.32 39.40 
41.98 2.18 28.98 6.02 0.77 14.36 42.97 
42.94 2.12 31.99 6.00 0.16 17.27 45.38 
43.67 2.07 35.04 6.01 0.01 22.00 48.00 
51.20 1.66 37.91 6.00 0.08 18.37 53.79 
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34.78 2.03 16.04 6.00 2.42 8.89 33.08 
38.18 1.77 19.02 5.99 1.32 9.89 37.75 
42.05 1.52 22.03 6.00 0.72 10.76 42.35 
46.02 1.30 25.01 6.01 0.40 11.52 46.75 
50.23 1.10 28.03 6.00 0.24 12.12 51.19 
58.46 0.79 30.96 6.00 0.32 11.80 59.17 
 
 
Table A.8. Properties of the model proteins (Cyt c, Azo and Ova). 
 
 
 
 
Model protein 
 
Properties 
Cyt c Azo Ova 
Molecular weight 
(kDa) 
~11.70 23.60 42.70 
pI 9.60  4.60  4.50  
∆Temp > 51ºC > 42ºC  > 56ºC 
𝞴max (nm) 409 342 280 
 
 
 
 
Table A.9. Mixture points for each system constituted by copolymer + salt + water, to the determination 
of the TLs. 
Copolymer Salt 
Mixture Points 
𝟏𝟎𝟎 𝒘𝑪𝒐𝒑𝒐𝒍 𝟏𝟎𝟎 𝒘𝑺𝒂𝒍𝒕 
Pluronic L-35 
Phosphate buffer 
(pH = 6.6) 
23 
6 
26 
29 
32 
35 
38 
Pluronic 10R5 
Phosphate buffer 
(pH = 6.6) 
23 
6 
26 
29 
32 
35 
38 
Pluronic 17R4 
Phosphate buffer 
(pH = 6.6) 
16 
6 
19 
22 
25 
28 
31 
 
 
Table A.10.  Inputs for 5 g of aqueous system considered. 
 Process  Step Input Value 
Fractionation 
process 
ATPS 
Pluronic L-35 (g) 1.15 
Potassium phosphate buffer 
(g) 
0.365 
Distilled water (g) 3.47 
Electricity (kWh) 0.233 
AMTPS Electricity (kWh) 0.00425 
Ultrafiltration 
NaOH (g) 3.98E-04 
Distilled water (g) 9.96E-02 
Electricity (kWh) 0.703 
Isolation process Acid precipitation 
TCA (g) 1.61E-05 
Distilled water (g) 9.90E-04 
Electricity (kWh) 0.467 
 
 
 
 
 
Table A.11. GHG emission factors and activity name taken from Ecoinvent version 3.4 used in the calculation of the carbon footprint. 
Input Reference Activity name GHG emissions 
 
unit  (kg CO2eq./reference unit)a 
Distilled water kg --- 0.311 
Electricity kWh Market for electricity, low voltage, Portugal 0.413 
Pluronic L-35 kg Ethylene glycol production, Europeb 1.841 
  Propylene glycol production, Europeb 4.526 
Potassium phosphate buffer kg Chemical production, inorganic, Globalc 2.109 
Trichloroacetic acid kg Trichloroacetic acid production, Europe 2.866 
Sodium hydroxide kg sodium hydroxide to generic market for neutralizing agent, Globald 1.955 
a Global warming potentials for converting the mass of each GHG into mass of CO2 eq. are those recommended by the Intergovernmental Panel on Climate Change 
(IPCC)3 for a time horizon of 100 years. 
b In the absence of data for the production of Pluronic L-35, an average value of the two processes was calculated. 
c In the absence of data for the production of Potassium phosphate buffer, this process was selected as more similar 
 
 
 
 
 
 
 
 
 
 
 
 
Table A.12. Characteristics and chemical structure of the copolymers and non-ionic surfactants used in this work. 
 
 
 
Copolymer/ 
Surfactant 
Molecular weight 
(g.mol-1) 
Hydrophilic-lipophilic 
balance (HLB) 
wt% PEG Structure 
Pluronic L-35 1900 18 - 23 50 
 
Pluronic 10R5 2000 12 - 18 50 
 Pluronic 17R4 2700 7 - 12 40 
Triton X-100 647 13.5 --- 
 
n = 7-8, Triton X-114 
n = 9-10, Triton X-110 
Triton X-114 537 12.4 --- 
Reverse  PluronicNormal  Pluronic
Reverse  PluronicNormal  Pluronic
 
 
 
 
 
Fig. A.1. Macroscopic view of the pseudo-ternary system composed of Pluronic L-35. (a) Initial mixture 
for all extraction ATPS; (b) ATPS formation for the purification of the three model proteins, at 25ºC; (c) 
AMTPS formation for azocasein and ovalbumin purification, at a temperature above the cloud point (ºC) 
of the copolymer used. 
 
 
 
Fig. A.2. Partition coefficient - log(K) obtained for each studied system for: cytochrome c (■); azocasein 
(■); and ovalbumin (■), on the first purification step (ATPS). 
 
 
 
 
 
 
 
Figure A.3. Partition coefficient - log(K) obtained for each studied system for the azocasein (■); and 
ovalbumin (■), on the second purification step (AMTPS). 
 
 
 
Figure A.4. FPLC-SEC chromatograms of the purified fractions of (a) ATPS bottom phase, (b) AMTPS 
bottom and (c) AMTPS top phase respectively. 
 
 
 
 
 
 
 
Fig. A.5. Polishing of azocasein through acid precipitation, confirming the protein proper refolding. 
 
 
 
Fig. A.6. 1H NMR of the supernatant proving the recovery of Pluronic through azocasein precipitation 
polishing step.   
 
 
 
Supernat
ant 
 
 
 
 
 
Fig. A.7. FTIR spectra of the supernatant (red) and the resuspended proteinic pellet (orange), proving the 
recovery of Pluronic through azocasein precipitation polishing step. Focus on the peak at 1085 cm-1, 
characteristic of strong C-O stretching of primary alcohols. 
 
 
 
 
Fig. A.8. Example of the TLs calculated for the conventional ATPS (Pluronic L-35 + Phosphate buffer).  
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Table B.1. ASNase amine residues classification regarding the PEGylation probability as a function of pKa 
values. 
PEGylation 
Favorable 
(residue nº)a 
Possible 
(residue nº)b 
Difficult 
(residue nº)c 
N-terminal 
Leucine (pKa ≈ 7.6) 
1 - - 
Lysine  
pKa ≥ 10.5  
29, 34, 43, 49, 79, 107, 139, 
196, 207, 251, 288, 314 
22, 262 
71, 72, 104, 162, 172, 
186, 213, 229, 301 
TOTAL 12 2 9 
 
aPartially protonated and located on the protein surface. 
bPartially protonated and located on subunits interface. 
cFully protonated and/or in the protein inner region. 
 
 
Fig. B.1. Schematic representation of L-asparaginase (PDB code 3ECA) PEGylation with mPEG-NHS (5kDa). 
Spheres represent N-terminal regions and PEGylation can occur randomly or site specifically depending 
on the amino acids protonation.  
 
 
 
 
 
 
 
 
 
 
 
Fig. B.2. Electrophoresis (SDS-PAGE) in polyacrylamide gel stained with silver of L-asparaginase (ASNase) 
conjugation with PEG 2 kDa at 100 mM of PBS at different pH values. Column 1- pure ASNase (1 mg·mL-
1), column 2- pH 6.0, column 3- pH 6.5, column 4- pH 7.0, column 5- pH 7.5, column 6- pH 8.0 and column 
7- Molecular weight standard (MW). 
 
 
 
Fig. B.3. Electrophoresis (SDS-PAGE) in polyacrylamide gel stained with CBB of L-asparaginase conjugation 
with PEG 2 kDa in PBS 100 mM pH 7.5 at different reaction times. Column 1- 0 min, column 2- 15 min, 
column 3- 30 min, column 4- 45 min, column 5- 60 min, column 6- 75 min, column 7- 90 min and column 
8- Molecular weight standard (MW). 
 
 
Fig. B.4. Purification of PEGylated L-asparaginase (ASNase) by anion exchange chromatography. (A) 
Chromatogram of the purification performed with a strong salt anion exchange column (Resource Q) with 
linear salt gradient, 12 column volumes, up to 170 mM of NaCl in Bis-Tris-HCl buffer, pH 7.0 1 M of NaCl. 
Gradient peaks are found in 35 mM, 67 mM, 78 mM and 92 mM NaCl. (B) Electrophoresis gel (Native-
PAGE) stained with CBB. Column 1- PEGylation reaction before purification, column 2-elution fraction at 
35 mM of NaCl, column 3- elution fraction at 67 mM of NaCl, columns 4 to 6- elution fractions at 78 mM of 
NaCl and columns 7 to 10: elution fractions at 92 mM of NaCl. 
 
 
 
 
 
Fig. B.5. Purification by size exclusion chromatography (Superdex 200 10/300 GL column) of 
monoPEGylated L-asparaginase (from anion exchange chromatography). In hatched (70% area), 
monoPEG-ASNase eluted in 10.65 mL and in 11.39 mL, pure ASNase (control). Elution occurred 
isocratically, 1 mL·min-1, with 50 mM of Tris-HCl buffer, at pH 8.6. 
 
Fig. B.6. Purification by size exclusion chromatography (Superdex 200 10/300 GL column) of 
polyPEGylated L-asparaginase (ASNase). In hatched (58% peak area), polyPEG-ASNase eluted a range of 
8.28 to 9.61 mL. Elution occurred isocratically, 1 mL·min-1, with 50 mM of Tris-HCl buffer, at pH 8.6. 
 
 
 
 
 
 
 
 
Fig. B.7. Cytotoxicity of monoPEG-ASNase in HUVEC cells. Assays performed at 48 and 72 h, with cells 
alone (control), without enzyme (PBS) and enzyme concentrations measured in activity (0.01, 0.05, 0.1, 
0.3 and 0.6 U·mL-1). Gray bars - free ASNase, white bars - monopegylated ASNase. Error bars represent 
the standard deviation. 
 
 
Fig. B.8. Calibration curve obtained by plotting the Kav value of each marker and the logarithms of their 
molecular weights (MW).
 
 
 
 
 
 
 
 
Fig. B.9. Chromatogram of the PEGylation reaction mixture obtained for the Cyt-c PEGylation in 0.1 M of potassium phosphate buffer at different pH values, 1:25 of molar 
proportion (protein:mPEG-NHS, 5 KDa), at room temperature and for 30 minutes. The peaks correspond to both Cyt-c PEGylated forms and unreacted protein. The studied 
pHs were: 7 (A), 8 (B), 9 (C), 10 (D), 11 (E), and 12 (F). 
 
 
 
 
 
 
 
Fig. B.10. Oxidation kinetics for Cyt-c, Cyt-c-PEG-4 and Cyt-c-PEG-8, using ABTS as substrate (0.025-0.300 
mM), with an initial concentration of Cyt-c of 0.6 mg.mL-1, and in presence of 25 mM of H2O2.  
 
 
 
 
 
 
 
 
 
 
Cyt-c Cyt-c-PEG-4 Cyt-c-PEG-8 
T (K) 1/T (K-1) kd (h-1) lnkd T (K) 1/T (K-1) kd (h-1) lnkd T (K) 1/T (K-1) kd (h-1) lnkd 
343.15 2.91E-03 0.173 -1.75 343.15 2.91E-03 0.101 -2.29 343.15 2.91E-03 0.077 -2.57 
348.15 2.87E-03 0.219 -1.52 348.15 2.87E-03 0.154 -1.87 348.15 2.87E-03 0.111 -2.20 
353.15 2.83E-03 0.339 -1.08 353.15 2.83E-03 0.157 -1.85 353.15 2.83E-03 0.116 -2.15 
358.15 2.79E-03 0.369 -1.00 358.15 2.79E-03 0.295 -1.22 358.15 2.79E-03 0.165 -1.80 
363.15 2.75E-03 0.459 -0.78 363.15 2.75E-03 0.422 -0.86 363.15 2.75E-03 0.264 -1.33 
368.15 2.72E-03 0.587 -0.53 368.15 2.72E-03 0.551 -0.60 368.15 2.72E-03 0.352 -1.04 
Fig. B.11. Semi-log plots of irreversible denaturation for Cyt-c, Cyt-c-PEG-4 and Cyt-c-PEG-8, at different temperatures (T = 343.15 K – 368.15 K). Experimental reaction 
conditions: 0.24 mL of Cyt-c (1.2x10-3 μM); 0.03 mL of ABTS (25 mM); and 0.03 mL of H2O2 (25 mM). 
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Table C.1. Recovery towards the top and bottom phases (in percentage) of the unreacted cytochrome c (Cyt-c) and the site-specific PEGylated forms (Cyt-c-PEG-4 and Cyt-c-
PEG-8) in the ABS composed of 15 wt% of PEG + 20 wt% of potassium phosphate buffer (pH = 7). 
  Cyt-c Cyt-c-PEG-4 Cyt-c-PEG-8 
PEG MW 
(g.mol-1) 
 Rec Top (%)  Rec Bot (%)  Rec Top (%)  Rec Bot (%)  Rec Top (%)  Rec Bot (%) 
300 20. ± 3  80 ± 3  99.98 ± 0.01 0.02 ± 0.01 99.94 ± 0.01 0.06 ± 0.01 
600 24.8 ± 0.2 75.2 ± 0.2 99.93 ± 0.01 0.07 ± 0.01 99.86 ± 0.01 0.14 ± 0.01 
1000 0.3 ± 0.1 99.6 ± 0.1 99.5 ± 0.2 0.4 ± 0.2 99.9 ± 0.01 0.10 ± 0.01 
1500 0.12 ± 0.05 99.88 ± 0.05 99.3 ± 0.6 0.7 ± 0.6 99.87 ± 0.01 0.13 ± 0.01 
2000 0.11 ± 0.04 99.89 ± 0.04 92 ± 3 8 ± 3 98.5 ± 0.4 1.5 ± 0.4 
4000 0.02 ± 0.01  99.98 ± 0.01 0.02 ± 0.01 99.98 ± 0.01 22 ± 2 78 ± 2 
6000 0.02 ± 0.01 99.98 ± 0.01 0.02 ± 0.02 99.98 ± 0.02 45 ± 1 55 ± 1 
8000 0.02 ± 0.01 99.98 ± 0.01 0.05 ± 0.05 99.95 ± 0.05 46 ± 1 54 ± 1 
 
Table C.2. Recovery towards the top and bottom phases (in percentage) of the unreacted cytochrome c (Cyt-c) and site-specific PEGylated forms (Cyt-c-PEG-4 and Cyt-c-PEG-
8) in the ABS composed of PEG 1500 + of potassium phosphate buffer (pH = 7) considering different mixture points. 
 
 
 
 
 
 
 
 Cyt-c Cyt-c-PEG-4 Cyt-c-PEG-8 
Mixture point  Rec Top (%)  Rec Bot (%)  Rec Top (%)  Rec Bot (%)  Rec Top (%)  Rec Bot (%) 
(15; 15 wt%) 0.07 ± 0.01 99.93 ± 0.01 99.94 ± 0.01 0.06 ± 0.01 99.92 ± 0.03 0.08 ± 0.03 
(17.5; 15 wt%) 0.10 ± 0.01 99.90 ± 0.01 99.90 ± 0.01 0.10 ± 0.01 99.89 ± 0.01 0.11 ± 0.01 
(20; 15 wt%) 0.12 ± 0.01 99.88 ± 0.01 99.3 ± 0.6 0.7 ± 0.6 99.87 ± 0.01 0.13 ± 0.01 
(22.5; 15 wt%) 0.12 ± 0.01 99.88 ± 0.01 97.1 ± 0.4 2.9 ± 0.4 99.83 ± 0.03 0.17 ± 0.03 
(25; 15 wt%) 0.12 ± 0.02 99.88 ± 0.02 92.4 ± 0.1 7.6 ± 0.1 99.81 ± 0.01 0.19 ± 0.01 
 
 
 
 
Table C.3. Weight fraction compositions for TLs and respective TLLs at the Top and Bottom (Bot) phases of the phase formers, namely the potassium phosphate buffer (PB), 
PEG (1500 and 8000) and water (W).  
 
PEG 1500    
[PB] 
(wt%) 
[PEG] 
(wt%) 
[PB]Top 
(wt%) 
[PEG]Top 
(wt%) 
[W]
Top 
(wt%) 
[PB]Bot 
(wt%) 
[PEG]Bot 
(wt%) 
[W]
Bot 
(wt%) 
TLL 
15 15 2.55 40.56 56.89 21.79 1.06 77.15 43.94 
17.5 15 1.79 46.42 51.78 24.83 0.33 74.83 51.53 
20 15 1.29 51.55 47.16 27.63 9.13×10-2 72.28 57.81 
22.5 15 0.89 56.97 42.14 30.21 2.21×10-2 69.76 64.06 
25 15 0.69 60.33 38.98 33.04 3.50×10-3 66.95 68.45 
PEG 8000     
[PB] 
(wt%) 
[PEG] 
(wt%) 
[PB]Top 
(wt%) 
[PEG]Top 
(wt%) 
[W]
Top 
(wt%) 
[PB]Bot 
(wt%) 
[PEG]Bot 
(wt%) 
[W]
Bot 
(wt%) 
TLL 
20 15 1.12 57.49 41.39 26.67 4.95×10-6 73.33 62.91 
 
Table C.4. Composition of the streams of the single-step and multi-step processes using polymer-based ABS in terms of phase forming agents, namely phosphate buffer (PB), 
polyethylene glycol (PEG MW = 1500 and 8000) and water (W). 
 
Single-step process Multi-step process 
Stream 
[PB] 
(wt%) 
[PEG 1500] 
(wt%) 
[W] 
(wt%) 
Stream 
[PB] 
(wt%) 
[PEG 1500] 
(wt%) 
[PEG 8000] 
(wt%) 
[W] 
(wt%) 
i 20 15 65 i 20 0 15 65 
ii 1.29 51.55 47.16 ii, iii 26.67 0 4.95E-06 73.33 
iii 27.63 9.13E-02 72.28 iv, v 1.12 0 57.49 41.39 
    vi 27.63 9.13E-02 < 4.95E-06 72.28 
    vii 1.29 51.55 < 4.95E-06 47.16 
 
 
 
 
Table C.5. Parameters obtained through the Merchuk equation (Eq. 1) with the respective standard 
deviations (std) and correlation factors (R2) along with the weight fraction data (wt%) for the systems 
composed of polyethylene glycol polymers (1) + C6H5K3O7/C6H8O7 pH 7 (2) + H2O systems determined in 
the present work. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mPEG 2 kDa 
 
A ± std =  87.44 ± 5.58 
B ± std =  -0.354 ± 0.029 
C ± std = 2.3×10-4 ± 
2.4×10-5 
 
R2 =  0.9888 
PEG 2 kDa 
 
A ± std =  83.18 ± 5.50 
B ± std = -0.314 ± 0.030 
C ± std = 2.0×10-4 ± 
2.1×10-5 
 
R2 =  0.9855 
wt%(1) wt%(2) wt%(1) wt%(2) 
6.13 19.19 12.05 15.36 
7.01 18.39 12.25 15.15 
8.80 17.31 12.56 14.98 
9.85 16.56 12.89 14.95 
10.57 16.14 13.18 14.74 
12.47 15.03 13.51 14.64 
13.63 14.31 13.75 14.41 
15.08 12.99 14.13 14.29 
15.56 12.81 14.39 14.03 
15.93 12.46 14.79 13.92 
16.49 12.29 15.25 13.76 
16.88 11.95 15.92 13.33 
17.45 11.68 16.44 13.09 
17.88 11.26 16.82 12.76 
18.59 10.95 17.41 12.53 
19.30 10.70 18.04 12.36 
20.27 10.53 18.73 12.14 
21.83 10.42 19.75 12.00 
22.90 10.08 20.82 11.24 
24.32 9.26 21.70 10.88 
25.60 8.81 22.66 10.46 
27.01 8.29 23.76 10.01 
29.22 7.82 24.49 9.45 
31.05 7.09 26.22 9.13 
33.90 6.53 28.07 8.70 
36.89 5.95 31.05 8.31 
40.02 5.11 35.88 6.62 
43.11 4.27 41.59 5.77 
45.93 2.75 44.28 4.29 
  47.05 2.69 
    
    
    
    
 
 
 
 
Table C.6. Parameters obtained through the Merchuk equation (Eq. 1) with the respective standard 
deviations (std) and correlation factors (R2) along with the weight fraction data (wt%) for the systems 
composed of polyethylene glycol (1) + C6H5K3O7/C6H8O7 pH 7 (2) + H2O systems determined in the present 
work. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PEG 6 kDa 
 
A ± std = 118.9 ± 6.2 
B ± std = -0.501 ± 0.024 
C ± std = 3.0×10-4 ± 
2.3×10-5 
 
R2 = 0.9966  
PEG 10 kDa 
 
A ± std = 171 ± 21.8 
B ± std = -0.665 ± 0.054 
C ± std = 4.0×10-4 ± 
4.3×10-5 
 
R2 =  0.9937 
PEG 20 kDa 
 
A ± std = 74.20 ± 2.62 
B ± std = -0.526 ± 0.022 
C ± std = 5.8×10-4 ± 8.2×10-5 
 
R2 =  0.9941 
wt%(1) wt%(2) wt%(1) wt%(2) wt%(1) wt%(2) 
10.43 12.52 8.27 11.98 7.39 10.02 
10.68 12.50 8.49 11.93 8.19 9.49 
10.94 12.42 8.70 11.93 9.56 8.99 
11.13 12.22 8.90 11.89 11.46 8.27 
11.29 12.12 9.17 11.86 13.01 7.74 
11.66 12.13 9.47 11.65 15.03 7.09 
11.97 12.05 9.69 11.54 17.54 6.38 
12.28 11.92 9.90 11.42 17.72 6.53 
12.63 11.78 10.03 11.25 18.71 6.10 
13.00 11.66 10.37 11.22 19.83 5.58 
13.37 11.53 10.79 11.31 20.77 5.34 
13.87 11.44 11.15 11.04 22.26 4.70 
14.32 11.29 11.62 11.00 24.70 4.02 
15.08 10.85 11.92 10.72 26.49 3.26 
15.62 10.67 12.23 10.53 28.32 3.00 
16.35 10.56 13.13 10.71 32.86 2.31 
17.01 10.27 13.75 10.04 46.52 0.84 
17.68 10.03 14.16 9.77   
18.69 9.94 14.79 9.59   
19.57 9.64 15.47 9.31   
20.50 9.30 16.35 9.27   
21.50 8.86 17.18 9.00   
23.42 8.00 17.94 8.65   
25.12 7.65 19.16 8.43   
27.11 7.21 20.30 8.09   
29.30 6.66 22.33 7.98   
32.24 6.00 24.14 7.43   
35.66 5.27 26.60 7.00   
41.46 4.57 35.64 5.11   
46.09 3.37     
      
      
      
      
 
 
 
 
 
Fig C.1. Diagram of a single-step process to fractionate selectively the unreacted cytochrome c from their PEGylated conjugates (Cyt-c-PEG-4 and Cyt-c-PEG-8) using ABS. The 
proposed strategy indicates that after the PEGylation reaction the ABS composed of PEG 1500 + potassium phosphate buffer (pH = 7) is applied and able to separate the 
PEGylated conjugates (Cyt-c-PEG-4 and Cyt-c-PEG-8) from Cyt-c with the presented recovery yields. The recycling of Cyt-c for a novel PEGylation reaction is herein projected 
through a cold acetone precipitation step followed by the resuspension of the protein pellet in the conventional PEGylation buffer (100 mM potassium phosphate buffer, pH 
=7).
 
 
 
 
 
Fig C.2. Far-UV CD spectra of Cyt-c control (▬), Cyt-c-PEG-4 (▬), and Cyt-c-PEG-8 (▬) purified through 
aqueous biphasic system. 
 
 
Fig. C.3. Ternary phase diagrams of the ABS composed of (A) mPEG 2kDa () and PEG 2 kDa () + 
C6H5K3O7/C6H8O7 (pH = 7) (B) PEG 2 (), 6 (), 10 (▲), and 20 () kDa + C6H5K3O7/C6H8O7 (pH = 7) at T = 
(298 ± 1) K and atmospheric pressure. 
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Table D.1. Partition coefficients (K) of Cyt-c and Cyt-c-PEG in PEG + potassium phosphate buffer in lab-
scale ABS. 
PEG + potassium phosphate buffer ABS KCyt-c KCyt-c-PEG 
PEG 600  0.496 1114 
PEG 1000  0.005 1548 
PEG 1500  0.002 1128 
PEG 2000  0.002 154 
PEG 4000  0.001 5.24 
Preferential Partition Potassium 
phosphate buffer-rich 
phase 
PEG-rich phase 
 
 
 
Fig. D.1. Phase diagrams of polyethylene glycol + potassium phosphate buffer and mixture point (MP) 
adopted to test the FCPC. 
 
